(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 14 October 2004 (14.10.2004)

PCT

(10) International Publication Number WO 2004/087680 A1

- (51) International Patent Classification⁷: **C07D 239/84**, A61K 31/517, A61P 25/28, 25/20, 25/22, 25/24, 3/04, 9/12, 9/00, 25/16, 25/08, 3/00
- (21) International Application Number:

PCT/JP2004/004554

- (22) International Filing Date: 30 March 2004 (30.03.2004)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/458,424

31 March 2003 (31.03.2003) U

- (71) Applicants (for all designated States except US): TAISHO PHARMACEUTICAL CO., LTD. [JP/JP]; 24-1, Takata 3-chome, Toshima-ku, Tokyo 170-8633 (JP). ARENA PHARMACEUTICALS INC. [US/US]; 6166 Nancy Ridge Drive, San Diego, CA 92121 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): SEKIGUCHI, Yoshinori [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takata 3-chome, Toshima-ku, Tokyo 170-8633 (JP). KANUMA, Kosuke [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takata 3-chome, Toshima-ku, Tokyo 170-8633 (JP). OMODERA, Katsunori [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takata 3-chome, Toshima-ku, Tokyo 170-8633 (JP). BUSUJIMA, Tsuyoshi [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takata 3-chome, Toshima-ku, Tokyo 170-8633 (JP). TRAN, Thuy-Anh [US/US]; 4833 Fairport Way, San Diego, CA 92130 (US). HAN, Sangdon [KR/US]; 9953 Fieldthorn

Street, San Diego, CA 92127 (US). **CASPER, Martin** [US/US]; 6341 Peach Way, San Diego, CA 92130 (US). **KRAMER, Bryan, A.** [US/US]; 8863 Duncan Road, San Diego, CA 92126 (US).


- (74) Agents: ASAMURA, Kiyoshi et al.; Room 331, New Ohtemachi Bldg., 2-1, Ohtemachi 2-chome, Chiyoda-ku, Tokyo 100-0004 (JP).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CII, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF



(57) Abstract: The present invention relates to novel compounds of Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease,

hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

1

DESCRIPTION

MOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT PELATED TO THE USE THEREOF

5 FIELD OF THE INVENTION

The present invention relates to compounds which act as antagonists for MCH receptors and to the use of these compounds in pharmaceutical compositions.

BACKGROUND OF THE INVENTION

- Melanin Concentrating Hormone (MCH), a cyclic peptide, has been identified as the endogenous ligand of the orphan G-protein coupled receptor SLC-1. See, for example, Shimomura et al., Biochem. Biophys. Res. Commun. 261, 622-26 (1999). Studies have indicated that MCH acts as a neurotransmitter/neuromodulator to alter a number of behavioral responses such as feeding habits. For example, injection of MCH into rats has been reported to increase their consumption of food.
- 15 Reports indicate that genetically engineered mice which lack MCH show lower body weight and increased metabolism. See Saito et al., TEM, vol. 11, 299 (2000). As such, the literature suggests that discovery of MCH antagonists that interact with SCL-1 expressing cells will be useful in developing obesity treatments. See Shimomura et al., Biochem. Biophys. Res. Commun. 261, 622-26 (1999).

Another larger loop, composed primarily of hydrophilic amino acids, joins transmembrane helices five and six on the intracellular side of the membrane. The membrane. The carboxy terminus of the receptor lies intracellularly, and the amino terminus lies in the extracellular space. It is thought that the loop joining helices five and six, as well as the carboxy terminus, interact with the G protein. Currently, Gq, Gs, Gi, and Go are G proteins that have been identified as possible proteins that interact with the receptor.

Under physiological conditions, GPCRs exist in the cell membrane in equilibrium between

two different states or conformations: an "inactive" state and an "active" state. A receptor in an inactive state is unable to link to the intracellular transduction pathway to produce a biological response. Changing the receptor conformation to the active ctate allows linkage to the transduction pathway and produces a biological response.

5

A receptor may be stabilized in an active state by an endogenous ligand or an exogenous agonist ligand. Recent discoveries, including but not exclusively limited to, modifications to the amino acid sequence of the receptor, provide alternative mechanisms other than ligands to stabilize the active state conformation. These approaches effectively stabilize the receptor in an active state by simulating the effect of a ligand binding to the receptor. Stabilization by such ligand-independent 10 approaches is termed "constitutive receptor activation." In contrast, antagonists can competitively bind to the receptor at the same site as agonists, but do not activate the intracellular response initiated by the active form of the receptor, and therefore inhibit the intracellular responses by agonists.

Certain 2-aminoquinazoline derivatives have been reported to be NPY antagonists which are said to be effective in the treatment of disorders and diseases associated with the NPY receptor 15 subtype Y5. See PCT Patent Application 97/20823. Quinazoline derivatives have also been found to be useful by enhancing antitumor activity. See PCT Patent Application 92/07844. And also the quinoline derivatives which have an antagonist activity for MCH receptor are known in these patents, WO03/070244, WO03/105850, WO03/45313, WO03/045920, and WO04/04726.

Recently, our current knowledge of human obesity has advanced dramatically. Previously, 20 obesity was viewed as an oppugnant behavior of inappropriate eating in the setting of appealing foods. Studies of animal models of obesity, biochemical alterations in both humans and animals, and the complex interactions of psychosocial and cultural factors that create receptiveness to human obesity indicate that this disease in humans is multifaceted and deeply entrenched in biologic systems. Thus, it is almost certain that obesity has multiple causes and that there are different types of obesity. Not 25 only does MCHR1 antagonist have potent and durable anti-obesity effects in rodents, it has surprising antidepressant and anxiolytic properties as well (Borowsky et al., Nature Medicine, 8, 825-830, 2002). MCHR1 antagonists have been reported to show antidepressant and anxiolytic activities in rodent models such as social interaction, forced swimming test and ultrasonic vocalization. These findings

5

indicate that MCHR1 antagonists could be useful for treatment of obesity patients with multiple causes. Moreover, MCHR1 antagonists could be used to treat subjects not only with obesity, but also those with depression and anxiety. These advantages make it different from NPY receptor antagonists, with which anxiogenic-like activity can be expected, as NPY itself has anxiolytic-like effect.

Obesity is also regarded as a chronic disease and the possibly of long-term treatment is a concept that is receiving more attention. In this context, it is noteworthy that the depletion of MCH leads to hypophagia as well as leanness (Shimada et al., Nature, 396, 670-674, 1998). By contrast, NPY (Erickson et al., Nature, 381, 415-418, 1996), as well as the Y1 (Fedrazzini et al., Nature Medicine, 4, 722-726, 1998) and Y5 receptors (Marsh et al., Nature Medicine, 4, 718-721, 1998), 10 disrupted mice maintained a stable body weight or rather became obese. Considering the above reports, MCHR1 antagonists can be more attractive than Y1 or Y5 receptor antagonists in terms of long-term treatment of obese patients.

An increasing number of children and adolescents are overweight. Although not all overweight children will necessarily become overweight adults, the growing occurrence of obesity in 15 childhood is likely to be reflected in increasing obesity in adult years. The high prevalence of obesity in our adult population and the likelihood that the nation of the future will be even more obese demands a re-examination of the health implications of this disease. See, Health Implications of Obesity. NIH Consens. Statement Online 1985 Feb 11-13; 5(9):1-7.

"Clinical obesity" is a measurement of the excess body fat relative to lean body mass and is defined as a body weight more than 20% above the ideal body weight. Recent estimates suggest that 1 in 2 adults in the United States is clinically obese, an increase of more than 25% over the past decades. Flegal M.D. et al., 22 Int. J. Obes. Relat. Metab. Disor. 39 (1998). Both overweight conditions and clinical obesity are a major health concerns worldwide, in particular because clinical obesity is often accompanied by numerous complications, i.e., hypertension and Type II diabetes, 25 which in turn can cause coronary artery disease, stroke, late-stage complications of diabetes and premature death. (See, e.g., Nishina P.M. et al., 43 Metab. 554 (1994)).

Although the etiologic mechanisms underlying obesity require further clarification, the net effect of such mechanisms leads to an imbalance between energy intake and expenditure. Both genetic and environmental factors are likely to be involved in the pathogenesis of obesity. These include excess caloric intake, decreased physical activity, and metabolic and endocrine abnormalities.

Treatment of overweight conditions and clinical obesity via pharmaceutical agents are not only of importance with respect to the conditions themselves, but also with respect to the possibility of preventing other diseases that are associated with, e.g., clinical obesity, as well as enhancement of the positive feeling of "self" that often accompanies those who are overweight or clinically obese and who encounter a significant reduction in body weight. Given the foregoing discussion, it is apparent that compounds which help in the treatment of such disorders would be useful and would provide an advance in both research and clinical medicine. The present invention is directed to these, as well as other, important ends.

SUMMARY OF THE INVENTION

The present invention is drawn to compounds, which bind to and modulate the activity of a GPCR referred to herein as MCH, and uses thereof. The term MCH, as used herein, includes the human sequences found in GeneBank accession number NM_005297, naturally-occurring allelic variants, mammalian orthologs, biologically active fragments and recombinant mutants thereof.

One aspect of the present invention relates to certain substituted heterocyclic compounds represented by Formula (I):

wherein Q is:

5

10

25

 R_1 is selected from the group consisting of:

(i) C₁₋₈ alkyl, and

 C_{1-8} alkyl substituted by substituent(s) independently selected from the group

consisting of:

60X0,

·halogen,

•C₁₋₅ alkoxy carbonyl,

•C₁₋₅ alkoxy,

 $\bullet C_{1-5}$ alkoxy substituted by carbocyclic aryl,

•mono-C₁₋₅ alkylamino,

•mono-C₁₋₅ alkylamino substituted by carbocyclic aryl,

•di-C₁₋₅ alkylamino,

•di-C₁₋₅ alkylamino substituted by carbocyclic aryl,

•C_{1.5} alkylthio,

•C_{3.6} cycloalkyl,

•C₃₋₆ cycloalkyl substituted by C_{1-5} alkyl,

•C₃₋₆ cycloalkenyl,

•carbocyclyl,

20 •carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from

the group consisting of:

••hydroxy,

••halogen,

∘∗nitro,

∞amino,

••C₁₋₅ alkylcarbonylamino,

••C₃₋₆ cycloalkylcarbonylamino,

••carbocyclic aryl,

••C₁₋₅ alkyl,

€C₁₋₅ alkyl substituted by halogen,

°+C₁₋₅ alkylsulfonyl,

**C2-6 alkenyl,

«C1-5 alkoxy, and

••C₁₋₅ alkoxy substituted by halogen,

«mono-carbocyclic arylamino,

•mono-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:

··halogen,

••C₁₋₅ alkyl,

••C₁₋₅ alkyl substituted by halogen,

••C₁₋₅ alkoxy, and

••C₁₋₅ alkoxy substituted by halogen,

•di-carbocyclic arylamino,

•di-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:

··halogen,

••C₁₋₅ alkyl,

••C₁₋₅ alkyl substituted by halogen,

••C₁₋₅ alkoxy, and

••C₁₋₅ alkoxy substituted by halogen,

*carbocyclic aryloxy,

*carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:

••halogen,

•• C₁₋₅ alkyl,

5

10

15

20

25

••C₁₋₅ alkyl substituted by halogen, ◦•C₁₋₅ alkoxy, [∞]C₁₋₅ alkoxy substituted by halogen, and ocarbocyclic aryl, 5 chydroxy, heterocyclyl, and cheterocyclyl substituted by halogen, C₂₋₅ alkenyl, and (ii) C₂₋₅ alkenyl substituted by substituent(s) independently selected from the 10 group consisting of: oxo, and •carbocyclic aryl, C2.5 alkynyl, (iii) C₃₋₁₂ cycloalkyl, and (iv) 15 C₃₋₁₂ cycloalkyl substituted by carbocyclic aryl, (v) carbocyclyl, and carbocyclyl substituted by substituent(s) independently selected from the group consisting of: ·hydroxy, and 20 ·carbocyclic aryl, (vi) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: ·halogen, 25 «cyano, •nitro, •amino, •C₁₋₁₀ alkyl,

•C₁₋₁₀ alkyl substituted by substituent(s) independently selected from the group consisting of: ⇔halogen, eeono, and 5 **carbocyclic aryl, ·carboxy, C₁₋₅ alkoxy carbonyl, •C₁₋₇ alkoxy, •C₁₋₇ alkoxy substituted by substituent(s) independently selected from the 10 group consisting of: ··halogen, and ••carbocyclic aryl, •C₃₋₆ cycloalkoxy, •carbocyclic aryloxy, •carbocyclic aryloxy substituted by substituent(s) independently selected 15 from the group consisting of: ••halogen, ··nitro, ••C₁₋₅ alkyl, 20 ••C₁₋₅ alkyl substituted by halogen, ••C₁₋₅ alkoxy, and ••C₁₋₅ alkoxy substituted by halogen, •heterocyclyloxy, •heterocyclyloxy substituted by substituent(s) independently selected from 25 the group consisting of: ··halogen, ••nitro, ••C₁₋₅ alkyl,

••C₁₋₅ alkyl substituted by halogen, ..•C₁₋₅ alkoxy, and «C1-5 alkony substituted by halogen, emono-C₁₋₅ alkylamino, 5 ·di-C₁₋₅ alkylamino, ^eC₁₋₅ alkylcarbonylamino, •C₃₋₆ cycloalkylcarbonylamino, °C₁₋₅ alkoxy carbonylamino, ·carbocyclic aryl azo, 10 •carbocyclic aryl azo substituted by substituent(s) independently selected from the group consisting of: ••mono-C₁₋₅ alkylamino, and ••di-C₁₋₅ alkylamino, •C₁₋₅ alkylthio, 15 •C₁₋₅ alkylthio substituted by halogen, ·carbocyclic arylthio, •carbocyclic arylthio substituted by nitro, •amino sulfonyl, •heterocyclyl sulfonyl, 20 •C₃₋₆ cycloalkyl, • C_{3-6} cycloalkyl substituted by C_{1-5} alkyl, ·carbocyclic aryl, •carbocyclic aryl substituted by C₁₋₅ alkoxy, •hydroxy, 25 •heterocyclyl, and •heterocyclyl substituted by C₁₋₅ alkyl, (vii) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the

group consisting of: ·halogen, ${}^{\circ}C_{1-5}$ alkyl, °C₁₋₅ alkyl substituted by halogen, 5 •C₁₋₅ alkoxy, °C₁₋₅ alkoxy substituted by halogen, •C₁₋₅ alkoxy carbonyl, •C₁₋₅ alkoxy carbonyl substituted by carbocyclic aryl, •carbocyclic aryloxy, •carbocyclic aryloxy substituted by substituent(s) independently selected 10 from the group consisting of: ··halogen, ••nitro, ••cyano, 15 ••hydroxy, ••C₁₋₅ alkyl, ••C_{1.5} alkyl substituted by halogen, ••mono-C₁₋₅ alkylamino, ••di-C₁₋₅ alkylamino, ••C₁₋₅ alkylcarbonylamino, 20 ••C₃₋₆ cycloalkylcarbonylamino, •• C_{1-5} alkoxy, ••C₁₋₅ alkoxy substituted by halogen, «C₃₋₆ cycloalkyl, 25 ∞C₂₋₅ alkenyl, «C2-5 alkynyl, ••carboxy,

••C₁₋₅ alkoxycarbonyl,

••mono-C₁₋₅ alkylaminocarbonyl, «di-C₁₋₅ alkylaminocarbonyl, «mono-C₂₋₆ cycloalkylaminocarbonyl, «di-C3-6 cycloalkylaminocarbonyl, 5 ∞mono-C₁₋₅ alkylaminocarbonylamino, «di-C₁₋₅ alkylaminocarbonylamino, «mono-C₃₋₆ cycloalkylaminocarbonylamino, ••di-C₃₋₆ cycloalkylaminocarbonylamino, ••C₁₋₅ alkylthio, 10 ••C₁₋₅ alkylthio substituted by halogen, ••C₁₋₅ alkylsulfinyl, ••C₁₋₅ alkylsulfinyl substituted by halogen, ••C₁₋₅ alkylsulfonyl, and ••C₁₋₅ alkylsulfonyl substituted by halogen, 15 •heterocyclyloxy, •heterocyclyloxy substituted by substituent(s) independently selected from the group consisting of: ••halogen, ••nitro, 20 •• C_{1-5} alkyl, ••C₁₋₅ alkyl substituted by halogen, ••C₁₋₅ alkoxy, and ••C₁₋₅ alkoxy substituted by halogen, *carbocyclic aryl, and 25 *heterocyclyl; R_2 is C_{1-5} alkyl or $-N(R_{2a})(R_{2b})$; wherein R_{2a} and R_{2b} are independently hydrogen or C₁₋₅ alkyl,

 R_3 is C_{1-5} alkyl;

 R_4 is -NHNH₂, -NHNHBoc, -N(R_{4a})(R_{4b}), morpholino, 4-acetyl-piperazyl, or 4-phenyl-piperazyl; wherein R_{4a} is hydrogen or C_{1-5} alkyl; R_{4b} is C_{1-5} alkyl, C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

·hydroxy,

 $^{\circ}$ 5 •C₁₋₅ alkoxy,

eamino,

·-NHBoc,

*C₃₋₆ cycloalkyl,

•carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

••C₁₋₅ alkyl,

••C₁₋₅ alkoxy, and

••-SO₂NH₂, and

•heterocyclyl,

 C_{3-6} cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

·halogen,

•C₁₋₅ alkyl,

•C₁₋₅ alkoxy, and

a group of Formula (III):

25

10

15

20

5

substituted by substituent(s) independently selected from the group consisting of:

- ecarbocyclic aryl,
- halogenated carbocyclic aryl, and
- *carbocyclic aryl substituted by C_{1-5} alkoxy;

L is selected from the group consisting of Formulae (IV) to (XIX):

wherein R_5 and R_6 are independently hydrogen or C_{1-5} alkyl; and A and B are independently a single bond, $-CH_2$ -, or $-(CH_2)_2$ -;

 X_1, X_2, X_3 and X_4 are independently selected from the group consisting of hydrogen, halogen, C_{1-4} alkyl, C_{1-4} alkyl substituted by halogen, C_{1-4} alkylthio, C_{1-4} alkylsulfinyl,

 C_{14} alkylsulfonyl, C_{14} alkoxy, C_{14} alkoxy substituted by halogen, nitro, amino, mono- C_{14} alkylamino, di- C_{14} alkylamino, piperidyl, morpholinyl, mono- C_{14} alkylaminosulfonyl and hydroxy; provided that at least one substituent selected from the group consisting of X_1 , X_2 , X_3 and X_4 is not hydrogen;

and

Y is selected from the group consisting of:

- (i) -C(O)NR₇-, -C(S)NR₇-, or -C(O)O- when L is selected from the group consisting of Formulae (IV) to (XIX); wherein R₇ is hydrogen or C₁₋₅ alkyl;
- -S(O)₂-, -C(O)-, a single bond or -CH₂- when L is selected from the group consisting of Formulae (IV) to (XI), and Q is Formula (IIa) or (IIb);
- (iii) -S(O)₂-, -C(O)-, a single bond or -CH₂- when L is selected from the group consisting of Formulae (VII) to (XI), and Q is Formula (IIc); and
- (iv) -OC(O)- when L is selected from the group consisting of Formulae (XII) to (XIX);

wherein carbocyclic aryl is phenyl, naphthyl, or biphenyl; carbocyclyl is indanyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, adamantly, 9*H*-fluorenyl, menthyl, 1,2,3,4-tetrahydro-naphthalen-1-yl, or 1*H*-indolyl;

heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl,

3,4-dihydro-2*H*-benzo[b][1,4]dioxepinyl, 4,5,6,7-tetrahydro-benzo[b]thienyl, 4*H*-benzo[1,3]dioxinyl, benzo[1,3]dioxolyl, benzo[2,1,3]thiadiazolyl, benzothiazolyl, furyl, isoxazolyl, morpholinyl, oxazolyl, piperidyl, pyrazolyl, pyridyl, tetrahydrofuryl, thienyl, dibenzofuranyl, 1*H*-benzoimidazolyl, or thiazolyl; and

halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate or solvate thereof.

One aspect of the present invention pertains to pharmaceutical compositions comprising at least one compound, as described herein, in combination with a pharmaceutically acceptable carrier.

10

5

15

20

25

One aspect of the present invention pertains to methods for the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction comprising administering to an individual suffering from said condition a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition thereof.

One aspect of the present invention pertains to methods for the prophylaxis or treatment of an eating disorder, obesity or an obesity related disorder comprising administering to an individual suffering from the condition a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition thereof.

One aspect of the present invention pertains to methods for the prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy comprising administering to an individual suffering from the condition a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition.

One aspect of the present invention pertains to compounds of the present invention, as described herein, or a pharmaceutical composition thereof, for use in a method of treatment of the human or animal body by therapy.

One aspect of the present invention pertains to compounds of the present invention, as described herein, or a pharmaceutical composition thereof, for use in a method of prophylaxis or treatment of an eating disorder, obesity or an obesity related disorder of the human or animal body by therapy.

One aspect of the present invention pertains to compounds of the present invention, as

described herein, or a pharmaceutical composition thereof, for use in a method of prophylaxis or
treatment of anxiety, depression, schizophrenia, addiction, or epilepsy of the human or animal body
by therapy.

One aspect of the present invention pertains to compounds of the present invention, as

described herein, for the manufacture of a medicament for use in the prophylaxis or treatment of an eating disorder, obesity or obesity related disorders.

One aspect of the present invention pertains to compounds of the present invention, as described herein, for the manufacture of a medicament for use in the prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy.

One aspect of the present invention pertains to methods of decreasing food intake of an individual comprising administering to the individual a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition thereof.

One aspect of the present invention pertains to methods of inducing satiety in an individual comprising administering to said individual a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition thereof.

One aspect of the present invention pertains to methods of controlling or reducing weight gain in an individual comprising administering to said individual a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition thereof.

One aspect of the present invention pertains to methods of modulating a MCH receptor in an individual comprising contacting the receptor with a compound, as described herein. In some embodiments, the compound is an antagonist. In some embodiments, the modulation of the MCH receptor is for the prophylaxis or treatment of an eating disorder, obesity or obesity related disorder. In some embodiments, the modulation of the MCH receptor reduces food intake of the individual. In some embodiments, the modulation of the MCH receptor induces satiety in the individual. In some embodiments, the modulation of the MCH receptor controls or reduces weight gain of the individual. In some embodiments, the modulation of the MCH receptor is for prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy.

In some embodiments, the individual is a mammal.

In some embodiments, the mammal is a human.

In some embodiments, the human has a body mass index of about 18.5 to about 45. In some embodiments, the human has a body mass index of about 25 to about 45. In some embodiments, the human has a body mass index of about 30 to about 45. In some embodiments, the human has a body

WO 2004/087680 PCT/JP2004/004554

17

mass index of about 35 to about 45.

One aspect of the present invention pertains to methods of producing a pharmaceutical composition comprising admixing a compound, as described herein, and a pharmaceutically acceptable carrier.

This application claims priority to US Provisional Patent Application, Serial No. 60/458,424, filed March 31, 2003; and is incorporated herein by reference in its entirety.

DETAILED DESCRIPTION OF THE INVENTION

One aspect of the present invention relates to certain substituted heterocyclic compounds

10 represented by Formula (I):

$$Q \setminus_{L} Y \setminus_{R_1}$$

or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein Q, L, Y, and R_1 are as described herein, supra and infra.

It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment.

Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.

- In some embodiments of the present invention, Q is Formulae (IIa), (IIb), or (IIc);

 R₁ is selected from the group consisting of:
 - (i) C₁₋₈ alkyl, and
 C₁₋₈ alkyl substituted by substituent(s) independently selected from the group consisting of:

		•C ₁₋₅ alkoxy substituted by carbocyclic aryl,
		°mono-C ₁₋₅ alkylamino,
		°di-C ₁₋₅ alkylamino,
		°C ₃₋₆ cycloalkyl,
5		°C ₃₋₆ cycloalkenyl,
		·carbocyclyl,
		carbocyclic aryl,
		*carbocyclic aryl substituted by substituent(s) independently selected from
		the group consisting of:
10		••hydroxy,
		••halogen,
		••nitro,
		••C ₁₋₅ alkylcarbonylamino,
		••C ₃₋₆ cycloalkylcarbonylamino,
15		••C ₁₋₅ alkyl,
		••C ₁₋₅ alkyl substituted by halogen,
		••C ₁₋₅ alkylsulfonyl,
		••C ₂₋₆ alkenyl,
		••C ₁₋₅ alkoxy,
20		••C ₁₋₅ alkoxy substituted by halogen, and
		••carbocyclic aryl,
		•heterocyclyl, and
		•heterocyclyl substituted by halogen,
	(ii)	C ₂₋₅ alkenyl, and
25		C ₂₋₅ alkenyl substituted by carbocyclic aryl,
	(iii)	C ₂₋₅ alkynyl,
	(iv)	C ₃₋₁₂ cycloalkyl, and
		C ₃₋₁₂ cycloalkyl substituted by carbocyclic aryl,

	(v)	carbocyclyl, and
		carbocyclyl by substituent(s) independently selected from the group
		consisting of:
		·hydroxy, and
5		«carbocyclic aryl,
	(vi)	carbocyclic aryl, and
		carbocyclic aryl substituted by substituent(s) independently selected from the
		group consisting of:
		•halogen,
10		•cyano,
		•nitro,
		•C ₁₋₁₀ alkyl,
•		${}^{ullet}C_{110}$ alkyl substituted by substituent(s) independently selected from the
		group consisting of:
15		••halogen,
		••oxo, and
		••carbocyclic aryl,
		•carboxy,
		•C ₁₋₅ alkoxy carbonyl,
20		•C ₁₋₇ alkoxy,
		•C ₁₋₇ alkoxy substituted by substituent(s) independently selected from the
		group consisting of:
		••halogen, and
		**carbocyclic aryl,
25		*carbocyclic aryloxy,
		•carbocyclic aryloxy substituted by nitro,
		•mono-C ₁₋₅ alkylamino,
		•di-C ₁₋₅ alkylamino,

•C₁₋₅ alkoxy carbonylamino, *carbocyclic aryl azo, ocarbocyclic aryl azo substituted by substituent(s) independently selected from the group consisting of: 5 «mono-C₁₋₅ alkylamino, and **di-C₁₋₅ alkylamino, ∘C₁₋₅ alkylthio, •C₁₋₅ alkylthio substituted by halogen, •carbocyclic arylthio, 10 •carbocyclic arylthio substituted by nitro, •amino sulfonyl, ·heterocyclyl sulfonyl, •C₃₋₆ cycloalkyl, • C_{3-6} cycloalkyl substituted by C_{1-5} alkyl, 15 •carbocyclic aryl, ·heterocyclyl, and •heterocyclyl substituted by C_{1-5} alkyl, heterocyclyl, and (vii) heterocyclyl substituted by substituent(s) independently selected from the 20 group consisting of: ·halogen, •C₁₋₅ alkyl, •C₁₋₅ alkyl substituted by halogen, •C₁₋₅ alkoxy, 25 ∘C₁₋₅ alkoxy carbonyl, *C₁₋₅ alkoxy carbonyl substituted by carbocyclic aryl, ·carbocyclic aryloxy,

·carbocyclic aryl, and

•heterocyclyl;

 R_2 is $-N(R_{2a})(R_{2b})$, wherein R_{2a} is hydrogen or C_{1-5} alkyl; R_{2b} is C_{1-5} alkyl;

 R_3 is C_{1-5} alkyl;

 R_4 is $-N(R_{4a})(R_{4b})$ wherein R_{4a} is hydrogen or C_{1-5} alkyl; R_{4b} is C_{1-5} alkyl;

L is selected from Formula (V), (VIII), (IX), (XIII), (XVI), or (XVII);

 X_1, X_2, X_3 and X_4 are independently selected from the group consisting of hydrogen, halogen, and C₁₋₄ alkyl; provided that at least one substituent selected from the group consisting of X_1 , X_2 , X_3 and X_4 is not hydrogen; and

Y is selected from the group consisting of:

10

15

5

- $-C(O)NR_{7-}$, $-C(S)NR_{7-}$, or -C(O)O- when L is selected from the group (i) consisting of Formula (V), (VIII), (IX), (XIII), (XVI), or (XVII); wherein R₇ is hydrogen or C₁₋₅ alkyl;
- -S(O)₂-, -C(O)-, a single bond or -CH₂- when L is selected from the group (ii) consisting of Formula (VIII) or (IX); and

1H-indolyl;

-OC(O)- when L is selected from the group consisting of Formula (XIII), (iii) (XVI), or (XVII);

wherein carbocyclic aryl is phenyl or naphthyl; carbocyclyl is indanyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, adamantly, 9H-fluorenyl, menthyl, 1,2,3,4-tetrahydro-naphthalen-1-yl, or

20

heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl,

3,4-dihydro-2*H*-benzo[b][1,4]dioxepinyl, 4,5,6,7-tetrahydro-benzo[b]thienyl, 4H-benzo[1,3]dioxinyl, benzo[1,3]dioxolyl, benzo[2,1,3]thiadiazolyl, benzothiazolyl, furyl, isoxazolyl, morpholinyl, oxazolyl, piperidyl, pyrazolyl, pyridyl, tetrahydrofuryl, thienyl, dibenzofuranyl, 1H-benzoimidazolyl, or thiazolyl; and

25

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments of the present invention, Q is Formula (IIc) and can be represented by

the following formula:

5 or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R_4 , L, Y, and R_1 are as described herein, supra and infra.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

(i) C_{1-5} alkyl, and

C₁₋₅ alkyl substituted by substituent(s) independently selected from the group

consisting of:

•C₁₋₅ alkoxy carbonyl,

·carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

15

10

••halogen,

•• C_{1-5} alkyl,

••C₂₋₅ alkenyl, and

•• C_{1-5} alkoxy,

•C₁₋₅ alkylthio, and

20

•heterocyclyl,

(ii) C₃₋₆ cycloalkyl, and

C_{3.6} cycloalkyl substituted by carbocyclic aryl,

- (iii) carbocyclyl,
- (iv) carbocyclic aryl, and

25 carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

•halogen, ecyano, onitro, •C₁₋₅ alkyl, 5 °C₁₋₅ alkyl substituted by substituent(s) independently selected from the group consisting of: ∞halogen, "oxo, and ··carbocyclic aryl, 10 •C₁₋₅ alkoxy carbonyl, •C₁₋₇ alkoxy, ${}^{ullet}C_{1-7}$ alkoxy substituted by substituent(s) independently selected from the group consisting of: ··halogen, and 15 ··carbocyclic aryl, ·cycloalkoxy, carbocyclic aryloxy, •mono-C₁₋₅ alkylamino, •di-C₁₋₅ alkylamino, 20 •C₁₋₅ alkylthio, •C₁₋₅ alkylthio substituted by halogen, ·carbocyclic aryl, ·heterocyclyl, and •heterocyclyl substituted by C₁₋₅ alkyl, 25 (v) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: ·halogen,

•C₁₋₅ alkyl, ∘C₁₋₅ alkyl substituted by halogen, C₁₋₅ alkoxy carbonyl *C₁₋₅ alkoxy carbonyl substituted by carbocyclic aryl, and 5 ocarbocyclic aryl; L is Formula (V); and Y is $-C(O)NR_7$; wherein R_7 is hydrogen or C_{1-5} alkyl; wherein carbocyclic aryl is phenyl or naphthyl; 10 carbocyclyl is indanyl, adamantly, or 9H-fluorenyl; heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, 3,4-dihydro-2*H*-benzo[b][1,4]dioxepinyl, 4*H*-benzo[1,3]dioxinyl, benzo[1,3]dioxolyl, benzothiazolyl, furyl, isoxazolyl, piperidyl, pyridyl, or thienyl; and 15 halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate or solvate thereof. In some embodiments of the present invention, R_{4a} is hydrogen or methyl; R_{4b} is methyl; R₅ and R₆ are hydrogen; A is a single bond and B is a single bond or -CH₂-; and R₇ is hydrogen; or a pharmaceutically acceptable salt, hydrate or solvate thereof. 20 In some embodiments of the present invention, R_1 is selected from the group consisting of: (i) C₁₋₅ alkyl, and

(i) C₁₋₅ alkyl, and

C₁₋₅ alkyl substituted by substituent(s) independently selected from the group consisting of:

•C₁₋₅ alkoxy carbonyl,

•carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••halogen,

5

••C₁₋₅ alkyl,

 $^{\circ\circ}C_{2\text{--}5}$ alkenyl, and

 $^{\circ\circ}C_{1-5}$ alkowy,

°C₁₋₅ alkylthio, and

heterocyclyl,

(ii) $C_{3.6}$ cycloalkyl, and $C_{3.6}$ cycloalkyl substituted by carbocyclic aryl,

- (iii) carbocyclyl,
- (iv) carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

- ·halogen,
- •cyano,
- •nitro,

15 •C₁₋₅ alkyl,

- •C₁₋₅ alkyl substituted by halogen,
- $\cdot C_{1-5}$ alkoxy carbonyl,
- \cdot C₁₋₅ alkoxy,
- •C₁₋₅ alkoxy substituted by halogen,

20 •cycloalkoxy,

- •carbocyclic aryloxy,
- ${}^{ullet}C_{1-5}$ alkylthio, and
- •carbocyclic aryl,

(v) heterocyclyl, and

25 heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

- ·halogen,
- •C₁₋₅ alkyl,

•C₁₋₅ alkyl substituted by halogen, and carbocyclic aryl; wherein carbocyclic aryl is phenyl or naphthyl; carbocyclyl is 9H-fluorenyl; 5 heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl, 4H-benzo[1,3]dioxinyl, benzo[1,3]dioxolyl, furyl, isoxazolyl, or thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate or solvate thereof. 10 In some embodiments of the present invention, R_1 is selected from the group consisting of: (i) C₁₋₅ alkyl, and C₁₋₅ alkyl substituted by substituent(s) independently selected from the group consisting of: •C₁₋₅ alkoxy carbonyl, 15 ·carbocyclic aryl, •carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: ··halogen, ••C₁₋₅ alkyl, and 20 ••C₂₋₅ alkenyl, $\cdot C_{1-5}$ alkylthio, C₃₋₆ cycloalkyl, and (ii) C₃₋₆ cycloalkyl substituted by carbocyclic aryl, (iii) carbocyclic aryl, and 25 carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: ·halogen,

·cyano,

•nitro, ∘C₁₋₅ alkyl, °C₁₋₅ alkyl substituted by halogen, °C₁₋₅ alkoxy carbonyl, 5 *C₁₋₅ alkoxy, ecycloalkoxy, *carbocyclic aryloxy, ^eC₁₋₅ alkylthio, and •carbocyclic aryl, 10 heterocyclyl, and (iv) heterocyclyl substituted by substituent(s) independently selected from the group consisting of: $\cdot C_{1-5}$ alkyl, •C₁₋₅ alkyl substituted by halogen, and 15 •carbocyclic aryl; wherein carbocyclic aryl is phenyl or naphthyl; heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, 3,4-dihydro-2*H*-benzo[b][1,4]dioxepinyl, benzo[1,3]dioxolyl, furyl, or isoxazolyl; and 20 halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

N-benzyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(2-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;
N-biphenyl-2-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;
N-(4-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;
N-butyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

urea;

10 urea;

 $N-cyclohexyl-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)urea; \\ N-(2-chlorophenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)urea; \\ N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2.6-dimethylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyc$

5 N-(2,4-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-urea;

 $N-(2,4-dichlorophenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ eyelohexyl)-urea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,3-dimethylphenyl)-

ethyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}-amino)benzoate;

ethyl 4-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}-amino)benzoate;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-ethylphenyl)urea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethyl-6-methylphenyl)urea;

ethyl N-{[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}-leucinate;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(4-fluorophenyl)urea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-[1-(3-isopropenylphenyl)-1-methylethyl]urea;

 $methyl\ N-\{[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)amino]carbonyl\}-methioninate;$

25 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(4-methoxyphenyl)-urea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2-methoxyphenyl)-urea;\\$

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(3-methoxyphenyl)-urea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-{4-(methylthio)-phenyl]urea;

5 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(4-methoxybenzyl)-urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-1-naphthylurea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[(2S)-2-phenylcyclopropyl]urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-phenylurea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-phenoxyphenyl)-urea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclohexyl)-N'-pentylurea; \\ N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino}\ cyclohexyl)-N'-[2-(trifluoromethyl)-N'-[2-(trifluoromethyl)-N'-pentylurea;]$

15 phenyl]urea;

20

urea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(4-methylphenyl)urea; \\ N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-mesitylurea; \\ N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(3-methylphenyl)urea; \\ N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2-methylphenyl)urea; \\ N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-[1-(1-naphthyl)ethyl]-N'-(1-naphthyl)ethyl$

methyl N-{[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}-phenylalaninate;

 $N\hbox{-}(cis-4\hbox{-}\{[4\hbox{-}(dimethylamino)quinazolin-2\hbox{-}yl]amino})\,cyclohexyl)\hbox{-}N'\hbox{-}(2,4,6\hbox{-}wl)$

25 trichlorophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(1-phenylethyl)urea;
1-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3-(1-phenyl-ethyl)-urea;
1-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3-(1-naphthalen-1-yl-ethyl)-urea;

WO 2004/087680 PCT/JP2004/004554

30

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[2-(methylthio)-

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ eyelohexyl)-N'-(2,3,5,6-tetrachlorophenyl)urea;$

phenyl]urea;

5 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,3-dimethyl-6-nitrophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2,4,6-tribromophenyl)urea;

N-(2,4-dibromo-6-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}10 cyclohexyl)urea;

 $N-(2,4-dibromophenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclohexyl)-urea;$

N-(2,4-dichlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-urea;

N-(2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

 $N-(2,5-dimethoxyphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)urea;$

 $N-(2,6-diethylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)-20 \quad urea;$

 $N-(2-chloro-5-nitrophenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)urea;$

N-[2-chloro-6-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]-amino}cyclohexyl)urea;

25 N-(2-chloro-6-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

N-(2-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea; N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethoxyphenyl)urea; $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2-ethyl-6-isopropylphenyl)urea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-fluorobenzyl)urea;

5 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-iodophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-isopropyl-6-methylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-isopropylphenyl)-urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxy-4-nitrophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxy-5-methylphenyl)urea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2-methyl-3-yl)-N'-(2$

15 nitrophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methyl-4-nitrophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methyl-5-nitrophenyl)urea;

- N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methylbenzyl)urea;
 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-nitrophenyl)urea;
 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-propylphenyl)urea;
 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-phenoxyphenyl)urea;
- 25 N-(2-tert-butyl-6-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

 $N-(2-tert-butylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-urea;\\$

- $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-[3-(methylthio)-phenyl]urea;$
- N-1,3-benzodioxol-5-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-urea;
- 5 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3,4,5-trimethoxyphenyl)urea;
 - N-(3,4-dichlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-urea:
- N-(3,4-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-10 urea;
 - $N-(3,4-dimethoxyphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)urea;\\$
 - N-(3,5-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-urea;
- N-(3,5-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;
 - $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(3,5-dimethylphenyl)-urea;$
- methyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}-
- 20 amino)benzoate;
 - $N-(3-chloro-2-methylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)urea;$
 - N-(3-chloro-4-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;
- 25 N-(3-chloro-4-methoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;
 - N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3-ethylphenyl)urea; N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3-fluorobenzyl)urea;

 $N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)urea;$

N-(4-bromo-2,6-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

5 N-(4-bromobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea; N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

 $N-(4-chloro-2-methylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)urea;$

N-(4-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-ethoxyphenyl)urea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-fluoro-2-nitrophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(4-fluorobenzyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(4-iodophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(4-methoxy-2-methylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(4-methylbenzyl)urea;
N-(5-chloro-2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-20 cyclohexyl)urea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(5-fluoro-2-methylphenyl) urea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-9H-fluoren-9-ylurea; N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-phenylethyl)urea;

N-cyclopentyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(diphenylmethyl)urea;
N-[1-(4-bromophenyl)ethyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

- N-(4-bromo-2,6-dimethylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;
- $N-(4-bromo-2-methylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)urea;\\$
- 5 ethyl N-{[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}-phenylalaninate;
 - $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ eyelohexyl)-N'-[2-(2-thienyl)ethyl]-urea;$
- N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-10 yl]amino}cyclohexyl)urea;
 - N-(2,6-dibromo-4-isopropylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;
 - N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;
- N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;
 - N-(4-butyl-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;
 - N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[5-methyl-2-
- 20 (trifluoromethyl)-3-furyl]urea;
 - N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(6-fluoro-4H-1,3-benzodioxin-8-yl)urea;
 - $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(3,5-dimethylisoxazol-4-yl)urea;$
- 25 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(3-methyl-5-phenylisoxazol-4-yl)urea;
 - $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(5-methyl-3-phenylisoxazol-4-yl)urea;$

N-(2-bromophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;

N-biphenyl-2-yl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohenyl)methyl]-urea;

N-butyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;
N-(3-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;

N-cyclohexyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-urea;

10 N-(3-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;

N-(2-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,6-15 dimethylphenyl)urea;

N-(3,4-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;

N-(2,4-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;

N-(2,4-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-methyl]urea;

 $N-(3,5-dichlorophenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)-methyl]urea;$

N-(2,3-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-25 methyl]urea;

 $N-(2,6-difluor ophenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ eyclohexyl)-methyl] urea;$

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(2,3-yl)amino)cyclohexyl)methyllamino(cyclohexyl)me$

36

WO 2004/087680 PCT/JP2004/004554

dimethylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-ethylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethyl-6-5 methylphenyl)urea;

 $ethyl\ N-(\{[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]amino\}-carbonyl)leucinate;$

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) methyl]-N'-(4-fluorophenyl) urea;$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-fluorophenyl)urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(2-fluorophenyl)urea;$

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl) methyl]-N'-[1-(3-yl]amino]cyclohexyl) methyll-N'-[1-(3-yl]amino]cyclohexyl) methyll-N'-[1-(3-yl]amino]cyclohexyll$

15 isopropenylphenyl)-1-methylethyl]urea;

 $methyl\ N-(\{[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]amino\}-carbonyl)methioninate;$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-methoxyphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-methyl-2-nitrophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methoxyphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-25 methoxyphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[4-(methylthio)phenyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-1-

naphthylurea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-phenylurea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-pentylurea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[2-

5 (trifluoromethyl)phenyl]urea;

 $N-\{(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) methyl]-N'-(4-methylphenyl) urea;$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-mesitylurea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-

10 methylphenyl)urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) methyl]-N'-(2-methylphenyl) urea;$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,4,6-trichlorophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(1-phenylethyl)urea;

 $1\hbox{-}[4\hbox{-}(4\hbox{-}dimethylamino-quinazolin-2-ylamino})\hbox{-}cyclohexylmethyl]\hbox{-}3\hbox{-}(1\hbox{-}phenyl-ethyl)\hbox{-}urea;$

1-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-3-(1-naphthalen-1-ylethyl)-urea;

20 N-(2,6-diisopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

 $N-[2-(difluoromethoxy)phenyl]-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)methyl]urea;$

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-[2-yl]amino]cyclohexyl)methyl]-N'-[2-yl]amino]cyclohexyl)methyl]-N'-[2-yl]amino]cyclohexyl)methyl]-N'-[2-yl]amino]cyclohexyl)methyl]-N'-[2-yl]amino]cyclohexyl)methyl]-N'-[2-yl]amino]cyclohexyl)methyl]-N'-[2-yl]amino]cyclohexyl)methyl]-N'-[2-yl]amino]cyclohexyl)methyl]-N'-[2-yl]amino]cyclohexyl)methyl]-N'-[2-yl]amino]cyclohexyl)methyl]-N'-[2-yl]amino]cyclohexyl)methyl]-N'-[2-yl]amino]cyclohexyl]-N'-[2-y$

25 (methylthio)phenyl]urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) methyl]-N'-(2,3,5,6-tetrachlorophenyl) urea;\\$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,3-dimethyl-

6-nitrophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,4,6-tribromophenyl)urea;

N-(2,4-dibromo-6-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-5 cyclohexyl)methyl]urea;

N-(2,4-dichlorobenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;

 $N-(2,5-dimethoxyphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)methyl]urea;\\$

N-(2,6-dibromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

 $N-(2,6-dichlorophenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)-methyl]urea;\\$

N-(2,6-diethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)15 methyl]urea;

 $N-(2-chloro-5-methylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)methyl]urea;\\$

 $N-[2-chloro-6-(trifluoromethyl)phenyl]-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]-amino\}cyclohexyl)methyl]urea;$

N-(2-chloro-6-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

N-(2-chlorobenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethyl-6-25 isopropylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethylphenyl)urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(2-fluoro-5-yl)amino)cyclohexyl)methyllamino)cyclohexyllamino)cyc$

nitrophenyl)urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) methyl]-N'-(2-fluorobenzyl) urea;$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-

5 iodophenyl)urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) methyl]-N'-(2-isopropyl-6-methylphenyl) urea;\\$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-isopropylphenyl)urea;

10 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methoxy-5-methylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methoxy-5-nitrophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methyl-3-nitrophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methyl-4-nitrophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methyl-5-nitrophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methyl-6-nitrophenyl)urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)methyl]-N'-(2-methylbenzyl)urea;$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-(2-

25 nitrophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-propylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-

phenoxyphenyl)urea;

N-(2-tert-butyl-6-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

N-(2-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-5 methyl]urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)methyl]-N'-[3-(methylthio)phenyl]urea;$

 $N-(3,4-difluor ophenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-methyl]urea;$

10 N-(3,5-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;

 $N-(3,5-dimethoxyphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)methyl]urea;\\$

N-(3-chloro-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-15 cyclohexyl)methyl]urea;

 $N-(3-chloro-4-fluorophenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)methyl]urea;$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-ethylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[3-fluoro-5-(trifluoromethyl)phenyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-fluorobenzyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4,5-dimethyl-25 2-nitrophenyl)urea;

N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

 $N-(4-bromo-2,6-difluor ophenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-1]-(dimethylamino)quinazolin-2-yl]-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-1]-(dimethylamino)quinazolin-2-yl]-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-1]-(dimethylamino)quinazolin-2-yl]-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-1]-(dimethylamino)quinazolin-2-yl]-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-1]-(dimethylamino)quinazolin-2-yl]-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]-1]-(dimethylamino)quinazolin-2-yl]-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]-1]-(dimethylamino)quinazolin-2-yl]-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]-1]-(dimethylamino)quinazolin-2-yl]-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]-1]-(dimethylamino)quinazolin-2-yl]-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]-1]-(dimethylamino)quinazolin-2-yl]-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]-1]-(dimethylamino)quinazolin-2-yl]-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]-1]-(dimethylamino)quinazolin-2-yl]-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]-1]-(dimethylamino)quinazolin-2-yl]-(dimethy$

cyclohexyl)methyl]urea;

N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(4-chloro-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

5 cyclohexyl)methyl]urea;

N-(4-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-fluoro-2-nitrophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-fluorobenzyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-iodophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-methoxy-2-methylphenyl)urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(4-methyl-3-nitrophenyl)urea;\\$

 $N-(5-chloro-2-methylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)methyl]urea;$

20 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(5-fluoro-2-methylphenyl)urea;

N-cyclopentyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-1-2-yl]amino]cyclohexyl)methyl]-N'-1-2-yl]amino]cyclohexyl)methyl]-N'-1-2-yl]amino]cyclohexyl)methyl]-N'-1-2-yl]amino]cyclohexyl)methyl]-N'-1-2-yl]amino]cyclohexyl)methyl]-N'-1-2-yl]amino]cyclohexyl)methyl]-N'-1-2-yl]amino]cyclohexyl)methyl]-N'-1-2-yl]amino]cyclohexyl)methyl]-N'-1-2-yl]amino]cyclohexyl)methyl]-N'-1-2-yl]amino]cyclohexyl)methyl]-N'-1-2-yl]amino]cyclohexyl)methyl]-N'-1-2-yl]amino]cyclohexyl)methyl]-N'-1-2-yl]amino]cyclohexyl)methyl]-N'-1-2-yl]amino]cyclohexyl)methyl]-N'-1-2-yl]amino]cyclohexyl)methyl]-N'-1-2-yl]amino]cyclohexyl)methyl]-N'-1-2-yl]amino]cyclohexyl)methyl]-N'-1-2-yl]amino]cyclohexyl)methyl]-N'-1-2-yl]amino]cyclohexyl)methyl]-N'-1-2-yl]amino[cyclohexyl]amino[c$

25 (diphenylmethyl)urea;

N-(4-bromo-2,6-dimethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

N-(4-bromo-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

cyclohexyl)methyl]urea;

N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-3-thienylurea;

5 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[5-methyl-2-(trifluoromethyl)-3-furyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(6-fluoro-4H-1,3-benzodioxin-8-yl)urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(3,5-1)-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(3,5-1)-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(3,5-1)-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(3,5-1)-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(3,5-1)-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(3,5-1)-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(3,5-1)-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(3,5-1)-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(3,5-1)-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl)-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl)-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl)-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl)-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexylamino]cyclohexylamino[cis-4-(dimethylamino)quinazolin-2-yl]amino[cis-4-(dimethylamino)quinazolin-2-yl]amino[cis-4-(dimethylamino)quinazolin-2-yl]amino[cis-4-(dimethylamino)quinazolin-2-yl]amino[cis-4-(dimethylamino)quinazolin-2-yl]amino[cis-4-(dimethylamino)quinazolin-2-yl]amino[cis-4-(dimethylamino)quinazolin-2-yl]amino[cis-4-(dimethylamino)quinazolin-2-yl]amino[cis-4-(dimethylamino)quinazolin-2-yl]amino[cis-4-(dimet$

10 dimethylisoxazol-4-yl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methyl-5-phenylisoxazol-4-yl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(5-methyl-3-phenylisoxazol-4-yl)urea; and

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[3-(trifluoromethoxy)-phenyl]urea;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

N-(2-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;
N-biphenyl-2-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;
N-butyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;
N-(2-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,6-dimethylphenyl)-

25 urea;

 $N-(2,4-difluorophenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} eyclohexyl)-urea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,3-dimethylphenyl)-

urea;

ethyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}-amino)benzoate;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethyl-6-

5 methylphenyl)urea;

ethyl N-{[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]-carbonyl}leucinate;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(4-fluorophenyl)urea;\\$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[1-(3-

10 isopropenylphenyl)-1-methylethyl]urea;

 $methyl\ N-\{[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)amino]-carbonyl\} methioninate;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[4-(methylthio)phenyl]urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-1-naphthylurea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[(2S)-2-phenylcyclopropyl]urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-phenoxyphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-pentylurea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-[2-(trifluoromethyl)-phenyl]urea;$

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-mesitylurea;$

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclohexyl)-N'-(2-methylphenyl)\ urea;$

N-(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-[1-(1-naphthyl)ethyl]-

urea;

methyl N-{[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}-phenylalaninate;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,4,6-trichlorophenyl)urea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclohexyl)-N'-(1-phenylethyl)urea;$

1-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3-(1-phenyl-ethyl)-urea;

5 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2,3,5,6-tetrachlorophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,4,6-tribromophenyl)urea;

N-(2,4-dibromo-6-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

10 cyclohexyl)urea;

 $N-(2,4-dibromophenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-urea;$

N-(2,4-dichlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-urea;

N-(2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

N-(2,6-diethylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-urea;

N-[2-chloro-6-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]-20 amino}cyclohexyl)urea;

N-(2-chloro-6-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

 $N-(2-chlorobenzyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) urea;\\$

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2-ethoxyphenyl)urea;\\$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethyl-6-isopropylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethylphenyl)urea; N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-fluorobenzyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-iodophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-isopropyl-6-methylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-isopropylphenyl)-5 urea:

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methyl-3-nitrophenyl)urea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclohexyl)-N'-(2-methyl-4-nitrophenyl)urea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methyl-5-nitrophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methylbenzyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-nitrophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-propylphenyl)urea;

N-(2-tert-butyl-6-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

N-(2-tert-butylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-urea;

N-1,3-benzodioxol-5-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-20 urea:

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(3,4,5-trimethoxyphenyl)urea;

 $N-(3,4-dimethoxyphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)urea;\\$

N-(3-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

N-(3-chloro-4-methoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]-amino}cyclohexyl)urea;

N-(4-bromo-2,6-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

5 N-(4-bromobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea; N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]-amino}cyclohexyl)urea;

 $N-(4-chloro-2-methylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino)-cyclohexyl)urea;\\$

N-(4-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-fluorobenzyl)urea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-methoxy-2-methylphenyl)urea;

N-(5-chloro-2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-15 cyclohexyl)urea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(diphenylmethyl)urea; \\ N-[1-(4-bromophenyl)ethyl]-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)urea; \\$

N-(4-bromo-2,6-dimethylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-20 cyclohexyl)urea;

 $N-(4-bromo-2-methylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)urea;\\$

ethyl N-{[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}-phenylalaninate;

N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(2,6-dibromo-4-isopropylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

- N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;
- N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;
- 5 N-(4-butyl-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;
 - N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[5-methyl-2-(trifluoromethyl)-3-furyl]urea;
- N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3-methyl-5-10 phenylisoxazol-4-yl)urea;
 - N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(5-methyl-3-phenylisoxazol-4-yl)urea;
 - $N-(2-chlorophenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-methyl] urea;$
- N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,6-dimethylphenyl)urea;
 - $N-(2,4-difluor ophenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-methyl]urea;\\$
- N-(3,5-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-20 methyl]urea;
 - $N-(2,3-dichlorophenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-methyl]urea;$
 - $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(2,3-dimethylphenyl)urea;$
- 25 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethyl-6-methylphenyl)urea;
 - ethyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}-carbonyl)leucinate;

20 tribromophenyl)urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(4-fluorophenyl)urea;$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-[4-(methylthio)phenyl]urea;

 $\label{eq:normalized-state} N-[(\text{cis-4-}\{[\text{4-}(\text{dimethylamino})\text{quinazolin-2-yl}]\text{amino}\}\text{cyclohexyl})\text{methyl}]-N'-phenylurea;}$

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclohexyl)methyl]-N'-[2-(trifluoromethyl)phenyl]urea;$

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(4-methylphenyl)urea;$

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl) methyl]-N'-mesitylurea;$

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(2-methylphenyl)urea;$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,4,6-trichlorophenyl)urea;

N-(2,6-diisopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,3-dimethyl-6-nitrophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,4,6-

N-(2,4-dibromo-6-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

N-(2,6-dibromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

25 N-(2,6-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-methyl]urea;

N-(2,6-diethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;

N-[2-chloro-6-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]-amino}cyclohexyl)methyl]urea;

 $N-(2-chloro-6-methylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino)-cyclohexyl)methyl]urea;$

5 N-(2-chlorobenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethyl-6-isopropylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-

10 ethylphenyl)urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) methyl]-N'-(2-iodophenyl) urea;$

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclohexyl) methyl]-N'-(2-isopropyl-6-methylphenyl) urea;$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-isopropylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methoxy-5-methylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methyl-3-20 nitrophenyl)urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) methyl]-N'-(2-methyl-6-nitrophenyl) urea;$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-propylphenyl)urea;

25 N-(2-tert-butyl-6-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

N-(2-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;

N-(3,4-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;

 $N-(3,5-difluorophenyl)-N'-[(\varepsilon is-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ eyelohexyl)-methyl]urea;$

5 N-(3-chloro-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

N-(3-chloro-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

N-(4-bromo-2,6-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-10 cyclohexyl)methyl]urea;

 $N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]-amino\}cyclohexyl)methyl]urea;$

N-(4-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(diphenylmethyl)urea;

N-(4-bromo-2,6-dimethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[5-methyl-2-20 (trifluoromethyl)-3-furyl]urea; and

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methyl-5-phenylisoxazol-4-yl)urea;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

25 (i) C_{1-8} alkyl, and

 C_{1-3} alkyl substituted by substituent(s) independently selected from the group consisting of:

•mono-C₁₋₅ alkylamino,

```
•di-C<sub>1-5</sub> alkylamino,
                                  •C3-6 cycloalkyl,
                                  °C3-6 cycloalkenyl,
                                  ecarbocyclic aryl,
 5
                                  ecarbocyclic aryl substituted by substituent(s) independently selected from
                                  the group consisting of:
                                           "halogen,
                                            **C<sub>1-5</sub> alkyl, and
                                            ••C<sub>1.5</sub> alkoxy,
10
                                  •heterocyclyl,
                                  C<sub>2-5</sub> alkynyl,
                         (ii)
                                  C2-5 alkenyl, and
                         (iii)
                                  C<sub>2-5</sub> alkenyl substituted by carbocyclic aryl,
                                  C<sub>3-12</sub> cycloalkyl,
                         (iv)
15
                                  carbocyclyl,
                         (v)
                         (vi)
                                  carbocyclic aryl, and
                                  carbocyclic aryl substituted by substituent(s) independently selected from the
                                  group consisting of:
                                  ·halogen,
20
                                   •cyano,
                                   •nitro,
                                   •C<sub>1-10</sub> alkyl,
                                   •C<sub>1-10</sub> alkyl substituted by substituent(s) independently selected from the
                                   group consisting of:
25
                                            ••halogen, and
                                            ••0XO,
                                   ·carboxy,
```

 $\cdot C_{1-5}$ alkoxy carbonyl,

•C₁₋₅ alkoxy, ${}^{\circ}C_{1-5}$ alkoxy substituted by substituent(s) independently selected from the group consisting of: ∞halogen, and 5 «carbocyclic aryl, ecarbocyclic aryloxy, «carbocyclic aryloxy substituted by nitro, «mono-C₁₋₅ alkylamino, •di-C₁₋₅ alkylamino, 10 •C₁₋₅ alkoxy carbonylamino, •carbocyclic aryl azo, •carbocyclic aryl azo substituted by substituent(s) independently selected from the group consisting of: ••mono-C₁₋₅ alkylamino, and 15 ••di-C₁₋₅ alkylamino, •C₁₋₅ alkylthio, $\bullet C_{1-5}$ alkylthio substituted by halogen, •carbocyclic arylthio, •carbocyclic arylthio substituted by nitro, 20 •amino sulfonyl, •heterocyclyl sulfonyl, •C₃₋₆ cycloalkyl, • C_{3-6} cycloalkyl substituted by C_{1-5} alkyl, ·carbocyclic aryl, and 25 cheterocyclyl, heterocyclyl, and (vii) heterocyclyl substituted by substituent(s) independently selected from the

group consisting of:

•C₁₋₅ alkyl, ^cC₁₋₅ alkoxy carbonyl, ecarbocyclic aryloxy, ocarbocyclic aryl, and 5 •heterocyclyl; L is Formula (V); and Y is $-C(S)NR_{7}$; wherein R_7 is hydrogen or C_{1-5} alkyl; wherein carbocyclic aryl is phenyl or naphthyl; carbocyclyl is indanyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, or 10 adamantly; heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, 4,5,6,7-tetrahydro-benzo[b]thienyl, benzo[1,3]dioxolyl, benzo[2,1,3]thiadiazolyl, furyl, isoxazolyl, morpholinyl, oxazolyl, piperidyl, pyrazolyl, pyridyl, tetrahydrofuryl, or thienyl; and 15 halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate or solvate thereof. In some embodiments of the present invention, R_{4a} is hydrogen or methyl; R_{4b} is methyl; R₅ and R₆ are hydrogen; A is a single bond; B is a single bond or -CH₂-; and R₇ is hydrogen; or a pharmaceutically acceptable salt, hydrate or solvate thereof. 20 In some embodiments of the present invention, R_1 is selected from the group consisting of: (i) C₁₋₆ alkyl, and C₁₋₆ alkyl substituted by substituent(s) independently selected from the group consisting of: °C₃₋₆ cycloalkyl, ${}^{\circ}C_{3-6}$ cycloalkenyl, 25 *carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from

the group consisting of:

••halogen,

••C₁₋₅ alkyl, and

••C₁₋₅ alkoxy,

•heterocyclyl,

 $\qquad \qquad \text{(ii)} \qquad C_{3\text{-}12} \text{ cycloalkyl},$

(iii) carbocyclyl,

(iv) carbocyclic aryl, andcarbocyclic aryl substituted by substituent(s) independently selected from thegroup consisting of:

10 •halogen,

•cyano,

•nitro,

 $\cdot C_{1-5}$ alkyl,

•C₁₋₅ alkyl substituted by halogen,

15 •C₁₋₅ alkoxy carbonyl,

•C₁₋₅ alkoxy,

•C₁₋₅ alkoxy substituted by halogen,

•mono-C₁₋₅ alkylamino,

•di-C₁₋₅ alkylamino,

20 ${}^{\bullet}C_{1-5}$ alkylthio, and

•carbocyclic aryl,

(v) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

25 ${}^{\circ}C_{1-5}$ alkyl,

•C₁₋₅ alkoxy carbonyl, and

carbocyclic aryl;

wherein carbocyclic aryl is phenyl or naphthyl;

carbocyclyl is indanyl, bicyclo[2.2.1]heptyl, or bicyclo[2.2.1]heptenyl; heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1,3]dioxolyl, isoxazolyl, tetrahydrofuryl, or thienyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

(i) C₁₋₅ alkyl, and

> C₁₋₅ alkyl substituted by substituent(s) independently selected from the group consisting of:

•carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

··halogen, and

••C₁₋₅ alkoxy,

carbocyclyl, (ii)

carbocyclic aryl, and (iii) carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

·halogen,

•cyano,

•nitro,

•C₁₋₅ alkyl,

 \cdot C₁₋₅ alkyl substituted by halogen,

•C₁₋₅ alkoxy carbonyl,

°C₁₋₅ alkoxy,

•C₁₋₅ alkoxy substituted by halogen,

•mono-C₁₋₅ alkylamino,

•di-C₁₋₅ alkylamino, and

10

5

15

20

25

·carbocyclic aryl,

(iv) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

5

°C₁₋₅ alkyl,

*C₁₋₅ alkoxy carbonyl, and

«carbocyclic aryl;

wherein carbocyclic aryl is phenyl or naphthyl;

carbocyclyl is bicyclo[2.2.1]heptyl;

10

heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1,3]dioxolyl,

isoxazolyl, or thienyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

N-(4-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-thiourea;

 $N-(4-cyanophenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-thiourea;\\$

 $N-cyclohexyl-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) thiourea; \\ N-cyclopentyl-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) thiourea; \\ N-(4-chlorophenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-thiourea; \\ \\ N-(4-chlorophenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-thiourea; \\ N-(4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-thiourea;$

N-(2,4-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-25 thiourea;

 $N-(2,4-dimethoxyphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl) thiourea; \\$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,6-dimethylphenyl)-

WO 2004/087680 PCT/JP2004/004554

57

thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-ethyl-6-isopropylphenyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-N'-(4-fluorophenyl)-

5 thiourea:

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-hexylthiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)-N'-isobutylthiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-methoxybiphenyl-3-yl)thiourea;

10 N-(1,3-benzodioxol-5-ylmethyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-[4-(methylthio)phenyl]\\ -thiourea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-methoxyphenyl)-

15 thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2-methoxyphenyl)-thiourea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-1-naphthylthiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-nitrophenyl)-

20 thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclohexyl)-N'-(pentafluorophenyl)-thiourea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-propylthiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(3,4,5-

25 trimethoxyphenyl)thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} \ cyclohexyl)-N'-(4-methylphenyl)-thiourea;$

N-(3,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-ethylphenyl)thiourea:

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-[2-(methylthio)-

5 phenyl]thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-[2-(trifluoromethoxy)-N'-]-[2-(trifluoromethoxy)-N'-[2-(trifluoromethoxy)-N'-[2-(trifluoromethoxy)-N'-]-[2-(trifluoromethoxy)-N'-[2-(trifluoromethoxy)-N'-[2-(trifluoromethoxy)-N'-]-[2-(trifluoromethoxy)-N'-[2-(trifluoromethoxy)-N'-[2-(trifluoromethoxy)-N'-]-[2-(trifluoromethoxy)-N'-[2-(trifluoromethoxy)-N'-]-[2-(trifluoromethoxy)-N'-[2-(trifluoromethoxy)-N'-]-[2-(triflu$ phenyl]thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,3,4-trifluorophenyl)thiourea:

10 N-(2,5-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(2-chloro-4-nitrophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethylphenyl)-

15 thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-iodophenyl)thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2-methoxy-4-yl)-N$ nitrophenyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxy-5-20 methylphenyl)thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(3-iodophenyl)-N$ thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(3-methoxyphenyl)-

25 thiourea:

N-[4-(difluoromethoxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-[4-(trifluoromethyl)-N'-]-[4-(trifluoromethyl)-N'-[4-(trifluoromethyl)-N'-]-[4-(trifluoromethyl)-N'-[4-(trifluoromethyl)-N'-]-[4-(trifluoromethyl)-N'-]-[4-(trifluoromethyl)-N'-[4-(trifluoromethyl)-N'-]-[4-(trifluoromethyl)-N'-[4-(trifluoromethyl)-N'-]-[4-(trifluoromethyl)-N'-$

phenyl]thiourea;

N-(4-bromo-2-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(4-iodophenyl)-N$

5 thiourea;

 $N-(5-chloro-2-methylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl) thiourea;$

 $N-[(1S,4R)-bicyclo[2.2.1]hept-2-yl]-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl) thiourea;$

N-[2-(4-chlorophenyl)ethyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2,4,6-tribromophenyl) thiourea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,4,6-trichlorophenyl)-

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-mesitylthiourea;$

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclohexyl)-N'-(2,4-dimethylphenyl)-thiourea:$

 $N-(2,6-diethylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-n'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-n'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino] cyclohexyl)-n'-(cis-4-(dimethylamino)quinazolin-2-yl]amino] cyclohexyl-(cis-4-(dimethylamino)quinazolin-2-yl]amino] cyclohexyl-(cis-4-(dimethylamino)quinazolin-2-yl]amino$

20 thiourea;

15 thiourea;

 $N-(2,6-diisopropylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl) thiourea;\\$

 $N-(2-bromo-4-methylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl) thiourea;\\$

25 N-(2-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2-ethyl-6-methylphenyl) thiourea;$

- $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2-isopropylphenyl)-thiourea;\\$
- $N-(3,5-dimethoxyphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl) thiourea; \\$
- 5 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(3,5-dimethylphenyl)-thiourea;
 - $N-(3-chloro-4-methylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl) thiourea;\\$
- methyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]10 carbonothioyl}amino)benzoate;
 - N-(4-bromo-2,6-dimethylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;
 - N-(4-bromo-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;
- N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;
 - $N-(4-chloro-2-methylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl) thiourea;\\$
- N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[1-(4-fluorophenyl)-20 ethyl]thiourea;
 - N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-fluorobenzyl)-thiourea;
 - $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(4-isopropylphenyl)-thiourea;$
- N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(4-methoxybenzyl)-thiourea;
 - methyl 4-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]-carbonothioyl}amino)benzoate;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(1-phenylethyl)-thiourea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(diphenylmethyl)-thiourea;

5 N-(cyclohexylmethyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-thiourea;

 $N-cyclooctyl-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) thiourea;\\$

N-cyclopropyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(1-naphthylmethyl)-

10 thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2,2-diphenylethyl)-thiourea;\\$

 $N-(2,3-dimethoxybenzyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-thiourea;\\$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,4,5-trimethylphenyl)thiourea;

 $N-[2-(2,5-dimethoxyphenyl)ethyl]-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)thiourea;\\$

N-biphenyl-2-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-fluorobenzyl)-thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methyl-4-nitrophenyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methylbenzyl)-

25 thiourea;

 $N-(3-chlorobenzyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclohexyl)-thiourea;$

ethyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]-

carbonothioyl}amino)benzoate;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclohexyl)-N'-(3-ethylphenyl)-thiourea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-N'-(3-fluorobenzyl)-5 thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(3-methoxybenzyl)-thiourea;$

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(3-methylbenzyl)-thiourea;$

N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(4-fluoro-2-methylphenyl) thiourea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-methoxy-2-

15 methylphenyl)thiourea;

N-(5-chloro-2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

 $N-(2,3-dihydro-1H-inden-5-yl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl) thiourea;$

N-cycloheptyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[(1R)-1-phenylethyl]-thiourea;

 $N-(2-cyclohex-1-en-1-ylethyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl) thiourea;\\$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2,3-dimethylphenyl)-thiourea;

N-(2,4-dibromo-6-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

- $N-(2,4-dichloro-6-methylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl) thiourea;\\$
- $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} \ cyclohexyl)-N'-(2,5-dimethylphenyl)-thiourea;$
- 5 N-(2-bromo-4-isopropylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;
 - $N-(2-bromo-5-fluorophenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl) thiourea;\\$
- N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethoxyphenyl)-10 thiourea;
 - N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-isopropyl-6-methylphenyl)thiourea;
 - N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxybenzyl)-thiourea;
- N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;
 - $N-1, 3-benzo dioxol-5-yl-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-thiourea;\\$
- N-(3-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-20 cyclohexyl)thiourea;
 - $N-[4-bromo-2-(trifluoromethoxy)phenyl]-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)thiourea;$
 - N-(4-chloro-2,5-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;
- N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(4-phenylbutyl)-thiourea;
 - N-bicyclo[2.2.1]hept-2-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

methyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]-carbonothioyl}amino)-4-methylthiophene-2-carboxylate;

methyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}eyclohexyl)amino]-carbonothioyl}amino)thiophene-2-carboxylate;

5 N-(2-bromo-4-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

 $N-(4-butyl-2-methylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl) thiourea;\\$

N-[4-(dimethylamino)-1-naphthyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-10 yl]amino}cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(5-methyl-3-phenylisoxazol-4-yl)thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,6-dimethylphenyl)thiourea;

N-(2,6-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]thiourea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(2-ethyl-6-isopropylphenyl)thiourea;\\$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-

20 isobutylthiourea;

 $N-(1,3-benzodioxol-5-ylmethyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]thiourea;$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-nitrophenyl)thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'(pentafluorophenyl)thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(tetrahydrofuran-2-ylmethyl)thiourea;

WO 2004/087680 PCT/JP2004/004554

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[2-(trifluoromethoxy)phenyl]thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,3,4-trifluorophenyl)thiourea;

5 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethylphenyl)thiourea;

 $N-(5-chloro-2-methylphenyl)-N'-\{(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)methyl] thiourea;$

N-[(1S,4R)-bicyclo[2.2.1]hept-2-yl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-

10 yl]amino}cyclohexyl)methyl]thiourea;

 $N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)methyl]thiourea;$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,4,6-tribromophenyl)thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,4,6-trichlorophenyl)thiourea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-mesitylthiourea;\\$

N-(2,6-diethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-20 methyl]thiourea;

 $N-(2,6-diisopropylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)methyl]thiourea;$

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl) methyl]-N'-(2-ethyl-6-methylphenyl) thiourea;\\$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-isopropylphenyl)thiourea;

 $N-(4-bromo-2,6-dimethylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)methyl] thiourea;\\$

N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea;

 $\label{eq:N-local-equation} N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} eyelohexyl)methyl]-N'-[1-(4-fluorophenyl)ethyl]thiourea;$

5 N-(5-chloro-2-methoxyphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]thiourea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} eyelohexyl) methyl]-N'-(diphenylmethyl) thiourea;$

N-cyclododecyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-10 thiourea;

N-(cyclohexylmethyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]thiourea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(2,3,5,6-tetrachlorophenyl)thiourea;$

N-(2,3-dimethoxybenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]thiourea;

 $N-(2,4-dichlorobenzyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)-methyl] thiourea;\\$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methoxy-5-20_nitrophenyl)thiourea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(4-methoxy-2-methylphenyl)thiourea;$

 $N-(2,4-dibromo-6-fluorophenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)methyl] thiourea;$

25 N-(2,4-dichloro-6-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]thiourea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(2,5-dimethylphenyl)thiourea;$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethoxyphenyl)thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-isopropyl-6-methylphenyl)thiourea;

5 N-[4-bromo-2-(trifluoromethoxy)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea;

N-bicyclo[2.2.1]hept-2-yl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]thiourea;

N-bicyclo[2.2.1]hept-5-en-2-yl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-10 cyclohexyl)methyl]thiourea;

N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]thiourea; and

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(5-methyl-3-phenylisoxazol-4-yl)thiourea;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

 $N-(4-bromophenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-thiourea;\\$

N-(4-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-thiourea;

 $N-(2,4-dichlorophenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclohexyl)-thiourea;$

N-(2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

25 cyclohexyl)thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclohexyl)-N'-(2,6-dimethylphenyl)-thiourea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethyl-6-

isopropylphenyl)thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2-methoxyphenyl)-thiourea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-1-naphthylthiourea;

5 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3,4,5-trimethoxyphenyl)thiourea;

N-(3,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethylphenyl)-

10 thiourea:

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxy-4-nitrophenyl)thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2-methoxy-5-methylphenyl) thiourea;$

N-(4-bromo-2-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} \ cyclohexyl)-N'-(4-iodophenyl)-thiourea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,4,6-

20 tribromophenyl)thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} \ cyclohexyl)-N'-(2,4,6-trichlorophenyl)-thiourea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-mesitylthiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,4-dimethylphenyl)-

25 thiourea;

 $N-(2,6-diethylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclohexyl)-thiourea;$

N-(2-bromo-4-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

WO 2004/087680 PCT/JP2004/004554

cyclohexyl)thiourea;

 $N-(2-chlorobenzyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-thiourea;\\$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethyl-6-

5 methylphenyl)thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2-isopropylphenyl)-thiourea;\\$

methyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]-carbonothioyl}amino)benzoate;

N-(4-bromo-2,6-dimethylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

 $N-(4-bromo-2-methylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl) thiourea;\\$

N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-15 yl]amino}cyclohexyl)thiourea;

 $N-(4-chloro-2-methylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl) thiourea;\\$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(1-naphthylmethyl)-thiourea;

N-(2,3-dimethoxybenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2,4,5-trimethylphenyl) thiourea;$

 $N-biphenyl-2-yl-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclohexyl) thiourea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-methyl-4-nitrophenyl)thiourea;

 $N-(3-chlorobenzyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-thiourea;\\$

- ethyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]-carbonothioyl} amino)benzoate;
- N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea;
- 5 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-fluoro-2-methylphenyl)thiourea;
 - N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)-N'-(4-methoxy-2-methylphenyl)thiourea;
- N-(5-chloro-2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-10 cyclohexyl)thiourea;
 - $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-[(1R)-1-phenylethyl]-thiourea;\\$
 - $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2,3-dimethylphenyl)-thiourea;$
- N-(2,4-dibromo-6-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;
 - $N-(2,4-dichloro-6-methylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl) thiourea;\\$
- N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethoxyphenyl)-20 thiourea;
 - N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-isopropyl-6-methylphenyl)thiourea;
 - $N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) thiourea;$
- N-1,3-benzodioxol-5-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-thiourea;
 - $N-(3-chloro-2-methylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl) thiourea;\\$

N-[4-bromo-2-(trifluoromethoxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2yl]amino) cyclohexyl)thiourea;

N-(4-chloro-2,5-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

5 N-bicyclo[2.2.1]hept-2-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

methyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonothioyl) amino)-4-methylthiophene-2-carboxylate;

methyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino}-10 carbonothioyl}amino)thiophene-2-carboxylate;

N-(4-butyl-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-[4-(dimethylamino)-1-naphthyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

15 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(5-methyl-3phenylisoxazol-4-yl)thiourea;

N-(2,6-diethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea;

N-(4-bromo-2.6-dimethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-20 cyclohexyl)methyl]thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,3,5,6tetrachlorophenyl)thiourea; and

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-vl]amino}cyclohexyl)methyl]-N'-(2-isopropyl-6methylphenyl)thiourea;

25 or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

R₁ is selected from the group consisting of:

(i) C₁₋₈ alkyl, and

		C ₁₋₈ alkyl substituted by substituent(s) independently selected from the group
		consisting of:
		*halogen,
		$^{\circ}C_{1.5}$ alkoxy,
5		°C ₁₋₅ alkoxy substituted by carbocyclic aryl,
		°carbocyclyl,
		carbocyclic aryl,
		•carbocyclic aryl substituted by substituent(s) independently selected from
		the group consisting of:
10		••halogen,
		••nitro, and
		••C ₁₋₅ alkoxy,
	(ii)	C ₂₋₅ alkenyl,
	(iii)	carbocyclyl,
15	(iv)	carbocyclic aryl, and
		carbocyclic aryl substituted by substituent(s) independently selected from the
		group consisting of:
		•halogen,
		•C ₁₋₅ alkyl,
20		•C ₁₋₅ alkyl substituted by halogen, and
		•C ₁₋₅ alkoxy;
		L is Formula (V); and
		Y is -C(O)O-;
		wherein carbocyclic aryl is phenyl or naphthyl;
25		carbocyclyl is 9H-fluorenyl or menthyl; and
		halogen is fluoro, chloro, bromo, or iodo;
	or a ph	narmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments of the present invention, R_{4a} is hydrogen or methyl; R_{4b} is methyl; R_5

and R_6 are hydrogen; A is a single bond; and B is a single bond or -CH₂-; or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

- 5 cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid 2-benzyloxy-ethyl ester;
 - cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid 4,5-dimethoxy-2-nitro-benzyl ester;
- cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid 2-chloro-benzyl ester;
 - cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid 4,5-dimethoxy-2-nitro-benzyl ester;
 - cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid 4-nitro-benzyl ester;
- cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid benzyl ester;
 cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid
 2-chloro-benzyl ester;
 - cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid 4-nitro-benzyl ester; and
- cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments of the present invention, R_1 is $C_{1-\delta}$ alkyl, and

- C₁₋₈ alkyl substituted by substituent(s) independently selected from the group consisting of:
- ·carbocyclic aryl,

25

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: ••halogen,

••C₁₋₅ alkyl,

∞C₁₋₅ alkyl substituted by halogen,

∘∘C₁₋₅ alkoxy, and

5 •• C₁₋₅ alkoxy substituted by halogen,

 R_4 is $-N(R_{4a})(R_{4b})$ wherein R_{4a} and R_{4b} are independently $C_{1.5}$ alkyl;

L is Formula (VIII) or (EG) wherein R₅ and R₆ are both hydrogen; A and B are each independently a single bond or -CH₂-; and

Y is a single bond;

wherein carbocyclic aryl is phenyl; and

halogen is fluoro or chloro;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments of the present invention, R_1 is C_{1-8} alkyl, and

 C_{1-8} alkyl substituted by substituent(s) independently selected from the group

15 consisting of:

•carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

•• C_{1-5} alkoxy, and

••C₁₋₅ alkoxy substituted by halogen,

wherein carbocyclic aryl is phenyl; and

halogen is fluoro or chloro;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments of the present invention, R₄ is -N(CH₃)₂; L is Formula (VIII) or (IX)

wherein A is a single bond and B is -CH₂-, or A is -CH₂- and B is a single bond; and Y is a single bond;
wherein carbocyclic arvl is phenyl; and halogen is fluoro; or a pharmaceutically acceptable salt,

hydrate or solvate thereof.

20

In some embodiments, compounds of the present invention are of Formula (I) wherein the

WO 2004/087680 PCT/JP2004/004554

75

compound is selected from the group consisting of:

 N^2 -[(1S,3R)-3-({[4-bromo-2-(trifluoromethoxy)benzyl]amino}-methyl)cyclopentyl]- N^4 , N^4 -dimethylquinazoline-2,4-diamine;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

- In some embodiments of the present invention, R_1 is selected from the group consisting of:
 - (i) C₁₋₈ alkyl, and

 C_{1-8} alkyl substituted by substituent(s) independently selected from the group consisting of:

- ·carbocyclic aryl,
- •carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
 - ••hydroxy,
 - ··halogen,
 - ··nitro,
- 15 •• C₁₋₅ alkylcarbonylamino,
 - ••C₃₋₆ cycloalkylcarbonylamino,
 - ••C₁₋₅ alkyl,
 - ••C₁₋₅ alkyl substituted by halogen,
 - ••C₁₋₅ alkylsulfonyl,
- 20 $\cdot \cdot C_{1-5}$ alkoxy,
 - ••C₁₋₅ alkoxy substituted by halogen, and
 - ••carbocyclic aryl,
 - •heterocyclyl, and
 - ·heterocyclyl substituted by halogen,
- 25 (ii) C_{3-12} cycloalkyl, and C_{3-12} cycloalkyl substituted by carbocyclic aryl,
 - (iii) carbocyclyl, and carbocyclyl by substituent(s) independently selected from the group

consisting of: *hydroxy, and ecarbocyclic aryl, (iv) carbocyclic aryl, and 5 carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, *C₁₋₅ alkoxy, and •nitro, 10 (v) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: ·halogen, and $\cdot C_{1-5}$ alkoxy, 15 R_4 is $-N(R_{4a})(R_{4b})$ wherein R_{4a} and R_{4b} are each independently C_{1-5} alkyl; L is Formula (XIII); wherein R₅ and R₆ are both hydrogen; A is a single bond and B is a single bond or -CH2-; and Y is $-C(O)NR_{7}$, wherein R_{7} is hydrogen or C_{1-5} alkyl; wherein carbocyclic aryl is phenyl or naphthyl, 20 carbocyclyl is indanyl, 9H-fluorenyl, 1,2,3,4-tetrahydro-naphthalen-1-yl, or 1*H*-indolyl; heterocyclyl is benzo[1,3]dioxolyl, pyridyl, dibenzofuranyl, 1H-benzoimidazolyl, or thiazolyl; and halogen is fluoro, chloro, bromo, or iodo; 25 or a pharmaceutically acceptable salt, hydrate or solvate thereof. In some embodiments of the present invention, R₁ is selected from the group consisting of:

> (i) C₁₋₈ alkyl substituted by substituent(s) independently selected from the group

C₁₋₈ alkyl, and

consisting of: carbocyclic aryl, ocarbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: 5 ••hydroxy, ∞halogen, enitro, ···C₁₋₅ alkylcarbonylamino, ••C₁₋₅ alkyl, 10 ••C₁₋₅ alkyl substituted by halogen, ••C₁₋₅ alkylsulfonyl, ••C₁₋₅ alkoxy, ••C₁₋₅ alkoxy substituted by halogen, and ••carbocyclic aryl, 15 •heterocyclyl, and •heterocyclyl substituted by halogen, (ii) C₃₋₁₂ cycloalkyl, and C₃₋₁₂ cycloalkyl substituted by carbocyclic aryl, (iii) carbocyclyl, 20 (iv) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: ·halogen, and •nitro, 25 heterocyclyl, and (v) heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

·halogen, and

•C₁₋₅ alkoxy,

and

wherein carbocyclic aryl is phenyl or naphthyl;

carbocyclyl is indanyl, 9H-fluorenyl, or 1,2,3,4-tetrahydro-naphthalen-1-yl;

heterocyclyl is benzo[1,3]dioxolyl, or pyridyl;

5

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments of the present invention, R_4 is $-N(CH_3)_2$; A and B are both a single bond; and Y is -C(O)NH-; or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2,3-dimethylbenzyl)-cyclohexanecarboxamide;

cis-N-(2-bromobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

15 cyclohexanecarboxamide;

 $cis-N-(2-chlorobenzyl)-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-1-(dimethylamino)quinazolin-2-yl]amino\}-1-(dimethylamino)quinazolin-2-yl]amino\}-1-(dimethylamino)quinazolin-2-yl]amino\}-1-(dimethylamino)quinazolin-2-yl]amino\}-1-(dimethylamino)quinazolin-2-yl]amino\}-1-(dimethylamino)quinazolin-2-yl]amino\}-1-(dimethylamino)quinazolin-2-yl]amino(quinazolin-2-yl]amino(quinazolin-2-yl)quinazolin-2-yl]amino(quinazolin-2-yl)quinazolin-2-yl]amino(quinazolin-2-yl)quinazolin-2-yl]amino(quinazolin-2-yl)quinazolin-2-yl]amino(quinazolin-2-yl)quinazolin-2-yl]amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amino(quinazolin-2-yl)quinazolin-2-yl|amin$

cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(4-methylbenzyl)-

cyclohexanecarboxamide;

20 cis-N-[3,5-bis(trifluoromethyl)benzyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexanecarboxamide;

cis-N-(2,4-dimethoxybenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(1,2,3,4-

25 tetrahydronaphthalen-1-yl)cyclohexanecarboxamide;

cis-N-(2,3-dihydro-1H-inden-2-yl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1S)-1-(4-nitrophenyl)ethyl]-

cyclohexanecarboxamide; cis-N-(3,5-dichlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide; eis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[4-(trifluoromethoxy)benzyl]-5 cyclohexanecarboxamide; cis-N-(4-bromobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(4-methoxybenzyl)cyclohexanecarboxamide; 10 cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2-fluoro-4-nitrophenyl)cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-fluoro-4-methylbenzyl)cyclohexanecarboxamide; cis-N-(5-chloro-2-methylbenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-15 cyclohexanecarboxamide; and cis-N-(2,4-dichloro-6-methylbenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt, hydrate or solvate thereof. In some embodiments, compounds of the present invention are of Formula (I) wherein the 20 compound is selected from the group consisting of: cis-N-(2,3-dimethoxybenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide; cis-N-(2,4-difluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide; 25 cis-N-(2,4-dichlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide; cis-N-(2,3-dichlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide;

cis-N-(2,5-dichlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide; cis-N-(3-chlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide; 5 cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-methoxybenzyl)cyclohexanecarboxamide; cis-N-(3,4-dimethoxybenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexanecarboxamide; cis-N-(3,5-dimethoxybenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-10 cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(4-hydroxy-3-methoxybenzyl)cyclohexanecarboxamide; cis-N-(1,3-benzodioxol-5-ylmethyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide; 15 cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1R)-1-(4-nitrophenyl)ethyl]cyclohexanecarboxamide, cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexanecarboxylic acid (trans-2-phenylcyclopropyl)-amide; cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1S)-1-(4-methylphenyl)ethyl]-20 cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1R)-1-(1-naphthyl)ethyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[3-(trifluoromethyl)benzyl]cyclohexanecarboxamide; 25 cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-methoxyphenyl)cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-iodobenzyl)cyclohexanecarboxamide;

```
cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(4-methoxybenzyl)-
    cyclohexanecarboxamide;
           cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-iodophenyl)-
    cyclohexanecarboxamide;
 5
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[3-(propionylamino)benzyl]-
    cyclohexanecarboxamide;
            cis-N-benzyl-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide;
            cis-N-[(6-chloropyridin-3-yl)methyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
10
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1R)-1-(3-methoxyphenyl)ethyl]-
    cyclohexanecarboxamide;
           cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[1-(4-fluorophenyl)ethyl]-
    cyclohexanecarboxamide;
            cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
15 cyclohexanecarboxamide;
            cis-N-[1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1S)-1-(1-naphthyl)ethyl]-
    cyclohexanecarboxamide;
20
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3,5-dimethylbenzyl)-
    cyclohexanecarboxamide;
            cis-N-(3-chloro-2-methylbenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(5-fluoro-2-methylbenzyl)-
25 cyclohexanecarboxamide;
            cis-N-(3-chloro-2,6-difluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
            cis-N-(biphenyl-3-ylmethyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
```

```
cyclohexanecarboxamide;
           cis-N-(biphenyl-4-ylmethyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
           cis-N-(6-chloro-2-fluoro-3-methylbenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
 5 cyclohexanecarboxamide;
           cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2-fluorobenzyl)-
    cyclohexanecarboxamide;
           cis-N-(2,6-difluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
10
           cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[4-(trifluoromethyl)benzyl]-
    cyclohexanecarboxamide;
           cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(1-naphthylmethyl)-
    cyclohexanecarboxamide;
           cis-N-(4-chlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
15 cyclohexanecarboxamide;
           cis-N-(3,4-dichlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
           cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-fluorobenzyl)-
    cyclohexanecarboxamide;
20
           cis-N-(2,5-difluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
           cis-N-(2,3-difluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
           cis-N-(3-bromobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
25 cyclohexanecarboxamide;
           cis-N-(3-bromo-4-fluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
           cis-N-(4-bromo-2-fluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
```

cyclohexanecarboxamide; cis-N-(5-bromo-2-fluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide: cis-N-(4-chloro-2-fluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-5 cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-methylbenzyl)cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2-methylbenzyl)cyclohexanecarboxamide; 10 cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[2-(trifluoromethoxy)benzyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2,3,4-trifluorobenzyl)cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2,4,5-trifluorobenzyl)-15 cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3,4,5-trifluorobenzyl)cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2,3,6-trifluorobenzyl)cyclohexanecarboxamide; 20 cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[3-fluoro-5-(trifluoromethyl)benzyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[4-fluoro-2-(trifluoromethyl)benzyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[2-fluoro-4-(trifluoromethyl)benzyl]-25 cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[4-fluoro-3-(trifluoromethyl)benzyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[2-fluoro-3-(trifluoromethyl)benzyl]-

cyclohexanecarboxamide; cis-N-[4-chloro-3-(trifluoromethyl)benzyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide: cis-N-(2-chloro-6-fluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino)-5 cyclohexanecarboxamide; cis-N-(3-chloro-4-fluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide; cis-N-(2-chloro-4-fluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide; 10 cis-N-[2-chloro-5-(trifluoromethyl)benzyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide; cis-N-[2-(difluoromethoxy)benzyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide; cis-N-[3-(difluoromethoxy)benzyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-15 cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[3-(trifluoromethoxy)benzyl]cyclohexanecarboxamide; cis-N-(2,6-dimethoxybenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1R)-1-phenylethyl]-20 cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1S)-1-(4-methoxyphenyl)ethyl]cyclohexanecarboxamide; cis-N-[bis(4-methoxyphenyl)methyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-25 cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[2-(trifluoromethyl)benzyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-9H-fluoren-9ylcyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[4-(methylsulfonyl)benzyl]-

cyclohexanecarboxamide; and

cis-N-(6-chloropyridin-3-yl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

5 cyclohexanecarboxamide;

10

15

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments of the present invention, R_1 is selected from the group consisting of:

(i) C_{1-8} alkyl, and

C₁₋₈ alkyl substituted by substituent(s) independently selected from the group

consisting of:

carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••C₁₋₅ alkoxy, and

••C₁₋₅ alkoxy substituted by halogen,

(ii) carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently selected from the

group consisting of:

·halogen, and

 $\cdot C_{1-7}$ alkoxy,

 R_4 is $-N(R_{4a})(R_{4b})$ wherein R_{4a} and R_{4b} are each independently C_{1-5} alkyl;

L is Formula (XIII) wherein $R_{\text{\scriptsize 5}}$ is hydrogen; A is a single bond and B is a single bond

or -CH₂-; and

Y is -C(O)O- or -OC(O)-;

25 wherein carbocyclic aryl is phenyl or naphthyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments of the present invention, R₄ is -N(CH₃)₂; or a pharmaceutically

5

10

acceptable salt, hydrate or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently selected from the

group consisting of:

halogen,

 ${}^{\circ}C_{1-10}$ alkyl,

•C₁₋₁₀ alkyl substituted by halogen,

•C₁₋₇ alkoxy, and

•C₁₋₇ alkoxy substituted by halogen,

 R_4 is $-N(R_{4a})(R_{4b})$ wherein R_{4a} and R_{4b} are each independently C_{1-5} alkyl;

L is Formula (VIII) or (IX) wherein \boldsymbol{A} and \boldsymbol{B} are each independently a single bond or

-CH₂-; and

Y is -C(O)-,

wherein carbocyclic aryl is phenyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments of the present invention, R₄ is -N(CH₃)₂; R₅ and R₆ are both hydrogen; and A is a single bond, and B is -CH₂-; or A is a -CH₂-, and B is a single bond, or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

 $3,4-dichloro-N-[((1R,3S)-3-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclopentyl)-methyl] benzamide;$

N-[(1S,3R)-3-({[4-(dimethylamino)quinazolin-2-yl]amino}methyl)cyclopentyl]-4-fluorobenzamide;

4-chloro-N-[((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclopentyl)methyl]-benzamide; and

 $N-[((1R,3S)-3-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclopentyl) methyl]-3,5-difluorobenzamide;$

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

 $N-[((1R,3S)-3-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclopentyl) methyl]-3,5-dimethoxybenzamide;$

 $2,4,6-trichloro-N-[((1R,3S)-3-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclopentyl)-methyl] benzamide;$

N-[((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclopentyl)methyl]-3-fluoro-4-(trifluoromethyl)benzamide;

 $N-[((1R,3S)-3-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ eyelopentyl) methyl]-4-(trifluoromethoxy) benzamide; and$

N-[(1S,3R)-3-({[4-(dimethylamino)quinazolin-2-yl]amino}methyl)cyclopentyl]-2,4-

15 difluorobenzamide;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments of the present invention, Q is Formula (IIa) and can be represented by the following formula:

$$X_2$$
 X_3
 X_4
 X_4

20

or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein X_1 - X_4 , R_2 , L, Y, and R_1 are as described herein, supra and infra.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

25

(i) $C_{1.8}$ alkyl, and

WO 2004/087680 PCT/JP2004/004554

88

 C_{1-8} alkyl substituted by carbocyclic aryl,

(ii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

5 ·halogen,

 C_{1-10} alkyl,

°C₁₋₁₀ alkyl substituted by halogen,

 $^{\circ}C_{1-7}$ alkoxy, and

•C_{1.7} alkoxy substituted by halogen,

10 R_2 is -N(R_{2a})(R_{2b}), wherein R_{2a} and R_{2b} are each independently C_{1-5} alkyl; L is Formula (V) wherein R₅ and R₆ are both hydrogen; A and B are both a single bond;

> X_1, X_2, X_3 and X_4 are independently selected from the group consisting of hydrogen, halogen, and C_{1-4} alkyl; provided that at least one substituent selected from the group consisting of X₁, X₂, X₃ and X₄ is not hydrogen; and

Y is -C(O)-;

15

wherein carbocyclic aryl is phenyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

20 In some embodiments of the present invention, R_2 is $-N(CH_3)_2$; and X_1 , X_2 , X_3 and X_4 are independently selected from the group consisting of hydrogen, fluoro, and methyl; provided that at least one substituent selected from the group consisting of X1, X2, X3 and X4 is not hydrogen; or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the 25 compound is selected from the group consisting of:

N-(cis-4-{[4-(dimethylamino)-6-methylquinazolin-2-yl]amino}cyclohexyl)-2,2diphenylacetamide;

N-(cis-4-{[4-(dimethylamino)-6-methylquinazolin-2-yl]amino}cyclohexyl)-4-fluoro-3-

PCT/JP2004/004554

(trifluoromethyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-6-methylquinazolin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide; and

N-(cis-4-{[4-(dimethylamino)-6-methylquinazolin-2-yl]amino}cyclohexyl)-3,4,5-

5 trimethoxybenzamide;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

3-chloro-N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)-

10 benzamide;

3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)-benzamide;

 $N-(cis-4-\{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino\}\ cyclohexyl)-3,5-dimethoxybenzamide;$

N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yllamino}cyclohexyl)benzamide:

 $N-(cis-4-\{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino\} cyclohexyl)-4-methylbenzamide;$

N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)-4-fluorobenzamide;

N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)-3-methoxybenzamide;

N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide; and

N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)-3-

25 (trifluoromethyl)benzamide;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

(i) C_{1-3} alkyl, and

5

10

15

20

C₁₋₈ alkyl substituted by substituent(s) independently selected from the group consisting of:

*carbocyclic aryl,

*carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

«halogen,

**C₁₋₅ alkyl,

**C₁₋₅ alkyl substituted by halogen,

••C₁₋₅ alkoxy, and

••C₁₋₅ alkoxy substituted by halogen,

(ii) heterocyclyl, and

heterocyclyl substituted by halogen,

 R_2 is -N(R_{2a})(R_{2b}), wherein R_{2a} and R_{2b} are each independently $C_{1\text{--}5}$ alkyl;

L is Formula (XIII);

 X_1 , X_2 , X_3 and X_4 are independently hydrogen or halogen; provided that at least one substituent selected from the group consisting of X_1 , X_2 , X_3 and X_4 is not hydrogen; and

Y is $-C(O)NR_7$ - wherein R_7 is hydrogen or C_{1-5} alkyl;

wherein carbocyclic aryl is phenyl;

heterocyclyl is pyridyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments of the present invention, R₂ is -N(CH₃)₂; L is Formula (XIII) wherein A and B are both a single bond; X₁, X₂, X₃ and X₄ are independently hydrogen or fluoro; provided that at least one substituent selected from the group consisting of X₁, X₂, X₃ and X₄ is not hydrogen; and Y is -C(O)NH-; or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

15

20

methoxyphenyl)ethyl]cyclohexanecarboxamide;

cis-N-benzyl-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexanecarboxamide; cis-N-(3,5-dimethoxybenzyl)-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexanecarboxamide; 5 cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-(3-methoxybenzyl)cyclohexanecarboxamide; cis-N-[(6-chloropyridin-3-yl)methyl]-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino) cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-[3-(trifluoromethyl)-10 benzyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-[4-(trifluoromethyl)benzyl]cyclohexanecarboxamide; cis-N-[3,5-bis(trifluoromethyl)benzyl]-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2yl]amino}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-(3-iodobenzyl)cyclohexanecarboxamide; and cis-N-[1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt, hydrate or solvate thereof. In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of: cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-(4-methylbenzyl)cyclohexanecarboxamide; cis-N-(3-chlorobenzyl)-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-25 cyclohexanecarboxamide: cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-[(1R)-1-(3-

cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-(4-methoxybenzyl)-

cyclohexanecarboxamide;

cis-N-(2,4-dichlorobenzyl)-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-cyclohexanecarboxamide;

cis-N-(3,5-dichlorobenzyl)-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-

5 cyclohexanecarboxamide;

cis-N-(4-bromobenzyl)-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-cyclohexanecarboxamide;

cis-N-(2-bromobenzyl)-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-cyclohexanecarboxamide;

10 cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-[4-(trifluoromethoxy)-benzyl]cyclohexanecarboxamide; and

 $\label{lem:cis-4-} cis-4-\{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino\}-N-[(1S)-1-(4-methylphenyl)ethyl]cyclohexanecarboxamide;$

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments of the present invention, Q is Formula (IIb) and can be represented by the following formula:

$$\mathbb{R}_{N}$$
 \mathbb{R}_{N}
 \mathbb{R}_{N}

or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R₃, L, Y, and R₁ are as described herein, *supra* and *infra*.

In some embodiments of the present invention, R_1 is selected from the group consisting of: R_1 is selected from the group consisting of:

C₁₋₈ alkyl, and

C₁₋₈ alkyl substituted by substituent(s) independently selected from the group consisting of:

•carbocyclic aryl,

*carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

«halogen,

5

**C₁₋₅ alkyl, and

 $^{46}C_{1-5}$ alkoxy,

 R_3 is C_{1-5} alkyl;

L is Formula (XIII); wherein R₅ and R₆ are both hydrogen; A and B are both a single bond;

10

Y is $-C(O)NR_{7}$ -;

wherein carbocyclic aryl is phenyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments of the present invention, R₃ is isopropyl; and Y is -C(O)NH-; or a

15 pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments, compounds of the present invention is:

cis-N-(3-chlorobenzyl)-4-[(4-isopropylquinazolin-2-yl)amino]cyclohexanecarboxamide; or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In some embodiments of the present invention, R_1 is selected from hydrogen, $-CO_2^{t}Bu$, or $-CO_2Bn$ (Bn is a benzyl group);

 R_2 is -N(R_{2a})(R_{2b}), wherein R_{2a} is hydrogen or $C_{1\text{-}5}$ alkyl; R_{2b} is $C_{1\text{-}5}$ alkyl;

 R_3 is C_{1-5} alkyl;

 R_4 is -N(R_{4a})(R_{4b}) wherein R_{4a} is hydrogen or C_{1-5} alkyl; R_{4b} is C_{1-5} alkyl;

L is selected from Formula (V), (VIII), (IX), (XIII), (XVI), or (XVII);

25

 X_1 , X_2 , X_3 and X_4 are independently selected from the group consisting of hydrogen, halogen, and C_{1-4} alkyl; provided that at least one substituent selected from the group

consisting of X₁, X₂, X₃ and X₄ is not hydrogen; and

Y is a single bond;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

One aspect of the present invention pertains to pharmaceutical compositions comprising at least one compound, as described herein, in combination with a pharmaceutically acceptable carrier.

One aspect of the present invention pertains to methods for the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, including bulimia, anorezia, mental disorders including manic depression, schizophrenia, delirium, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction comprising administering to an individual suffering from the condition a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition thereof.

One aspect of the present invention pertains to methods for the prophylaxis or treatment of an eating disorder, obesity or an obesity related disorder comprising administering to an individual suffering from the condition a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition thereof.

One aspect of the present invention pertains to methods for the prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy comprising administering to an individual suffering from the condition a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition.

One aspect of the present invention pertains to compounds of the present invention, as described herein, or a pharmaceutical composition thereof, for use in a method of treatment of the human or animal body by therapy.

One aspect of the present invention pertains to compounds of the present invention, as

described herein, or a pharmaceutical composition thereof, for use in a method of prophylaxis or
treatment of an eating disorder, obesity or an obesity related disorder of the human or animal body by
therapy.

One aspect of the present invention pertains to compounds of the present invention, as

10

described herein, or a pharmaceutical composition thereof, for use in a method of prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy of the human or animal body by therapy.

One aspect of the present invention pertains to compounds of the present invention, as

described herein, for the manufacture of a medicament for use in the prophylaxis or treatment of an
eating disorder, obesity or obesity related disorders.

One aspect of the present invention pertains to compounds of the present invention, as described herein, for the manufacture of a medicament for use in the prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy.

One aspect of the present invention pertains to methods of decreasing food intake of an individual comprising administering to the individual a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition thereof.

One aspect of the present invention pertains to methods of inducing satiety in an individual comprising administering to said individual a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition thereof.

One aspect of the present invention pertains to methods of controlling or reducing weight gain in an individual comprising administering to said individual a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition thereof.

One aspect of the present invention pertains to methods of modulating a MCH receptor in an individual comprising contacting the receptor with a compound, as described herein. In some embodiments, the compound is an antagonist. In some embodiments, the modulation of the MCH receptor is for the prophylaxis or treatment of an eating disorder, obesity or obesity related disorder. In some embodiments, the modulation of the MCH receptor reduces food intake of the individual. In some embodiments, the modulation of the MCH receptor induces satiety in the individual. In some embodiments, the modulation of the MCH receptor controls or reduces weight gain of the individual. In some embodiments, the modulation of the MCH receptor is for prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy.

In some embodiments, the individual is a mammal.

In some embodiments, the mammal is a human.

In some embodiments, the human has a body mass index of about 18.5 to about 45. In some embodiments, the human has a body mass index of about 25 to about 45. In some embodiments, the human has a body mass index of about 30 to about 45. In some embodiments, the human has a body mass index of about 35 to about 45.

One aspect of the present invention pertains to methods of producing a pharmaceutical composition comprising admixing a compound, as described herein, and a pharmaceutically acceptable carrier.

One embodiment of the invention includes any compound of the invention which selectively binds an MCH receptor, such selective binding is preferably demonstrated by a Ki for one or more other GPCR(s), preferably NPY, being at least 10-fold greater than the Ki for any particular MCH receptor, preferable MCHR1.

As used herein, the term "alkyl" is intended to denote hydrocarbon compounds including straight chain and branched chain, including for example but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, tert-pentyl, n-hexyl, and the like.

The term "alkoxy" is intended to denote substituents of the formula -O-alkyl.

At various places in the present specification substituents of compounds of the invention are disclosed in groups. It is specifically intended that the invention include each and every individual subcombination of the members of such groups.

G-protein coupled receptors (GPCRs) represent a major class of cell surface receptors with which many neurotransmitters interact to mediate their effects. GPCRs are predicted to have seven membrane-spanning domains and are coupled to their effectors via G-proteins linking receptor activation with intracellular biochemical sequelae such as stimulation of adenylyl cyclase. Melanin Concentrating Hormone (MCH), a cyclic peptide, has been identified as the endogenous ligand of the orphan G-protein coupled receptor SLC-1. See, for example, Shimomura et al., Biochem. Biophys. Res. Commun. 261, 622-26 (1999). Studies have indicated that MCH acts as a neurotransmitter/modulator/regulator to alter a number of behavioral responses.

Mammalian MCH (19 amino acids) is highly conserved between rat, mouse, and human,

exhibiting 100% amino acid identity, but its physiological roles are less clear. MCH has been reported to participate in a variety of processes including feeding, water balance, energy metabolism, general arousal/attention state, memory and cognitive functions, and psychiatric disorders. For reviews, see 1. Baker, Int. Rev. Cytol. 126:1-47 (1991); 2. Baker, TEM 5:120-126 (1994); 3. Nahon, Critical Rev. 5 in Neurobiol 221:221-262, (1994); 4. Knigge et al., Peptides 18(7):1095-1097, (1996). The role of MCH in feeding or body weight regulation is supported by Qu et al., Nature 380:243-247, (1996), demonstrating that MCH is over expressed in the hypothalamus of ob/ob mice compared with ob/+mice, and that fasting further increased MCH mRNA in both obese and normal mice during fasting. MCH also stimulated feeding in normal rats when injected into the lateral ventricles as 10 reported by Rossi et al., Endocrinology 138:351-355, (1997). MCH also has been reported to functionally antagonize the behavioral effects of α -MSH; see: Miller et al., Peptides 14:1-10, (1993); Gonzalez et al., Peptides 17:171-177, (1996); and Sanchez et al., Peptides 18:3933-396, (1997). In addition, stress has been shown to increase POMC mRNA levels while decreasing the MCH precursor preproMCH (ppMCH) mRNA levels; Presse et al., Endocrinology 131:1241-1250, (1992). Thus 15 MCH can serve as an integrative neuropeptide involved in the reaction to stress, as well as in the regulation of feeding and sexual activity; Baker, Int. Rev. Cytol. 126:1-47, (1991); Knigge et al., Peptides 17:1063-1073, (1996).

The localization and biological activities of MCH peptide suggest that the modulation of MCH receptor activity can be useful in a number of therapeutic applications. MCH is expressed in the lateral hypothalamus, a brain area implicated in the regulation of thirst and hunger: Grillon et al., Neuropeptides 31:131-136, (1997); recently orexins A and B, which are potent orexigenic agents, have been shown to have very similar localization to MCH in the lateral hypothalamus; Sakurai et al., Cell 92:573-585 (1998). MCH mRNA levels in this brain region are increased in rats after 24 hours of food-deprivation; Herve and Fellmann, Neurpeptides 31:237-242 (1997); after insulin injection, a significant increase in the abundance and staining intensity of MCH immunoreactive perikarya and fibres was observed concurrent with a significant increase in the level of MCH mRNA;

Bahjaoui-Bouhaddi et al., Neuropeptides 24:251-258, (1994). Consistent with the ability of MCH to stimulate feeding in rats; Rossi et al., Endocrinology 138:351-355, (1997); is the observation that

MCH mRNA levels are upregulated in the hypothalami of obese ob/ob mice; Qu et al., Nature 380:243-247, (1996); and decreased in the hypothalami of rats treated with leptin, whose food intake and body weight gains are also decreased; Sahu, Endocrinology 139:795-798, (1998). MCH appears to act as a functional antagonist of the melanocortin system in its effects on food intake and on hormone secretion within the HPA (hypothalamopituitary/adrenal axis); Ludwig et al., Am. J. Physiol. Endocrinol. Metab. 274:E627-E633, (1998). Together these data suggest a role for endogenous MCH in the regulation of energy balance and response to stress, and provide a rationale for the development of specific compounds acting at MCH receptors for use in the treatment of obesity and stress-related disorders.

Accordingly, a MCH receptor antagonist is desirable for the prophylaxis or treatment of obesity or obesity related disorders. An obesity related disorder is a disorder that has been directly or indirectly associated to obesity, such as, type II diabetes, syndrome X, impaired glucose tolerance, dyslipidaemia, hypertension, coronary heart disease and other cardiovascular disorders including atherosclerosis, insulin resistance associated with obesity and psoriasis, for treating diabetic complications and other diseases such as polycystic ovarian syndrome (PCOS), certain renal diseases including diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis, end-stage renal diseases and microalbuminuria as well as certain eating disorders.

In species studied to date, a major portion of the neurons of the MCH cell group occupies a rather constant location in those areas of the lateral hypothalamus and subthalamus where they lie and may be a part of some of the so-called "extrapyramidal" motor circuits. These involve substantial striato- and pallidofugal pathways involving the thalamus and cerebral cortex, hypothalamic areas, and reciprocal connections to subthalamic nucleus, substantia nigra, and mid-brain centers;

Bittencourt et al., J. Comp. Neurol. 319:218-245, (1992). In their location, the MCH cell group may offer a bridge or mechanism for expressing hypothalamic visceral activity with appropriate and coordinated motor activity. Clinically it can be of some value to consider the involvement of this MCH system in movement disorders, such as Parkinson's disease and Huntingdon's Chorea in which extrapyramidal circuits are known to be involved.

Human genetic linkage studies have located authentic hMCH loci on chromosome 12 (12q23-24) and the variant hMCH loci on chromosome 5 (5q12-13) (Pedeutour et al., 1994). Locus 12q23-24 coincides with a locus to which autosomal dominant cerebellar atania type II (SCA2) has been mapped; Auburger et al., Cytogenet. Cell. Genet. 61:252-256, (1992); Twells et al., Cytogenet. 5 Cell. Genet. 61:262-265, (1992). This disease comprises neurodegenerative disorders, including an olivopontocerebellar atrophy. Furthermore, the gene for Darier's disease, has been mapped to locus 12q23-24; Craddock et al., Hum. Mol. Genet. 2:1941-1943, (1993). Dariers' disease is characterized by abnormalities I keratinocyte adhesion and mental illnesses in some families. In view of the functional and neuroanatomical patterns of the MCH neural system in the rat and human brains, the 10 MCH gene can represent a good candidate for SCA2 or Darier's disease. Interestingly, diseases with high social impact have been mapped to this locus. Indeed, the gene responsible for chronic or acute forms of spinal muscular atrophies has been assigned to chromosome 5q12-13 using genetic linkage analysis; Melki et al., Nature (London) 344:767-768, (1990); Westbrook et al., Cytogenet. Cell. Genet. 61:225-231, (1992). Furthermore, independent lines of evidence support the assignment of a major schizophrenia locus to chromosome 5q11.2-13.3; Sherrington et al., Nature (London) 336:164-167, (1988); Bassett et al., Lancet 1:799-801, (1988); Gilliam et al., Genomics 5:940-944, (1989). The above studies suggest that MCH can play a role in neurodegenerative diseases and disorders of emotion.

Additional therapeutic applications for MCH-related compounds are suggested by the

20 observed effects of MCH in other biological systems. For example, MCH can regulate reproductive functions in male and female rats. MCH transcripts and MCH peptide were found within germ cells in testes of adult rats, suggesting that MCH can participate in stem cell renewal and/or differentiation of early spermatocytes; Hervieu et al., Biology of Reduction 54:1161-1172, (1996). MCH injected directly into the medial preoptic area (MPOA) or ventromedial nucleus (VMN) stimulated sexual

25 activity in female rats; Gonzalez et al., Peptides 17:171-177, (1996). In ovariectomized rats primed with estradiol, MCH stimulated luteinizing hormone (LH) release while anti-MCH antiserum inhibited LH release; Gonzalez et al., Neuroendocrinology 66:254-262, (1997). The zona incerta, which contains a large population of MCH cell bodies, has previously been identified as a regulatory

site for the pre-ovulatory LH surge; MacKenzie et al., Neuroendocrinology 39:289-295, (1984). MCH has been reported to influence release of pituitary hormones including ACTH and oxytocin. MCH analogues can also be useful in treating epilepsy. In the PTZ seizure model, injection of MCH prior to seizure induction prevented seizure activity in both rats and guinea pigs, suggesting that 5 MCH-containing neurons can participate in the neural circuitry underlying PTZ-induced seizure; Knigge and Wagner, Peptides 18:1095-1097, (1997). MCH has also been observed to affect behavioral correlates of cognitive functions. MCH treatment hastened extinction of the passive avoidance response in rats; McBride et al., Peptides 15:757-759, (1994); raising the possibility that MCH receptor antagonists can be beneficial for memory storage and/or retention. A possible role for 10 MCH in the modulation or perception of pain is supported by the dense innervation of the periaqueductal grey (PAG) by MCH-positive fibers. Finally, MCH can participate in the regulation of fluid intake. ICV infusion of MCH in conscious sheep produced diuretic, natriuretic, and kaliuretic changes in response to increased plasma volume; Parkes, J. Neuroendocrinol. 8:57-63, (1996). Together with anatomical data reporting the presence of MCH in fluid regulatory areas of the brain, 15 the results indicate that MCH can be an important peptide involved in the central control of fluid homeostasis in mammals.

In a recent citation MCHR1 antagonists surprisingly demonstrated their use as an anti-depressants and/or anti-anxiety agents. MCHR1 antagonists have been reported to show antidepressant and anxiolytic activities in rodent models, such as, social interaction, forced swimming test and ultrasonic vocalization. Therefore, MCHR1 antagonists could be useful to independently treat subjects with depression and/or anxiety. Also, MCHR1 antagonists could be useful to treat subjects that suffer from depression and/or anxiety and obesity.

This invention provides a method of treating an abnormality in a subject wherein the abnormality is alleviated by decreasing the activity of a mammalian MCH1 receptor which comprises administering to the subject an amount of a compound which is a mammalian MCH1 receptor antagonist effective to treat the abnormality. In separate embodiments, the abnormality is a regulation of a steroid or pituitary hormone disorder, an epinephrine release disorder, an anxiety disorder, genta gastrointestinal disorder, a cardiovascular disorder, an electrolyte balance disorder, hypertension,

WO 2004/087680 PCT/JP2004/004554

diabetes, a respiratory disorder, asthma, a reproductive function disorder, an immune disorder, an endocrine disorder, a musculoskeletal disorder, a neuroendocrine disorder, a cognitive disorder, a memory disorder, a sensory modulation and transmission disorder, a motor coordination disorder, a sensory integration disorder, a motor integration disorder, a dopaminergic function disorder, a sensory transmission disorder, an olfaction disorder, a sympathetic innervation disorder, an affective disorder, a stress-related disorder, a fluid-balance disorder, a seizure disorder, pain, psychotic behavior, morphine tolerance, opiate addiction or migraine.

Compositions of the invention can conveniently be administered in unit dosage form and can be prepared by any of the methods well known in the pharmaceutical art, for example, as described in Remington's Pharmaceutical Sciences (Mack Pub. Co., Easton, PA, 1980).

The compounds of the invention can be employed as the sole active agent in a pharmaceutical or can be used in combination with other active ingredients which could facilitate the therapeutic effect of the compound.

Compounds of the present invention or a solvate or physiologically functional derivative

thereof can be used as active ingredients in pharmaceutical compositions, specifically as a MCH receptor antagonists. By the term "active ingredient" is defined in the context of a "pharmaceutical composition" and shall mean a component of a pharmaceutical composition that provides the primary pharmaceutical benefit, as opposed to an "inactive ingredient" which would generally be recognized as providing no pharmaceutical benefit. The term "pharmaceutical composition" shall mean a

composition comprising at one active ingredient and at least one ingredient that is not an active ingredient (for example and not limitation, a filler, dye, or a mechanism for slow release), whereby the composition is amenable to use for a specified, efficacious outcome in a mammal (for example, and not limitation, a human).

Pharmaceutical compositions, including, but not limited to, pharmaceutical compositions, comprising at least one compound of the present invention and/or an acceptable salt or solvate thereof (e.g., a pharmaceutically acceptable salt or solvate) as an active ingredient combined with at least one carrier or excipient (e.g., pharmaceutical carrier or excipient) can be used in the treatment of clinical conditions for which a MCH receptor antagonist is indicated. At least one compound of the present

invention can be combined with the carrier in either solid or liquid form in a unit dose formulation.

The pharmaceutical carrier must be compatible with the other ingredients in the composition and must be tolerated by the individual recipient. Other physiologically active ingredients can be incorporated into the pharmaceutical composition of the invention if desired, and if such ingredients are compatible with the other ingredients in the composition. Formulations can be prepared by any suitable method, typically by uniformly mixing the active compound(s) with liquids or finely divided solid carriers, or both, in the required proportions, and then, if necessary, forming the resulting mixture into a desired shape.

Conventional excipients, such as binding agents, fillers, acceptable wetting agents, tabletting lubricants, and disintegrants can be used in tablets and capsules for oral administration. Liquid preparations for oral administration can be in the form of solutions, emulsions, aqueous or oily suspensions, and syrups. Alternatively, the oral preparations can be in the form of dry powder that can be reconstituted with water or another suitable liquid vehicle before use. Additional additives such as suspending or emulsifying agents, non-aqueous vehicles (including edible oils), preservatives, and flavorings and colorants can be added to the liquid preparations. Parenteral dosage forms can be prepared by dissolving the compound of the invention in a suitable liquid vehicle and filter sterilizing the solution before filling and sealing an appropriate vial or ampoule. These are just a few examples of the many appropriate methods well known in the art for preparing dosage forms.

It is noted that when the MCH receptor antagonists are utilized as active ingredients in a pharmaceutical composition, these are not intended for use only in humans, but in other non-human mammals as well. Indeed, recent advances in the area of animal health-care mandate that consideration be given for the use of MCH receptor antagonists for the treatment of obesity in domestic animals (e.g., cats and dogs), and MCH receptor antagonists in other domestic animals where no disease or disorder is evident (e.g., food-oriented animals such as cows, chickens, fish, etc.).

Those of ordinary skill in the art are readily credited with understanding the utility of such compounds in such settings.

Pharmaceutically acceptable salts of the compounds of the invention can be prepared by reacting the free acid or base forms of these compounds with the appropriate base or acid in water, in

WO 2004/087680

an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, dioxane, or acetonitrile are preferred. For instance, when the compound (I) possesses an acidic functional group, it can form an inorganic salt such as an alkali metal salt (e.g., sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g., calcium salt, magnesium salt, barium salt, etc.), and an ammonium salt. When the compound (I) possesses a basic functional group, it can form an inorganic salt (e.g., hydrochloride, sulfate, phosphate, hydrobromate, etc.) or an organic salt (e.g., acetate, maleate, fumarate, succinate, methanesulfonate, p-toluenesulfonate, citrate, tartrate, etc.).

When a compound of the invention contains optical isomers, stereoisomers, regio isomers, rotational isomers, a single substance and a mixture of them are included as a compound of the invention. For example, when a chemical formula is represented as showing no stereochemical designation(s), such as Formula IV, then all possible stereoisomer, optical isomers and mixtures thereof are considered within the scope of that formula. Accordingly, Formula V, specifically designates the cis relationship between the two amino groups on the cyclohexyl ring and therefore this formula is also fully embraced by Formula IV.

The novel substituted quinazolines of the present invention can be readily prepared according to a variety of synthetic manipulations, all of which would be familiar to one skilled in the art.

Preferred methods for the preparation of compounds of the present invention include, but are not limited to, those described in Scheme 1-6.

The common intermediate (F) of the novel substituted quinazolines can be prepared as shown in Scheme 1. Commercially available 1*H*,3*H*-quinazoline-2,4-dione (A) is converted to 2,4-dihalo-quinazoline (B) by a halogenating agent with or without a base (wherein X is halogen such as chlore, brome, or iodo). The halogenating agent includes phosphorous oxychloride (POCl₃), phosphorous oxybromide (POBr₃), or phosphorus pentachloride (PCl₃). The base includes a tertiary amine (preferably *N*,*N*-diisopropylethylamine, etc.) or an aromatic amine (preferably *N*,*N*-dimethylaniline, etc.). Reaction temperature ranges from about 100°C to 200°C, preferably about 140°C to 180°C.

The halogen of 4-position of 2,4-dihalo-quinazoline (B) is selectively substituted by a primary

WO 2004/087680 PCT/JP2004/004554

or secondary amine (HNR_{4a}R_{4b}, wherein R_{4a} and R_{4b} are as defined above) with or without a base in an inert solvent to provide the corresponding 4-substitued amino adduct (C). The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydroxide (preferably sodium hydroxide, etc.), or a tertiary amine (preferably

- 5 N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.). The inert solvent includes lower alkyl alcohol solvents (preferably methanol, ethanol, 2-propanol, or butanol, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane, etc.), or amide solvents (preferably N,N-dimethylformamide or 1-methyl-pyrrolidin-2-one, etc.). Reaction temperature ranges from about 0°C to 200°C, preferably about 10°C to 150°C.
- In turn, this is substituted by the mono-protected diamine (D), wherein R₅, R₆, A, and B are as defined above and P is a protective group, with or without a base in an inert solvent to provide 2,4-disubstituted amino quinazoline (E). The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydroxide (preferably sodium hydroxide, etc.), or a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or
- 15 N-methylmorpholine, etc.). The inert solvent includes lower alkyl alcohol solvents (preferably methanol, ethanol, 2-propanol, or butanol, etc.) or amide solvents (preferably N,N-dimethylformamide or 1-methyl-pyrrolidin-2-one, etc.). Reaction temperature ranges from about 50°C to 200°C, preferably about 80°C to 150°C. Also this reaction can be carried out under microwave conditions.
- 20 Representative protecting groups suitable for a wide variety of synthetic transformations are disclosed in Greene and Wuts, *Protective Groups in Organic Synthesis*, second edition, John Wiley & Sons, New York, 1991, the disclosure of which is incorporated herein by reference in its entirety. The deprotection of the protective group leads to the common intermediate (F) of the novel substituted quinazolines.

Scheme 1

In another method, compounds of the present invention can be prepared wherein the aromatic ring is further substituted such as when Q is Formula (IIa). This method utilizes the conversion of an appropriately substituted 2-amino benzoic acid to the corresponding substituted 1*H*,3*H*-quinazoline-2,4-dione (A'); wherein X₁, X₂, X₃ and X₄ have the same meaning as described herein. Suitable conditions for the conversion to the substituted 1*H*,3*H*-quinazoline-2,4-dione (A') are known in the art, for example, potassium cyanate, sodium cyanate, urea, and the like. In a similar method as described above in Scheme 1, the substituted 1*H*,3*H*-quinazoline-2,4-dione (A') can be converted into useful intermediate (F') as described generally in Scheme 1.1.

WO 2004/087680 PCT/JP2004/004554

106

deprotection
$$X_2$$
 X_1
 $NR_{2a}R_{2b}$
 $NR_{2a}R_{2b}$
 $NR_{2a}R_{2b}$
 $NR_{2a}R_{2b}$
 $NR_{2a}R_{2b}$
 $NR_{2a}R_{2b}$
 $NR_{2a}R_{2b}$
 $NR_{2a}R_{2b}$

5

In a similar manner as described herein for intermediate (F), common intermediate (F') can be converted into novel quinazolines of Formula (I), wherein one or more of positions 5, 6, 7 or 8 on the quinazoline ring is/are substituted.

The conversion of the common intermediate (F) to the novel substituted quinazolines (G-I) of the present invention is outlined in Scheme 2.

The novel urea (G) of the present invention can be obtained by urea reaction using an isocyanate (R₁NCO) in an inert solvent with or without a base. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogenearbonate (preferably sodium hydrogenearbonate or potassium hydrogenearbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably *N*,*N*-diisopropylethylamine, triethylamine, or *N*-methylmorpholine, etc.), or an aromatic amine (preferably pyridine or imidazole, etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), aromatic solvents (preferably benzene or toluene, etc.), or polar solvents (preferably *N*,*N*-dimethylformamide or dinethyl sulfoxide, etc.). Reaction temperature ranges from about -20°C to 120°C, preferably about 0°C to 100°C.

The amine (F) is reacted with a isothiocyanate (R₁NCS) in an inert solvent with or without a base to provide the novel thiourea (H) of the present invention. The base includes an alkali metal

carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogenearbonate (preferably sodium hydrogenearbonate or potassium hydrogenearbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably *N,N*-diisopropylethylamine, triethylamine, or *N*-methylmorpholine, etc.), or an aromatic 5 amine (preferably pyridine or imidazole, etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), aromatic solvents (preferably benzene or toluene, etc.), or amide solvents (preferably *N,N*-dimethylformamide, etc.). Reaction temperature ranges from about -20°C to 120°C, preferably about 0°C to 100°C.

The novel urethane (I) of the present invention can be obtained by urethane reaction using R₁OCOCl, wherein X is halogen such as chloro, bromo, or iodo, in an inert solvent with or without a base. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably N₂N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.), or an aromatic amine (preferably pyridine, imidazole, or poly-(4-vinylpyridine), etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), aromatic solvents (preferably benzene or toluene, etc.), or polar solvents (preferably N₂N-dimethylformamide or dimethyl sulfoxide, etc.). Reaction temperature ranges from about -20°C to 120°C, preferably about 0°C to 100°C.

108

Scheme 2

$$\begin{array}{c} NR_{4a}R_{4b} \\ NR_{5} \\ NR_{5} \\ NR_{6} \\ NR_{7} \\ NR_{7} \\ NR_{8} \\ NR_{7} \\ NR_{8} \\ NR_{1} \\ NR_{1} \\ NR_{2} \\ NR_{3} \\ NR_{4} \\ NR_{5} \\ NR_{6} \\ NR_{1} \\ NR_{1} \\ NR_{2} \\ NR_{3} \\ NR_{4} \\ NR_{5} \\ NR_{5} \\ NR_{6} \\ NR_{1} \\ NR_{1} \\ NR_{1} \\ NR_{2} \\ NR_{1} \\ NR_{1} \\ NR_{2} \\ NR_{3} \\ NR_{4} \\ NR_{1} \\ NR_{1} \\ NR_{2} \\ NR_{3} \\ NR_{4} \\ NR_{1} \\ NR_{1} \\ NR_{2} \\ NR_{3} \\ NR_{4} \\ NR_{1} \\ NR_{2} \\ NR_{3} \\ NR_{4} \\ NR_{4} \\ NR_{5} \\ NR_{5}$$

Compounds of Formula (K) can be prepared as shown in Scheme 3.

[4-(Benzyloxycarbonylamino-methyl)-cyclohexyl]-carbamic acid *tert*-butyl ester (J) is synthesized by the method which is described in WO 01/72710. The deprotection of Boc-group is achieved by an acid to give the amine. The coupling of the amine with quinazoline core (C), which is synthesized as scheme 1, gives 2,4-disubstituted amino quinazoline. The deprotection of Z-group is achieved by hydrogen reduction to give compounds of Formula (K).

~ 109

Scheme 3

Compounds of Formula (L) can be prepared as shown in Scheme 4. The dicarboxylic acid of commercially available *cis*-cyclohexane-1,4-dicarboxylic acid is transformed to dibenzyl carbamate by curtius rearrangement. The deprotection of Z-group is achieved by hydrogen reduction to give the diamine. The mono-protection of the diamine can be achieved by the method described in *Synthetic communications*, 20, 2559-2564 (1990). The coupling of the amine with quinazoline core (C), which is synthesized as scheme 1, gives 2,4-disubstituted amino quinazoline. The deprotection of Boc-group is achieved by an acid to give the amine (L).

Scheme 4

$$O(2)$$
 $O(2)$
 $O(2)$

Compounds of Formula (M) can be prepared as shown in Scheme 5. This method utilizes 1-protected aminocyclopentane-3-carboxylic acids. The 1-protected aminocyclopentane-3-carboxylic acids that can be used are either commercially available or prepared using methods known in the art.

- One particularly useful compound is (1R,3S)-N-Boc-1-aminocyclopentane-3-carboxylic acid. The 1-protected aminocyclopentane-3-carboxylic acid can be converted to the orthogonally protected 1,3-diaminocyclopentane by an arrangement, such as, the Curtius, Hoffman, Lossen, Schmidt, and the like; and subsequently protected. In the Curtius Rearrangement method, the protected amine is generated by subjecting the isocyanate intermediate with an alcohol to give a useful urethane
- protection group, such as, Boc, Cbz, and the like. In a subsequent step, one protecting group is removed and allowed to react in a similar manner as described herein with intermediate (C) or (C'), depicted as Q-X in Scheme 5. The second protecting group is removed to achieve amine (M).

Scheme 5

15

In a similar manner as described herein for intermediate (F), compound (M) can be converted into novel quinazolines of Formula (I) using methods described herein.

Novel compounds of Formula (N) of the present invention can be prepared as shown in Scheme 6. This method can utilize any of the intermediate amines, such as, amines (F), (F'), (K), (L), and (M). The amine is coupled to a 2-halopyridine carboxylic acid or similar compound, such as an acid halide, to give the corresponding 2-halopyridyl product. Suitable coupling methods are known in

the art, such as, DCC, EDC, PyBoP, HATU, HBTU, BOP, and the like. In a subsequent step, the 2-halopyridyl product is converted to compounds of Formula (N) by treatment with an appropriate alcohol, under basic conditions, such as, NaH, KH, Cs₂CO₃, K₂CO₃, Na₂CO₃ and the like. In some circumstances, a metal alkoxide can be used, such as, sodium alkoxide, potassium alkoxide and the like. The alcohol or metal alkoxide can be either substituted or unsubstituted. In a similar manner, novel compounds of Formula (O) can be prepared using a substituted or unsubstituted phenol, wherein R₈-R₁₂ represent various substitutions on the phenyl ring, including but not limited those substitutions described herein.

Scheme 6

$$\begin{array}{c} R_{5} \\ Q \\ N \\ A \\ O \text{ or } 1 \end{array}$$

$$\begin{array}{c} R_{5} \\ R_{6} \\ N \\ O \text{ or } 1 \end{array}$$

$$\begin{array}{c} R_{5} \\ R_{6} \\ N \\ O \text{ or } 1 \end{array}$$

$$\begin{array}{c} R_{5} \\ R_{6} \\ N \\ O \text{ or } 1 \end{array}$$

$$\begin{array}{c} R_{5} \\ R_{6} \\ N \\ O \text{ or } 1 \end{array}$$

$$\begin{array}{c} R_{7} \\ R_{8} \\ R_{12} \\ O \text{ or } 1 \end{array}$$

$$\begin{array}{c} R_{8} \\ R_{12} \\ O \text{ or } 1 \end{array}$$

$$\begin{array}{c} R_{8} \\ R_{12} \\ O \text{ or } 1 \end{array}$$

$$\begin{array}{c} R_{8} \\ R_{12} \\ O \text{ or } 1 \end{array}$$

$$\begin{array}{c} R_{8} \\ R_{12} \\ O \text{ or } 1 \end{array}$$

$$\begin{array}{c} R_{8} \\ O \text{ or } 1 \end{array}$$

Examples

10

The compounds of the invention and their synthesis are further illustrated by the following examples. The following examples are provided to further define the invention without, however,

15 limiting the invention to the particulas of these examples. "Ambient temperature" as referred to in the following example is meant to indicate a temperature falling between 0 °C and 40 °C. The following compounds are named by Beilstein Auto Nom Version 4.0, CS Chem Draw Ultra Version 6.0, CS

compounds are named by Beilstein Auto Nom Version 4.0, CS Chem Draw Ultra Version 6.0, CS Chem Draw Ultra Version 6.0.2, Chem Draw Ultra Version 7.0.1, or ACD Name Version 7.0.

Abbreviations used in the instant specification, particularly the Schemes and Examples, are as follows:

5

¹H NMR: proton nuclear magnetic resonance spectrum

APCI: atmospheric pressure chemical ionization

Boc: t-butoxycarbonyl

(Boc)2O: di-tertiary-butyl dicarbonate

10 BuOH: butanol

CDCl₃: deuterated chloroform

CH₂Cl₂: dichloromethane

CHCl₃: chloroform

CI: chemical ionization

DIEA: diisopropylethylamine

DMA: N,N-dimethylacetamide

DMSO: dimethyl sulfoxide

EI: electron ionization

ESI: electrospray ionization

20 Et₂O: diethyl ether

EtOAc: acetic acid ethyl ester

EtOH: ethanol

FAB: fast atom bombardment

HATU : O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium-

25 hexafluorophosphate

H₂SO₄: sulfuric acid

HCl: hydrogen chloride

K₂CO₃: potassium carbonate

Me₂NH : dimethylamine

MeNH₂: methylamine

MeOH: methanol

MgSO₄: magnesium sulfate

5 NaH: sodium hydride

NaBH(OAc)₃: sodium triacetoxyborohydride

NaBH₃CN: sodium cyanoborohydride

NaBH₄: sodium borohydride

NaHCO₃: sodium hydrogencarbonate

10 Pd/C: palladium carbon

POCl₃: phosphoryl chloride

PVP : poly(4-vinylpyridine)

SOCI₂: thionyl chloride

TEA: triethylamine

15 TFA: trifluoroacetic acid

THF: tetrahydrofuran

ZC1: benzyloxycarbonyl chloride

s: singlet

d : doublet

20 t: triplet

q : qualtet

dd: doublet doublet

dt : doublet triplet

ddd: doublet doublet

25 brs: broad singlet

m: multiplet

J: coupling constant

Hz: Hertz

114

Example 1

1-(3,3-Dimethoxy-phenyl)-3-[cis-4-(4-dimethylamino-quinacolin-2-ylamino)-cyclohetyl]-urea hydrochloride

5

Step A: Synthesis of 2.4-dichloro-quinazoline.

To a suspension of 1*H*-quinazoline-2,4-dione (150 g, 925 mmol) in POCl₃ (549 mL, 5.89 mol) was added dimethyl-phenyl-amine (123 mL, 962 mmol). The mixture was stirred at reflux for 7 hr and concentrated. The solution was poured into ice water, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (silica gel, 50% CHCl₃ in hexane to 10% EtOAc in CHCl₃) to give 2,4-dichloro-quinazoline (159 g, 86%) as a pale yellow solid.

CI MS m/e 199, M⁺; ¹H NMR (300 MHz, CDCl₃) 8 7.71-7.81 (m, 1 H), 7.95-8.04 (m, 2 H), 8.27 (dt, *J* = 8.3, 1.1 Hz, 1 H).

15

Step B: Synthesis of (2-chloro-quinazolin-4-yl)-dimethyl-amine.

A solution of 2,4-dichloro-quinazoline (102 g, 530 mmol) in THF (1.2 L) was cooled to 4 °C and 50% aqueous Me₂NH (139 mL, 1.33 mol) was added. The mixture was stirred at ambient temperature for 80 min. The solution was alkalized with saturated aqueous NaHCO₃ (pH = 9), and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, and concentrated. The residue was suspended in 50% Et₂O in hexane (250 mL) and the mixture was stirred at ambient temperature for 30 min. The precipitate was collected by filtration, washed with 50% Et₂O in hexane, and dried at 80 °C to give (2-chloro-quinazolin-4-yl)-dimethylamine (104 g, 94%) as a pale yellow solid.

25 ESI MS m/e 207, M⁺; ¹H NMR (300 MHz, CDCl₃) δ 3.41 (s, 6 H), 7.68 (ddd, J = 8.4, 6.9, 1.4 Hz, 1 H), 7.73-7.78 (m, 2 H), 8.00 (d, J = 8.4 Hz, 1 H).

Step C: Synthesis of (cis-4-benzyloxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester.

To a suspension of *cis*-cyclohexane-1,4-dicarboxylic acid (25.0 g, 145 mmol) in benzene (125 mL) were added phosphorazidic acid diphenyl ester (81.9 g, 298 mmol) and triethylamine (30.1 g, 297 mmol). The reaction mixture was stirred at reflux for 2.5 hr. Benzyl alcohol (32.2 g, 298 mmol) was added and the mixture was stirred at reflux for 24 hr. The reaction mixture was concentrated and the residue was dissolved in EtOAc and H₂O. The organic layer was separated and the aqueous layer was extracted with EtOAc (twice). The combined organic layer was washed with 1 M aqueous KHSO₄, saturated aqueous NaHCO₃, and brine. The organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (silica gel, 33% EtOAc in hexane) to give (*cis*-4-benzyloxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester (52.0 g, 94%) as a colorless oil.

ESI MS m/e 405, M + Na⁺; ¹H NMR $(300 \text{ MHz}, \text{CDCl}_3) \delta 1.45-1.60 \text{ (m, 4 H)}, 1.60-1.80 \text{ (m, 4 H)}, 3.52-3.80 \text{ (m, 2 H)}, 4.70-5.00 \text{ (m, 2 H)}, 5.07 \text{ (s, 4 H)}, 7.15-7.40 \text{ (m, 10 H)}.$

Step D: Synthesis of (cis-4-amino-cyclohexyl)-carbamic acid tert-butyl ester.

- To a solution of (cis-4-benzyloxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester (91.7 g, 240 mmol) in MeOH (460 mL) was added 5% Pd/C (9.17 g). The reaction mixture was stirred at ambient temperature under hydrogen atmosphere for 2.5 days, filtrated through a pad of celite, and concentrated to give a diamine as a colorless oil. To a solution of the diamine in MeOH (550 mL) was added a solution of (Boc)₂O (6.59 g, 30.2 mmol) in MeOH (80 mL) dropwise over 4 hr.
- The reaction mixture was stirred at ambient temperature for 1.5 days and concentrated. After dissolution with H₂O, the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, and concentrated to give cis-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester (7.78 g, 15%, crude) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH. The solution was dried over MgSO₄, filtrated,
- and concentrated to give a recovered diamine (32.9 g) as a colorless oil. To a solution of the recovered diamine (32.9 g, 288 mmol) in MeOH (660 mL) was added a solution of (Boc)₂O (6.29 g, 28.8 mmol) in MeOH (80 mL) dropwise over 5 hr. The reaction mixture was stirred at ambient temperature for 9.5 hr and concentrated. After dissolution with H₂O, the aqueous layer was extracted with CHCl₃

(three times). The combined organic layer was dried over MgSO₄, filtrated, and concentrated to give (cis-4-amino-cyclohexyl)-carbamic acid tert-butyl ester (8.16 g, 16%, crude) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH. The solution was dried over MgSO₄, filtrated, and concentrated to give a recovered diamine (23.1 g) as a colorless oil. To a 5 solution of the recovered diamine (23.1 g, 202 mmol) in MeOH (462 mL) was added a solution of (Boc)₂O (4.42 g, 20.3 mmol) in MeOH (56 mL) dropwise over 4 hr. The reaction mixture was stirred at ambient temperature for 3.5 days and concentrated. After dissolution with H_2O , the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, and concentrated to give (cis-4-amino-cyclohexyl)-carbamic acid tert-butyl ester (5.01 g, 10% based 10 on starting material) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH. The solution was dried over MgSO₄, filtrated, and concentrated to give a recovered diamine (16.0 g) as a colorless oil. To a solution of the recovered diamine (16.0 g, 140 mmol) in MeOH (320 mL) was added a solution of (Boc)₂O (3.06 g, 14.0 mmol) in MeOH (40 mL) dropwise over 4 hr. The reaction mixture was stirred at ambient temperature for 17 hr and 15 concentrated. After dissolution with H_2O , the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, and concentrated to give (cis-4amino-cyclohexyl)-carbamic acid tert-butyl ester (3.53 g, 7% based on the starting material) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH. The solution was dried over MgSO₄, filtrated, and concentrated to give a recovered diamine (11.1 g) as a 20 colorless oil. ESI MS m/e 215, M + H $^{+}$; ¹H NMR (300 MHz, CDCl₃) δ 1.20-1.80 (m, 8 H), 1.44 (s, 9 H), 2.78-2.95

Step E: Synthesis of N^2 -(cis-4-amino-cyclohexyl)-N', N'-dimethyl-quinazoline-2.4-diamine,

(m, 1 H), 3.50-3.80 (m, 1 H), 4.30-4.82 (m, 1 H).

A mixture of (2-chloro-quinazolin-4-yl)-dimethyl-amine (3.00 g, 14.4 mmol) and (cis-4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (3.72 g, 17.4 mmol) in 2-propanol (10 mL) was stirred at reflux for 5.5 days, poured into saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated,

concentrated, and purified by flash chromatography (NH-silica, 20% EtOAc in hexane) to give [cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester including solvent (5.44 g) as a colorless oil. To a solution of the above material (5.44 g) in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (50 mL). The reaction mixture was stirred at ambient temperature

- 5 for 2 hr and concentrated. The residue was alkalized with saturated aqueous NaHCO3, and the precipitate was collected by filtration to give N^2 -(cis-4-amino-cyclohexyl)- N^4 , N^4 -dimethylquinazoline-2,4-diamine (2.26 g, 55%) as a white solid. The aqueous layer was extracted CHCl3 (three times). The combined organic layer was dried over MgSO₄, filtrated, and concentrated to give N^2 -(cis-4-amino-cyclohexyl)-N',N'-dimethyl-quinazoline-2,4-diamine (687 mg, 17%) as a white solid.
- 10 ESI MS m/e 285, M $^{+}$; 1 H NMR (300 MHz, DMSO-d $_{6}$) δ 1.22-1.82 (m, 8 H), 3.20 (s, 6 H), 3.38-3.52 (m, 1 H), 3.83-4.06 (m, 1 H), 6.56 (d, J = 7.5 Hz, 1 H), 7.01 (t, J = 7.6 Hz, 1 H), 7.29 (d, J = 8.3 Hz, 1 H)1 H), 7.47 (t, J = 8.3 Hz, 1 H), 7.86 (d, J = 7.5 Hz, 1 H).

Step F: Synthesis of 1-(3,4-dimethoxy-phenyl)-3-[cis-4-(4-dimethylamino-quinazolin-2-15 ylamino)-cyclohexyl]-urea hydrochloride.

To a solution of N^2 -(cis-4-amino-cyclohexyl)-N', N'-dimethyl-quinazoline-2, 4-diamine (500) mg, 1.75 mmol) in DMSO (5 mL) was added 4-isocyanato-1,2-dimethoxy-benzene (345 mg, 1.93 mmol). The mixture was stirred at ambient temperature for 1 hr and poured into water. The precipitate was filtrated, washed with water, and purified by medium-pressure liquid chromatography 20 (silica gel, 5% EtOAc in hexane) and flash chromatography (NH-silica, EtOAc) to give a pale yellow oil. To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. A suspension of the residue in Et₂O (20 mL) was stirred at ambient tempareture for 1 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 80 °C under reduced pressure to give 1-(3.4-dimethoxy-25 phenyl)-3-[cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-urea hydrochloride (757 mg,

ESI MS m/e 487, M (free) + Na⁺; 1 H NMR (300 MHz, CDCl₃) δ 1.68-2.07 (m, 8 H), 3.49 (s, 6 H), 3.79 (s, 6 H), 3.95, (brs, 1 H), 4.09 (brs, 1 H), 6.66 (d, J = 8.7 Hz, 1 H), 6.82 (d, J = 9.0 Hz, 1 H),

86%) as a white solid.

118

7.17-7.33 (m, 2 H), 7.48-7.66 (m, 2 H), 7.87 (d, J = 7.3 Hz, 1 H), 8.37 (brs, 1 H), 12.77 (brs, 1 H).

Example 2

5 1-(2,3-Dichloro-phenyl)-3-[cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride

Step A: Synthesis of (cis-4-hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester.

A suspension of cis-4-amino-cyclohexanecarboxylic acid (244 g, 1.71 mol) in MeOH (2.45 10 L) was cooled to -8 °C. Thionyl chloride (440 mL, 6.03 mol) was added dropwise. The resulting solution was stirred at ambient temperature for 4.5 hr and concentrated to give a white solid. To a suspension of the above solid in CHCl₃ (3.00 L) were added triethylamine (261 mL, 1.88 mol) and (Boc)₂O (409 g, 1.88 mol) successively. The reaction mixture was stirred at ambient temperature for 5 hr and poured into water. The aqueous layer was extracted with CHCl₃ (three times). The combined 15 organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (silica gel, 11% EtOAc in hexane to 10% MeOH in CHCl₃) and flash chromatography (NH-silica, 33% EtOAc in hexane to 9% MeOH in CHCl₃) to give a colorless oil (531 g). To a suspension cooled at -4 °C of lithium aluminum hydride (78.3 g, 2.06 mol) in Et₂O (7.9 L) was added a solution of the above oil (530.9 g) in Et₂O (5.3 L) below 0 °C. The resulting suspension was stirred at ambient 20 temperature for 2 hr. The reaction mixture was cooled on an ice-bath, quenched with cold water, and filtrated through a pad of celite. The filtrate was dried over MgSO4, filtrated, and concentrated. The residue was suspended in hexane (300 mL), filtrated, washed with hexane, and dried at 70 °C to give (cis-4-hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester (301 g, 77%) as a white solid. ESI MS m/e 252, M + Na $^{+}$; ¹H NMR (300 MHz, CDCl₃) δ 1.16-1.36 (m, 2 H), 1.45 (s, 9 H), 1.52-1.77 25 (m, 7 H), 3.51 (d, J = 6.2 Hz, 2 H), 3.75 (brs, 1 H), 4.30-4.82 (m, 1 H).

Step B: Synthesis of [cis-4-(benzyloxycarbonylamino-methyl)-cyclohexyl]-carbamic acid tert-butyl ester.

To a solution of (cis-4-hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester (17.7 g, 77.2 mmol) in THF (245 mL) were added triphenylphosphine (20.2 g, 77.0 mmol) and phthalimide (11.4 g, 77.5 mmol) successively. The resulting suspension was cooled on an ice-bath and 40% diethyl azodicarboxylate in toluene (33.6 mL, 74.1 mmol) was added over 1 hr. The reaction mixture 5 was stirred at ambient temperature for 2.5 days, concentrated, and purified by flash chromatography (silica gel, 33% EtOAc in hexane) to give a white solid. To a suspension of the above solid (27.5 g) in EtOH (275 mL) was added hydrazine hydrate (5.76 g, 115 mmol). The mixture was stirred at reflux for 2.25 hr, cooled, and concentrated. The residue was dissolved in 10% aqueous NaOH (350 mL) and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried 10 over MgSO₄, filtrated, and concentrated. To a solution of the above residue in CHCl₃ (275 mL) was added triethylamine (8.54 g, 84.4 mmol). The resulting solution was cooled to 0 °C and ZCl (14.4 g, 84.4 mmol) was added below 5 °C. The reaction mixture was stirred at ambient temperature for 16 hr and poured into saturated aqueous NaHCO3. The aqueous layer was extracted with CHCl3 (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by 15 flash chromatography (silica gel, 2% MeOH in CHCl₃) to give [cis-4-(benzyloxycarbonylaminomethyl)-cyclohexyl]-carbamic acid tert-butyl ester (25.3 g, 91%) as a colorless oil. ESI MS m/e 385, M + Na $^{+}$; 1 H NMR (300 MHz, CDCl₃) δ 1.13-1.31 (m, 2 H), 1.44 (s, 9 H), 1.48-1.75 (m, 7 H), 3.10 (t, J = 6.4 Hz, 2 H), 3.72 (brs, 1 H), 4.42-4.76 (m, 1 H), 4.76-4.92 (m, 1 H), 5.09 (s, 2)H), 7.27-7.38 (m, 5 H).

20

Step C: Synthesis of (cis-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester.

To a solution of [cis-4-(benzyloxycarbonylamino-methyl)-cyclohexyl]-carbamic acid tert-butyl ester (12.9 g, 35.6 mmol) in EtOAc (129 mL) was added 4 M hydrogen chloride in EtOAc (129 mL). The reaction mixture was stirred at ambient temperature for 3 hr, filtrated, washed with EtOAc, and dried under reduced pressure. The above solid was dissolved in saturated aqueous NaHCO₃ (pH = 9). The aqueous layer was extracted with CHCl₃ (five times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and dried under reduced pressure to give (cis-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester (8.88 g, 95%) as a colorless oil.

120

ESI MS m/e 263, M + H $^{+}$; ¹H NMIR (300 MHz, CDCl₃) δ 1.36-1.98 (m, 9 H), 2.96-3.32 (m, 3 H), 5.12 (brs, 3 H), 7.36 (s, 5 H).

Step D: Synthesis of [cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]5 carbamic acid benzyl ester.

A mixture of (2-chloro-quinazolin-4-yl)-dimethyl-amine obtained in step B of example 1 (50 g, 258 mmol) and (*cis*-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester (81 g, 309 mmol) in 2-propanol (75 mL) was stirred at reflux for 7 days. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (NH-silica gel, 13% to 50% EtOAc in hexane) to give [*cis*-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester (65.7 g, 59%) as a pale brown solid. ESI MS m/e 434, M + H⁺; ¹H NMIR (300 MHz, CDCl₃) 8 1.23-1.40 (m, 2 H), 1.52-1.73 (m, 5 H), 1.80-1.93 (m, 2 H), 3.11 (t, *J* = 6.3 Hz, 2 H), 3.26 (s, 6 H), 4.18-4.28 (m, 1 H), 4.82-4.93 (m, 1 H), 4.93-5.06 (m, 1 H), 5.10 (s, 2 H), 7.01 (ddd, *J* = 8.2, 6.5, 1.7 Hz, 1 H), 7.26-7.52 (m, 7 H), 7.81 (d, *J* = 9.0 Hz, 1 H).

Step E: Synthesis of N^2 -(cis-4-aminomethyl-cyclohexyl)-N',N'-dimethyl-quinazoline-2,4-diamine.

- To a solution of [cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl-methyl]-carbamic acid benzyl ester (12.1 g, 27.9 mmol) in MeOH (120 mL) was added 10% Pd/C (1.21 g). The mixture was stirred at 50 °C under hydrogen atmosphere for 19 hr, filtrated, concentrated, and purified by flash chromatography (NH-silica, 66% EtOAc in hexane to 15% MeOH in CHCl₃) to give N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine (6.9 g, 83%) as a pale yellow solid.
 - CI MS m/e 300, M + H⁺; ¹H NMR (300 MHz, CDCl₃) δ 0.90-1.51 (m, 5 H), 1.57-1.76 (m, 4 H), 1.81-1.96 (m, 2 H), 2.60 (d, J = 6.4 Hz, 2 H), 3.27 (s, 6 H), 4.24-4.30 (m, 1 H), 5.04 (d, J = 7.3 Hz, 1 H), 6.98-7.04 (m, 1 H), 7.40-7.51 (m, 2 H), 7.81 (d, J = 8.4 Hz, 1 H).

Step F: Synthesis of 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohemylmethyll-urea hydrochloride.

Using the procedure for the step F of example 1, the title compound was obtained.

5 ESI MS m/e 509, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.48-2.12 (m, 9 H), 3.37-3.44 (m. 2 H), 3.51 (s, 6 H), 4.37-4.49 (m, 1 H), 6.91-7.13 (m, 3 H), 7.27 (ddd, *J* = 8.4, 7.2, 1.2 Hz, 1 H), 7.50 (dd, *J* = 8.6, 1.2 Hz, 1 H), 7.67 (ddd, *J* = 8.4, 7.2, 1.2 Hz, 1 H), 7.89 (d, *J* = 8.4 Hz, 1 H), 3.17 (dd, *J* = 8.2, 1.7 Hz, 1 H), 8.24 (s, 1 H), 8.89 (d, *J* = 8.9 Hz, 1 H), 12.42 (s, 1 H).

10

Example 3

1-(2,6-Dichloro-phenyl)-3-[cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride

15 Step A: Synthesis of 1-(2,6-dichloro-phenyl)-3-[cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride.

Using the procedure for the step F of example 1, the title compound was obtained. ESI MS m/e 509, M (free) + Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.51-2.06 (m, 9 H), 3.37-3.42 (m, 2 H), 3.52 (s, 6 H), 4.37-4.47 (m, 1 H), 6.35-6.45 (m, 1 H), 6.96-7.06 (m, 1 H), 7.23-7.31 (m, 3 H), 7.43-7.49 (m, 1 H), 7.61-7.68 (m, 1 H), 7.91 (d, J = 7.9 Hz, 2 H), 8.72 (d, J = 8.7 Hz, 1 H), 12.64 (s, 1 H).

Example 4-845

To a solution of amines (30 μmol) as shown below in DMSO (300 μL) were added isocyanate or isothiocyanate (60 μmol) in DMSO (200 μL) at ambient temperature. The mixture was stirred at the same temperature for 22 hr. To the reaction mixture were added 2 M MeNH₂ in THF (30 μL, 60 μmol) or D-gulcamine (60 μmol) in DMSO (200 μL) at ambient temperature. After stirring at the

122

same temperature for 20 hr, the reaction mixture was filtrated through a pad of SCX, concentrated by a stream of dry N_2 , and purified by silica gel chromatography (silica gel, 2% to 7% 2 M $NH_3/MeOH$ in CHCl₂) and silica gel chromatography (NH-silica, 20% to 50% EtOAc in hexane) to give the desired product. The product was determined by ESI-MS or APCI-MS.

5

Example 046-005

To a solution of poly(4-vinylpyridine) (75 μL) in CH₂Cl₂ (200 μL) were added the amines (30 μmol) as shown below in CH₂Cl₂ (200 μL) and chloroformate (R₁OCOCl, 60 μmol) in CH₂Cl₂ (200 μL) at ambient temperature. After stirring at the same temperature for 17 hr, the reaction mixture was filtrated and concentrated by a stream of dry N₂. To the residue were added CH₂Cl₂ (700 μL) and PSA (300 μL). After the stirring at ambient temperature for 19 hr, the reaction mixture was filtrated and purified by silica gel chromatography (NH-silica, 20% EtOAc in hexane) and silica gel chromatography (silica gel, 2% to 7% 2 M NH₃/MeOH in CHCl₃) to give the desired product. The product was determined by ESI-MS or APCI-MS.

Wherein the amines are selected from

 N^2 -(cis-4-amino-cyclohexyl)-N',N'-dimethyl-quinazoline-2,4-diamine obtained in step E of example 1 or N^2 -(cis-4-aminomethyl-cyclohexyl)-N',N'-dimethyl-quinazoline-2,4-diamine obtained in step E of example 2.

Ex. No.	compound name	MS	class
4	N-(3-acetylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-	447 (N1 + H)	3
	yl]amino}cyclohexyl)urea	77/(1.1 / 11)	J
5	N-1-adamantyl-N'-(cis-4-([4-(dimethylamino)quinazolin-2-	463 (h [+ H)	3
	yl]amino) cyclohenyl)urea	(1	
6	N-(4-acetylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-	447 (M + H)	3
	yl]amino) cyclohexyl)urea	\ \tag{\frac{1}{2}}	
7	N-{[(cis-4-{[4-(dimethylamino)quinazolin-2-	433 (M + H)	3
	yl]amino) cyclohexyl)amino]carbonyl) benzamide		
8	N-[3,5-bis(trifluoromethyl)phenyl]-N'-(cis-4-{[4-	541 (M + H)	3
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea N-benzyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-		
ò	yl]amino) cyclohexyl)urea	419 (M + H)	2
	N-(2-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-		
10	vilamino} cyclohexyl)urea	483 (M + H)	1
	N-biphenyl-2-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-		
11	yl]amino) cyclohexyl)urea	481 (M + H)	1 1
	N-(4-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-		
12	yl]amino)cyclohexyl)urea	483 (M + H)	2
	N-butyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-	207 (25) 11	
13	yl]amino)cyclohexyl)urea	385 (M + H)	1
14	N-(3-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-	439 (M + H)	3
14	yl]amino}cyclohexyl)urea	439 (NI + II)	
15	N-(4-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-	439 (M + H)	3
10	yl]amino)cyclohexyl)urea	435 (141 / 11)	
16	N-cyclohexyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-	411 (M + H)	2
	yl]amino)cyclohexyl)urea		
17	N-(3-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-	430 (M + H)	3
	yl]amino}cyclohexyl)urea		
18	N-(2-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-	439 (M + H)	1
	yl]amino)cyclohexyl)urea		
19	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	433 (M + H)	1
	N'-(2,6-dimethylphenyl)urea N-(3,4-dichlorophenyl)-N'-(cis-4-([4-(dimethylamino)quinazolin-		
20	2-yl]amino}cyclohexyl)urea	473 (M + H)	3
	N-(2,4-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-		
21	2-yl]amino}cyclohexyl)urea	441 (M + H)	1
	N-(2,4-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-		
22	2-yl]amino}cyclohexyl)urea	473 (M + H)	2
	N-(3,5-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-	172 (3.6 . 11)	
23	2-yl]amino) cyclohexyl)urea	473 (M + H)	3
2 1	N-(2,3-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-	472 (N4 + TY)	,
24	2-y1]amino) cyclohexy1)urea	473 (M + H)	3
25	N-(2,6-difluorophenyl)-N'-(cis-4-([4-(dimethylamino)quinazolin-	441 (M + H)	3
د نــ	2-yl]amino) cyclohexyl)urea		ی
26	N-(2,5-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-	473 (M+H)	3
U	2-y1]amino)cyclohexyl)urea	-/2 (DI + II)	

Ex. No.	compound name	MS	class
27	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	433 (M + H)	1
	N'-(2,3-dimethylphenyl)urea	700 (111 / 11)	1
28	ethyl N-{[(cis-4-{[4-(dimethylamino)quinazolin-2-	415 (NL+H)	3
	yl]amino)cyclohenyl)amino]carbonyl)glycinate	415 (67 , 11)	
29	ethyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-	477 (M + H)	1
	yl]amino) cyclohexyl)amino]carbonyl) amino) benzoate		-
30	ethyl 4-({[(cis-4-{[4-(dimethylamino)quinazolin-2-	477 (M + H)	2
	yl]amino}cyclohexyl)amino]carbonyl)amino)benzoate	V	
31	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)-	433 (M + H)	2
	N'-(4-ethylphenyl)urea	· · · · · · · · · · · · · · · · · · ·	
32	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	357 (M + H)	3
	N'-ethylurea		
33	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)-	447 (M + H)	1
·	N'-(2-ethyl-6-methylphenyl)urea		
34	ethyl N-{[(cis-4-{[4-(dimethylamino)quinazolin-2-	471 (M + H)	1
	yl]amino}cyclohexyl)amino]carbonyl}leucinate N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
35	N'-(4-fluoro-3-nitrophenyl)urea	468 (M + H)	3
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
36	N'-(4-fluorophenyl)urea	423 (M + H)	1
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
37	N'-(3-fluorophenyl)urea	423 (M + H)	3
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	100 () () (1)	_
38	N'-(2-fluorophenyl)urea	423 (M + H)	3
20	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	117 (8 (+ 11)	1
39	N'-(4-isopropylphenyl)urea	447 (M + H)	3
10	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	487 (M + H)	1
40	N'-[1-(3-isopropenylphenyl)-1-methylethyl]urea	487 (NI + H)	1
41	methyl N-{[(cis-4-{[4-(dimethylamino)quinazolin-2-	475 (M + H)	1
	yl]amino}cyclohexyl)amino]carbonyl}methioninate	4/3 (M + H)	I
42	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	371 (M + H)	3
<i>ن</i> 4	N'-isopropylurea	371 (M · H)	
43	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	435 (M + H)	2
	N'-(4-methoxyphenyl)urea	455 (11 + 11)	
44	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	464 (M + H)	3
	N'-(4-methyl-2-nitrophenyl)urea		
45	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	435 (M + H)	2
	N'-(2-methoxyphenyl)urea		
46	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	435 (M + H)	2
	N'-(3-methoxyphenyl)urea		
47	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	451 (M + H)	1
	N'-[4-(methylthio)phenyl]urea		
48	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)-	449 (M + H)	2
	N'-(4-methoxybenzyl)urea	- (1)	
40	N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)-	433 (M + H)	3
	N'-(3-methylbenzyl)urea	(

Ex. No.	compound name	MS	class
50	N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	455 (M + H)	1
	N'-1-naphthylurea		<u> </u>
51	N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	445 (M + H)	1
	N'-[(2S)-2-phenylcyclopropyl]urea	·	
52	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	405 (M + H)	2
 	N'-phenylurea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-		
53		497 (M + H)	1
	N'-(4-phenoxyphenyl)urea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
54	N'-pentylurea	356 (M + H)	1
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	<u> </u>	
55	N'-[2-(trifluoromethyl)phenyl]urea	473 (M ± H)	1
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-		
56	N'-[3-(trifluoromethyl)phenyl]urea	473 (M + H)	3
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
57	N'-(4-methylphenyl)urea	419 (M + H)	2
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	117 (N.L.) IX	
58	N'-mesitylurea	447 (M + H)	1
59	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	419 (M + H)	2
33	N'-(3-methylphenyl)urea	417 (141 + 11)	-
60	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	419 (M + H)	1
	N'-(2-methylphenyl)urea		
61	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	483 (M + H)	l
	N'-[1-(1-naphthyl)ethyl]urea		
62	methyl N-{[(cis-4-([4-(dimethylamino)quinazolin-2-	491 (M + H)	1
	yl]amino}cyclohexyl)amino]carbonyl}phenylalaninate N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
63	N'-(2,4,6-trichlorophenyl)urea	507 (M + H)	1
	N-(3-chloro-4-methylphenyl)-N'-(cis-4-{[4-		
64	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea	453 (M + H)	3
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
65	N'-(1-phenylethyl)urea	433 (M + H)	l
	1-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3-(1-	422 (81 + 71)	,
66	phenyl-ethyl)-urea	433 (M + H)	1
67	1-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3-(1-	483 (M + H)	2
	naphthalen-1-yl-ethyl)-urea	403 (M + H)	
68	N-(2,6-diisopropylphenyl)-N'-(cis-4-{[4-	489 (M+H)	3
	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	405 (111 + 11)	,
69	N-[2-(difluoromethoxy)phenyl]-N'-(cis-4-{[4-	471 (M + H)	3
	(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)urea		
70	methyl 2-({[(cis-4-{[4-(dirnethylamino)quinazolin-2-	463 (M+H)	3
	yl]amino)cyclohexyl)amino]carbonyl)amino)benzoate		<u> </u>
71	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	451 (M + H)	2
	N'-[2-(methylthio)phenyl]urea		
72	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	541 (M + H)	1
L	N'-(2,3,5,6-tetrachlorophenyl)urea		l i

Ex. No.	compound name	MS	class
73	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(2,3-dimethyl-6-nitrophenyl)urea	478 (M + H)	2
74	N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)- N'-(2-4.5-trichlorophenyl)urea	507 (FI + H)	3
75	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(2.4,6-tribromophenyl)urea	638 (M + H)	1
76	N-(2,4-dibromo-6-fluorophenyl)-N'-(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	579 (M + H)	1
77	N-(2,4-dibromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea	561 (M + H)	1
78	N-(2,4-dichlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea	487 (M + H)	1
79	N-(2,4-dimethoxyphenyl)-N'-(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea	465 (M + H)	1
80	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(2,4-dimethylphenyl)urea	433 (M + H)	3
81	N-(2,5-dimethoxyphenyl)-N'-(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	465 (M + H)	2
82	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(2,5-dimethylphenyl)urea	433 (M + H)	3
83	N-(2,6-dibromo-4-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	579 (M + H)	3
84	N-(2,6-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	473 (M + H)	3
85	N-(2,6-diethylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin- 2-yl]amino)cyclohexyl)urea	461 (M + H)	1
86	N-(2-benzylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	495 (M + H)	3
87	N-(2-chloro-5-methylphenyl)-N'-(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	453 (M + H)	3
88	N-(2-chloro-5-nitrophenyl)-N'-(cis-4-([4- (dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea	484 (M + H)	2
89	N-[2-chloro-6-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea	507 (M + H)	1
90	N-(2-chloro-6-methylphenyl)-N'-(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	453 (M + H)	1
91	N-(2-chlorobenzyl)-N'-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea	453 (M + H)	1
92	ethyl 2-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}amino)benzoate	477 (M + H)	3
93	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(2-ethoxyphenyl)urea	449 (M + H)	1
94	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)- N'-(2-ethyl-6-isopropylphenyl)urea	475 (M + H)	1
95	N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)- N'-(2-ethylphenyl)urea	433 (M + H)	1

Ex. No.	compound name	MS	class
96	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	491 (M + H)	3
50	N'-[2-fluoro-3-(trifluoromethyl)phenyl]urea	491 (M + II)	3
٥7	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohegyl)-	491 (M+H)	3
	N'-[2-fluoro-5-(trifluoromethyl)phenyl]urea	4. 1 11 1 117	٠,
98	N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	437 (M + H)	3
	N'-(2-fluoro-5-methylphenyl)urea	727 (111 1 11)	
99	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	468 (M + H)	3
	IN - (2-Tiuoro-5-nitrophenyi)urea	100 (111 111)	
100	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	437 (M+H)	1
	N'-(2-fluorobenzyl)urea		
101	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	531 (M + H)	$_{1}$
	N'-(2-iodophenyl)urea		
102	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	461 (M + H)	1 1
	N'-(2-isopropyl-6-methylphenyl)urea		
103	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	447 (M + H)	1
	N'-(2-isopropylphenyl)urea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
104		480 (M + H)	2
	N'-(2-methoxy-4-nitrophenyl)urea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
105	N'-(2-methoxy-5-methylphenyl)urea	449 (M + H)	2
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
106	N'-(2-methoxy-5-nitrophenyl)urea	480 (M + H)	3
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
107	N'-(2-methyl-3-nitrophenyl)urea	464 (M + H)	1
100	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yt]amino}cyclohexyt)-		
108	N'-(2-methyl-4-nitrophenyl)urea	464 (M + H)	1
100	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	161/36177	,
109	N'-(2-methyl-5-nitrophenyl)urea	464 (M + H)	1
110	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	464 (M + H)	3
110	N'-(2-methyl-6-nitrophenyl)urea	404 (N1 + I1)	
111	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	433 (M + H)	1
	N'-(2-methylbenzyl)urea	(3.5) (1/1 - 11)	
112	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	455 (M + H)	3
	N'-2-naphthylurea		
113	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	450 (M + H)	ı
	N'-(2-nitrophenyl)urea		
114	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)-	447 (M + H)	1
	N'-(2-propylphenyl)urea		
115	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	497 (M + H)	2
	N'-(2-phenoxyphenyl)urea		
116	N-(2-tert-butyl-6-methylphenyl)-N'-(cis-4-{[4-	475 (M + H)	1
	(dimethylamino)quinazolin-2-yllamino)cyclohexyl)urea		
117	N-(2-tert-butylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-	461 (M + H)	1
	2-yl]amino}cyclohexyl)urea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
118	N'-[3-(methylthio)phenyl]urea	451 (M + H)	2
_	Ly-Chieutytuno/phenytjurea		

N-(cis-4-{{-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl}- N-(3-{(trifluoromethylbthio]phenyl) urea 120 N-(3-5-benzodiovel-5-yl-N*-(cis-4-{4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl}- N-(cis-4-{4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl}- N-(3-4-dichlorobenz) h-N-(cis-4-{4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl}- N-(3-4-dichlorobenz) h-N-(cis-4-{4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl) 487 (M+H) 2 2 2 2 2 2 2 2 2	Ex. No.	compound name	MS	class
N-(3-diffuloromethyl)thio[phenyl]urea	119		505 (M + H)	3
2-y1 animo cy-clohesy-flurea 1-y2-y1			303 (111 11)	
121 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)- N-(3,4-dichlorobenzyl)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea 487 (M+H) 2 2 2 2 2 2 2 2 2	120		445 (J.1 + H)	1
N-(3,4-5-trimethoxyphenyl)mea M-(3,4-5-trimethoxyphenyl)mea M-(3,4-5-trimethoxyphenyl)mea M-(3,4-5-trimethoxyphenyl)mea M-(3,4-5-trimethoxyphenyl)mea M-(3,4-5-trimethoxyphenyl)mea M-(3,4-5-trimethoxyphenyl)mea M-(3,4-5-trimethoxyphenyl)mea M-(3,4-5-trimethoxyphenyl)mea M-(3,5-5-trimethoxyphenyl)mea M-(3,5-5-trimethoxyphenyl)mea M-(3,5-5-trimethoxyphenyl)mea M-(3,5-5-trimethoxyphenyl)mea M-(3,5-5-trimethoxyphenyl)mea M-(3,5-5-trimethoxyphenyl)mea M-(3,5-5-trimethoxyphenyl)mea M-(3,5-5-trimethyl)mea M-(4,5-5-trimethyl)mea M-(4,5-				
122 N-(3,4-dichlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	121		495 (M + H)	1
122 2-yl amino}cyclohexyl)urea				
123 N-(3,4-diffluorophenyl)-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl burea 124 (M+H) 1	122	- · · · · · · · · · · · · · · · · · · ·	487 (M + H)	2
124 M-(3,4-dimethyaphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	122		111 /7 5 1 77	
	143		441 (M + H)	∠
	124		465 (M + H)	1
2-yl]amino}cyclohexyl)urea	17.	(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)urea	405 (111 111)	<u> </u>
126 N-(3,5-dimethoxyphenyl)-N'-(cis-4-{{4-} (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N-(cis-4-{{4-} (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N-(3,5-dimethylphenyl)urea 463 (M + H) 2 N-(3,5-dimethylphenyl)urea 463 (M + H) 2 N-(3,5-dimethylphenyl)-N'-(cis-4-{{4-} (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino}cyclohexyl)- N-(3,5-chloro-2-methylphenyl)-N'-(cis-4-{{4-} (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea 453 (M + H) 1 1 1 1 1 1 1 1 1	125		441 (M + H)	2
120			`	
N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)	126		465 (M + H)	2
N'-(3,5-dimethylphenyl)urea methyl 3-({[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)amino]carbonyl)amino)benzoate 463 (M+H) 2				
methyl 3-({[cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}aminojbenzoate	127		433 (M + H)	2
129 N-(3-chloro-2-methylphenyl)-N'-(cis-4-{{4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea 453 (M + H) 1 130 N-(3-chloro-4-fluorophenyl)-N'-(cis-4-{{4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea 457 (M + H) 2 131 N-(3-chloro-4-methoxyphenyl)-N'-(cis-4-{{4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea 469 (M + H) 1 132 N-(cis-4-{{4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(3-ethylphenyl)urea 433 (M + H) 2 133 N-(cis-4-{{4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(3-fluoro-5-(trifluoromethyl)phenyl]urea 491 (M + H) 3 134 N-(cis-4-{{4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(3-fluorobenzyl)urea 437 (M + H) 2 135 N-(cis-4-{{4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(3-nitrophenyl)urea 448 (M - H) 3 136 N-(cis-4-{{4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(4-{(tifluoromethyl)phenyl]urea 473 (M + H) 3 137 N-(cis-4-{{4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-{4- (tifluoromethyl)thio]phenyl}urea 478 (M + H) 3 138 N-(cis-4-{{4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-{4- (tifluoromethyl)thio]phenyl}urea 478 (M + H) 3 139 N-(cis-4-{{4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-{4- (tifluoromethyl)thio]phenyl}urea 511 (M + H) 3 140 N-(4-benzylphenyl)-N'-(cis-4-{{4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea 495 (M + H) 3 141 N-{4- benzylphenyl}-N'-(cis-4-{{4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea 495 (M + H) 3 142 N-{4- benzylphenyl}-N'-(cis-4-{{4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea 495 (M + H) 3 143 N-{4- benzylphenyl}-N'-(cis-4-{{4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea 495 (M + H) 3 144 N-{4- benzylphenyl}-N'-(cis-4-{{4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea 495 (M + H) 3 145 N-{4- benzylphenyl}-N'-(cis-4-{{4- (dimethylamino)quinazolin-2-yl]amino}cyclohexy	128		162 (N. 1. III)	```
dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea	120		403 (NI + H)	4
130 N-(3-chloro-4-fluorophenyl)-N'-(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea 457 (M + H) 2 131 N-(3-chloro-4-methoxyphenyl)-N'-(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea 469 (M + H) 1 132 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3-ethylphenyl)urea 433 (M + H) 2 133 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3-fluoro-5-(trifluoromethyl)phenyl]urea 437 (M + H) 3 134 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3-fluorobenzyl)urea 437 (M + H) 2 135 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3-nitrophenyl)urea 448 (M - H) 3 136 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-(trifluoromethyl)phenyl]urea 473 (M + H) 3 137 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-[(trifluoromethyl)thio]phenyl]urea 478 (M + H) 3 138 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-[4-[4	129	· · · · · · · · · · · · · · · · · · ·	453 (M + H)	1
(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea				
N-(3-chloro-4-methoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	130		457 (M + H)	2
131 (dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea				
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(3-ethylphenyl)urea	131		469 (M + H)	1
N'-(3-ethylphenyl)urea	122		122 (2.6 - 77)	
N'-[3-fluoro-5-(trifluoromethyl)phenyl]urea N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl) A37 (M + H) 2	132	N'-(3-ethylphenyl)urea	$\frac{433 \text{ (M} + \text{H)}}{1}$	
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(3-fluorobenzyl)urea			491 (M + H)	3
N'-(3-fluorobenzyl)urea N'-(3-fluorobenzyl)urea N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(3-nitrophenyl)urea N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-[4-(trifluoromethyl)phenyl]urea N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(4-[(trifluoromethyl)thio]phenyl}urea N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(4,5-dimethyl-2-nitrophenyl)urea N'-[4-(benzyloxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea N'-[4-benzyloxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea N'-[4-benzylphenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea N'-[4-benzylphenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea N'-[4-benzylphenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea			451 (117 11)	
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(3-nitrophenyl)urea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-[4-(trifluoromethyl)phenyl]urea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-{4-[(trifluoromethyl)thio]phenyl}urea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(4,5-dimethyl-2-nitrophenyl)urea N-[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-[4-(benzyloxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea N-(4-benzylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea N-[4-benzylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea N-[4-benzylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	1 1 1		437 (M + H)	2
N'-(3-nitrophenyl)urea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-[4-(trifluoromethyl)phenyl]urea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-{4-[(trifluoromethyl)thio]phenyl}urea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(4,5-dimethyl-2-nitrophenyl)urea N-[4-(benzyloxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea N-(4-benzylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea N-(4-benzylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea N-[4-benzylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea		N. (cis. 1.114 (dimethylamina) aninazalia 2 villamina) avalahavul)		
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-[4-(trifluoromethyl)phenyl]urea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-[4-[(trifluoromethyl)thio]phenyl}urea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(4,5-dimethyl-2-nitrophenyl)urea N-[4-(benzyloxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea N-[4-(benzyloxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea N-(4-benzylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	135		448 (M - H)	3
N'-[4-(trifluoromethyl)phenyl]urea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-[4-[(trifluoromethyl)thio]phenyl}urea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(4,5-dimethyl-2-nitrophenyl)urea N-[4-(benzyloxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea N-(4-benzylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea N-(4-benzylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea				
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-{4-[(trifluoromethyl)thio]phenyl}urea 138 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(4,5-dimethyl-2-nitrophenyl)urea 139 N-[4-(benzyloxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea 140 N-(4-benzylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea 141 N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea			473 (M + H)	3
N-(4-[(trifluoromethyl)thio]phenyl)urea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- A78 (M+H) 3			505 (N (+ 11)	
138 N'-(4,5-dimethyl-2-nitrophenyl)urea 478 (M+H) 3 3			303 (M + H)	
N'-(4,5-dimethyl-2-nitrophenyl)urea N-[4-(benzyloxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea N-(4-benzylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	133 1		478 (M + H)	3
(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)urea N-(4-benzylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea			170 (112 127)	
140 N-(4-benzylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea 141 N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	139		511 (M + H)	3
yllamino}cyclohexyl)urea 495 (M+H) 3 N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-			`	
N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4- 551/M+47]	140 1		495 (M + H)	3
rannou y lando gantazoni - 2-y Hannio (C) Clonex y Direx	141	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea	$551 \left(M + H \right)$	1

WO 2004/087680

Ex. No.	compound name	MS	class
142	N-(4-bromo-2,6-difluorophenyl)-N'-(cis-4-{[4-	519 (M + H)	1
<u> </u>	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea N-(4-bromo-2-chlorophenyl)-N'-(cis-4-{[4-	' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '	
143	cdimethylamino)quinazolin-2-yl]amino) cyclohe.:yl)urea	517 (NI + H)	3
—	N-(4-bromobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-		
144	yl]amino) cyclohexyl)urea	497 (M + H)	1
145	N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-	507 (M + H)	1
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea	307 (N1 111)	1
146	N-(4-chloro-2-methylphenyl)-N'-(cis-4-([4-	453 (M+H)	1
	(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)urea N-(4-chloro-2-nitrophenyl)-N'-(cis-4-{[4-	<u> </u>	
147	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea	484 (M + H)	3
	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-		
148	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea	507 (M + H)	3
149	N-(4-cyanophenyl)-N'-(cis-4-([4-(dimethylamino)quinazolin-2-	430 (M + H)	1
	yl]amino}cyclohexyl)urea	430 (M + H)	1
150	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	449 (M + H)	2
	N'-(4-ethoxyphenyl)urea N-[1-(4-bromophenyl)ethyl]-N'-(cis-4-{[4-		
151	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea	511 (M + H)	1
1.50	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
	N'-[2-(trifluoromethoxy)phenyl]urea	489 (M + H)	3
	N-(3-acetylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-	463 (M + H)	3
	yl]amino}cyclohexyl)thiourea	405 (1.1 + 11)	
	N-(4-acetylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea	463 (M + H)	3
	N-[3,5-bis(trifluoromethyl)phenyl]-N'-(cis-4-{[4-		
155	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	557 (M + H)	3
156	N-benzyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-	125 (N () 11)	
	yl]amino}cyclohexyl)thiourea	435 (M + H)	3
1 1 7 / 1	N-(3-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-	499 (M + H)	3
	yl]amino) cyclohexyl)thiourea	133 (412 1 12)	
	N-(4-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea	499 (M + H)	1
	N-butyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-		
	yl]amino) cyclohexyl)thiourea	$401 \left(M + H \right)$	3
160	N-(4-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-	416 (\$1 + 11)	
	yl]amino}cyclohexyl)thiourea	446 (M + H)	1
1 10 1	N-cyclohexyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-	427 (M + H)	2
	y!]amino}cyclohexy!)thiourea		
1 1 6 1	N-cyclopenty1-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea	413 (M+H)	2
	N-(3-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-		
10 1	yl]amino) cyclohexyl) thiourea	455 (M + H)	3
	N-(4-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-	155 (N.f.) TIV	
104	yl]amino} cyclohexyl)thiourea	455 (M + H)	2

Ex. No.	compound name	MS	class
165	N-(2,4-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-	489 (M + H)	1
	2-yl]amino)cyclohexyl)thiourea	103 (112 22)	<u> </u>
166	N-(2,4-dimethoxyphenyl)-N'-(cis-4-{[4-	431 (M + H)	1
	(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)thiourea	,	
167	N-(2,5-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin- 2-yl]amino}cyclohexyl)thiourea	457 (M + H)	3
	N-(2,5-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-		
168	2-yl]amino) cyclohexyl)thiourea	48o (M + H)	3
1:0	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	110 (2.6 . 17)	
169	N'-(2.6-dimethylphenyl)thiourea	449 (M + H)	1
170	N-(3,4-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-	489 (M + H)	3
1/0	2-y1]amino)cyclohexyDthiourea	40% (141) 11)	
171	N-(2,6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinazolin-	489 (M + H)	3
	2-yl]amino)cyclohexyl)thiourea		
172	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(4-ethoxyphenyl)thiourea	465 (M + H)	3
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
173	N'-(2-ethyl-6-isopropylphenyl)thiourea	491 (M + H)	1
17.1	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	105 (N.f.) III)	
174	N'-(2-furylmethyl)thiourea	425 (M + H)	3
175	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	439 (M + H)	11
	N'-(4-fluorophenyl)thiourea	135 (111 11)	
176	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	429 (M + H)	2
	N'-hexylthiourea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
177	N'-[4-(trans-4-propyleyclohexyl)phenyl]thiourea	545 (M + H)	3
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
178	N'-isobutylthiourea	401 (M + H)	2
179	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	527 (M + H)	2
1/3	N'-(4-methoxybiphenyl-3-yl)thiourea	327 (IVI + II)	-
180	N-(1,3-benzodioxol-5-ylmethyl)-N'-(cis-4-{[4-	479 (M + H)	2
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea		
181	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(3-methylphenyl)thiourea	435 (M + H)	3
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
182	N'-[4-(methylthio)phenyl]thiourea	467 (M + H)	2
1.00	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
183	N'-(4-methoxyphenyl)thiourea	451 (M + H)	2
184	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	399 (M + H)	3
104	N'-(2-methylprop-2-en-1-yl)thiourea	299 (M + H)	3
185	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	451 (M + H)	1
	N'-(2-methoxyphenyl)thiourea		
186	N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	359 (M + H)	3
N'-methylthiourea	N-methylthiourea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-		
187	N'-1-naphthylthiourea	471 (M + H)	1
L	μν-1-παρπαιγιαπυαιτα		

Ex. No.	compound name	MS	class
188	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-N'-(3-nitrophenyl)thiourea	466 (M+H)	3
189	N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohenyl)- N'-(4-nitrophenyl)thiourea	466 (M+H)	2
190	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(1,1,3,3-tetramethylbutyl)thiourea	457 (M+H)	3
191	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)- N'-phenylthiourea	421 (M + H)	3
192	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)- N'-(pentafluorophenyl)thiourea	511 (M+H)	2
193	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)- N'-propylthiourea	387 (N1 + H)	2
194	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-[3-(trifluoromethyl)phenyl]thiourea	489 (M + H)	3
195	N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)- N'-(3,4,5-trimethoxyphenyl)thiourea	511 (M + H)	1
196	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(tetrahydrofuran-2-ylmethyl)thiourea	429 (M + H)	3
197	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(4-methylphenyl)thiourea	435 (M + H)	2
198	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(2-methylphenyl)thiourea	435 (M + H)	3
199	N-(tert-butyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea	401 (M + H)	3
200	N-1-adamantyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea	479 (M + H)	3
201	N-(2-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea	499 (M + H)	3
202	N-(2-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea	455 (M + H)	3
203	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)- N'-(2-phenylethyl)thiourea	449 (M + H)	3
204	N-(3,4-dimethoxyphenyl)-N'-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	481 (M + H)	1
205	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(4-ethylphenyl)thiourea	449 (M + H)	2
206	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)- N'-[2-(methylthio)phenyl]thiourea	467 (M + H)	2
207	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-[2-(trifluoromethoxy)phenyl]thiourea	505 (M + H)	2
208	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-[2-(trifluoromethyl)phenyl]thiourea	489 (M + H)	3
209	N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)- N'-(2,3,4-trifluorophenyl)thiourea	475 (M + H)	2
210	N-(2,3-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin- 2-yl]amino}cyclohexyl)thiourea	489 (M+H)	3

Ex. No.	compound name	MS	class
211	N-(2,4-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-	457 (M + H)	3
	2-yl]amino}cyclohexyl)thiourea		
212	N-(2,5-dimethoxyphenyl)-N'-(cis-4-{[4-	481 (ř. (+ H)	2
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea		
213	N-(2,6-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-	457 (M+H)	3
	2-yl]amino}cyclohexyl)thiourea		
214	'N-(2-chloro-4-nitrophenyl)-N'-(cis-4-{[4-	500 (M + H)	2
	(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)thiourea		
215	N-[2-(difluoromethoxy)phenyl]-N'-(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea	487 (M + H)	3
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
216	N'-(2-ethylphenyl)thiourea	446 (VI + H)	1
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
217	N'-[2-fluoro-5-(trifluoromethyl)phenyl]thiourea	507 (M + H)	3.
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	100 (3.6 - 77)	
218	N'-(2-fluorophenyl)thiourea	439 (M + H)	3
210	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	5.17 (M + II)	2
219	N'-(2-iodophenyl)thiourea	547 (M + H)	2
220	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	496 (M + H)	1
220	N'-(2-methoxy-4-nitrophenyl)thiourea	450 (11 : 11)	1
221	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	465 (M + H)	1
	N'-(2-methoxy-5-methylphenyl)thiourea		
222	N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	521 (M + H)	3
	N'-{3-[(trifluoromethyl)thio]phenyl)thiourea		
223	N-(3,5-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-	489(M + H)	3
	2-yl]amino}cyclohexyl)thiourea N-(3,5-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-		
224	2-yl]amino}cyclohexyl)thiourea	457 (M + H)	3
	N-(3-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-		_
225	yl]amino}cyclohexyl)thiourea	446 (M + H)	3
226	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	439 (M + H)	3
226	N'-(3-fluorophenyl)thiourea	439 (M + H)	3
227	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	547 (M + H)	2
	N'-(3-iodophenyl)thiourea		
228	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	451 (M + H)	2
	N'-(3-methoxyphenyl)thiourea		
229	N-[4-(difluoromethoxy)phenyl]-N'-(cis-4-{[4-	487 (M + H)	2
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea		
230	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	505 (M + H)	3
	N'-[4-(trifluoromethoxy)phenyl]thiourea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-		
231	N'-[4-(trifluoromethyl)phenyl]thiourea	489 (M + H)	2
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-		
232	N'-{4-[(trifluoromethyl)thio]phenyl)thiourea	521 (M + H)	3
	N-(4-bromo-2-chlorophenyl)-N'-(cis-4-{[4-	500 34 55	
233	(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)thiourea	533 (M + H)	1

Ex. No.	compound name	MS	class
234	N-(4-bromo-2-fluorophenyl)-N'-(cis-4-{[4-	517 (îM + H)	3
234	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	317 (1/1 11)	
235	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(cis-4-([4-	523 (NL+H)	3
	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea	525 (1)	-
236	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	507 (M + H)	3
	N'-[4-fluoro-3-(trifluoromethyl)phenyl]thiourea		
237	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	547 (M + H)	1
	N'-(4-iodophenyl)thiourea	2.1.1	
238	N-(5-chloro-2-methylphenyl)-N'-(cis-4-{[4-	469 (M + H)	2
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea		
239	N-[(1S,4R)-bicyclo[2,2,1]hept-2-yl]-N'-(cis-4-{[4-	439 (M+H)	2
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	123 (21 22)	
	tert-butyl [4-({[(cis-4-{[4-(dimethylamino)quinazolin-2-		
240	yl]amino}cyclohexyl)amino]carbonothioyl}amino)phenyl]-	536 (M + H)	3
	carbamate		
241	N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-(cis-4-{[4-	509 (M + H)	3
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	, ,	
242	N-[2-(4-chlorophenyl)ethyl]-N'-(cis-4-{[4-	483 (M + H)	2
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	·	
243	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	557 (M + H)	3
	N'-(2.3,4.5-tetrachlorophenyl)thiourea		
244	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	523 (M + H)	3
	N'-(2,4,5-trichlorophenyl)thiourea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	654 (M + H)	
245	N'-(2.4,6-tribromophenyl)thiourea		1
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-		
246	N'-(2,4,6-trichlorophenyl)thiourea	523 (M + H)	1
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-		
247	N'-(2.4,6-trifluorophenyl)thiourea	475 (M + H)	3
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
248	N'-mesitylthiourea	463 (M + H)	1
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
249	N'-(2,4-dimethylphenyl)thiourea	449 (M + H)	1
	N-(2,6-diethylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-	455 3 () 33	
250	2-yl]amino}cyclohexyl)thiourea	477 (M + H)	1
0.51	N-(2,6-diisopropylphenyl)-N'-(cis-4-{[4-	505 /3 f + TX	_
251	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	505 (M + H)	2
2 7 2	N-(2-bromo-4-methylphenyl)-N'-(cis-4-{[4-	512 /2 (· XX)	1
252	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	513 (M + H)	1
252	N-[2-chloro-5-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-	502 (N.C.) III)	2
253	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	523 (M + H)	3
751	N-(2-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-	150 (3.1 × 11)	1
254	yl]amino) cyclohexyl)thiourea	465 (M + H)	1
755	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	162 /81 + 118	1
255	N'-(2-ethyl-6-methylphenyl)thiourea	463 (M + H)	1
756	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	162 (NI) TT	1
256	N'-(2-isopropylphenyl)thiourea	463 (M + H)	l

Ex. No.	compound name	MS	class
257	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	467 (M + H)	3
	N'-[3-(methylthio)phenyl]thiourea	10/(171 111)	<u> </u>
258	N-(3,4-dichlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-	503 (NI+H)	3
	2-yl]amino) oyolohenyl)thiourea N-(3,5-dimethoxyphenyl)-N'-(cis-4-{[4-		-
259	(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)thiourea	481 (M + H)	2
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
260	N'-(3,5-dimethylphenyl)thiourea	449 (M + H)	2
261	N-[3-(benzyloxy)phenyl]-N'-(cis-4-([4-	127 3 () IV	
261	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	527 (M + H)	3
262	N-(3-chloro-4-methylphenyl)-N'-(cis-4-{[4-	469 (M + H)	2
202	(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)thiourea	405 (M + H)	<u> </u>
263	methyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-	479 (M + H)	1
	yl]amino)cyclohexyl)amino]carbonothioyl)amino)benzoate		
264	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(3-phenylpropyl)thiourea	463 (M + H)	3
	N-[4-(benzyloxy)phenyl]-N'-(cis-4-{[4-		
265	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea	527 (M + H)	3
266	N-(4-bromo-2,6-dimethylphenyl)-N'-(cis-4-{[4-		-
266	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	527 (M + H)	1
267	N-(4-bromo-2-methylphenyl)-N'-(cis-4-{[4-	513 (M + H)	1
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	313 (N1 + 11)	1
268	N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-	567 (M + H)	1
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea		
269	N-(4-chloro-2-methylphenyl)-N'-(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea	469 (M + H)	1
	N-(4-chloro-3-nitrophenyl)-N'-(cis-4-{[4-		
270	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	500 (M + H)	3
271	N-(4-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-	160 (11 (11)	
	yl]amino}cyclohexyl)thiourea	469 (M + H)	3
	ethyl 4-({[(cis-4-{[4-(dimethylamino)quinazolin-2-	493 (M + H)	3
	yl]amino)cyclohexyl)amino]carbonothioyl)amino)benzoate	195 (111 - 11)	
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	467 (M + H)	2
	N'-[1-(4-fluorophenyl)ethyl]thiourea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
//4	N'-(4-fluorobenzyl)thiourea	453 (M + H)	2
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
///	N'-(4-isopropylphenyl)thiourea	463 (M + H)	2
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	10.6.2.4	
/ / O I	N'-(4-methoxy-2-nitrophenyl)thiourea	496 (M+H)	3
277	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	465 (M + H)	2
	N'-(4-methoxybenzyl)thiourea	405 (M + M)	
	methyl 4-({[(cis-4-{[4-(dimethylamino)quinazolin-2-	479 (M + H)	2
	yl]amino) cyclohexyl)amino]carbonothioyl) amino)benzoate		
	N-(cis-4-{[4-(dirnethylamino)quinazolin-2-yl]amino}cyclohexyl)-	480 (N1 + H)	3
	N'-(4-methyl-2-nitrophenyl)thiourea		

Ex. No.	compound name	MS	class
280	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	449 (M + H)	3
	N'-(4-methylbenzyl)thiourea		
281	N-(4-buty/pheny/)-N'-(cis-4-{[4-(dimethy/lamino)quinazolin-2-	477 (M + H)	3
	yl]antino}cyclohexyDthiourea N-(5-chloro-2-methoxyphenyl)-N'-(cis-4-{[4-		
282	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	485 (M + H)	3
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yt]amino)cyclohexyl)-		_
283	N'-(1-phenylethyl)thiourea	449 (M + H)	2
284	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	511 (M + H)	2
<i>-</i> 204	N'-(diphenylmethyl)thiourea	211 (11 - 11)	
285	N-cyclododecyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-	511 (M + H)	3
	yl]amino)cyclohexyl)thiourea		
286	N-(cyclohexylmethyl)-N'-(cis-4-([4-(dimethylamino)quinazolin-	441 (M + H)	2
	2-yl]amino}cyclohexyl)thiourea N-cyclooctyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-		
287	yl]amino}cyclohexyl)thiourea	455 (M + H)	2
	N-cyclopropyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-		
288	yl]amino}cyclohexyl)thiourea	385 (M + H)	2
200	N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	105 (N1 + II)	1
289	N'-(1-naphthylmethyl)thiourea	485 (M + H)]
290	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	525 (M + H)	2
	N'-(2,2-diphenylethyl)thiourea	323 (1.1 11)	
291	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	557 (M + H)	3
	N'-(2,3,5,6-tetrachlorophenyl)thiourea		
292	N-(2,3-dimethoxybenzyl)-N'-(cis-4-{{4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea	495 (M + H)	1
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
293	N'-(2,4,5-trimethylphenyl)thiourea	463 (M + H)	1 1
	N-(2,4-dichlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-	502 (N.f.) IX	
294	2-yl]amino}eyclohexyl)thiourea	503 (M + H)	3
295	N-(2,5-dibromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-	577 (M + H)	3
دود	2-yl]amino)cyclohexyl)thiourea		
296	N-[2-(2,5-dimethoxyphenyl)ethyl]-N'-(cis-4-{[4-	509 (M + H)	2
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea		
297	N-biphenyl-2-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-	497 (M + H)	1
	yl]amino)cyclohexyl)thiourea N-(2-chloro-5-nitrophenyl)-N'-(cis-4-{[4-	·	
298	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	500 (M + H)	3
	N-(2-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-		
299	yl]amino)cyclohexyl)thiourea	446 (M + H)	3
200	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	152 / \ 1 = 11\	٦
300	N'-(2-fluorobenzy1)thiourea	453 (M + H)	2
301	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	496 (M + H)	3
	N'-(2-methoxy-5-nitrophenyl)thiourea	+20 (M1 + 11)	
302	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	480 (M + H)	1 1
J (1-	N'-(2-methyl-4-nitrophenyl)thiourea	(<u></u>

Ex. No.	compound name	MS	class
303	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	449 (M + H)	2
303	N'-(2-methylbenzyl)thiourea	443 (101 / 11)	
304	N-(3,4-dimethoxybenzyl)-N'-(cis-4-([4-	495 (M+H)	3
	(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)thiourea		
305	N-(3-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-	469 (M + H)]
	yl]amino) cyclohexyl)thiourea		
306	ethyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-	493 (M ± H)	1
	yl]amino}cyclohexyl)amino]carbonothioyl}amino)benzoate N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-		
307	N'-(3-ethylphenyl)thiourea	446 (VI + H)	2
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
308	N'-(3-fluorobenzy1)thiourea	453 (M + H)	2
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		_
309	N'-(3-methoxybenzyl)thiourea	465 (M + H)	2
210	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	449 (M + H)	2
310	N'-(3-methylbenzyl)thiourea	449 (M + H)	
311	N-(4-bromo-3-chlorophenyl)-N'-(cis-4-{[4-	533 (M + H)	3
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea		
312	N-(4-bromo-3-methylphenyl)-N'-(cis-4-{[4-	513 (M + H)	3
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea		<u> </u>
313	4-({[(cis-4-{[4-(dimethylamino)quinazolin-2- yl]amino}cyclohexyl)amino]carbonothioyl}amino)benzoic acid	465 (M + H)	3
	N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-		
314	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	523 (M + H)	1
	N-(4-decylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-		
315	yl]amino)cyclohexyl)thiourea	561 (M + H)	3
316	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	453 (M + H)	1
310	N'-(4-fluoro-2-methylphenyl)thiourea	455 (1/1 + 11)	1
317	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	558 (M + H)	3
	N'-[4-(4-nitrophenoxy)phenyl]thiourea	330 (111 11)	
318	N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	574 (M + H)	3
<u> </u>	N'-{4-[(4-nitrophenyl)thio]phenyl)thiourea 4-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
319	cyclohexyl)amino]carbonothioyl}amino)benzenesulfonamide	500 (M + H)	3
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
320	N'-(4-methoxy-2-methylphenyl)thiourea	465 (M + H)	1
	N-{[(cis-4-{[4-(dimethylamino)quinazolin-2-y1]amino}-	170 (3.5 . 17)	
321	cyclohexyl)amino]carbonothioyl}-4-methoxybenzamide	479 (M + H)	3
222	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	463 (M + H)	3
322	N'-[2-(4-methylphenyl)ethyl]thiourea	+03 (M + H)	,
323	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	513 (M + H)	3
123	N'-(4-phenoxyphenyl)thiourea		
324	N-(5-chloro-2,4-dimethoxyphenyl)-N'-(cis-4-{[4-	515 (M + H)	1
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea		<u> </u>
1 4 7 5 1	N-(2,3-dihydro-1H-inden-5-yl)-N'-(cis-4-{[4-	461 (M + H)	2
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea		L

Ex. No.	compound name	MS	class
326	(2E)-N-{[(cis-4-{[4-(dimethylamino)quinazolin-2-	475 (M + H)	3
	yl]amino}cyclohexyl)amino]carbonothioyl)-3-phenylacrylamide	7,3 (111 11)	
327	N-[(2E)-but-2-en-1-yl]-N'-(cis-4-([4-(dimethylamino)quinazolin-	399 (iv(+ H)	3
	2-y1]amino) cycloheny/Othiourea N-cycloheptyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-		
328	yl]amino) cyclohexyl)thiourea	441 (M + H)	2
220	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-		
329	N'-[(1R)-1-phenylethyl]thiourea	449 (M + H)	1
330	butyl 2-({[(cis-4-{[4-(dimethylamino)quinazolin-2-	505 (M+H)	3
	yl]amino) cyclohexyl)amino]carbonyl) amino)benzoate	303 (1 1 11)	
331	dimethyl 5-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}amino)isophthalate	521 (M + H)	3
}i	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-		
332	N'-[4-(trifluoromethoxy)phenyl]urea	489 (M + H)	3
333	N-(4-bromo-2,6-dimethylphenyl)-N'-(cis-4-{[4-	511 (3.1 + 17)	
333	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea	511 (M + H)	1
334	N-(4-bromo-2-methylphenyl)-N'-(cis-4-{[4-	497 (M + H)	1
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-		
335	N'-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-y1)urea	535 (M + H)	3
22.6	ethyl N-{[(cis-4-{[4-(dimethylamino)quinazolin-2-		
336	yl]amino}cyclohexyl)amino]carbonyl}phenylalaninate	505 (M + H)	1
337	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	439 (M + H)	2
	N'-[2-(2-thienyl)ethyl]urea	+37 (N1 ⁺ H)	
338	N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	463 (M + H)	1
	N-(2,6-dibromo-4-isopropylphenyl)-N'-(cis-4-{[4-		
339	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea	603 (M + H)	1
340	N-(2-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-	120 () (+ 11)	
	yl]amino}cyclohexyl)urea	430 (M + H)	3
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	411 (M + H)	3
<u></u>	N'-2-thienylurea		
342	N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	519 (M + H)	1
	N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-N'-(cis-4-{[4-		
343	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea	$477 \left(M + H \right)$	1
344	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	411 (M + H)	3
J44 	N'-3-thienylurea	411 (M + H)	
345	N-(4-tert-buty/phenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-	461 (M + H)	3
	2-yl]amino) cyclohexyl)urea N-(4-butyl-2-methylphenyl)-N'-(cis-4-{[4-		
346	(dimethylamino)quinazolin-2-yl]arnino)cyclohexyl)urea	475 (M + H)	1
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)-	477 (M+H)	
347	N'-[5-methyl-2-(trifluoromethyl)-3-furyl]urea		1
312	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	487 (M + H)	3
	N'-(5-phenyl-2-thienyl)urea	70 / (M T II)	٥

Ex. No.	compound name	MS	class
349	N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	481 (M + H)	
J-17	N'-(6-fluoro-4H-1,3-benzodioxin-8-yl)urea	481 (M + H)	2
	benzyl 4-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	546 (M + H)	3
330	cyclohexyDamino]carbonyl)aminoipiperidine-1-carboxylate	240 (ta ± H)	j j
351	N-[4-(dimethylamino)phenyl]-N'-(cis-4-{[4-	448 (M+H)	3
1	(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)urea	440 (11 / 11)	ر. ا
352	N-(2,6-dichloropyridin-4-y1)-N'-(cis-4-{[4-	474 (M + H)	3
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea	7/7 (1:1 : 11)	٠,٠
353	N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	424 (M + H)	2
	N'-(3.5-dimethylisoxazol-4-yl)urea	727 (1.1 * 11)	<u> </u>
354	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	486 (M + H)	1
	N'-(3-methyl-5-phenylisoxazol-4-yl)urea	100 (11 11)	
355	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	486 (M + H)	1
	N'-(5-methyl-3-phenylisoxazol-4-yl)urea		
356	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	383 (M + H)	3
	N'-prop-2-yn-1-ylthiourea		
357	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	568 (M + H)	3
	N'-[4-(piperidin-1-ylsulfonyl)phenyl]thiourea		
358	N-(2-cyclohex-1-en-1-ylethyl)-N'-(cis-4-{[4-	453 (M + H)	2
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-		
359	N'-(2.3-dimethylphenyl)thiourea	449 (M + H)	1
	N-(2,4-dibromo-6-fluorophenyl)-N'-(cis-4-{[4-		
360	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	595 (M + H)	1
	N-(2,4-dichloro-6-methylphenyl)-N'-(cis-4-{[4-		
361	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	└ 503 (M + H)	1
2.60	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
362	N'-(2,5-dimethylphenyl)thiourea	449 (M + H)	2
2.62	N-(2-bromo-4-isopropylphenyl)-N'-(cis-4-{[4-	711 (24 : 77)	
363	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	541 (M + H)	2
364	N-(2-bromo-5-fluorophenyl)-N'-(cis-4-{[4-	517 (N1 + III)	
304	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea	517 (M + H)	2
365	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	465 (M + H)	1
303	N'-(2-ethoxyphenyl)thiourea	405 (141 + 11)	I
366	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	477 (M + H)	1
300	N'-(2-isopropyl-6-methylphenyl)thiourea	4//(1/1 / 11/)	<u> </u>
367	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	465 (M + H)	2
J U /	N'-(2-methoxybenzyl)thiourea	105 (11 + 11)	
368	N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-(cis-4-{[4-	479 (M + H)	1
	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea	\-\ \(\)	
369	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	449 (M + H)	3
	N'-(3,4-dimethylphenyl)thiourea	- (
370	N-1,3-benzodioxol-5-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-	465 (M + H)	1
$\frac{2}{371}$ N	2-yl]amino}cyclohexyl)thiourea		
	N-(3-chloro-2-methylphenyl)-N'-(cis-4-{[4-	469 (M + H)	1
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	- \ "/	•

Ex. No.	compound name	MS	class
	N-[4-bromo-2-(trifluoromethoxy)phenyl]-N'-(cis-4-{[4-	583 (M + H)	
372	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	383 (M + H)	1
373	N-(4-chloro-2,5-dimethoxyphenyl)-N'-(cis-4-{[4-	515 (M+H)	1
3/3 	(dimethylamino)quinazolin-2-yl]amino)cyclohettyl)thiourea	313 (ET ± EI)	!
374	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	477 (i:I + H)	2
3/4	N'-(4-phenylbutyl)thiourea	4// (1.1 + 11)	
375	N-(4-tert-butylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-	477 (M + H)	3
	2-yl]amino}cyclohexyl)thiourea	4// (1/1 / 11)	ال
376	N-(5-chloro-2-fluorophenyl)-N'-(cis-4-{[4-	473 (M + H)	3
27.0	(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)thiourea	1/3 (112 1 11)	
377	N-bicyclo[2,2,1]hept-2-yl-N'-(cis-4-{[4-	439 (M+H)	1
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	(3) (11 - 11)	
378	N-bicyclo[2,2,1]hept-5-en-2-yl-N'-(cis-4-{[4-	437 (M + H)	3
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	(2.2 / 2.2)	
379	N-(cyclopropylmethyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-	399 (M + H)	3
	2-yl]amino}cyclohexyl)thiourea		
	ethyl 2-({[(cis-4-{[4-(dimethylamino)quinazolin-2-	770 3 6 77	
380	yl]amino}cyclohexyl)amino]carbonothioyl}amino)-4,5,6,7-	553 (M + H)	3
	tetrahydro-1-benzothiophene-3-carboxylate		
201	methyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-	JOO (N.C. TIV)	1
381	yl]amino}eyclohexyl)amino]carbonothioyl)amino)-4-	499 (M + H)	l
	methylthiophene-2-carboxylate		
202	methyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-	485 (M + H)	1
382	yl]amino}cyclohexyl)amino]carbonothioyl)amino)thiophene-2-	+63 (M + M)	ı
	carboxylate N-(2-bromo-4-fluorophenyl)-N'-(cis-4-{[4-		
383	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea	517 (M + H)	2
	N-(3-chloro-4-fluorophenyl)-N'-(cis-4-{[4-	· · · · · · · · · · · · · · · · · · ·	
384	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	473 (M + H)	3
	N-(4-butyl-2-methylphenyl)-N'-(cis-4-{[4-		
385	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	491 (M + H)	1
	N-[4-(dimethylamino)phenyl]-N'-(cis-4-{[4-	16.4 (3.6 . 77)	
386	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	464 (M + H)	3
207	N-[3-(diethylamino)propyl]-N'-(cis-4-{[4-	150 (N.C. III)	
387	(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)thiourea	458 (M + H)	3
200	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	458 (M + H)	2
388	N'-(2-morpholin-4-ylethyl)thiourea	438 (NI + H)	3
200	N-[4-(dimethylamino)-1-naphthyl]-N'-(cis-4-{[4-	511 () (+ 17)	1
389	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	514 (M + H)	1
300	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	422 (M + H)	3
390	N'-pyridin-3-ylthiourea	7-2 (NI ' II)	, , , , , , , , , , , , , , , , , , ,
201	N-(4-{(E)-[4-(dimethylamino)phenyl]diazenyl)phenyl)-N'-(cis-4-	568 (M + H)	3
391	{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea	· · · · · · · · · · · · · · · · · · ·	
392	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	472 (M + H)	3
	N'-(3-morpholin-4-ylpropyl)thiourea	1/2 (1/1 / 11)	
203	N-[4-(diethylamino)phenyl]-N'-(cis-4-{[4-	492 (M + H)	3
	(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)thiourea		

Ex. No.	compound name	MS	class
394	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	525 (M + H)	3
	N'-{4-[(E)-phenyldiazenyl]phenyl}thiourea	223 (M + M)	3
395	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	456 (M + H)	3
	N'-(2-piperidin-1-ylethy))thiourea	730 (1/1 / 11)	
396	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	436 (M + H)	3
	N'-(pyridin-3-ylmethyl)thiourea	15 0 (1 X + 14)	
397	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	487 (M + H)	3
	N'-[4-(1H-pyrazol-1-yl)phenyl]thiourea	10 (111 11)	
398	N-2,1,3-benzothiadiazol-4-yl-N'-(cis-4-{[4-	479 (M+H)	3
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	- (*	
399	N-2,1,3-benzothiadiazol-5-yl-N'-(cis-4-{[4-	479 (M + H)	3
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea	· · · · · · · · · · · · · · · · · · ·	
400	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	440 (M + H)	3
	N'-(3,5-dimethylisoxazol-4-yl)thiourea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
401	N'-[4-(1.3-oxazol-5-yl)phenyl]thiourea	488 (M + H)	3
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
402	N'-(5-methyl-3-phenylisoxazol-4-yl)thiourea	502 (M + H)	1
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
403	N'-(6-morpholin-4-ylpyridin-3-yl)thiourea	507 (M + H)	3
10.1	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	51 (34 , 77)	
404	N'-(6-phenoxypyridin-3-yl)thiourea	514 (M + H)	3
405	N-(3-acetylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	461 /N(+ II)	3
403	yl]amino}cyclohexyl)methyl]urea	461 (M + H)	3
406	N-1-adamantyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	477 (M + H)	3
	yl]amino}cyclohexyl)methyl]urea	4//(IVI / II)	
407	N-(4-acetylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	461 (M + H)	3
	yl]amino)cyclohexyl)methyl]urea		
408	N-({[(cis-4-([4-(dimethylamino)quinazolin-2-	447 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino}carbonyl)benzamide		
409	N-[3,5-bis(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-	555 (M + H)	3
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea		
410	N-benzyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea	433 (M + H)	3
	N-(2-bromophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
411	yl]amino}cyclohexyl)methyl]urea	497 (M + H)	2
	N-biphenyl-2-yl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
412	vl]amino}cyclohexyl)methyl]urea	495 (M + H)	2
	N-(4-bromophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
413	yl]amino) cyclohexyl)methyl]urea	497 (M + H)	3
414	N-butyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	200 (1) (
	yl]amino) cyclohexyl)methyl]urea	366 (M+H)	2
415	N-(3-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	453 (M + H)	
	yl]amino) cyclohexyl)methyl]urea		2
116	N-(4-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	152 /Nf a 115	2
	yl]amino}cyclohexyl)methyl]urea	453 (M+H)	_ 3

Ex. No.	compound name	MS	class
417	N-cyclohexyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	425 (M+H)	2
	yl]amino}cyclohexyl)methyl]urea		
418	N-(3-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	444 (M + H)	2
	yt]amino) cyclohexyfimethyt]urea		
419	N-(2-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	453 (M + H)	1
	yl]amino)cyclohexyl)methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
420	yllamino)cyclohexyl)methyl]-N'-(2,6-dimethylphenyl)urea	447 (M + H)	1
	N-(3,4-dichlorophenyl)-N'-[(cis-4-{[4-		
421	(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)methyl]urea	487 (M + H)	2
122	N-(2,4-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-	455 (M + H)	,
422	2-y1]amino}cyclohexy1)methy1]urea	433 (NT ± II)	1
423	N-(2,4-dichlorophenyl)-N'-[(cis-4-{[4-	487 (M + H)	2
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	10 (111 11)	_
424	N-(3,5-dichlorophenyl)-N'-[(cis-4-{[4-	487 (M + H)	1
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea		
425	N-(2,3-dichlorophenyl)-N'-[(cis-4-{[4-	487 (M + H)	1
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea N-(2,6-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-		
426	2-yl]amino) cyclohexyl)methyl]urea	455 (M + H)	2
	N-(2,5-dichlorophenyl)-N'-[(cis-4-{[4-		
427	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	487 (M + H)	3
428	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	117 /N (± LI)	1
428	yl]amino)cyclohexyl)methyl]-N'-(2,3-dimethylphenyl)urea	447 (M1 + H)	1
429	ethyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-	429 (M + H)	3
7-27	yl]amino}cyclohexyl)methyl]amino}carbonyl)glycinate		
430	ethyl 3-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-	491 (M + H)	3
	yl]amino\cyclohexyl)methyl]amino\carbonyl)amino]benzoate		
431	ethyl 4-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonyl)amino]benzoate	491 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
432	yl]amino)cyclohexyl)methyl]-N'-(4-ethylphenyl)urea	447 (M + H)	2
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	0.5 (3.4) 73	
433	vl]amino)cvclohexyl)methyl]-N'-ethylurea	371 (M + H)	3
434	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	461 (M + H)	1
454	yl]amino)cyclohexyl)methyl]-N'-(2-ethyl-6-methylphenyl)urea	401 (M + M)	1
435	ethyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-	485 (M + H)	1
455	yl]amino}cyclohexyl)methyl]amino}carbonyl)leucinate	105 (111 + 11)	
436	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	482 (M + H)	3
	yl]amino)cyclohexyl)methyl]-N'-(4-fluoro-3-nitrophenyl)urea		
437	N-[(cis-4-([4-(dimethylamino)quinazolin-2-	437 (M + H)	1
	yl]amino) cyclohexyl)methyl]-N'-(4-fluorophenyl)urea		
438	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-(3-fluorophenyl)urea	437 (M + H)	2
120	N-[(cis-4-{[4-(dimethy/lamino)quinazolin-2-		
	[yl]amino)cyclohexyl)methyl]-N'-(2-fluorophenyl)urea	437 (M + H)	2

W-\(\(\(\(\)\)\(\)\(\)\(\)\(\)\(\)\(\)\(\	Ex. No.	compound name	MS	class
	440	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	461 (M + H)	3
			101 (111 11)	
	441	"	501 (M + H)	2
N-[(cis-+([-(dimethylamino)quinazolin-2-yllamino)cyclohexyllmethyll-N'-isopropylurea 449 (M + H) 2 449 (M + H) 3 449 (M + H) 2 449 (M + H) 2 449 (M + H) 2 449 (M + H) 3 449 (M + H) 2 449 (M + H) 3 449 (M + H) 4 440 (M + H)	442	l l l l l l l l l l l l l l l l l l l	489 (M + H)	2
N-[(cis-4-([4-(dimethylamino)quinazolin-2-ylamino)cyclohexylmethyl]-N'-(4-methoxyphenyl)urea 449 (M+H) 2	443		385 (M + H)	3
N-{(cis-4-{{4-(dimethylamino)quinazolin-2-vl]amino)cyclohexyl)methyl}-N-{(-is-methyl2-nitrophenyl)urea} 478 (M+H) 2	444		449 (VI + H)	2
	1.15		179 /bf + III	
1410	445	yljamino) cyclohexyl)methylj-N'-(4-methyl-2-nitrophenyl)urea	4/8 (M + H)	<u> </u>
	446	"` ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '	449 (M + H)	2
144	770		772 (111 - 11)	
M-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-[4-(methylthio)phenyl]urea	447		449 (M + H)	2
1448 y amino cyclohexy methy -N'-[4-(methylthio)pheny]urea 1405 M+H 1 1 1 1 1 1 1 1 1				
N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-(4-methoxybenzyl)urea 463 (M + H) 3 N-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-1-naphthylurea 469 (M + H) 2 N-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-[(2S)-2-phenylcyclopropyl]urea 459 (M + H) 3 N-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-phenylurea 419 (M + H) 1 N-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-[4-phenoxyphenyl)urea 413 (M + H) 2 N-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-[2-(trifluoromethyl)phenyl]urea 487 (M + H) 1 N-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-[3-(trifluoromethyl)phenyl]urea 487 (M + H) 3 N-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-(4-methylphenyl)urea 433 (M + H) 1 N-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-(3-methylphenyl)urea 430 (M + H) 1 N-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-(3-methylphenyl)urea 430 (M + H) 1 N-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-(3-methylphenyl)urea 430 (M + H) 3 N-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-(3-methylphenyl)urea 430 (M + H) 3 N-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-(3-methylphenyl)urea 430 (M + H) 3 N-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]aminolcyc	448	-	465 (M + H)	1
143				
N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-1-naphthylurea 469 (M + H) 2 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[(2S)-2-phenylcyclopropyl]urea 459 (M + H) 3 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-phenylurea 419 (M + H) 1 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-phenoxyphenyl)urea 413 (M + H) 2 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-pentylurea 487 (M + H) 1 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[2-(trifluoromethyl)phenyl]urea 487 (M + H) 1 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[3-(trifluoromethyl)phenyl]urea 433 (M + H) 1 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-mesitylurea 461 (M + H) 1 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methylphenyl)urea 433 (M + H) 1 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methylphenyl)urea 433 (M + H) 1 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methylphenyl)urea 433 (M + H) 1 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(1-(a-methylphenyl)urea 433 (M + H) 1 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(1-(a-methylphenyl)urea 497 (M + H) 3 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclo	449	7.7	463 (M + H)	3
v amino cyclohexyl)methyl]-N'-1-naphthylurea v amino cyclohexyl)methyl]-N'-[(2S)-2-phenylcyclopropyl]urea v amino cyclohexyl)methyl]-N'-[(2S)-2-phenylcyclopropyl]urea v amino cyclohexyl)methyl]-N'-phenylurea v amino cyclohexyl)methyl]-N'-phenylurea v amino cyclohexyl)methyl]-N'-phenylurea v amino cyclohexyl)methyl]-N'-(4-phenoxyphenyl)urea v amino cyclohexyl)methyl]-N'-phenylurea v amino cyclohexyl)methyl]-N'-[2-(trifluoromethyl)phenyllurea v amino cyclohexyl)methyl]-N'-[3-(trifluoromethyl)phenyllurea v amino cyclohexyl)methyl]-N'-(4-methylphenyl)urea v amino cyclohexyl)methyl]-N'-(4-methylphenyl)urea v amino cyclohexyl)methyl]-N'-(4-methylphenyl)urea v amino cyclohexyl)methyl]-N'-(4-methylphenyl)urea v amino cyclohexyl)methyl]-N'-(3-methylphenyl)urea v amino cyclohexyl)methyl amino cyclohexyl)m				
N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[(2S)-2-phenylcyclopropyl]urea 459 (M + H) 1	450		469 (M + H)	2
Variation Vari	151		450 (N (+ TT)	,
yl]amino}cyclohexyl)methyl]-N'-phenylurea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-phenoxyphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-pentylurea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[2-(trifluoromethyl)phenyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[3-(trifluoromethyl)phenyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-mesitylurea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea	451	yl]amino)cyclohexyl)methyl]-N'-[(2S)-2-phenylcyclopropyl]urea	459 (N1 + H)	3
M-[(cis-4-{[4-(dimethylamino)quinazolin-2-ylamino)cyclohexyl)methyl]-N'-(4-phenoxyphenyl)urea M-[(cis-4-([4-(dimethylamino)quinazolin-2-ylamino)cyclohexyl)methyl]-N'-pentylurea 413 (M+H) 2 454 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-ylamino)cyclohexyl)methyl]-N'-pentylurea 487 (M+H) 1 455 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-ylamino}cyclohexyl)methyl]-N'-[2-(trifluoromethyl)phenyl]urea 487 (M+H) 1 456 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-ylamino}cyclohexyl)methyl]-N'-[3-(trifluoromethyl)phenyl]urea 487 (M+H) 3 457 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-ylamino}cyclohexyl)methyl]-N'-(4-methylphenyl)urea 433 (M+H) 1 458 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-ylamino}cyclohexyl)methyl]-N'-(3-methylphenyl)urea 433 (M+H) 1 459 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-ylamino}cyclohexyl)methyl]-N'-(3-methylphenyl)urea 433 (M+H) 1 460 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-ylamino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea 433 (M+H) 1 461 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-ylamino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea 497 (M+H) 3 462 463 (M+H) 3 463 (M+H) 3 464 3 465 (M+H) 46	452		419 (M + H)	1.
ylamino\cyclohexyl\methyl\-N'-(4-phenoxyphenyl\)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl\amino\cyclohexyl\)methyl\-N'-penty\lurea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl\amino\cyclohexyl\)methyl\-N'-[2-(trifluoromethyl\)phenyl\]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl\amino\cyclohexyl\)methyl\-N'-[3-(trifluoromethyl\)phenyl\]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl\amino\cyclohexyl\)methyl\-N'-(4-methylphenyl\)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl\amino\cyclohexyl\)methyl\-N'-(3-methylphenyl\)urea N-[(cis-4-{[4-(dimethylamino\quinazolin-2-yl\amino\cyclohexyl\)methyl\-N'-(3-methylphenyl\)urea N-[(cis-4-{[4-(dimethylamino\quinazolin-2-yl\amino\cyclohexyl\)methyl\-N'-(2-methylphenyl\)urea N-[(cis-4-{[4-(dimethylamino\quinazolin-2-yl\amino\cyclohexyl\)methyl\-N'-(2-methylphenyl\)urea N-[(cis-4-{[4-(dimethylamino\quinazolin-2-yl\amino\cyclohexyl\)methyl\-N'-(2-methylphenyl\)urea N-[(cis-4-{[4-(dimethylamino\quinazolin-2-yl\amino\cyclohexyl\)methyl\-N'-(2-methylphenyl\)urea N-[(cis-4-{[4-(dimethylamino\quinazolin-2-yl\amino\cyclohexyl\)methyl\-N'-[1-(1-naphthyl\)ethyl\]urea N-[(cis-4-{[4-(dimethylamino\quinazolin-2-yl\amino\cyclohexyl\)methyl\-N'-[1-(1-naphthyl\)ethyl\]urea methyl\-N-(\cic\)(\cic\)(\cic\)\-1-(\cic\)	732			
N-[(cis-4-{[4-(dimethylamino)quinazolin-2-ylamino)cyclohexyl)methyl]-N'-pentylurea 413 (M+H) 2 454 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-ylamino)cyclohexyl)methyl]-N'-[2-(trifluoromethyl)phenyl]urea 487 (M+H) 1 455 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-ylamino}cyclohexyl)methyl]-N'-[3-(trifluoromethyl)phenyl]urea 487 (M+H) 3 457 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-ylamino}cyclohexyl)methyl]-N'-(4-methylphenyl)urea 433 (M+H) 1 458 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-ylamino}cyclohexyl)methyl]-N'-mesitylurea 461 (M+H) 1 459 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-ylamino}cyclohexyl)methyl]-N'-(3-methylphenyl)urea 433 (M+H) 2 460 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-ylamino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea 433 (M+H) 1 461 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-ylamino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea 433 (M+H) 1 461 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-ylamino}cyclohexyl)methyl]-N'-(1-(1-naphthyl)ethyl)urea 497 (M+H) 3 462 M-H) 3 463 M-H 3 464 M-H 3 465 M-H 465	453		511 (M + H)	3
VI]amino}cyclohexyl)methyl]-N'-pentylurea VI]amino}cyclohexyl)methyl]-N'-[2-(trifluoromethyl)phenyl]urea VI]amino}cyclohexyl)methyl]-N'-[2-(trifluoromethyl)phenyl]urea VI]amino}cyclohexyl)methyl]-N'-[3-(trifluoromethyl)phenyl]urea VI]amino}cyclohexyl)methyl]-N'-[3-(trifluoromethyl)phenyl]urea VI]amino}cyclohexyl)methyl]-N'-(4-methylphenyl)urea VI]amino}cyclohexyl)methyl]-N'-(4-methylphenyl)urea VI]amino}cyclohexyl)methyl]-N'-(4-methylphenyl)urea VI]amino}cyclohexyl)methyl]-N'-mesitylurea VI]amino}cyclohexyl)methyl]-N'-(3-methylphenyl)urea VI]amino}cyclohexyl)methyl]-N'-(3-methylphenyl)urea VI]amino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea VI]amino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea VI]amino}cyclohexyl)methyl]-N'-(1-(1-naphthyl)ethyl]urea VI]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea VI]amino				
N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[2-(trifluoromethyl)phenyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[3-(trifluoromethyl)phenyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-mesitylurea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea	454	-	413 (M + H)	2
yl]amino}cyclohexyl)methyl]-N'-[2-(trifluoromethyl)phenyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[3-(trifluoromethyl)phenyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-mesitylurea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea 162		<u> </u>		
N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[3-(trifluoromethyl)phenyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-mesitylurea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea	455		487 (M + H)	1
yl]amino}cyclohexyl)methyl]-N'-[3-(trifluoromethyl)phenyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-mesitylurea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea 162		N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-mesitylurea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea 162	456		487 (M + H)	3
yl]amino}cyclohexyl)methyl]-N'-(4-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-mesitylurea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea 162	157		122 (M + II)	1
yl]amino}cyclohexyl)methyl]-N'-mesitylurea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea 162	43/	yl]amino}cyclohexyl)methyl]-N'-(4-methylphenyl)urea	433 (M+H)	1
Volume V	158	1 * 1	461 (M + H)	,
yl]amino}cyclohexyl)methyl]-N'-(3-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-methyl N-({[4-(dimethylamino)quinazolin-2-methyl N-({[4-(dimethylam	45/0		401 (111 111)	
yl[amino] cyclohexyl) methyl]-N'-(3-methylphenyl) urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl) methyl]-N'-(2-methylphenyl) urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl) methyl]-N'-[1-(1-naphthyl) ethyl] urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-sol(M+H)]} 3)	459	"' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '	433 (M + H)	2
yl]amino)cyclohexyl)methyl]-N'-(2-methylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-}s05 (M+H)]}) methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-}s05 (M+H)]}) 3		 		
N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-square}} 505 (M+H) 3	460		433 (M + H)	1
yl]amino)cyclohexyl)methyl]-N'-[1-(1-naphthyl)ethyl]urea methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-} 505 (M+H) 3		<u> </u>		
methyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-	461	1 ", " , " , " , " , " , " , " , " , " ,	497 (M + H)	3
16' 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				
	462	' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '	505 (M + H)	3

Ex. No.	compound name	MS	class
463	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	521 (M + H)	l
100	yl]amino}cyclohexyl)methyl]-N'-(2,4,6-trichlorophenyl)urea	27 (M ± H)	1
464	N-(3-chloro-4-methylphenyl)-N'-[(cis-4-{[4-	467 (M + H)	3
704	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	70/ (III / III	
465	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	447 (M + H)	2
	yl]amino}cyclohexyl)methyl]-N'-(1-phenylethyl)urea	77 (11 - 11)	
466	1-[4-(4-Dimethylamino-quinazolin-2-ylamino)-	447 (M + H)	2
	cyclohexylmethyl]-3-(1-phenyl-ethyl)-urea		
467	1-[4-(4-Dimethylamino-quinazolin-2-ylamino)-	497 (M + H)	2
	cyclohexylmethyl]-3-(1-naphthalen-1-yl-ethyl)-urea		
463	N-(2,6-diisopropy/lphenyl)-N'-[(cis-4-{[4-	503 (M + H)	1
	(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)methyl]urea		
469	N-[2-(difluoromethoxy)phenyl]-N'-[(cis-4-{[4-	485 (M + H)	2
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea methyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-		
470	yl]amino}cyclohexyl)methyl]amino}carbonyl)amino]benzoate	477 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
471	yl]amino}cyclohexyl)methyl]-N'-[2-(methylthio)phenyl]urea	465 (M + H)	2
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
472	yl]amino) cyclohexyl)methyl]-N'-(2,3,5,6-tetrachlorophenyl)urea	555 (M + H)	2
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
473	cyclohexyl)-methyl]-N'-(2,3-dimethyl-6-nitrophenyl)urea	492 (M + H)	l
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	521 (N.4 + TT)	
474	yl]amino}cyclohexyl)methyl]-N'-(2.4,5-trichlorophenyl)urea	521 (M + H)	3
475	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	(652 /N(+ U)	,
4/3	yl]amino)cyclohexyl)methyl]-N'-(2,4,6-tribromophenyl)urea	652 (M + H)	l
476	N-(2,4-dibromo-6-fluorophenyl)-N'-[(cis-4-{[4-	593 (M + H)	1
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	333 (M · 11)	
/1 / /	N-(2,4-dibromophenyl)-N'-[(cis-4-{[4-	575 (M + H)	3
	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea	22/	
478	N-(2,4-dichlorobenzyl)-N'-[(cis-4-{[4-	501 (M + H)	2
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea		
479	N-(2,4-dimethoxyphenyl)-N'-[(cis-4-([4-	479 (M + H)	3
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea N-(2,5-dimethoxyphenyl)-N'-[(cis-4-{[4-	<u>' </u>	
480	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	479 (M + H)	2
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		· · ·
481	yl]amino}cyclohexyl)methyl]-N'-(2,5-dimethylphenyl)urea	447 (M + H)	3
	N-(2,6-dibromo-4-fluorophenyl)-N'-[(cis-4-{[4-	·	
482	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea	593 (M + H)	1
	N-(2,6-dichlorophenyl)-N'-[(cis-4-{[4-		
483	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	487 (M + H)	1
	N-(2,6-diethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-		
484	2-yl]amino) cyclohexyl)methyl]urea	475 (M + H)	1
	N-(2-benzylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	509 (M + H)	3
10-7-1			

Ex. No.	compound name	MS	class
486	N-(2-chloro-5-methylphenyl)-N'-[(cis-4-{[4-	467 (M + H)	2
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	107 (112)	
487	N-(2-chloro-5-nitrophenyl)-N'-[(cis-4-([4-	498 (M + H)	3
	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea	<u> </u>	
488	N-[2-chloro-6-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-	521 (M + H)	1
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea N-(2-chloro-6-methylphenyl)-N'-[(cis-4-{[4-		
489	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	467 (M + H)	1
	N-(2-chlorobenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
490	yl]amino}cyclohexyl)methyl]urea	467 (M + H)	1
101	ethyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-	401 /54 : III	,
491	yl]amino}cyclohexyl)methyl]amino)carbonyl)amino]benzoate	491 (M + H)	3
492	N-[(cis-4-([4-(dimethylamino)quinazolin-2-	463 (M + H)	?
492	yl]amino}cyclohexyl)methyl]-N'-(2-ethoxyphenyl)urea	403 (N1 · 11)	
493	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	489 (M + H)	1
	yl]amino}cyclohexyl)methyl]-N'-(2-ethyl-6-isopropylphenyl)urea	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	
494	N-[(cis-4-([4-(dimethylamino)quinazolin-2-	447 (M + H)	1
	yl]amino}cyclohexyl)methyl]-N'-(2-ethylphenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
495	cvclohexyl)methyl]-N'-[2-fluoro-3-(trifluoromethyl)phenyl]urea	505 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
496	cyclohexyl)methyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]urea	505 (M + H)	3
107	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	151 /N (+ TT)	
497	yl]amino}cyclohexyl)methyl]-N'-(2-fluoro-5-methylphenyl)urea	451 (M + H)	3
498	N-[(cis-4-([4-(dimethylamino)quinazolin-2-	482 (M + H)	2
470	yl]amino}cyclohexyl)methyl]-N'-(2-fluoro-5-nitrophenyl)urea	402 (N1 · 11)	<u>-</u>
499	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	451 (M + H)	2
	yl]amino)cyclohexyl)methyl]-N'-(2-fluorobenzyl)urea		
500	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	545 (M + H)	1
<u> </u>	yl]amino}cyclohexyl)methyl]-N'-(2-iodophenyl)urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
501	cyclohexyl)methyl]-N'-(2-isopropyl-6-methylphenyl)urea	475 (M + H)	1
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
502	yl]amino}cyclohexyl)methyl]-N'-(2-isopropylphenyl)urea	461 (M + H)	1
-02	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	10 1 (3 (, 11)	
503	yl]amino)cyclohexyl)methyl]-N'-(2-methoxy-4-nitrophenyl)urea_	494 (M + H)	3
504	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	463 (M + H)	1
304	cyclohexyl)methyl]-N'-(2-methoxy-5-methylphenyl)urea	403 (IVI + II)	1
505	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	494 (M + H)	2
	yl]amino)cyclohexyl)methyl]-N'-(2-methoxy-5-nitrophenyl)urea		
506	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	478 (M + H)	1
<u> </u>	yl]amino) cyclohexyl)methyl]-N'-(2-methyl-3-nitrophenyl)urea	·	
507	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	478 (M + H)	2
<u> </u>	yl]amino) cyclohexyl)methyl]-N'-(2-methyl-4-nitrophenyl)urea		
508	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-(2-methyl-5-nitrophenyl)urea	478 (M + H)	2
L	Ly rjammo y cyclonexy) ymeury i j-iv -(2-meury i-2-mu opneny i)urea		J

510 N 510 N 511 N 511 N 512 N	I-[(cis-4-{[4-(dimethylamino)quinazolin-2- l]amino}cyclohexyl)methyl]-N'-(2-methyl-6-nitrophenyl)urea I-[(cis-4-{[4-(dimethylamino)quinazolin-2- l]amino}cyclohexyl)methyl]-N'-(2-methylbenzyl)urea I-[(cis-4-{[4-(dimethylamino)quinazolin-2- l]amino}cyclohexyl)methyl]-N'-2-naphthylurea I-[(cis-4-{[4-(dimethylamino)quinazolin-2- l]amino}cyclohexyl)methyl]-N'-(2-nitrophenyl)urea	478 (M + H) 447 (M + H) 469 (M + H) 464 (M + H)	2
510 N 511 N 511 N 512 N 91	I-[(cis-4-{[4-(dimethylamino)quinazolin-2- l]amino}cyclohemyl)methyl]-N'-(2-methylbenzyl)urea I-[(cis-4-{[4-(dimethylamino)quinazolin-2- l]amino}cyclohemyl)methyl]-N'-2-naphthylurea I-[(cis-4-{[4-(dimethylamino)quinazolin-2- l]amino}cyclohemyl)methyl]-N'-(2-nitrophenyl)urea	447 (M + H) 469 (M + H)	2
510 yl 511 N 512 N yl	Hamino cyclohemy Dinethy I]-N'-(2-methylbenzyl) urea I-[(cis-4-{[4-(dimethylamino)quinazolin-2- I]amino cyclohemy Dimethyl]-N'-2-naphthylurea I-[(cis-4-{[4-(dimethylamino)quinazolin-2- I]amino cyclohemy Dimethyl]-N'-(2-nitropheny Durea	469 (M+H)	-
511 N y 1	I-[(cis-4-{[4-(dimethylamino)quinazolin-2-]amino}cyclohexyl)methyl]-N'-2-naphthylurea I-[(cis-4-{[4-(dimethylamino)quinazolin-2-]amino}cyclohexyl)methyl]-N'-(2-nitrophenyl)urea		-
511 yl	l]amino)cyclohexy1)methy1]-N'-2-naphthylurea I-[(cis-4-{[4-(dimethylamino)quinazolin-2- l]amino}cyclohexy1)methy1]-N'-(2-nitropheny1)urea		3
512 N	I-[(cis-4-{[4-(dimethylamino)quinazolin-2-]amino}cyclohexyl)methyl]-N'-(2-nitrophenyl)urea	464 (M + H)	
OIZ yl	l]amino}cyclohexyl)methyl]-N'-(2-nitrophenyl)urea	464 (M + H)	i '
N.		` '	2
513 1	-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
V1	l]amino}cyclohexyl)methyl]-N'-(2-propylphenyl)urea	461 (M + H)	1
N	I-[(cis-4-{[4-(dimethylamino)quinazolin-2-	511 /N (a 11)	2
514 y	l]amino)cyclohexyl)methyl]-N'-(2-phenoxyphenyl)urea	511 (M + H)	
	I-(2-tert-butyl-6-methylphenyl)-N'-[(cis-4-{[4-	489 (M + H)	1
(0	dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	70% (111 / 11)	
ו אור ו	I-(2-tert-buty/pheny/)-N'-[(cis-4-{[4-(dimethy/lamino)quinazolin-	475 (M + H)	1
2-	-yl]amino)cyclohexyl)methyl]urea		
	I-[(cis-4-{[4-(dimethylamino)quinazolin-2-	465 (M + H)	2
N	l]amino}cyclohexyl)methyl]-N'-[3-(methylthio)phenyl]urea l-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
	yclohexyl)methyl]-N'-{3-[(trifluoromethyl)thio]phenyl}urea	519 (M + H)	3
N	I-1,3-benzodioxol-5-yl-N'-[(cis-4-{[4-		
1 10 1	dimethylamino)quinazolin-2-yl]amino) cyclohexyl)methyl]urea	463 (M + H)	3
	I-[(cis-4-{[4-(dimethylamino)quinazolin-2-	509 (M + H)	3
520 y	l]amino)cyclohexyl)methyl]-N'-(3,4,5-trimethoxyphenyl)urea	209 (M + H)	
1 3/1 1	I-(3,4-dichlorobenzyl)-N'-[(cis-4-{[4-	501 (M + H)	3
	dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	201 (111 11)	
1 5// 1	1-(3,4-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-	455 (M + H)	1 [
	-yl]amino) cyclohexyl)methyl]urea		
1 5/5 1	V-(3,4-dimethoxyphenyl)-N'-[(cis-4-{[4-	479 (M + H)	3
	dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea J-(3,5-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-		
1 5 7/1	-yl]amino) cyclohexyl)methyl]urea	455 (M + H)	1
	V-(3,5-dimethoxyphenyl)-N'-[(cis-4-{[4-	1.70 (3.4 . 77)	
	dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	479 (M + H)	2
526 N	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	447 (M + H)	3
320 y	l]amino}cyclohexyl)methyl]-N'-(3,5-dimethylphenyl)urea	44/(M+11)	3
	nethyl 3-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-	477 (M + H)	3
У	l]amino}cyclohexyl)methyl]amino}carbonyl)amino]benzoate		ļ
1 5/8 1	N-(3-chloro-2-methylphenyl)-N'-[(cis-4-{[4-	467 (M + H)	1
((dimethylamino)quinazolin-2-yl]amino) cyclohexyl)methyl]urea		
1 5 70 1	N-(3-chloro-4-fluorophenyl)-N'-[(cis-4-{[4-dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea	471 (M + H)	1
	V-(3-chloro-4-methoxyphenyl)-N'-[(cis-4-{[4-		
	dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	483 (M + H)	3
N	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
1 3 4 1	'l]amino}cyclohexyl)methyl]-N'-(3-ethylphenyl)urea	447 (M + H)	2

Ex. No.	compound name	MS	class
532	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	505 (M + H)	2
	cyclohexyl)methyl]-N'-[3-fluoro-5-(trifluoromethyl)phenyl]urea	303 (11 11)	
533	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	451 (i.4 + H)	2
	yllarnino) cyclohexyl)methyll-N'-(3-fluorobenzyl)urea		
534	N-[(cis-4-([4-(dimethylamino)quinazolin-2-	511 (F1 + H)	3
	yl]amino}cyclohexyl)methyl]-N'-(3-phenoxyphenyl)urea butyl 4-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-		
535	yl]amino}cyclohexyl)methyl]amino}carbonyl)amino]benzoate	519 (M + H)	3
	N-[(cis-4-{[4-(directhy lamino)quinazolin-2-		
536	yl]amino) cyclohexyl)methyl]-N'-[4-(trifluoromethyl)phenyl]urea	437 (M + H)	3
537	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	510 (\(\hat{\) \(\hat{\)}\)	3
337	cyclohexy1)methyl]-N'-{4-[(trifluoromethy1)thio]pheny1)urea	519 (M + H)	ا ا
538	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	492 (M + H)	2
	cyclohexyl)methyl]-N'-(4,5-dimethyl-2-nitrophenyl)urea	152 (111 + 11)	
539	N-[4-(benzyloxy)phenyl]-N'-[(cis-4-{[4-	525 (M + H)	3
	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(4-benzylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	<u> </u>	
540	yl]amino}cyclohexyl)methyl]urea	509 (M + H)	3
	N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-		
541	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	565 (M + H)	2
542	N-(4-bromo-2,6-difluorophenyl)-N'-[(cis-4-{[4-	522 (N.C.) III)	1
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	533 (M + H)	1
543	N-(4-bromo-2-chlorophenyl)-N'-[(cis-4-{[4-	531 (M + H)	3
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea		
544	N-(4-bromobenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	511 (M + H)	3
	yl]amino}cyclohexyl)methyl]urea N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-		
545	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	521 (M + H)	1
	N-(4-chloro-2-methylphenyl)-N'-[(cis-4-{[4-		
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	467 (M + H)	2
547	N-(4-chloro-2-nitrophenyl)-N'-[(cis-4-{[4-	498 (M + H)	3
J+7	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	490 (M + H)	
548	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-	521 (M + H)	3
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea		
744	N-(4-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	444 (M + H)	1
	ył]amino}cyclohexyl)methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
550	yl]amino}cyclohexyl)methyl]-N'-(4-ethoxyphenyl)urea	463 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
221	yl]amino) cyclohexyl)methyl]-N'-(4-fluoro-2-nitrophenyl)urea	482 (M + H)	2
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	505 (71) 11	
	cyclohexyl)methyl]-N'-[4-fluoro-3-(trifluoromethyl)phenyl]urea	505 (M + H)	3
553	N-{(cis-4-{[4-(dimethylamino)quinazolin-2-	451 (M + H)	2
	yl]amino}cyclohexyl)methyl]-N'-(4-fluorobenzyl)urea	(m · 11)	
554	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	533 (M+H)	3
	yl]amino}cyclohexyl)methyl]-N'-[4-(heptyloxy)phenyl]urea		

Ex. No.	compound name	MS	class
555	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	545 (M + H)	2
	yl]amino}cyclohexyl)methyl]-N'-(4-iodophenyl)urea	343 (111 / 11)	
556	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	463 (M + H)	2
	cyclohexyl)methyl]-N'-(4-methoxy-2-methylphenyl)urea	132 (7 2 2 2 2)	
557	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	494 (iM + H)	3
	yllamino) cyclohexyl)methyll-N'-(4-methoxy-2-nitrophenyl)urea		
558	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	478 (M + H)	2
	yl]amino)cyclohexyl)methyl]-N'-(4-methyl-3-nitrophenyl)urea		
559	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	447 (M + H)	3
	yl]amino)cyclohexyl)methyl]-N'-(4-methylbenzyl)urea N-(4-butoxyphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	-	
560		491 (M + H)	3
	yl]amino}cyclohexyl)methyl]urea N-(4-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
561	vl]amino}cyclohexyl)methyl]urea	475 (M + H)	3
	N-biphenyl-4-yl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
562	vl]amino}cyclohexyl)methyl]urea	495 (M + H)	3
	N-(5-chloro-2,4-dimethoxyphenyl)-N'-[(cis-4-{[4-		
563	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	513 (M + H)	3
	N-(5-chloro-2-methoxyphenyl)-N'-[(cis-4-{[4-	102 (N.C.) III)	,
564	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	483 (M + H)	3
565	N-(5-chloro-2-methylphenyl)-N'-[(cis-4-{[4-	467 (M + H)	2
363	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	407 (M + H)	
566	N-(5-chloro-2-nitrophenyl)-N'-[(cis-4-{[4-	498 (M + H)	3
300	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	130 (111 / 11)	
567	N-[(cis-4-([4-(dimethylamino)quinazolin-2-	451 (M + H)	2
	yl]amino)cyclohexyl)methyl]-N'-(5-fluoro-2-methylphenyl)urea		
568	N-(2,3-dihydro-1H-inden-5-yl)-N'-[(cis-4-{[4-	459 (M + H)	3
<u> </u>	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea		
569	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	507 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N'-9H-fluoren-2-ylurea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
570	yl]amino)cyclohexyl)methyl]-N'-9H-fluoren-9-ylurea	507 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
571	yl]amino)cyclohexyl)methyl]-N'-(2-phenylethyl)urea	447 (M + H)	3
-	N-cyclopentyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
572	yllamino) cyclohexyl)methyllurea	411 (M + H)	2
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	500 () (. XX)	,
573	yl]amino)cyclohexyl)methyl]-N'-(diphenylmethyl)urea	509 (M + H)	1
	methyl 4-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-	177 (N.1 + TT)	2
574	yllamino)cyclohexyl)methyllamino)carbonyl)amino]benzoate	477 (M + H)	3
275	N-[1-(4-bromophenyl)ethyl]-N'-[(cis-4-{[4-	525 (M + H)	3
575	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea	525 (M T M)	
576	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	503 (M+H)	3
3/0	cyclohexyl)methyl]-N'-[2-(trifluoromethoxy)phenyl]urea	303 (11 11)	
577	N-(3-acety/phenyl)-N'-[(cis-4-{[4-(dimethylarnino)quinazolin-2-	477 (M + H)	3
) / /	yl]amino}cyclohexyl)methyl]thiourea	177 (174 1 11)	

Ex. No.	compound name	MS	class
578	N-(4-acety/lpheny/l)-N'-[(cis-4-{[4-(dimethy/lamino)quinazolin-2-	477 (M + H)	3
	yl]amino) cyclohexyl)methyl]thiourea		
579	N-[3,5-bis(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethyl-	571 (NI + H)	3
	amino)quinazolin-2-yl]amino) cyclohegy/Dmethyl]thiourea		
580	N-benzyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2- yl]amino}cyclohexyl)methyl]thiourea	449 (M+H)	3
	N-(3-bromophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
581	vl]amino) cyclohexyl)methyl]thiourea	513 (M + H)	3
	N-(4-bromophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
582	yl]amino}cyclohexyl)methyl]thiourea	513 (M + H)	3
583	N-butyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	415 (M + H)	3
202	yl]amino)cyclohexyl)methyl]thiourea	415 (M + 11)	
584	N-(4-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	460 (M + H)	3
	yl]amino)cyclohexyl)methyl]thiourea		
585	N-cyclohexyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2- yl]amino}cyclohexyl)methyl]thiourea	441 (M + H)	3
	N-cyclopentyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
586	yl]amino}cyclohexyl)methyl]thiourea	427 (M + H)	3
	N-(3-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	460 (3.6 - 77)	
587	yl]amino)cyclohexyl)methyl]thiourea	469 (M + H)	3
588	N-(4-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	469 (M + H)	3
200	yl]amino}cyclohexyl)methyl]thiourea	409 (M + 11)	
589	N-(2,4-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-	503 (M + H)	3
	quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea		
590	N-(2,4-dimethoxyphenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea	495 (M + H)	3
	N-(2,5-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-		
591	2-yl]amino}cyclohexyl)methyl]thiourea	471 (M + H)	3
	N-(2,5-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-	500 (D.f. , TX)	
592	quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea	503 (M + H)	3
593	N-[(cis-4-([4-(dimethylamino)quinazolin-2-	463 (M + H)	2
ر در در	yl]amino}cyclohexyl)methyl]-N'-(2,6-dimethylphenyl)thiourea	405 (141 + 11)	
594	N-(3,4-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-	503 (M + H)	3
	quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea	` · · · · ·	
595	N-(2,6-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea	503 (M + H)	2
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
596	yl]amino)cyclohexyl)methyl]-N'-(4-ethoxyphenyl)thiourea	479 (M + H)	3
705	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	~^~	
597	cyclohexyl)methyl]-N'-(2-ethyl-6-isopropylphenyl)thiourea	505 (M + H)	2
598	N-[(cis-4-([4-(dimethylamino)quinazolin-2-	439 (M + H)	3
298	yl]amino)cyclohexyl)methyl]-N'-(2-furylmethyl)thiourea	907 (DI T II)	
599	N-[(cis-4-([4-(dimethylamino)quinazolin-2-	453 (M + H)	3
	yl]amino)cyclohexyl)methyl]-N'-(4-fluorophenyl)thiourea	(-/- (-/-	
600	N-[(cis-4-([4-(dimethylamino)quinazolin-2-	443 (M+H)	3
L	yl]amino}cyclohexyl)methyl]-N'-hexylthiourea		L

Ex. No.	compound name	MS	class
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
601	cyclohexyl)methyl]-N'-[4-(trans-4-propylcyclohexyl)phenyl]-	559 (M + H)	3
	thiourea	,	-
602	N-[(cis-4-{[4-(dimethylamino)quinacolin-2-		
002	yl]amino)cyclohexyl)methyl]-N'-isobutylthiourea	415 (M + H)	2
100	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
603	cyclohexyl)methyl]-N'-(4-methoxybiphenyl-3-yl)thiourea	541 (M + H)	3
	N-(1,3-benzodioxol-5-y/lmethyl)-N'-[(cis-4-{[4-(dimethylamino)-		
604	quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea	[493 (N1 + H)	2
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	 	
605	vl]amino) cyclohexyl)methyl]-N'-(3-methylphenyl)thiourea	446 (V1 + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
606	vl]amino) cyclohexyl)methyl]-N'-[4-(methylthio)phenyl]thiourea	481 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
607	yl]amino)cyclohexyl)methyl]-N'-(4-methoxyphenyl)thiourea	465 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
608	cyclohexyl)methyl]-N'-(2-methylprop-2-en-1-vl)thiourea	413 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
609	yl]amino}cyclohexyl)methyl]-N'-(2-methoxyphenyl)thiourea	465 (M + H)	3
	N-{(cis-4-{{4-(dimethy lamino)quinazolin-2-		
610	yl]amino}cyclohexyl)methyl]-N'-methylthiourea	373 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
611	yl]amino}cyclohexyl)methyl]-N'-1-naphthylthiourea	485 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	<u> </u>	
612	yl]amino}cyclohexyl)methyl]-N'-(3-nitrophenyl)thiourea	480 (M + H)	3
	N-[(cis-4-{[4-(dimethy/lamino)quinazolin-2-		
613	yl]amino}cyclohexyl)methyl]-N'-(4-nitrophenyl)thiourea	480 (M + H)	2
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
614	cyclohexyl)methyl]-N'-(1,1,3,3-tetramethylbutyl)thiourea	471 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
615	yl]amino)cyclohexyl)methyl]-N'-phenylthiourea	435 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
616	yl]amino}cyclohexyl)methyl]-N'-(pentafluorophenyl)thiourea	525 (M + H)	2
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
	yl]amino)cyclohexyl)methyl]-N'-propylthiourea	401 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
618	cyclohexyl)methyl]-N'-[3-(trifluoromethyl)phenyl]thiourea	503 (M + H)	3
	N-[(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}-		
619	cyclohexyl)methyl]-N'-(3,4,5-trimethoxyphenyl)thiourea	525 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
620	cyclohexyl)methyl]-N'-(tetrahydrofuran-2-ylmethyl)thiourea	443 (M + H)	2
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
		445 (M + H)	3
	yl]amino) cyclohexyl)methyl]-N'-(4-methylphenyl)thiourea		
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	449 (M + H)	3
	yl]amino) cyclohexyl)methyl]-N'-(2-methylphenyl)thiourea	` ' '	
623	N-(tert-buty1)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	415 (M + H)	3
	yl]amino}cyclohexyl)methyl]thiourea	\	

Ex. No.	compound name	MS	class
624	N-1-adamantyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	493 (M+H)	3
024	yl]amino}cyclohexy])methyl]thiourea	433 (NI + H)	3
625	N-(2-bromophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	513 (M + H)	3
W20	yl]amino}cyclohexyl)methyl]thiourea	212 (11 + 11)	
626	N-(2-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	469 (M + H)	3
020	yl]amino]cyclohexyl)methyl]thiourea	405 (10 + 11)	3
627	N-[(cis-4-\[4-(dimethylamino)quinazolin-2-	463 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N'-(2-phenylethyl)thiourea	403 (111 + 11)	,
628	N-(3,4-dimethoxyphenyl)-N'-[(cis-4-{[4-(dimethylamino)-	495 (M + H)	3
	quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea	43.5 (1/1 / 11)	
629	N-[(cis-4-{[4-(dimethy/lamino)quinazolin-2-	463 (M + H)	3
	yl]amino)cyclohexyl)methyl]-N'-(4-ethylphenyl)thiourea	(05 (11 / 11)	
630	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	481 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N'-[2-(methylthio)phenyl]thiourea	701 (112 11)	
631	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	519 (M + H)	2
	cyclohexyl)methyl]-N'-[2-(trifluoromethoxy)phenyl]thiourea		
632	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	503 (M + H)	3
	cyclohexyl)methyl]-N'-[2-(trifluoromethyl)phenyl]thiourea		
633	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	489 (M + H)	2
	yl]amino}cyclohexyl)methyl]-N'-(2,3,4-trifluorophenyl)thiourea		
63.4	N-(2,3-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-	503 (M + H)	3
	quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea		
635	N-(2,4-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-	471 (M + H)	3
	2-yl]amino)cyclohexyl)methyl]thiourea		
636	N-(2,5-dimethoxyphenyl)-N'-[(cis-4-{[4-(dimethylamino)-	495 (M + H)	3
	quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(2,6-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-		
637	2-yl]amino}cyclohexyl)methyl]thiourea	471 (M + H)	3
	N-(2-chloro-4-nitrophenyl)-N'-[(cis-4-{[4-(dimethylamino)-		
638	quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea	514 (M + H)	3
	N-[2-(difluoromethoxy)phenyl]-N'-[(cis-4-{[4-(dimethylamino)-		
639	quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea	501 (M + H)	3
	N-{(cis-4-{[4-(dimethylamino)quinazolin-2-		
640	yl]amino}cyclohexyl)methyl]-N'-(2-ethylphenyl)thiourea	463 (M + H)	2
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
641	cyclohexyl)methyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]-	521 (M + H)	3
	thiourea	()	_
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
642	yl]amino}cyclohexyl)methyl]-N'-(2-fluorophenyl)thiourea	453 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
643	yl]amino}cyclohexyl)methyl]-N'-(2-iodophenyl)thiourea	561 (M + H)	3
- 1	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	610 .7. f . 77	
944	cyclohexyl)methyl]-N'-(2-methoxy-4-nitrophenyl)thiourea	510 (M+H)	3
645	N-{(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	170 /51 - 75	
042	cyclohexyl)methyl]-N'-(2-methoxy-5-methylphenyl)thiourea	479 (M + H)	3
6.14	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	52.5 (NA + TI)	
646	cyclohexyl)methyl]-N'-{3-[(trifluoromethyl)thio]phenyl}thiourea	535 (M + H)	3

Ex. No.	compound name	MS	class
647	N-(3,5-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-	503 (M + H)	3
	quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(3,5-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-		
648	2-yl]amino}cyclohexyl)methyl]thiourea	471 (F1 + H)	3
	N-(3-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
645	yl]amino}cyclohexyl)methyl]thiourea	460 (M + H)	3
650	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	453 (M + H)	3
030	yl]amino}cyclohexyl)methyl]-N'-(3-fluorophenyl)thiourea	455 (M + H)	3
651	N-[(cis-4-([4-(dimethylamino)quinazolin-2-	561 (M + H)	3
	yl]amino) cyclohexyl)methyl]-N'-(3-iodophenyl)thiourea		
652	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	465 (M + H)	3
<u> </u>	vi]amino) cyclohexyl)methyl]-N'-(3-methoxyphenyl)thiourea	<u> </u>	
653	N-[4-(difluoromethoxy)phenyl]-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea	501 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-vl]amino}-		
654	cyclohexyl)methyl]-N'-[4-(trifluoromethoxy)phenyl]thiourea	519 (M + H)	3
l	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
655	cyclohexyl)methyl]-N'-[4-(trifluoromethyl)phenyl]thiourea	503 (M + H)	3
656	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	525 (M + III)	2
656	cyclohexyl)methyl]-N'-{4-[(trifluoromethyl)thio]phenyl}thiourea	535 (M + H)	3
657	N-(4-bromo-2-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-	547 (M + H)	3
	quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea	347 (141 + 11)	
658	N-(4-bromo-2-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-	531 (M + H)	3
	quinazolin-2-yl]amino) cyclohexyl) methyl] thiourea		
659	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethyl-	537 (M + H)	3
	amino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclo-		
660	hexyl)methyl]-N'-[4-fluoro-3-(trifluoromethyl)phenyl]thiourea	521 (M + H)	3
ļ	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
661	yl]amino)cyclohexyl)methyl]-N'-(4-iodophenyl)thiourea	561 (M + H)	3
((2)	N-(5-chloro-2-methylphenyl)-N'-[(cis-4-([4-(dimethylamino)-	402 /N (+ II)	
662	quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea	483 (M + H)	2
663	N-[(1S,4R)-bicyclo[2.2.1]hept-2-yl]-N'-[(cis-4-{[4-(dimethyl-	453 (M + H)	2
005	amino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea	455 (141 + 11)	
	tert-butyl {4-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-		
664	yl]amino}cyclohexyl)methyl]amino)carbonothioyl)amino]phenyl	550 (M + H)	3
	}-carbamate		
665	N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-[(cis-4-{[4-(dimethyl-	523 (M + H)	2
	amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-[2-(4-chlorophenyl)ethyl]-N'-[(cis-4-{[4-(dimethylamino)-		
666	quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea	497 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
667	cyclohexyl)methyl]-N'-(2,3,4,5-tetrachlorophenyl)thiourea	571 (M + H)	3
(10	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	627 / N.S. + IX	
668	yl]amino) cyclohexyl)methyl]-N'-(2,4,5-trichlorophenyl)thiourea	537 (M + H)	3
669	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	668 (M + H)	,
7007	yl]amino)cyclohexyl)methyl]-N'-(2,4,6-tribromophenyl)thiourea	000 (M + H)	

Ex. No.	compound name	MS	class
(70	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	537 (M + H)	2
670	yl]amino}cyclohexyl)methyl]-N'-(2,4,6-trichlorophenyl)thiourea	337 (111 111)	
671	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	489 (M + H)	3
 □	yl]amino}cyclohexyl)methyl]-N'-(2,4,6-trifluorophenyl)thiourea		
672	N-[(cis-4-([4-(dimethylamino)quinazolin-2-	477 (M1 + H)	2
شر0	yl]amino)cyclohexyl)methyl]-N'-mesitylthiourea		
673	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	463 (M + H)	3
0/3	yl]amino}cyclohexyl)methyl]-N'-(2,4-dimethylphenyl)thiourea		
674	N-(2,6-diethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-	491 (M + H)	1
0/4	2-yl]amino}cyclohexyl)methyl]thiourea	`	
675	N-(2,6-diisopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-	519 (M + H)	2
	quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea		
676	N-(2-bromo-4-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-	527 (M + H)	3
0,0	quinazolin-2-yl]amino) cyclohexyl) methyl]thiourea	<u> </u>	
677	N-[2-chloro-5-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethyl-	537 (M + H)	3
0 / /	amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea		
678	N-(2-chlorobenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	483 (M + H)	3
	yl]amino)cyclohexyl)methyl]thiourea		
679	N-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)-	477 (M + H)	2
	cyclohexyl)methyl]-N'-(2-ethyl-6-methylphenyl)thiourea		
680	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	477 (M + H)	2
	yl]amino)cyclohexyl)methyl]-N'-(2-isopropylphenyl)thiourea		
681	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	481 (M + H)	3
	yl]amino) cyclohexyl)methyl]-N'-[3-(methylthio)phenyl]thiourea		
682	N-(3,4-dichlorobenzyl)-N'-[(cis-4-([4-(dimethylamino)-	517 (M + H)	3
	quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea		
683	N-(3,5-dimethoxyphenyl)-N'-[(cis-4-{[4-(dimethylamino)-	495 (M + H)	3
<u> </u>	quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea		-
684	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	463 (M + H)	3
	yllamino)cyclohexyl)methyl]-N'-(3,5-dimethylphenyl)thiourea		
685	N-[3-(benzyloxy)phenyl]-N'-[(cis-4-([4-(dimethylamino)-	541 (M + H)	3
 	quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 3-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	 	
686	cyclohexyl)methyl]amino)carbonothioyl)amino]benzoic acid	479 (M + H)	3
	N-(3-chloro-4-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-		
687		483 (M + H)	3
<u> </u>	quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea methyl 3-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
688	methyl 3-[({[(cls-4-{[4-(dimethylamino)quinazoim-2-yljamino}	493 (M + H)	3
-	cyclohexyl)methyl]amino)carbonothioyl)amino]benzoate	-	
689	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	477 (M + H)	3
	yl]amino)cyclohexyl)methyl]-N'-(3-phenylpropyl)thiourea		
690	N-[4-(benzyloxy)phenyl]-N'-[(cis-4-([4-(dimethylamino)-	541 (M + H)	3
	quinazolin-2-yl]amino) cyclohexyl)methyl]thiqurea		
691	N-(4-bromo-2,6-dimethylphenyl)-N'-[(cis-4-{[4-(dimethyl-	541 (M + H)	1
	amino)quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea		1
692	N-(4-bromo-2-methylphenyl)-N'-[(cis-4-([4-(dimethylamino)-	$\int 527 (M + H)$	3
l	quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea		

Ex. No.	compound name	MS	class
693	N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethyl-	581 (M + H)	2
0,5,5	amino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea	201 (112 12)	
694	N-(4-chloro-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-	433 (iv1 + H)	3
	quinazolin-2-yl]amino) cyclohenyl)methyl]thiourea		
695	N-(4-chlorobenzyl)-N'-[(cis-4-([4-(dimethylamino)quinazolin-2-	483 (M+H)	3
	yl]amino}cyclohexyl)methyl]thiourea ethyl 4-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)-		
696	cyclohexyl)methyl]amino) carbonothioyl)amino]benzoate	507 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
697	cyclohexyl)methyl]-N'-[1-(4-fluorophenyl)ethyl]thiourea	481 (M + H)	2
(00	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	167 O.4 (TX)	2
698	yl]amino) cyclohexyl)methyl]-N'-(4-fluorobenzyl)thiourea	467 (M + H)	3
690	N-[(cis-4-([4-(dimethylamino)quinazolin-2-	477 (M + H)	3
0.75	yl]amino}cyclohexyl)methyl]-N'-(4-isopropylphenyl)thiourea	477 (141 + 11)	
700	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	510 (M + H)	3
	cyclohexyl)methyl]-N'-(4-methoxy-2-nitrophenyl)thiourea		
701	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	479 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N'-(4-methoxybenzyl)thiourea methyl 4-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
702	cyclohexyl)methyl]amino) carbonothioyl)amino]benzoate	493 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
703	cyclohexyl)methyl]-N'-(4-methyl-2-nitrophenyl)thiourea	494 (M + H)	3
704	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	463 (M + H)	3
/04	yl]amino}cyclohexyl)methyl]-N'-(4-methylbenzyl)thiourea	+03 (M + H)	3
705	N-(4-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	491 (M + H)	3
703	yl]amino}cyclohexyl)methyl]thiourea	137 (114 14)	
706	N-(5-chloro-2-methoxyphenyl)-N'-[(cis-4-{[4-(dimethylamino)-	499 (M + H)	2
	quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea	` '	
707	N-[(cis-4-{[4-(dimethylamino)quinazolin-2- yl]amino}cyclohexyl)methyl]-N'-(1-phenylethyl)thiourea	463 (M + H)	3
<u> </u>	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
708	yl]amino}cyclohexyl)methyl]-N'-(diphenylmethyl)thiourea	525 (M + H)	2
	N-cyclododecyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	50 5 (2.5) ***	
709	yl]amino}cyclohexyl)methyl]thiourea	525 (M + H)	2
710	N-(cyclohexylmethyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-	455 (M + H)	2
/10	2-yl]amino}cyclohexyl)methyl]thiourea	433 (141 / 11)	
711	N-cyclooctyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	469 (M + H)	3
<u> </u>	yl]amino}cyclohexyl)methyl]thiourea	103 (11	
712	N-cyclopropyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	399 (M + H)	3
	yl]amino}cyclohexyl)methyl]thiourea		
713	N-[(cis-4-{[4-(dimethylamino)quinazolin-2- yl]amino)cyclohexyl)methyl]-N'-(1-naphthylmethyl)thiourea	466 (M+H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
714	yl]amino)cyclohexyl)methyl]-N'-(2,2-diphenylethyl)thiourea	539 (M + H)	3
	N-[(cis-4-([4-(dimethy/lamino)quinazolin-2-y/l]amino)-		
715	cyclohexyl)methyl]-N'-(2,3,5,6-tetrachlorophenyl)thiourea	571 (M + H)	1

	Ex. No.	compound name	MS	class
17	716	N-(2,3-dimethoxybenzyl)-N'-[(cis-4-{[4-(dimethylamino)-	509 (N (+ LI)	
17	710		309 (M + H)	
	717		477 (M + H)	१ २ ।
	-			
1719	718		517 (M + H)	2
			` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` `	
N-[2-(2,5-dimethoxyphenyl)ethyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 523 (iM + H) 3 N-biphenyl-2-yl-N'-[(cis+4-([4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 514 (M + H) 3 N-(2-chloro-5-nitrophenyl)-N'-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea 460 (M + H) 3 N-(2-cyanophenyl)-N'-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-(2-fluorobenzyl)thiourea 467 (M + H) 3 N-((cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-(2-fluorobenzyl)thiourea 467 (M + H) 3 N-((cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-(2-methoxy-5-nitrophenyl)thiourea 463 (M + H) 3 N-((cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-(2-methyl-4-nitrophenyl)thiourea 463 (M + H) 3 N-((cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-((cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyllhiourea 463 (M + H) 3 N-((cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyllhiourea 463 (M + H) 3 N-((cis-4-([4-(dimethylamino)quinazolin-2-yl]aminocyclohexyl)methyllhiourea 463 (M + H) 3 N-((cis-4-([4-(dimethylamino)quinazolin-2-yl]aminocyclohexyl)methyllhiourea 547 (M + H) 3 3 N-((cis-4-([4-(dimethylaminocyclohexyl)methyllhiourea 547 (M + H) 3 3 N-((cis-4-([4-(dimethylaminocyclohexyl)methyllhiourea 547 (M + H) 3 3 N-((cis-4-([4-(dimethylaminocyclohexyl)methyllhiourea 547	719		591 (M + H)	3
N-biphenyl-2-yl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yllamino)cyclohexyl)methyllthiourea	720		523 (M + H)	3
N-(2-chloro-5-nitrophenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 460 (M + H) 3	721		511 (M + H)	3
Acceptance Acc	722		511 (N.C.) TIN	
	122		314 (N1 + H)	٥
N-[(cis-4-([4-(dimethylamino)quinazolin-2-ylamino)-cyclohexyl)methyl]-N'-(2-fluorobenzyl)thiourea 467 (M + H) 3	723		460 (NI + H)	3
vylamino)cyclohexy1)methyl]-N'-(2-fluorobenzy1)thiourea 467 (M + H) 3 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexy1)methyl]-N'-(2-methyl-4-nitropheny1)thiourea 494 (M + H) 3 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexy1)methyl]-N'-(2-methyl-4-nitropheny1)thiourea 494 (M + H) 3 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexy1)methyl]-N'-(2-methylbenzy1)thiourea 463 (M + H) 3 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexy1)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexy1)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexy1)methyl]thiourea 463 (M + H) 3 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexy1)methyl]-N'-(3-ethylpheny1)thiourea 463 (M + H) 3 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexy1)methyl]-N'-(3-ethylpheny1)thiourea 467 (M + H) 3 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexy1)methyl]-N'-(3-methoxybenzy1)thiourea 463 (M + H) 3 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexy1)methyl]-N'-(3-methoxybenzy1)thiourea 463 (M + H) 3 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexy1)methyl]-N'-(3-methylbenzy1)thiourea 463 (M + H) 3 N-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexy1)methyl]-N'-(3-methylbenzy1)thiourea 547 (M + H) 3 N-(4-bromo-3-chloropheny1)-N'-[(cis-4-([4-(dimethylamino)-quinazolin-2-yl]amino)cyclohexy1)methyl]thiourea 547 (M + H) 3 N-(4-bromo-3-methylpheny1)-N'-[(cis-4-([4-(dimethylamino)-quinazolin-2-yl]amino)cyclohexy1)methyl]thiourea 547 (M + H) 3 N-(4-chloro-2-(trifluoromethyl)pheny1]-N'-[(cis-4-[4-(dimethylamino)-quinazolin-2-yl]amino)cyclohexy1)methyl]thiourea 547 (M + H) 3 N-(4-decylpheny1)-N'-[(cis-4-[4-(dimethylamino)quinazolin-2- 575 (M + H) 3 N-(4-decylpheny1)-N'-[(cis-4-[4-(dimethylamino)quinazolin-2- 575 (M + H) 3 N-(4-decylpheny1)-N'-[(cis-4-[4-(dimethylamino)quinazolin-2- 575 (M + H			400 (111 / 11)	
N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]-N'-(2-methyl-thiourea 194 (M + H) 3 197	724		467 (M + H)	3
cyclohexyl)methyl]-N'-(2-methoxy-5-nitrophenyl)thiourea N-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)-cyclohexyl)methyl]-N'-(2-methyl-4-nitrophenyl)thiourea N-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)-cyclohexyl)methyl]-N'-(2-methylbenzyl)thiourea N-(3,4-dimethoxybenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(3-chlorobenzyl)-N'-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 1730				
N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]-N'-(2-methyl-4-nitrophenyl)thiourea 494 (M + H) 3 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methylbenzyl)thiourea 463 (M + H) 3 N-(3,4-dimethoxybenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 509 (M + H) 3 N-(3,4-dimethoxybenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 483 (M + H) 3 N-(3,4-dimethylamino)cyclohexyl)methyl]thiourea 483 (M + H) 3 N-(3-chlorobenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 507 (M + H) 3 Oxidia	725		510 (M + H)	2
cyclohexyl)methyl]-N'-(2-methyl-4-nitrophenyl)thiourea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methylbenzyl)thiourea N-(3,4-dimethoxybenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(3-chlorobenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl)thiourea 1730 ethyl 3-[(([cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl)thiourea 1731 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-ethylphenyl)thiourea 1732 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-ethylphenyl)thiourea 1733 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-ethylphenyl)thiourea 1734 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methylbenzyl)thiourea 1735 N-(4-bromo-3-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methylbenzyl)thiourea 1736 N-(4-bromo-3-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 1737 N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 1738 N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 1739 N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 1730 N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 1731 N-[4-decylphenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 1732 N-[4-decylphenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea				
N-{(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methylbenzyl)thiourea N-{3,4-dimethoxybenzyl}-N'-{(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-{3-chlorobenzyl}-N'-{(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-{3-chlorobenzyl}-N'-{(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-{3-chlorobenzyl}-N'-{(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-{(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-{3-ethylphenyl)thiourea N-{(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-{3-fluorobenzyl)thiourea N-{(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-{3-methoxybenzyl)thiourea N-{(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-{3-methoxybenzyl)thiourea N-{(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-{463 (M + H) 3 479 (M + H) 3 479 (M + H) 3 N-{(4-bromo-3-chlorophenyl)-N'-{(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl}thiourea N-{463 (M + H) 3 N-{450 (M + H)	726		494 (M + H)	3
yl]amino}cyclohexyl)methyl]-N'-(2-methylbenzyl)thiourea N-(3,4-dimethoxybenzyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(3-chlorobenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 483 (M + H) 3 N-(3-chlorobenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 483 (M + H) 3 N-(3-chlorobenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-ethylphenyl)thiourea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methoxybenzyl)thiourea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-bromo-3-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-bromo-3-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea	727			_
quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 729 N-(3-chlorobenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 730 ethyl 3-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 731 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-ethylphenyl)thiourea 732 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-ethylphenyl)thiourea 733 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methoxybenzyl)thiourea 734 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methoxybenzyl)thiourea 735 N-(4-bromo-3-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 736 N-(4-bromo-3-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 737 N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 738 N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 738 N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 739 N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 730 N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 731 N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 732 N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea	/27	-	463 (M + H)	3
729 N-(3-chlorobenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 730 ethyl 3-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 731 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-ethylphenyl)thiourea 732 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-fluorobenzyl)thiourea 733 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methoxybenzyl)thiourea 734 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methoxybenzyl)thiourea 735 N-(4-bromo-3-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 736 N-(4-bromo-3-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 737 N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 738 N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 738 N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 738 N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea	728	N-(3,4-dimethoxybenzyl)-N'-[(cis-4-{[4-(dimethylamino)-	500 (NI ± H)	2
yl]amino}cyclohexyl)methyl]thiourea ethyl 3-[({[cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]amino}carbonothioyl)amino]benzoate N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-ethylphenyl)thiourea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-fluorobenzyl)thiourea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methoxybenzyl)thiourea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methylbenzyl)thiourea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-bromo-3-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-bromo-3-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea	/20		309 (M + H)	3
ethyl 3-[({[cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]amino}carbonothioyl)amino]benzoate 731 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]-N'-(3-ethylphenyl)thiourea 732 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-fluorobenzyl)thiourea 733 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methoxybenzyl)thiourea 734 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methylbenzyl)thiourea 735 N-(4-bromo-3-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 736 N-(4-bromo-3-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 737 N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 738 N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 739 N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 730 N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 731 N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 732 N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea	729		483 (N(+ H)	3
cyclohexyl)methyl]amino}carbonothioyl)amino]benzoate 731 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-ethylphenyl)thiourea 732 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-fluorobenzyl)thiourea 733 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methoxybenzyl)thiourea 734 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methylbenzyl)thiourea 735 N-(4-bromo-3-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 736 N-(4-bromo-3-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 737 N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 738 N-[4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 738 N-[4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea			(102 (114 11)	
731 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-ethylphenyl)thiourea 732 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-fluorobenzyl)thiourea 733 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methoxybenzyl)thiourea 734 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methylbenzyl)thiourea 735 N-(4-bromo-3-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 736 N-(4-bromo-3-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 737 N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 738 N-[4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 738 N-[4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea			507 (M + H)	3
vl]amino}cyclohexyl)methyl]-N'-(3-ethylphenyl)thiourea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-fluorobenzyl)thiourea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methoxybenzyl)thiourea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methylbenzyl)thiourea N-(4-bromo-3-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-bromo-3-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-[4-decylphenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-[4-decylphenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea			<u> </u>	
N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-fluorobenzyl)thiourea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methoxybenzyl)thiourea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methylbenzyl)thiourea N-(4-bromo-3-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-bromo-3-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea	731		463 (M + H)	3
yl]amino}cyclohexyl)methyl]-N'-(3-fluorobenzyl)thiourea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methoxybenzyl)thiourea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methylbenzyl)thiourea N-(4-bromo-3-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-bromo-3-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea		N-f(cis-4-{f4-(dimethylamino)quinazolin-?-		
N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methoxybenzyl)thiourea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methylbenzyl)thiourea N-(4-bromo-3-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-bromo-3-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea	/ 4 / 1		467 (M + H)	3
VI]amino}cyclohexyl)methyl]-N'-(3-methoxybenzyl)thiourea 479 (M+H) 3 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methylbenzyl)thiourea 463 (M+H) 3 N-(4-bromo-3-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 547 (M+H) 3 N-(4-bromo-3-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 527 (M+H) 3 N-(4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 537 (M+H) 3 N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 575 (M+H) 3		^	170 () () ()	
yl]amino}cyclohexyl)methyl]-N'-(3-methylbenzyl)thiourea N-(4-bromo-3-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-bromo-3-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea	/33		4/9 (M + H)	3
735 N-(4-bromo-3-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 736 N-(4-bromo-3-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 737 N-(4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 738 N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 739 N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea	73.1	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	462 (N4 ± 11)	2
quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea N-(4-bromo-3-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea			403 (M + H)	
736 N-(4-bromo-3-methylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 737 N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-\{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 738 N-(4-decylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 739 N-(4-decylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea	1 / 3 7 1		547 (M + H)	3
quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-} N-(4-decylphenyl)-N'-[(cis-4-(dimethylamino)quinazolin-2-] N-(4-dimethylamino)quinazolin-2-]			(2.2	
N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-} 575 (M + H) 3			527 (M + H)	3
amino)quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-				
N-(4-decylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	737		537 (M + H)	3
1.5/5/104 + 10.1				
	738	yl]amino)cyclohexyl)methyl]thiourea	575 (M + H)	3

N-[(cis-4-[(4-(dimethylamino)quinazolin-2-yf]amino)- cyclohexylmethyll-N'-(4-fluoro-2-methylphenyl)thiourea 572 (kl + H) 3 N-[(cis-4-([4-(dimethylamino)quinazolin-2-yf]amino)- cyclohexylmethyll-N'-[4-(4-dintehylamino)quinazolin-2-yf]amino)- cyclohexylmethyll-N'-[4-(4-dintehylamino)quinazolin-2-yf]amino)- cyclohexylmethyll-N'-[4-(dintehylamino)quinazolin-2-yf]amino)- cyclohexylmethyll-N'-[4-methoxy-2-methylphenyl)thiourea 479 (M + H) 3 N-[(cis-4-([4-(dimethylamino)quinazolin-2-yf]amino)- cyclohexylmethyll-N'-[4-methoxy-2-methylphenyl)thiourea 479 (M + H) 2 cyclohexylmethyll-N'-[4-methoxy-2-methylphenyl)thiourea 477 (M + H) 3 N-[(cis-4-([4-(dimethylamino)quinazolin-2-yf]amino)- cyclohexylmethyll-N'-[2-(4-methylphenyl)thiourea 477 (M + H) 3 N-[(cis-4-([4-(dimethylamino)quinazolin-2-yf]amino)- cyclohexylmethyll-N'-[4-methoxy-2-methylphenyl)thiourea 527 (M + H) 3 N-[(cis-4-([4-(dimethylamino)quinazolin-2-yf]amino)-cyclohexylmethylphenyl)thiourea 529 (M + H) 3 N-[(cis-4-([4-(dimethylamino)quinazolin-2-yf]amino)-cyclohexylmethylphenylphinourea 475 (M + H) 3 N-(2)-dihydro-[H-inden-5-yf]-N'-[(cis-4-([4-(dimethyl-amino)quinazolin-2-yf]amino)-cyclohexylmethylphiourea 455 (M + H) 3 N-(cis-4-([4-(dimethylamino)quinazolin-2-yf]amino)-cyclohexylmethylphiourea 463 (M + H) 3 N-(cis-4-([4-(dimethylamino)quinazolin-2-yf]amino)-cyclohexylmethylphiourea 519 (M + H) 3 dimethyl S-[(([cis-4-([4-(dimethylamino)quinazolin-2-yf]amino)-cyclohexylmethylphioly-N-[(cis-4-([4-(dimethylamino)quinazolin-2-yf]amino)-cyclohexylmethylphioly-N-[(cis-4-([4-(dimethylamino)quinazolin-2-yf]amino)-cyclohexylmethylphioly-N-[(cis-4-([4-(dimethylamino)quinazolin-2-yf]amino)-cyclohexylmethylphioly-N-[(cis-4-([4-(dimethylamino)quinazolin-2-yf]amino)-cyclohexylmethylphioly-N-[(cis-4-([4-(dimethylamino)quinazolin-2-yf]amino)-cyclohexylmethylphioly-N-[(cis-4-([4-(dimethylamino)quinazolin-2-yf]amino)-cyclohexylmethylphioly-N-[(cis-4-([4-(dimethylamino)quinaz	Ex. No.	compound name	MS	class
Cyclohexy methy -N'-(-t-fluoro-2-methy pheny)thiourea	739	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	467 (M + H)	3
140	, 35		407 (101 / 11)	ر ــــــــــــــــــــــــــــــــــــ
N-{(cis-4-([4-(dimethylamino)quinazolin-2-y1]amino)-	7:10		572 (M + HN	વ
1			3/2((1 (11)	٠ '
1-{\(\(\cis-4-\text{\(\cin-4-\text{\(\cis-4	7.1.1		583 (M + H)	3
742 cyclohexyl)methyl]amino\carbonothioyl)amino benzene-sulfonamide 514 (M+ H) 3 743 N-{(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]-N'-{4-methoxy-2-methylphenyl)thiourea 479 (M+ H) 2 744 N-{(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]-N'-{2-(4-methylphenyl)thiourea 477 (M+ H) 3 745 N-{(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]-N'-{(-thenoxyphenyl)thiourea 527 (M+ H) 3 746 N-{(5-chloro-2,4-dimethoxyphenyl)-N'-{(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyllthiourea 529 (M+ H) 3 747 M-{(3-dihydro-1H-inden-5-yl)-N'-{(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyllthiourea 475 (M+ H) 3 748 N-cyclohexyl-methyllthiourea 455 (M+ H) 3 749 N-{(cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl-methyll-methyllamino)quinazolin-2-yllamino}cyclohexyl-methyllamino)quinazolin-2-yllamino cyclohexyl-methyllamino cyclohexyl-meth			300 1117 117	
Sulfonamide N-[(cis-4-{[4-(dimeth)-lamino)quinazolin-2-y-1]amino}-yclobexyl)methyl]-N'-(4-methoxy-2-methylphenyl)thiourea 479 (M+H) 2 2 2 2 2 2 2 2 2				
N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]-N'-(4-methoxy-2-methylphenyl)thiourea 479 (M+H) 3	742		514 (M + H)	3
143 cyclohexylmethyl]-N'-(4-methoxy-2-methylphenyl)thiourea 147 (M+H) 2				
1.	743		479 (M + H)	2
cyclohexylmethyl]-N'-[2-(4-methylphenyl)ethyl]thiourea N-((cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-(4-phenoxyphenyl)thiourea N-(5-chloro-2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea N-(2,3-dihydro-1H-inden-5-yl)-N'-(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea N-(2,3-dihydro-1H-inden-5-yl)-N'-(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-([(R)-1-phenylethyl]thiourea N-((cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-([(R)-1-phenylethyl]thiourea putyl 2-(([(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-([(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-([(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-([(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-([(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea N-((-bromo-2,6-dimethylphenyl)-N'-([(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea N-((-bromo-2-methylphenyl)-N'-([(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea N-((cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea			*	
N-[(cis-4-{[4-(dimethylamino)quinazolin-2-ylamino}cyclohexyl)methyl]-N'-(4-phenoxyphenyl)thiourea S27 (M + H) 3 N-(5-chloro-2,4-dimethoxyphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea S29 (M + H) 3 N-(2,3-dihydro-1H-inden-5-yl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 475 (M + H) 3 N-(2,3-dihydro-1H-inden-5-yl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 455 (M + H) 3 N-(2,3-dihydro-1H-inden-5-yl)-N'-[(1R)-1-phenylethyl]thiourea 463 (M + H) 3 N-(2,1-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]amino)quinazolin-2-yl]amino]cyclohexyl)methyl]amino)quinazolin-2-yl]amino]cyclohexyl)methyl]amino)quinazolin-2-yl]amino]cyclohexyl)methyl]amino)quinazolin-2-yl]amino]cyclohexyl)methyl]-N'-[(4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl)methyl]-N'-[(4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl)methyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea S25 (M + H) 3 N-(4-bromo-2-de-dimethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea S25 (M + H) 3 N-(4-bromo-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea S25 (M + H) 3 N-(4-bromo-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea S11 (M + H) 3 N-(6-is-4-([4-(dimethylamino)quinazolin-2-yl]amino)-cyclohexyl)methyl]urea S19 (M + H) 3 N-(6-is-4-([4-(dimethylamino)quinazolin-2-yl]amino)-cyclohexyl)methyl]urea S19 (M + H) 3 N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea S19 (M + H) 3 N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea S19 (M + H) 3 S10 (M +	744		477 (M + H)	3
yl]amino}cyclohexyl)methyl]-N'-((-1-phenoxyphenyl)thiourea N-(5-chloro-2,4-dimethoxyphenyl)-N'-((cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(2,3-dihydro-1H-inden-5-yl)-N'-((cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-cyclohepyl-N'-((cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-cyclohepyl-N'-((cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]mino}cyclohexyl)minolycyclohexyl)methyl]mino}cyclohexyl)minolycyclohexyl)minolycyclohexyl)minolycyclohexyl)minolycyclohexyl)minolycyclohexyl)minolycyclohexyl)minolycyclohexyl)minolycyclohexyl)minolycyclohex			<u> </u>	
N-(5-chloro-2,4-dimethoxyphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(2,3-dihydro-1H-inden-5-yl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea A75 (M + H) 3	745		527 (M + H)	3
amino)quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea N-(2,3-dihydro-1H-inden-5-yl)-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea N-cycloheptyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)methyl]-N'-[(1R)-1-phenylethyl]thiourea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)methyl]mino)carbonyl)amino]benzoate dimethyl 5-[(([(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]mino)carbonyl)amino]benzoate dimethyl 5-[(([(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]mino)carbonyl)amino]benzoate N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-[4-(trifluoromethoxy)phenyl]urea N-(4-bromo-2,6-dimethylphenyl)-N'-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea N-(4-bromo-2-methylphenyl)-N'-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea Toso N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]aminolcyclohexyl)methyl]urea N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]aminolcyclohexyl)methyl]urea N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]aminolcyclohexyl)methyl]urea N-(cis-4-([4-(dimethylaminolquinazolin-2-yl]aminolcyclohexyl)methyl]urea N-(cis-4-([4-(dimethylaminolquinazolin-2-yl]aminolcyclohexyl)methyl]urea N-(cis-4-([4-(dimethylaminolquinazolin-2-yl]aminolcyclohexyl)methyl]urea N-(cis-4-([4-(dimethylaminolquinazolin-2-yl]aminolcyclohexyl)methyl]urea				
N-(2,3-dihydro-1H-inden-5-yl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyDmethyl]thiourea N-cycloheptyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyDmethyl]thiourea 455 (M + H) 3	746	· · · · · · · · · · · · · · · · · · ·	529 (M + H)	3
amino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea N-cycloheptyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea butyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}cyclohexyl)methyl]amino)cyclohexyl)methyl]amino)cyclohexyl)methyl]amino}cyclohexyl)methyl]mino}cyclohexyl)methyl]mino}cyclohexyl)methyl]mino}cyclohexyl)methyl]n-Y-[4-(tifluoromethoxy)phenyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]h-N-[(cis-4-{[4-(dimethylamino)cyclohexyl)methyl]urea N-(4-bromo-2-dimethylphenyl)-N'-[(cis-4-{[4-(dimethylamino}cyclohexyl)methyl]urea N-(4-bromo-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino}cyclohexyl)methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea				
N-cycloheptyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[(1R)-1-phenylethyl]thiourea butyl 2-[(([(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonyl)amino]benzoate dimethyl 5-[(([(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonyl)amino]benzoate N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]mino}carbonyl)amino]isophthalate N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]vn'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(4-bromo-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea	747		475 (M + H)	3
yl]amino}cyclohexyDmethyl]thiourea 749 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyDmethyl]-N'-[(1R)-1-phenylethyl]thiourea 750 butyl 2-[([([cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyDmethyl]amino}carbonyDmino]benzoate 751 dimethyl 5-[(([cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyDmethyl]amino}carbonyDmino]benzoate 752 dimethyl 5-[([([cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyDmethyl]-N'-[4-(trifluoromethoxyDhenyl]urea 753 N-(4-bromo-2.6-dimethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyDmethyl]urea 754 N-(4-bromo-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyDmethyl]urea 755 N-([(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyDmethyl]urea 756 Vl]amino}cyclohexyDmethyl]-N'-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)urea 757 Vl]amino}cyclohexyDmethyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyDmethyl]urea 758 N-((cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyDmethyl]urea 759 N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyDmethyl]urea 759 N-(2,6-dibromo-4-isopropylphenyD-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyDmethyl]urea 750 N-(2-cyanophenyD-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyDmethyl]urea				
N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-[(1R)-1-phenylethyl]thiourea butyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonyl)amino]benzoate dimethyl 5-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonyl)amino]isophthalate N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[4-(trifluoromethoxy)phenyl]urea N-(4-bromo-2,6-dimethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(4-bromo-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea 756 thyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea} 453 (M + H) 3 453 (M	748		455 (M + H)	3
ylamino)cyclohexyl)methyl]-N'-[(1R)-1-phenylethyl]thiourea butyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonyl)amino]benzoate fill dimethyl 5-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonyl)amino]isophthalate fill N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[4-(trifluoromethoxy)phenyl]urea fill N-(4-bromo-2.6-dimethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea fill N-(4-bromo-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea fill N-((cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea fill N-((cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea fill N-(([(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea fill N-((cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea fill N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea fill N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea fill N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea fill N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea fill N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea				
butyl 2-[({{(cis-4-{{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonyl)amino]benzoate fil dimethyl 5-[({{(cis-4-{{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonyl)amino]isophthalate fil N-{(cis-4-{{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-{[4-(trifluoromethoxy)phenyl]urea} fil N-{(4-bromo-2.6-dimethylphenyl)-N'-{(cis-4-{{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea} fil N-{(4-bromo-2.6-dimethylphenyl)-N'-{(cis-4-{{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea} fil N-{(4-bromo-2-methylphenyl)-N'-{(cis-4-{{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea} fil N-{(cis-4-{{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea} fil N-{(cis-4-{{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea} fil N-{(cis-4-{{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea} fil N-{(cis-4-{{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea} fil N-{(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-{(cis-4-{{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea}} fil N-{(2,6-dibromo-4-isopropylphenyl)-N'-{(cis-4-{{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea}} fil N-{(2,6-dibromo-4-isopropylphenyl)-N'-{(cis-4-{{[4-(dimethylamino)quinazolin-2-yl]amino}	749	, ", , , , , , , , , , , , , , , , , ,	463 (M + H)	3
yllamino}cyclohexyl)methyl]amino}carbonyl)amino]benzoate 751 dimethyl 5-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonyl)amino]isophthalate 752 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[4-(trifluoromethoxy)phenyl]urea 753 N-(4-bromo-2,6-dimethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea 754 N-(4-bromo-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea 755 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea 756 ethyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)urea 757 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonyl)phenylalaninate 758 N-((cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea 759 N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea 759 N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea 750 N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea 750 N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea	7.50		510 /N (+ TI)	3
dimethyl 5-[({[cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonyl)amino]isophthalate 752 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[4-(trifluoromethoxy)phenyl]urea 753 N-(4-bromo-2,6-dimethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea 754 N-(4-bromo-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea 755 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea 756 ethyl N-({[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}cyclohexyl)methyl]amino}cyclohexyl)methyl]amino}cyclohexyl)methyl]methyl]methyl]urea 757 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[2-(2-thienyl)ethyl]urea 758 N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea 759 N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea 750 N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea	/50		218 (W1 + H)	5
yl]amino}cyclohexyl)methyl]amino}carbonyl)amino]isophthalate 752 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}- cyclohexyl)methyl]-N-[4-(trifluoromethoxy)phenyl]urea 753 N-(4-bromo-2,6-dimethylphenyl)-N'-[(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea 754 N-(4-bromo-2-methylphenyl)-N'-[(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}- cyclohexyl)methyl]-N'-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin- 6-yl)urea 756 ethyl N-(([(cis-4-([4-(dimethylamino)quinazolin-2- yl]amino}cyclohexyl)methyl]amino}carbonyl)phenylalaninate 757 N-[(cis-4-{[4-(dimethylamino)quinazolin-2- yl]amino}cyclohexyl)methyl]-N'-[2-(2-thienyl)ethyl]urea 758 N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea 759 N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea 750 N-(2-cyanophenyl)-N'-[(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea 750 N-(2-cyanophenyl)-N'-[(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea	751		525 (Nf - LII)	2
cyclohexyl)methyl]-N'-[4-(trifluoromethoxy)phenyl]urea N-(4-bromo-2,6-dimethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(4-bromo-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-((cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)urea ethyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}cyclohexyl)methyl]amino}cyclohexyl)methyl]methyl]methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea	/51		232 (M ± H)	
Cyclohexyl)methyl]-N'-[4-(trifluoromethoxy)phenyl]urea N-(4-bromo-2,6-dimethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]urea N-(4-bromo-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]urea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]-N'-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)urea cthyl N-(([(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]amino}carbonyl)phenylalaninate S19 (M + H) 3 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-(2-(2-dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2-cyanop	752	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	503 (M + H)	3
(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)methyl]urea N-(4-bromo-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]-N'-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)urea ethyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]amino}-carbonyl)phenylalaninate N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea	134		303 (M + H)	
754 N-(4-bromo-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]-N'-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)urea ethyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]amino}-carbonyl)phenylalaninate N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]-N'-[2-(2-thienyl)ethyl]urea N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino}-cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino}-cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino}-cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino}-cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino}-cyclohexyl)methyl]urea	753		525 (M + H)	1
(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)methyl]urea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}- cyclohexyl)methyl]-N'-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin- 6-yl)urea 756 ethyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2- yl]amino}cyclohexyl)methyl]amino}carbonyl)phenylalaninate N-[(cis-4-{[4-(dimethylamino)quinazolin-2- yl]amino}cyclohexyl)methyl]-N'-[2-(2-thienyl)ethyl]urea N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2- 160 N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2- 1750 N-(2-cyanoph	, , , ,			
N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}- cyclohexyl)methyl]-N'-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin- 6-yl)urea 549 (M + H) 3 6-yl)urea 519 (M + H) 3 3 3 3 3 3 3 3 3	754		511 (M + H)	2
cyclohexyl)methyl]-N'-(2,2,4,4-tetrafluoro-4H-1,3-benzodioxin-6-yl)urea thyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonyl)phenylalaninate N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-d44 (M+H) 3-d44 (M+H			(
6-yl)urea ethyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonyl)phenylalaninate 757 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[2-(2-thienyl)ethyl]urea 758 N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea 759 N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea 760 N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-d44 (M+H) 3				
ethyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonyl)phenylalaninate 757 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea 758 N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea 759 N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea 760 N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-d44 (M+H) 3	755		$\frac{549 (M + H)}{1}$	3
yl]amino}cyclohexyl)methyl]amino}carbonyl)phenylalaninate N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-d44 (M+H) 3				
N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[2-(2-thienyl)ethyl]urea N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-d444 (M+H) 3-d444 (M+H) 3	756	• • • • • • • • • • • • • • • • • • •	519 (M + H)	3
yl]amino) cyclohexyl)methyl]-N'-[2-(2-thienyl)ethyl]urea N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)methyl]urea N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-([4-(dimethylamino)quinazolin-2-(M+H))] 2		 		
758 N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea 759 N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea 760 N-(2-cyanophenyl)-N'-[(cis-4-([4-(dimethylamino)quinazolin-2-d444 (M+H) 3	757	1 4, ,4 ,	453 (M + H)	3
759 (dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-d444 (M+H) 3-d444 (M+H) 3-d44		<u> </u>	<u> </u>	
N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-d444 (M+H)]}] 444 (M+H)	758		477 (M + H)	3
(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-444 (M+H) 3	<u> </u>			
N-(2-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	759		617 (M + H)	2
(6D 1	<u> </u>	 		
	760	yl]amino) cyclohexyl)methyl]urea	444 (M + H)	3

PCT/JP2004/004554

Ex. No.	compound name	MS	class
761	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	425 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N'-2-thienylurea	123 (112 - 11)	
762	N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N'-[(cis-4-{[4-	533 (M + H)	3
	(dimethylamino)quinazolin-2-yl]amino) cyclohenyl)methyl]urea		
763	N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-N'-[(cis-4-{[4-	491 (M+H)	3
	(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)methyl]urea		
764	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	425 (M + H)	2
	yl]amino}cyclohexyl)methyl]-N'-3-thienylurea N-(4-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-	,	
765	2-y1]amino}cyclohexy1)methy1]urea	475 (M + H)	3
	N-(4-butyl-2-methylphenyl)-N'-[(cis-4-{[4-		
766	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	489 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclo-		
767	hexyl)methyl]-N'-[5-methyl-2-(trifluoromethyl)-3-furyl]urea	491 (M + H)	1
7.60	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	501 (N.C.) II)	
768	yl]amino}cyclohexyl)methyl]-N'-(5-phenyl-2-thienyl)urea	501 (M + H)	3
769	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclo-	495 (M + H)	2
/ 0.9	hexyl)methyl]-N'-(6-fluoro-4H-1,3-benzodioxin-8-yl)urea	490 (N1 + 11)	
	benzyl 4-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-		
770	yl]amino}cyclohexyl)methyl]amino)carbonyl)amino]piperidine-	560 (M + H)	3
 	1-carboxylate		
771	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-y1]amino}-	SCC (Nf + TI)	_
771	cyclohexyl)methyl]-N'-[4-(6-methyl-1,3-benzothiazol-2-yl)-	566 (M + H)	3
ļ <u></u>	phenyl]urea N-[4-(dimethylamino)phenyl]-N'-[(cis-4-{{4-	<u> </u>	
772	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	462 (M + H)	3
	N-(2,6-dichloropyridin-4-yl)-N'-[(cis-4-{[4-		
773	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea	488 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	120 (21 + 17)	
774	yl]amino}cyclohexyl)methyl]-N'-(3,5-dimethylisoxazol-4-yl)urea	438 (M + H)	2
775	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-y1]amino)-	500 (M + H)	1
//3	cyclohexyl)methyl]-N'-(3-methyl-5-phenylisoxazol-4-yl)urea	300 (M + 11)	1
776	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	500 (M + H)	2
	cyclohexyl)methyl]-N'-(5-methyl-3-phenylisoxazol-4-yl)urea		
777	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	397 (M + H)	3
	yl]amino)cyclohexyl)methyl]-N'-prop-2-yn-1-ylthiourea		1
778	N-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)-	582 (M + H)	3
<u> </u>	cyclohexyl)methyl]-N'-[4-(piperidin-1-ylsulfonyl)phenyl]thiourea N-(2-cyclohex-1-en-1-ylethyl)-N'-[(cis-4-{[4-(dimethylamino)-		
779	quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea	467 (M + H)	3
780	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-		
	v amino cyclohexyl)methyl]-N'-(2,3-dimethylphenyl)thiourea	463 (M + H)	3
781	N-(2,4-dibromo-6-fluorophenyl)-N'-[(cis-4-{[4-(dimethyl-	(00 05 17	
	amino)quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea	609 (M + H)	2
782	N-(2,4-dichloro-6-methylphenyl)-N'-[(cis-4-{[4-(dimethyl-	517/N1 = 11\	· ·
	amino)quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea	517 (M + H)	2

N-{(cis-+{{-(dimethyl-N-(2,5-dimethyl-phenyl)thiourea} }	class
N=(2-bromo-4-isopropy)pheny)-N=(cis-4-{(4-dimethyl-amino)quinazolin-2-ylamino)quinazolin-2-	2
	4
aminojquinazolin-2-ylaminojcyclohexy)methyllthiourea N-(2-bromo-5-fluorophenyl)-N'-{(cis-4-{4-(dimethylamino)-ylamino}-ylamino}-ylamino}-ylaminojcyclohexy)methyllthiourea N-{(cis-4-{4-(dimethylamino)quinazolin-2-ylamino}-yclohexy)methyll-N'-(2-ethoxyphenyl)thiourea N-{(cis-4-{4-(dimethylamino)quinazolin-2-ylamino}-yclohexy)methyll-N'-(2-insopropyl-6-methylphenyl)thiourea N-{(cis-4-{4-(dimethylamino)quinazolin-2-ylamino}-yclohexy)methyll-N'-(2-insopropyl-6-methylphenyl)thiourea N-{(cis-4-{4-(dimethylamino)quinazolin-2-ylamino}-yclohexy)methyllhiourea N-{(cis-4-{4-(dimethylamino)quinazolin-2-ylamino}-yclohexy)methyllthiourea N-{(cis-4-{4-(dimethylamino)quinazolin-2-ylamino}-yclohexy)methyllthiourea N-{(cis-4-{4-(dimethylamino)quinazolin-2-ylamino}-yclohexy)methyllthiourea N-{(3-chloro-2-methylphenyl-N'-{(cis-4-{4-(dimethylamino)quinazolin-2-ylamino}-yclohexy)methyllthiourea N-{(4-chloro-2-methylphenyl-N'-{(cis-4-{4-(dimethylamino)quinazolin-2-ylamino}-yclohexy)methyllthiourea N-{(4-chloro-2-methylphenyl-N'-{(cis-4-{4-(dimethylamino)quinazolin-2-ylamino}-yclohexy)methyllthiourea N-{(4-chloro-2-fluorophenyl-N'-{(cis-4-{4-(dimethylamino)quinazolin-2-ylamino}-yclohexy)methyllthiourea N-{(4-chloro-2,5-dimethoxyphenyl-N'-{(cis-4-{4-(dimethylamino)quinazolin-2-ylamino}-yclohexylmethyllthiourea N-{(4-chloro-2-fluorophenyl-N'-{(cis-4-{4-(dimethylamino)quinazolin-2-ylamino}-yclohexylmethyllthiourea N-{(4-chloro-2-fluorophenyl-N'-{(cis-4-{4-(dimethylamino)quinazolin-2-ylamino}-yclohexylmethyllthiourea N-{(5-chloro-2-fluorophenyl-N'-{(cis-4-{4-(dimethylamino)quinazolin-2-ylamino}-yclohexylmethyllthiourea N-{(cis-4-{4-(dimethylamino)quinazolin-2-ylamino}-yclohexylmethyllthiourea N-{(cis-4-{4-(dimethylamino)quinazolin-2-ylamino}-yclohexylmethyllthiourea N-{(cis-4-{4-(dimethylamino)quinazolin-2-ylamino}-yclohexylmethyllthiourea N-{(cis-4-{4-(dimethylamino)quinazolin-2-ylamino}-yclohexylmethyllthiourea N-{(cis-4-{4-(dimethylamino)quinazolin-2-ylamino}-yclohexylmethyllthiourea N-{(cis-4-{4-(dimethylamino)qui	3
N=[(cis-4-{[4-(dimethylamino)quinazolin-2-ylamino}cyclohexylmethyl]-N-(2-ethoxyphenyl)thiourea 479 (M+H)	
quinazolin-2-yllamino)cyclohexylmethyllthiourea N-{(cis-4-{{4-(dimethylamino)quinazolin-2-yllamino}-cyclohexyl)methyl}-N-{2-isopropyl-6-methylphenyl)thiourea N-{(cis-4-{{4-(dimethylamino)quinazolin-2-yllamino}-cyclohexyl)methyl}-N-{2-isopropyl-6-methylphenyl)thiourea N-{(cis-4-{{4-(dimethylamino)quinazolin-2-yllamino}-cyclohexyl)methyl}-N-{2-isopropyl-6-methylphenyl)thiourea N-{(cis-4-{{4-(dimethylamino)quinazolin-2-yllamino}-cyclohexyl)methyl}-N-{2-isopropyl-6-methylphenyl)thiourea N-{(cis-4-{{4-(dimethylamino)quinazolin-2-yllamino}-cyclohexyl)methyllthiourea N-{(cis-4-{{4-(dimethylamino)quinazolin-2-yllamino}-cyclohexyl)methyllthiourea N-{(cis-4-{{4-(dimethylamino)quinazolin-2-yllamino}-cyclohexyl)methyllthiourea N-{3-benzodioxol-5-ylN-{(cis-4-{4-(dimethylamino)quinazolin-2-yllamino}-cyclohexyl)methyllthiourea N-{3-benzodioxol-5-ylN-{(cis-4-{4-(dimethylamino)quinazolin-2-yllamino}-cyclohexyl)methyllthiourea N-{4-behoro-2-methylphenyl-N-{(cis-4-{4-(dimethylamino)quinazolin-2-yllamino}-cyclohexyl)methyllthiourea N-{4-behoro-2-filurophenyl-N-{(cis-4-{4-(dimethylamino)quinazolin-2-yllamino}-cyclohexyl)methyllthiourea N-{(cis-4-{{4-(dimethylamino)quinazolin-2-yllamino}-cyclohexyl)methyllthiourea N-{(-tert-butylphenyl)-N-{(cis-4-{4-(dimethylamino)quinazolin-2-yllamino}-cyclohexyl)methyllthiourea N-{3-chloro-2-flurophenyl-N-{(cis-4-{4-(dimethylamino)quinazolin-2-yllamino}-cyclohexyl)methyllthiourea N-{5-chloro-2-flurophenyl-N-{(cis-4-{4-(dimethylamino)quinazolin-2-yllamino}-cyclohexyl)methyllthiourea N-bicyclo[2.2.1]hept-2-yl-N-{(cis-4-{4-(dimethylamino)quinazolin-2-yllamino}-cyclohexyl)methyllthiourea N-bicyclo[2.2.1]hept-2-yl-N-{(cis-4-{4-(dimethylamino)quinazolin-2-yllamino}-cyclohexyl)methyllthiourea N-bicyclo[2.2.1]hept-2-yl-N-{(cis-4-{4-(dimethylamino)quinazolin-2-yllamino}-cyclohexyl)methyllthiourea N-bicyclo[2.2.1]hept-2-pl-N-{(cis-4-{4-(dimethylamino)quinazolin-2-yllamino}-cyclohexyl)methyllthiourea N-{(cyclopropyllmethyll-N-{(cis-4-{4-(dimethylamino)quinazolin-2-yllamino}-cyclohexyl)met	3
VIJamino}cyclohexyl)methyl]-N'-(2-ethoxyphenyl)thiourea V-((cis-4-{(4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]-N'-(2-isopropyl-6-methylphenyl)thiourea V-((cis-4-{(4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]-N'-(2-isopropyl-6-methylphenyl)thiourea V-((cis-4-{(4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-(2-methoxybenzyl)thiourea V-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-{(4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]hiourea V-((is-4-(4-(4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]hiourea V-((is-4-(4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]hiourea V-((is-4-(4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-[(cis-4-(4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-[(cis-4-(4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-[(cis-4-(4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-((cis-4-(4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-((cis-4-(4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-((cis-4-(4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-((cis-4-(4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-((cis-4-(4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-((cis-4-(4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-((cis-4-(4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-((cis-4-(4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-((cis-4-(4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-((cis-4-(4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-((cis-4-(4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-((cis-4-(4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-((cis-4-(4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-((cis-4-(4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-((cis-4-(4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-(cis-4-(4-(dimethylamino)quinazolin-2-yl]amino)cyclohe	<u> </u>
M-[(cis-4-[(4-(dimethylamino)quinazolin-2-yl]amino)	2
788 N-{(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N-(2-methoxybenzyl)thiourea 789 N-{(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N-(2-methoxybenzyl)thiourea 780 N-{(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea 780 N-{(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea 781 N-{(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea 783 N-{(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea 784 N-{(a-chloro-2-methylphenyl)-N'-{(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-{(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-{(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea 789 N-{(a-chloro-2,5-dimethoxyphenyl)-N'-{(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea 790 N-{(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea 791 N-{(a-chloro-2-fluorophenyl)-N'-{(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea 792 N-{(a-chloro-2-fluorophenyl)-N'-{(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea 793 N-{(a-chloro-2-fluorophenyl)-N'-{(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea 794 N-{(a-chloro-2-fluorophenyl)-N'-{(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea 795 N-{(cyclopropylmethyl)-N'-{(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea 796 N-{(a-chloro-2-fluorophenyl)-N'-{(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea 798 N-{(a-chloro-2-fluorophenyl)-N'-{(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 799 N-{(a-chloro-2-fluorophenyl)-N'-{(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 800 N-{(a-chloro-2-dilamino)cyclohexyl)methyl]thiourea 801 N-{(a-chloro-2-fluorophenyl)-N'-{(cis-4-{[4-(dimethylamino)quinazolin-2-y	
788 N-{(is-4-{[4-(dimethylamino)quinazolin-2-ylaminoquinazolin-2-ylaminoquinazoli	1
yl]amino) cyclohexyl)methyl]-N'-(2-methoxybenzyl)thiourea N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-{[4-(dimethylamino)cyclohexyl)methyl]thiourea N-((cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea N-(3-benzodioxol-5-yl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea N-(3-chloro-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea N-(4-bromo-2-(trifluoromethoxy)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea N-(4-chloro-2,5-dimethoxyphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-chloro-2,5-dimethoxyphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-eth-butylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(5-chloro-2-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2,2,1]hept-2-yl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]mino]carbonothioyl)amino]- 456 (M + H)	
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 493 (M + H)	3
amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N-(3.4-dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-1,3-benzodioxol-5-yl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(3-chloro-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-[4-bromo-2-(trifluoromethoxy)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-[4-bromo-2-(trifluoromethoxy)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-[4-bromo-2-(s-dimethoxyphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-[4-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(3-chloro-2-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(3-chloro-2-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(3-chloro-2-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(3-chloro-2-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(3-chloro-2-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(3-chloro-2-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(3-chloro-2-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 2-[(([cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea nethyl 3-[(([cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- thiophene-2-carboxylate N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- thio	
amino/quinazolin-2-yi]amino/cyclohexyl)methyl[thiourea N-[(cis-4-{{4-(dimethylamino)quinazolin-2-yi]amino}cyclohexyl)methyl]-N'-(3.4-dimethylamino)-quinazolin-2-yi]amino}cyclohexyl)methyl]thiourea N-(3-chloro-2-methylphenyl)-N'-[(cis-4-{{4-(dimethylamino)-quinazolin-2-yi]amino}cyclohexyl)methyl]thiourea N-(4-chloro-2-methylphenyl)-N'-[(cis-4-{{4-(dimethylamino)-quinazolin-2-yi]amino}cyclohexyl)methyl]-N'-[(cis-4-{{4-(dimethylamino)-quinazolin-2-yi]amino}cyclohexyl)methyl]-N'-[(cis-4-{{4-(dimethylamino)quinazolin-2-yi]amino}cyclohexyl)methyl]thiourea N-(4-chloro-2,5-dimethoxyphenyl)-N'-[(cis-4-{{4-(dimethylamino)quinazolin-2-yi]amino}cyclohexyl)methyl]thiourea N-(6-chloro-2,5-dimethoxyphenyl)-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yi]amino}cyclohexyl)methyl]thiourea N-(6-chloro-2-yi]amino}cyclohexyl)methyl]thiourea N-(5-chloro-2-fluorophenyl)-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yi]amino}cyclohexyl)methyl]thiourea N-bicyclo[2.2.1]hept-2-yl-N'-(cis-4-{{4-(dimethylamino)-quinazolin-2-yi]amino}cyclohexyl)methyl]thiourea N-bicyclo[2.2.1]hept-2-yl-N'-[(cis-4-{{4-(dimethylamino)-quinazolin-2-yi]amino}cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{{4-(dimethylamino)-quinazolin-2-yi]amino}cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{{4-(dimethylamino)-quinazolin-2-yi]amino}cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{{4-(dimethylamino)-quinazolin-2-yi]amino}cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-(cis-4-{{4-(dimethylamino)-quinazolin-2-yi]amino}cyclohexyl)methyl]thiourea nethyl 3-(({{cis-4-({4-(dimethylamino)quinazolin-2-yi]amino}cyclohexyl)methyl]amino}carbonothioyl)tamino} nethyl 3-(({{cis-4-({4-(dimethylamino)quinazolin-2-yi]amino}cyclohexyl)methyl]amino}carbonothioyl)tamino} nethyl 3-(cyclohexyl)methyl)amino)carbonothioyl)tamino} N-(2-bromo-4-fluorophenyl)-N'-(cis-4-{{4-(dimethylamino)quinazolin-2-yi]amino}cyclohexyl)methyl]amino}carbonothioyl)tamino}	3
yljamino)cyclohexyl)methyl]-N'-(3.4-dimethylphenyl)thiourea N-1,3-benzodioxol-5-yl-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(3-chloro-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-[4-bromo-2-(trifluoromethoxy)phenyl]-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]-thiourea N-(4-chloro-2,5-dimethoxyphenyl)-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-chloro-2,5-dimethoxyphenyl)-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(5-chloro-2-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2,2,1]hept-3-en-2-yl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2,2,1]hept-3-en-2-yl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 2-[(([cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea methyl 3-[(([cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea methyl 3-[(([cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea methyl 3-[(([cis-4-([4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino]-thiophene-3-carboxylate} N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino]-thiophene-2-carboxylate} N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino]-thiophene-3-carboxylate} N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino]-thiophene-3-carboxylat	
N-1,3-benzodioxol-5-yl-N'-[(cis-4-{[4-(dimethylamino}-quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea 479 (M + H)	3
quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea N-(3-chloro-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea N-[4-bromo-2-(trifluoromethoxy)phenyl]-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino) cyclohexyl)methyl]-thiourea N-(4-chloro-2,5-dimethoxyphenyl)-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea N-(4-chloro-2,5-dimethoxyphenyl)-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea N-((cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea N-(4-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea N-(5-chloro-2-fluorophenyl)-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea N-bicyclo[2,2,1]hept-2-yl-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea ethyl 2-[(([cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea ethyl 2-[(([cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea methyl 3-[(([cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea nethyl 3-[(([cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea nethyl 3-[(([cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea nethyl 3-[(([cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino} cyclohexyl)methyl]amino} cyclohexyl)methyl]thiourea N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino} cyclohexyl)methyl]amino} cyclohexyl)methyl]thiourea N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino} cyclohexyl)methyl]thiourea N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino} cyclohexyl)methyl]thiou	
quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(3-chloro-2-methylphenyl)-N'-[(cis-4-([4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-[4-bromo-2-(trifluoromethoxy)phenyl]-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]-thiourea N-(4-chloro-2,5-dimethoxyphenyl)-N'-[(cis-4-([4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(4-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(5-chloro-2-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2,2,1]hept-2-yl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2,2,1]hept-5-en-2-yl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 2-[(([cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 2-[(([cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea nethyl 3-[(([cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea pthyl 3-[(([cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea nethyl 3-[(([cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea nethyl 3-[(([cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea nethyl 3-[(([cis-4-([4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea nethyl 3-[(([cis-4-([4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea nethyl 3-[(([cis-4-([4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea nethyl 3-[(([cis-4-([4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea	3
quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-[4-bromo-2-(trifluoromethoxy)phenyl]-N'-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-thiourea N-(4-chloro-2,5-dimethoxyphenyl)-N'-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea N-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea N-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea N-(4-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(5-chloro-2-fluorophenyl)-N'-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea N-bicyclo[2.2.1]hept-2-yl-N'-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea N-bicyclo[2.2.1]hept-5-en-2-yl-N'-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea ethyl 2-[(([(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea ethyl 3-[(([(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea methyl 3-[(([(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea methyl 3-[(([(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea methyl 3-[(([(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea methyl 3-[(([cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea methyl 3-[(([cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea methyl 3-[(([cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea methyl 3-[(([cis-4-([4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea methyl 3-[(([cis-4-([4-([4-([4-([4-([4-([4-([4-([4-([4-(
quinazolin-2-y1]amino}cyclohexyl)methy1]thiourea N-[4-bromo-2-(trifluoromethoxy)pheny1]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-y1]amino}cyclohexyl)methy1]- 793 N-(4-chloro-2,5-dimethoxyphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-y1]amino}cyclohexyl)methy1]thiourea 794 N-(4-chloro-2,5-dimethoxyphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-y1]amino}cyclohexyl)methy1]thiourea 795 N-((cis-4-{[4-(dimethylamino)quinazolin-2-y1]amino}cyclohexyl)methy1]thiourea 796 N-(4-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-y1]amino}cyclohexyl)methy1]thiourea 797 N-(5-chloro-2-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-y1]amino}cyclohexyl)methy1]thiourea 798 N-bicyclo[2,2,1]hept-5-en-2-y1-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-y1]amino}cyclohexyl)methy1]thiourea 799 N-bicyclo[2,2,1]hept-5-en-2-y1-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-y1]amino}cyclohexyl)methy1]thiourea 800 N-(cyclopropylmethy1)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-y1]amino}cyclohexyl)methy1]thiourea 801 N-(cyclopropylmethy1)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-y1]amino}cyclohexyl)methy1]thiourea 802 y1]amino)cyclohexyl)methy1]amino}carbonothioyl)amino]- 803 N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-y1]amino}cyclohexyl)methy1]amino}carbonothioyl)amino]- 803 N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-y1]amino}cyclohexyl)methy1]thiourea 803 N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino]quinazolin-2-y1]amino}cyclohexyl)methy1]amino}carbonothioyl)amino]- 809 N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino]quinazolin-2-y1]amino}cyclohexyl)methy1]amino}carbonothioyl)amino]- 800 N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino]quinazolin-2-y1]amino}cyclohexyl)methy1]amino}carbonothioyl)amino]- 801 N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino]quinazolin-2-y1]amino}cyclohexyl)methy1]amino}carbonothioyl)amino]- 803 N-(2-bromo-4-fluorophenyl)-N'-	3
(dimethyl-amino)quinazolin-2-yl]amino)cyclohexyl)methyl]- thiourea 794 N-(4-chloro-2,5-dimethoxyphenyl)-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 795 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 796 N-(4-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 797 N-(5-chloro-2-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 798 N-bicyclo[2.2.1]hept-2-yl-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 799 N-bicyclo[2.2.1]hept-5-en-2-yl-N'-[(cis-4-{[4-(dimethyl-amino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 800 N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 801 N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 802 yl]amino]cyclohexyl)methyl]amino]carbonothioyl)amino]- 499 (M+H) 803 N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- 499 (M+H)	
thiourea 794 N-(4-chloro-2,5-dimethoxyphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 795 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 796 N-(4-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 797 N-(5-chloro-2-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 798 N-bicyclo[2.2.1]hept-2-yl-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 799 N-bicyclo[2.2.1]hept-5-en-2-yl-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 800 N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea 801 yl]amino}cyclohexyl)methyl]thiourea 802 yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- 456 (M + H) 457 (M + H) 458 (M + H) 458 (M + H) 459 (M + H) 450 (M + H) 450 (M + H) 450 (M + H) 451 (M + H) 452 (M + H) 453 (M + H) 453 (M + H) 453 (M + H) 454 (M + H) 455 (M + H) 455 (M + H) 456 (M + H) 457 (M + H) 458 (M + H) 458 (M + H) 459 (M + H)	2
N-(4-chloro-2,5-dimethoxyphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-phenylbutyl)thiourea N-(4-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(5-chloro-2-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2,2,1]hept-2-yl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2,2,1]hept-5-en-2-yl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 2-[({[(cis-4-{[4-(dimethylamino}quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea methyl 3-[({[(cis-4-{[4-(dimethylamino}quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino}-yulnazolin-2-yl]amino}carbonothioyl)amino]- yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino}-yulnazolin-2-yl]amino}carbonothioyl)amino]- N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino}-yulnazolin-2-yuln	2
amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-phenylbutyl)thiourea N-(4-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(5-chloro-2-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2.2.1]hept-2-yl-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2.2.1]hept-5-en-2-yl-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 3-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- 491 (M + H) 487 (M + H) 453 (M + H) 451 (M + H) 451 (M + H) 451 (M + H) 452 (M + H) 453 (M + H) 453 (M + H) 453 (M + H) 454 (M + H) 455 (M + H)	
N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-phenylbutyl)thiourea N-(4-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(5-chloro-2-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2,2,1]hept-2-yl-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2,2,1]hept-5-en-2-yl-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2,2,1]hept-5-en-2-yl-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 2-[(([(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- 1567 (M + H) 1568 (M + H) 1569 (M + H) 1569 (M + H) 1569 (M + H) 1569 (M + H)	3
yl]amino}cyclohexyl)methyl]-N'-(4-phenylbutyl)thiourea N-(4-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(5-chloro-2-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2,2,1]hept-2-yl-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2,2,1]hept-5-en-2-yl-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2,2,1]hept-5-en-2-yl-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- 43 (M + H) 451 (M + H) 463 (M + H) 451 (M + H) 463 (M + H) 470 (M + H) 471 (M + H) 471 (M + H) 472 (M + H)	
N-(4-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(5-chloro-2-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2.2.1]hept-2-yl-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2.2.1]hept-5-en-2-yl-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2.2.1]hept-5-en-2-yl-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 3-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- nethyl 3-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- thiophene-2-carboxylate N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-yl]amino}carbonothioyl)amino]- thiophene-2-carboxylate N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-yl]amino}carbonothioyl)amino]- 1531 (N + H)	3
2-yl]amino}cyclohexyl)methyl]thiourea N-(5-chloro-2-fluorophenyl)-N'-[(cis-4-([4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2.2.1]hept-2-yl-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2.2.1]hept-5-en-2-yl-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 3-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- ### ### ### ### ### ### ### ### ### #	
N-(5-chloro-2-fluorophenyl)-N'-[(cis-4-([4-(dimethylamino)-quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea N-bicyclo[2.2.1]hept-2-yl-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea N-bicyclo[2.2.1]hept-5-en-2-yl-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea ethyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]thiourea ethyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]amino} carbonothioyl)amino]- 457 (M+H) methyl 3-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl]amino} carbonothioyl)amino]- thiophene-2-carboxylate N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-thiophene-3-carboxylate}	3
quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2.2.1]hept-2-yl-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2.2.1]hept-5-en-2-yl-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- 453 (M + H) 451 (M + H) 451 (M + H) 453 (M + H) 451 (M + H) 453 (M + H) 453 (M + H) 451 (M + H) 453 (M + H) 453 (M + H) 451 (M + H) 451 (M + H) 453 (M + H)	
N-bicyclo[2.2.1]hept-2-yl-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2.2.1]hept-5-en-2-yl-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- 4.5,6,7-tetrahydro-1-benzothiophene-3-carboxylate methyl 3-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- thiophene-2-carboxylate N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-yl]amino}carbonothioyl)amino]- thiophene-2-carboxylate	3
quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-bicyclo[2.2.1]hept-5-en-2-yl-N'-[(cis-4-{[4-(dimethyd-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethydamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- 4.5,6,7-tetrahydro-1-benzothiophene-3-carboxylate methyl 3-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- thiophene-2-carboxylate N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-yl]amino}carbonothioyl)amino]- 53.1 (M+H)	
N-bicyclo[2,2,1]hept-5-en-2-yl-N'-[(cis-4-{[4-(dimethyl-amino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- 4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate methyl 3-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- thiophene-2-carboxylate N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-state]carboxylate]non-state]carboxylate N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-state]carboxylate]non-state]carboxylate	2
amino)quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- 4.5.6.7-tetrahydro-1-benzothiophene-3-carboxylate methyl 3-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- thiophene-2-carboxylate N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-state]carboxylate]carbonothioyl)amino]- N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-state]carboxylate]carboxylate]carboxylate]carboxylate	
N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- 4.5,6.7-tetrahydro-1-benzothiophene-3-carboxylate methyl 3-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- thiophene-2-carboxylate N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-yl]amino}carbonothioyl)amino]- 803 N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-yl]amino}carbonothioyl)amino}carbonothioyl)	2
quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea ethyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- 4.5,6.7-tetrahydro-1-benzothiophene-3-carboxylate methyl 3-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- thiophene-2-carboxylate N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-state]cost}	
ethyl 2-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- 4.5,6.7-tetrahydro-1-benzothiophene-3-carboxylate methyl 3-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- thiophene-2-carboxylate N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-state]amino}carbonothioyl)amino]- solution (M+H)	2
yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- 4.5.6.7-tetrahydro-1-benzothiophene-3-carboxylate methyl 3-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- thiophene-2-carboxylate N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)- 531 (N + H)	
4.5,6.7-tetrahydro-1-benzothiophene-3-carboxylate methyl 3-[({[cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- thiophene-2-carboxylate N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-531 (N (+ H)	3
methyl 3-[({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonothioyl)amino]- thiophene-2-carboxylate N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-	
802 yl]amino)cyclohexyl)methyl]amino)carbonothioyl)amino]- thiophene-2-carboxylate N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-	*****
thiophene-2-carboxylate N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-	3
N-(2-bromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-	
quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea	3
N-(3-chloro-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)-	
quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea 487 (M + H)	3

Ex. No.	compound name	MS	class
805	N-(4-butyl-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)-	505 (M + H)	3
	quinazolin-2-yl]amino)cyclohexyl)methyl]thiourea	`	
806	N-[4-(dimethylamino)phenyl]-N'-[(cis-4-{[4-(dimethylamino)-	478 (M + H)	3
	quinazolin-2-yl]amino) cyclohenyl)methyl]thiourea		
807	N-[3-(diethylamino)propyl]-N'-[(cis-4-([4-(dimethylamino)-	472 (M + H)	3
	quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea		
808	N-[(cis-4-{[4-(dimethy/lamino)quinazolin-2-	472 (M + H)	3
	yi]amino}cyclohexyl)methyl]-N'-(2-morpholin-4-ylethyl)thiourea N-{(cis-4-{{4-(dimethylamino)quinazolin-2-		
805		436 (M+H)	3
	yl]amino}cyclohexyl)methyl]-N'-pyridin-3-ylthiourea N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
810	cyclohexyl)methyl]-N'-(3-morpholin-4-ylpropyl)thiourea	486 (M + H)	3
	N-[4-(diethylamino)phenyl]-N'-[(cis-4-([4-(dimethylamino)-		
811	quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea	506 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
812	cyclohexyl)methyl]-N'-{4-[(E)-phenyldiazenyl]phenyl}thiourea	539 (M + H)	3
	N-{(cis-4-{{4-(dimethylamino)quinazolin-2-		
813	yl]amino}cyclohexyl)methyl]-N'-(2-piperidin-1-ylethyl)thiourea	470 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
814	cyclohexyl)methyl]-N'-[4-(1H-pyrazol-1-yl)phenyl]thiourea	501 (M + H)	3
	N-2,1,3-benzothiadiazol-4-yl-N'-[(cis-4-{[4-(dimethylamino)-		
815	quinazolin-2-yl]amino) cyclohexyl)methyl]thiourea	493 (M + H)	3
	N-2,1,3-benzothiadiazol-5-yl-N'-[(cis-4-{[4-(dimethylamino)-		
816	quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea	493 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
817	cyclohexyl)methyl]-N'-(3,5-dimethylisoxazol-4-yl)thiourea	454 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	700 (3 t · TX)	2
818	cyclohexyl)methyl]-N'-[4-(1,3-oxazol-5-yl)phenyl]thiourea	502 (M + H)	3
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-		
819	eyclohexyl)methyl]-N'-(5-methyl-3-phenylisoxazol-4-yl)-	516 (M + H)	2
1	thiourea		
020	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	521 (M + H)	3
820	cyclohexyl)methyl]-N'-(6-morpholin-4-ylpyridin-3-yl)thiourea	321 (M + H)	3
821	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	528 (M + H)	3
01	yl]amino}cyclohexyl)methyl]-N'-(6-phenoxypyridin-3-yl)thiourea	328 (N1 + 11)	<u> </u>
822	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	468 (M + H)	2
	N'-(4-fluoro-2-nitrophenyl)urea	408 (N1 + 11)	
823	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	491 (M + H)	3
843	N'-[4-fluoro-3-(trifluoromethyl)phenyl]urea	451 (14 + 14)	٠,٠
824	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	437 (M + H)	1
027	N'-(4-fluorobenzyl)urea	10 / (MA / 11)	<u> </u>
825	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	519 (M + H)	3
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	N'-[4-(heptyloxy)phenyl]urea		
826	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	531 (M + H)	2
	N'-(4-iodophenyl)urea		
827	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	449 (M + H)	1
	N'-(4-methoxy-2-methylphenyl)urea	(1.1 / 11)	

Ex. No.	compound name	MS	class
828	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(4-methoxy-2-nitrophenyl)urea	480 (M + H)	3
829	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)- N'-(4-methyl-3-nitrophenyl)urea	464 (J-1 + H)	3
830	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)- N'-(4-methylbenzyl)urea	433 (M + H)	2
831	N-(4-butoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	477 (M + H)	3
832	N-(4-butylphenyl)-N'-(cis-4-([4-(dimethylamino)quinazolin-2- yl]amino)cyclohexyl)urea	461 (N1+H)	3
833	N-biphenyl-4-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	481 (M+H)	3
834	N-(5-chloro-2,4-dimethoxyphenyl)-N'-(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	499 (M+H)	1
835	N-(5-chloro-2-methoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	469 (M + H)	3
836	N-(5-chloro-2-methylphenyl)-N'-(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea	453 (M + H)	3
837	N-(5-chloro-2-nitrophenyl)-N'-(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	484 (M + H)	3
838	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(5-fluoro-2-methylphenyl)urea	437 (M + H)	2
839	N-(2,3-dihydro-1H-inden-5-yl)-N'-(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	445 (M + H)	3
840	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)- N'-9H-fluoren-2-ylurea	493 (M + H)	3
841	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)- N'-9H-fluoren-9-ylurea	493 (M + H)	2
842	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-(2-phenylethyl)urea	433 (M + H)	2
843	N-cyclopentyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	397 (M + H)	2
844	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)- N'-(diphenylmethyl)urea	495 (M + H)	1
845	methyl 4-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}amino)benzoate	463 (M + H)	3
846	2-(benzyloxy)ethyl (cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)carbamate	464 (M + H)	2
847	2,2-dimethylpropyl (cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)carbamate	400 (M + H)	3
848	4,5-dimethoxy-2-nitrobenzyl (cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino)cyclohexyl)carbamate	525 (M + H)	1
849	3-(trifluoromethyl)phenyl (cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)carbamate	474 (M + H)	3
850	4-bromophenyl (cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)carbamate	484 (M + H)	3

Ex. No.	compound name	MS	class
851	2-methoxyphenyl (cis-4-{[4-(dimethylamino)quinazolin-2-	436 (M + H)	3
	yl]amino) cyclohexyl)carbamate	155 (11. 12.)	_
852	2-methoxyethyl (cis-4- ([4-(dimethylamino)quinazolin-2-	338 (ist + H)	3
	yl]amino)cyclohexyl)carbamate		
853	octyl (cis-4-{[4-(dimethylamino)quinazolin-2-	442 (M + H)	3
	yl]amino) cyclohexyl)carbamate	,	
854	ethyl (cis-4-{[4-(dimethylamino)quinazolin-2-	358 (M + H)	3
	vl]amino}cyclohexyl)carbamate		
855	4-nitrobenzyl (cis-4-{[4-(dimethylamino)quinazolin-2- yl]amino}cyclohexyl)carbamate	465 (M+H))
	2-naphthyl (cis-4-{[4-(dimethylamino)quinazolin-2-		
856	yl]amino}cyclohexyl)carbamate	456 (M + H)	3
	allyl (cis-4-{[4-(dimethylamino)quinazolin-2-		
857	yl]amino}cyclohexyl)carbamate	370 (M + H)	3
	benzyl (cis-4-{[4-(dimethylamino)quinazolin-2-		
858	yl]amino}cyclohexyl)carbamate	420 (M + H)	2
0.50	phenyl (cis-4-{[4-(dimethylamino)quinazolin-2-	107 (M + H)	7
859	yl]amino)cyclohexyl)carbamate	406 (M + H)	3
860	(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl (cis-4-{[4-	468 (M + H)	3
300	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)carbamate	408 (117 11)	
861	4-methylphenyl (cis-4-{[4-(dimethylamino)quinazolin-2-	420 (M + H)	3
001	yl]amino}cyclohexyl)carbamate	+20 (IVI + H)	
862	methyl (cis-4-{[4-(dimethylamino)quinazolin-2-	344 (M + H)	3
	yl]amino}cyclohexyl)carbamate		
863	2-chlorobenzyl (cis-4-{[4-(dimethylamino)quinazolin-2-	454 (M + H)	2
	yl]amino}cyclohexyl)carbamate 9H-fluoren-9-ylmethyl (cis-4-{[4-(dimethylamino)quinazolin-2-		
864	yl]amino) cyclohexyl)carbamate	508 (M + H)	3
	2,2,2-trichloroethyl (cis-4-{[4-(dimethylamino)quinazolin-2-		
865	yllamino)cyclohexyl)carbamate	460 (M + H)	3
	2-(benzyloxy)ethyl [(cis-4-{[4-(dimethylamino)quinazolin-2-		
866	yl]amino}cyclohexyl)methyl]carbamate	478 (M + H)	3
2.5	2,2-dimethylpropyl [(cis-4-{[4-(dimethylamino)quinazolin-2-	13.4 (3.4 . 33)	
867	yl]amino}cyclohexyl)methyl]carbamate	414 (M + H)	3
0.00	4,5-dimethoxy-2-nitrobenzyl [(cis-4-([4-(dimethylamino)-	520 /N(+ II)	3
868	quinazolin-2-yl]amino}cyclohexyl)methyl]carbamate	539 (M + H)	3
869	3-(trifluoromethyl)phenyl [(cis-4-{[4-(dimethylamino)quinazolin-	488 (M + H)	3
307	2-yl]amino}cyclohexyl)methyl]carbamate	488 (M + H)	ر
870 871 872	4-bromophenyl [(cis-4-{[4-(dimethylamino)quinazolin-2-	498 (M + H)	3
	yl]amino)cyclohexyl)methyl]carbamate		
	2-methoxyphenyl [(cis-4-{[4-(dimethylamino)quinazolin-2-	450 (M + H)	3
	yl]amino)cyclohexyl)methyl]carbamate	,	
	2-methoxyethyl [(cis-4-([4-(dimethylamino)quinazolin-2-	402 (M + H)	3
	yl]amino)cyclohexyl)methyl]carbamate	` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` ` `	
873	octyl [(cis-4-{[4-(dimethylamino)quinazolin-2-	456 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate		

Ex. No.		MS	class
874	ethyl [(cis-4-{[4-(dimethylamino)quinazolin-2-	372 (M + H)	
	yl]amino)cyclohexyl)methyl]carbamate		3
875	4-nitrobenzyl [(cis-4-{[4-(dimethylamino)quinazolin-2-	479 (i/1 + H)	
	yl]amino) cyclohenyl) methyl]carbamate		2
876	2-naphthyl [(cis-4-{[4-(dimethylamino)quinazolin-2-		
8/0	yl]amino) cyclohexyl)methyl]carbamate	470 (M + H)	3
877	allyl [(cis-4-{[4-(dimethylamino)quinazolin-2-		_
0//	yl]amino) cyclohexyl)methyl]carbamate	384 (M + H)	3
878	benzyl [(cis-4-{[4-(dimethylamino)quinazolin-2-	15.00	
8/8	yl]amino)cyclohexyl)methyl]carbamate	434 (M+H)	2
879	phenyl [(cis-4-{[4-(dimethylamino)quinazolin-2-	420 (M + H)	
8/5	yl]amino) cyclohexyl)methyl]carbamate		3
	(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl [(cis-4-{[4-	482 (M + H)	
880	(dimethyl-amino)quinazolin-2-yl]amino)cyclohexyl)methyl]		3
	carbamate		
881	4-methylphenyl [(cis-4-{[4-(dimethylamino)quinazolin-2-	434 (M + H)	2
881	vl]amino}cyclohexyl)methyl]carbamate		3
882	methyl [(cis-4-{[4-(dimethylamino)quinazolin-2-	358 (M + H)	3
002	yl]amino)cyclohexyl)methyl]carbamate		3
883	2-chlorobenzyl [(cis-4-{[4-(dimethylamino)quinazolin-2-	468 (M + H)	
	yl]amino)cyclohexyl)methyl]carbamate		2
884	9H-fluoren-9-ylmethyl [(cis-4-{[4-(dimethylamino)quinazolin-2-	522 (M + H)	3
	yl]amino)cyclohexyl)methyl]carbamate		
285	2,2,2-trichloroethyl [(cis-4-{[4-(dimethylamino)quinazolin-2-	474 (M + H)	2
	yl]amino}cyclohexyl)methyl]carbamate		3

Example 886

N-(cis-4-{[4-(Dimethylamino)-6-methylquinacolin-2-yl]amino}cyclohexyl)-2,2-diphenylacetamide trifluoroacetate

5 Step A: Synthesis of 6-methyl-1 H-quinazoline-2,4-dione.

To a suspension of 2-amino-5-methylbenzoic acid (5.27 g, 0.035 mol) in 150 mL H_2O and 2 mL acetic acid was added potassium cyanate (3.67 g, 0.045 mol) predissolved in 30 mL H_2O . The reaction mixture was stirred for 5 hours and then 10 g NaOH pellets were added with continued stirring. The mixture was cooled to 0 °C in an ice bath and another 30 g NaOH pellets were added.

10 During the addition of NaOH a precipitate was formed. This precipitate was filtered and resuspended in 100 mL H₂O and 3M HCl was added by pipette until the ageous solution was slightly acidic. The precipitate was then filtered and washed with ice cold H₂O to yield 6-methyl-1

H-quinazoline-2,4-dione (2.29 g, 37%) as an off white solid.

ESI-MS m/e 177.1 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.18 (s, 1 H), 11.02 (s, 1 H), 7.66 (s, 1 H), 7.45 (d, J = 8.4 Hz, 1 H), 7.05 (d, J = 8.4 Hz, 1 H), 2.31 (s, 3H).

Step B: Synthesis of 2.4-dichloro-6-methyl-quinazoline.

To a solution of 6-methyl-1 *H*-quinazoline-2,4-dione (2.29 g, 0.013 mol) in 20 mL POCl₃ was added *N*, *N*-dimethylaniline (1.81 mL, 0.014 mol). The mixture was heated to reflux (125 °C) and stirred for 4 hours until the starting material completely dissolved and the solution turned dark purple in color. The solution was then cooled and poured slowly on ice (40 g; caution highly exothermic) to quench the reaction. The aqueous layer was then extracted three times with CH₂Cl₂ (40 mL). The organic layer was dried over MgSO₄, concentrated, and subjected to purification by chromatography (100% CH₂Cl₂) to yield 2,4-dichloro-6-methyl-quinazoline (2.5 g, 90 %) as a slightly yellow solid.

25 ¹H NMR (400 MHz, DMSO-d₀) 8 8.05 (s, 1H), 8.01 (d, J = 9.2 Hz, 1 H), 7.94 (d, J = 8.8 Hz, 1 H), 2.57 (s, 3 H).

163

Step C: Synthesis of (2-chloro-6-methly-quinazolin-4-yl)-dimethyl-amine.

A solution of 2,4-dichloro-6-methyl-quinazoline (2.5 g, 0.012 mol) in CH₂Cl₂ (100 mL) was cooled on an ice bath with stirring. Dimethylamine (23.5 mL, 0.047 mol) was added slowly to the solution removed from the ice bath. The mixture stirred for 1 hour and the excess solvents were evaporated. The compound was subject to purification by chromatography (100 % CH₂Cl₂) to yield (2-chloro-6-methly-quinazolin-4-yl)-dimethyl-amine (2.4 g, 92%) as a white solid. ESI-MS m/e 222.2 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) 8 7.96 (s, 1 H), 7.61 (d, J = 8 Hz, 1 H), 7.54 (d, J = 8.4 Hz, 1 H), 3.34 (brs, 6 H), 2.45 (s, 3 H).

10 Step D: Synthesis of

cis-[4-(4-dimethylamino-6-methyl-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester.

To a solution of (2-chloro-6-methly-quinazolin-4-yl)-dimethyl-amine (0.5 g, 0.0023 mol) in 0.5 mL 2-propanol was added of *cis*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester(483mg,

- 15 0.0023mol), and DIEA (786 uL, 0.0045 mol). The reaction mixture was heated in a microwave synthesizer at 170° C for 1 hour. The solvent was evaporated and the material subjected to chromatography (2-4 % 2M NH₃ in MeOH / CH₂Cl₂) to yield cis-[4-(4-dimethylamino-6-methyl-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester (850 mg, 94 %) as a white solid.
- 20 ESI-MS m/e 400.4 M + H⁺; ¹H NMR (400 MHz, CD₃OD) δ 7.68 (s, 1 H), 7.37 (d, J = 8.4 Hz, 1 H), 7.28 (d, J = 8.4 Hz, 1 H), 4.05 (m, 1 H), 3.54 (brs, 1 H), 3.26 (s, 6 H), 2.38 (s, 3 H), 1.76-1.59 (m, 8 H), 1.44 (s, 9 H).

Step E: Synthesis of $cis-N^2$ -(4-amino-cyclohexyl)-6, N^4 , N^4 -trimethyl-quinazoline-2,4-diamine.

To a solution of cis-[4-(4-dimethylamino-6-methyl-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid text-butyl ester (850 mg, 0.0021 mol) in 30 mL CH₂Cl₂ was added TFA (325 uL, 0.042 mol). The solution was stirred at room temperature for 4 hours. The excess solvent was evaporated off and the resulting oil was dissolved in 30 mL CH₂Cl₂. The organic layer was extracted with 30 mL of a dilute NaOH (aq) / NaHCO₃ (aq) solution. The aqueous layer was back extracted twice with CH₂Cl₂ and the organic layers combined, dried over MgSO₄, and concentrated to yield

cis- N^2 -(4-amino-cyclohexyl)-6, N^4 , N^4 -trimethyl-quinazoline-2,4-diamine (459 mg, 72 %) as a white 5 solid.

ESI-MS m/e 300.2 M + H⁺; ¹H NMR (400 MHz, CD₃OD) δ 7.69 (s, 1 H), 7.38 (d, J = 8.4 Hz, 1 H), 7.30 (d, J = 8.8 Hz, 1 H), 4.07 (m, 1 H), 3.27 (s, 6 H), 2.85 (m, 1 H), 2.39 (s, 3 H), 1.84-1.70 (m, 6 H), 1.57-1.52 (m, 2 H).

10 Step F: Synthesis of N-(cis-4-{[4-(dimethylamino)-6-methylquinazolin-2-yl]amino}-cyclohexyl)-2,2-diphenylacetamide trifluoroacetate

To a solution of *cis-N*²-(4-amino-cyclohexyl)-6, N⁴, N⁴-trimethyl-quinazoline-2,4-diamine (24.9 mg, 0.083 mmol) in 0.5 mL DMF was added pyridine (16.2 uL, 0.2 mmol) and diphenylacetyl chloride (23.0 mg, 0.1 mmol). The reaction mixture was stirred overnight and then 0.5 mL of DMSO was added to the mixture. The compound was then subject to purification by prep LCMS to yield N-(*cis*-4-{[4-(dimethylamino)-6-methylquinazolin-2-yl]amino} cyclohexyl)-2,2-diphenylacetamide trifluoroacetate (13.6 mg, 27%) as a white solid.

ESI-MS m/e 494.4 M + H⁴⁺; ¹H NMR (400 MHz, CD₃OD) & 7.96 (s, 1 H), 7.63 (d, *J* = 8.4 Hz, 1 H), 7.31-7.23 (m, 11 H), 4.16 (brs, 1 H), 3.89 (brs, 1 H), 3.54 (brs, 6 H), 2.66 (s, 1 H), 2.47 (s, 3 H),

Example 887

20 1.86-1.79 (m, 8 H).

N-(eis-4-{[4-(Dimethylamino)-6-methylquinazolin-2-yl]amino}cyclohexyl)-4-fluoro-3-(trifluoroscetate

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-6-methylquinazolin-2-yl]amino}-cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide trifluoroacetate.

WO 2004/087680

165

Using a similar procedure as described in step F of Example 886, the title compound was obtained (12.5 mg, 25%) as a white solid.

ESI-NIS m/e 490.2 M + H⁺; ¹H NN IR (400 NHz, CD₃OD) 8 0.19-0.15 (m, 2 H), 7.98 (s, 1 H), 7.64 (d, J = 8.4 Hz, 1 H), 7.49 (t, J = 9.2 Hz, 1 H), 7.44 (brs, 1 H), 4.24 (brs, 1 H), 4.03 (brs, 1 H), 3.56 (s, 5 6 H), 2.47 (s, 3 H), 2.01-1.81 (m, 8 H).

Example 888

N-(cis-4-{[4-(Dimethylamino)-6-methylquinazolin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromet hyl)benzamide trifluoroacetate

Step A: Synthesis of N-(cis-4-{{4-(dimethylamino)-6-methylquinazolin-2-yl]amino}-cyclohexyl)-3,5-bis(trifluoromethyl)benzamide trifluoroacetate.

Using a similar procedure as described in step F of Example 886, the title compound was obtained (18.4 mg, 0.028 mmol, 34%) as a white solid.

ESI-MS m/e 540.4 M + H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.53 (s, 2 H), 8.18 (s, 1 H), 7.97 (s, 1 H), 7.64 (d, J = 8.4 Hz, 1 H), 7.37 (brs, 1 H), 4.26 (brs, 1 H), 4.07 (brs, 1 H), 3.56 (brs, 6 H), 2.47 (s, 3 H), 2.07-1.32 (m, 8 H).

20

Example 889

N-(cis-4-{[4-(Dimethylamino)-6-methylquinazolin-2-yl]amino}cyclohexyl)-3,4,5-trimethoxybe nzamide trifluoroacetate

25 Step A: Synthesis of H-(cis-4-{[4-(dimethylamino)-6-methylquinazolin-2-yl]amino}-cyclohexyl)-3,4,5-trimethoxybenzamide trifluoroacetate.

Using a similar procedure as described in step F of Example 886, the title compound was obtained (21.2 mg, 0.035 mmol, 42%) as a white solid.

166

ESI-MS m/e $494.4 \text{ M} + \text{H}^+$; ¹H NMR $(400 \text{ MHz}, \text{CD}_3\text{OD}) \delta 7.98 \text{ (s, 1 H)}, 7.64 \text{ (d, J} = 8.4 \text{ Hz, 1 H)}, 7.37 \text{ (brs, 1 H)}, 7.17 \text{ (s, 2 H)}, 4.28 \text{ (brs, 1 H)}, 4.02 \text{ (brs, 1 H)}, 3.91 \text{ (s, 6 H)}, 3.82 \text{ (s, 3 H)}, 3.63 \text{ (brs. 6 H)}, 2.47 \text{ (s, 3 H)}, 2.07-1.81 \text{ (m, 8 H)}.$

5

Enample 390

cis-4-{[4-(Dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-M-(4-methylbenzyl)cyclohexane carboxamide trifluoroacetate

10 Step A: Synthesis of 6,7-difluoro-1H-quinazoline-2,4-dione.

A solution of KOCN (6.1 g, 75 mmol) in H₂O (52 mL) was added to a solution of 2-amino-4,5-difluoro benzoic acid (10 g, 58 mmol) in H₂O/AcOH (260 mL/3.5 mL). The mixture was stirred overnight at room temperature, and then NaOH (55 g, 1.37 mol) was slowly added in a portion of 3~4 grams. During the addition of NaOH, the reaction was changed to a clear purple solution, and then formation of precipitates was observed. After stirring about 10 min, the precipitates were filtered and resuspended in H₂O. The aqueous suspension was acidified to pH 4 with 4N-HCl and stirred for another 10 more min. The precipitates were filtered and washed with cold water and dried to give 7.0 g (61 %) of 6,7-difluoro-1H-quinazoline-2,4-dione.

ESI MS m/e 199 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.46 (s, 1 H), 11.26 (s, 1 H), 7.81 (dd, 20 J = 10.0, 8.4 Hz, 1 H), 7.08 (dd, J = 11.2, 6.8 Hz, 1 H).

Step B: Synthesis of 2,4-dichloro-6,7-difluoroquinazoline.

To a suspension of 6,7-difluoro-1H-quinazoline-2,4-dione (6.9 g, 35 mmol) in POCl₃ (21 mL) was slowly added N,N-dimethylaniline (4.9 mL, 35 mmol). The reaction was heated at reflux (120 °C) for 7 h until the starting material was completely dissolved and the entire solution turned a dark purple color. The reaction was allowed to cool and poured very slowly onto ice (1 L); watch out for heat generation!! The resulting precipitate was filtered and washed with ice water. The crude product was purified from a short column of silica with CH₂Cl₂ as an eluting solvent. The desired product (7.2

167

88 %) was obtained as a white solid.

ESI MS m/e 236 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.01 (dd, J = 9.2, 8.0 Hz, 1 H), 7.76 (dd, J = 10.0, 7.2 Hz, 1 H).

5 Step C: Synthesis of 2-chloro-6,7-difluoro-4-dimethylaminoquinazoline.

10 crude reaction mixture gave solid precipitate, which was filtered and dried.

A solution of 2, 4-dichloro-6,7-difluoro quinazoline (6.1 g, 26 mmol) in THF (60 mL) was cooled to 2~4 °C in an ice bath and 2M-Me₂NH in MeOH (25 mL, ~2 eq.) was slowly added. The reaction was stirred for 70 min. at room temperature, neutralized with saturated aqueous NaHCO₃, and concentrated until the most volatile solvent was removed. Addition of water into the concentrated

2-Chloro-6,7-difluoro-4-dimethylaminoquinazoline pure compound (5.6 g, 90 %) was isolated as a yellowish white solid from a short column of silica using $CH_2Cl_2/MeOH$ (100/0 to 90/10) as an eluting solvent.

ESI MS m/e 244 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.78 (dd, J = 11.2, 8.0 Hz, 1 H), 7.50 (dd, 15 J = 11.2, 80 Hz, 1 H), 3.40 (s, 6 H).

Step D: Synthesis of *cis*-4-(4-dimethylamino-6,7-difluoroquinazolin-2-ylamino)-cyclohexane-carboxylic acid ethyl ester.

A suspended solution of 2-chloro-6,7-difluoro-4-dimethylamino quinazoline (0.45 g, 1.85 mmol) and cis-(4-ethoxycarbonyl) aminocyclohexane hydrochloride (0.38 g, 1eq.) in IPA (2.5 mL) and DIEA (0.5 mL, ~2eq.) was reacted for 2 h at 155 °C in a Smith microwave synthesizer. The reaction was quenched and purified by column chromatography (DCM:MeOH = 100:0 to 90:10) to give 0.25 g (36 %) of

cis-4(4-dimethylamino-6,7-difluoroquinazolin-2-ylamino)-cyclohexanecarboxylic acid ethyl ester.

ESI MS m/e 379 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.57 (dd, J = 11.0, 8.0 Hz, 1 H), 7.17 (dd, J = 12.0, 7.0 Hz, 1H), 4.96 (d, J = 7.0 Hz, 1 H), 4.15 (q, J = 7.0 Hz, 2 H), 4.13 (brs, 1 H), 3.23 (s, 6 H), 2.48 (m, 1 H), 1.94 (m, 2 H), 1.83-1.68 (m, 6 H), 1.25 (t, J = 7.0 Hz, 3 H).

168

Step E: Synthesis of

cis-4-(4-dimethylamino-6,7-difluoroquinazolin-2-ylamino)-cyclohexanecarboxylic acid.

carboxylic acid ethyl ester (0.71 g, 1.9 mmol) in 4 N-HCl (15 mL) was stirred at 82 °C for 3 h. During the reaction, the heterogenous solution turned to be a clear solution, and then the precipitate was formed. The solid was filtered, washed with cold water several times, and dried to give 0.55 g (85 %) of cis-4(4-dimethylamino-6,7-difluoroquinazolin-2-ylamino)-cyclohexane carboxylic acid as a white solid.

A suspension of cis-4(4-dimethylamino-6,7-difluoroquinazolin-2-ylamino)-cyclohexane

ESI MS m/e $351 \text{ M} + \text{H}^{+}$; ${}^{1}\text{H} \text{ NMIR} (400 \text{ MHz}, \text{DMSO-}d_{6}) \delta 12.15 (brs, 1 H), 8.18 (m, 2 H), 7.47 (m, 10 H), 3.99 (brs, 1 H), 3.38 (s, 6 H), 2.38 (brs, 1 H), 1.75-1.59 (m, 8 H).$

Step F: Synthesis of

cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-(4-methylbenzyl)cyclohexane carboxamide trifluoroacetate.

- mg, 0.06 mmol) and 4-methylbenzyl amine (7.5 mg, 0.06 mmol) was stirred overnight in the presence of HATU (25 mg, 1.1 eq.) and Et₃N (5 drops).

 cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-(4-methylbenzyl)cyclohexanecarb oxamide trifluoroacetate (13 mg, 39 %) was obtained from a prep-HPLC.
- 20 ESI MS m/e 454 M + H⁺; 1 H NMR (400 MHz, DMSO- $d_{6})$ δ 11.9 (brs, 1 H), 8.19 (m, 2 H), 8.10 (b, 1 H), 7.49 (m, 1 H), 7.05 (s, 4 H), 4.16 (d, J = 6.0 Hz, 2 H), 4.08 (brs, 1 H), 3.39 (s, 6 H), 2.26 (m, 1 H), 2.20 (s, 3 H), 1.71-1.57 (m, 8 H).

25 Example 391

cis-H-(3-Chlorobenzyl)-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexane carboxamide trifluoroacetate

169

Step A: Synthesis of

cis-ll-(3-chlorobenzyl)-4-{[4-(dimethylamino)-6,7-diffuoroquinazolin-2-yt]amino)cyclohemanec arbozamide trifluoroacetate.

Using a similar procedure as described in step F of Example 390, the title compound was obtained.

ESI MS m/e $474 \text{ M} + \text{H}^+$; ¹H NMR $(400 \text{ MHz}, \text{DMSO-} d_6) \& 12.1 \text{ (brs, 1 H)}, \& 31 \text{ (t, } J = 7.6 \text{ Hz, 1 H)}, \& 8.19 \text{ (m, 2 H)}, & 7.49 \text{ (t, } J = 8.0 \text{ Hz, 1 H)}, & 7.30-7.21 \text{ m, 3 H)}, & 7.13 \text{ (d, } J = 7.6 \text{ Hz, 1 H)}, & 4.21 \text{ (d, } J = 6.0 \text{ Hz, 2 H)}, & 4.08 \text{ (brs, 1 H)}, & 3.44 \text{ (s, 6 H)}, & 2.29 \text{ (brs, 1 H)}, & 1.85-1.59 \text{ (m, 8 H)}.$

10

Example 892

 $\label{lem:cis-4-lemmo} \emph{cis-4-} \{ [4-(Dimethylamino)-6,7-difluoroquinazolin-2-yl] amino} - \mathcal{N}- \{ (1R)-1-(3-methoxyphenyl) ethyl] cyclohexanecarboxamide trifluoroacetate$

15

Step A: Synthesis of

cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-[(1R)-1-(3-methoxyphenyl)et hyl]cyclohexanecarboxamide trifluoroacetate.

Using a similar procedure as described in step F of Example 890, the title compound was 20 obtained.

ESI MS m/e $484 \text{ M} + \text{H}^+$; $^1\text{H} \text{ NMR} (400 \text{ MHz}, \text{DMSO-}d_6) \, 8 \, 11.8 \, (\text{brs}, 1 \, \text{H}), \, 8.19 \, (\text{m}, 1 \, \text{H}), \, 8.12 \, (\text{m}, J=8.0 \, \text{Hz}, 1 \, \text{H}), \, 8.07 \, (\text{brs}, 1 \, \text{H}), \, 7.49 \, (\text{t}, J=8.0 \, \text{Hz}, 1 \, \text{H}), \, 7.14 \, (\text{t}, J=8.0 \, \text{Hz}, 1 \, \text{H}), \, 6.80 \, (\text{d}, J=7.6 \, \text{Hz}, 1 \, \text{H}), \, 6.79 \, (\text{s}, 1 \, \text{H}), \, 6.70 \, (\text{d}, J=7.6 \, \text{Hz}, 1 \, \text{H}), \, 4.82 \, (\text{m}, 1 \, \text{H}), \, 4.03 \, (\text{brs}, 1 \, \text{H}), \, 3.66 \, (\text{s}, 3 \, \text{H}), \, 3.37 \, (\text{s}, 1 \, \text{H}), \, 2.26 \, (\text{brs}, 1 \, \text{H}), \, 1.69-1.52 \, (\text{m}, 8 \, \text{H}), \, 1.23 \, (\text{d}, J=7.2 \, \text{Hz}, 3 \, \text{H}).$

25

Example 893

N-(3,4-Dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

170

cyclohexyl)urea trifluoroacetate

Step A: Synthesis of cis-(4-benzylonycarbonylamino-cyclohenyl)-carbanic acid icn-butyl exter.

To a suspension of *cis-4-tert*-butoxycarbonylamino-cyclohexane carboxylic acid (50 g, 0.21 mol) in benzene was added triethylamine (37 mL, 0.27 mol) and diphenylphosphoryl azide (48.7 mL, 0.23 mol). The reaction mixture was stirred at 80 °C for 1 hour. Benzyl alcohol (30 mL, 0.29 mol) was added and the reaction mixture was stirred at reflux overnight. The solvent benzene was removed under vacuum and the resulting slurry dissolved in ethyl acetate. The organic layer was extracted with H₂O and separated. The aqueous layer was extracted twice more with ethyl acetate. The organic

layers were combined, dried over MgSO₄, concentrated, and subjected to chromatography (30% ethyl acetate in hexanes) to give *cis*-(4-benzyloxycarbonylamino-cyclohexyl)-carbamic acid *tert*-butyl ester (54.1 g, 0.16 mol, 75%) as a colorless oil.

ESI-MS m/e $349.4 \text{ M} + \text{H}^+$; ¹H NMR (400 MHz, DMSO-d₆) δ 7.34-7.28 (m, 5 H), 7.12 (d, J = 5.6 Hz, 1 H), 6.62 (brs, 1 H), 4.98 (s, 2 H), 3.39-3.37 (m, 2 H), 1.60-1.45 (m, 8 H), 1.37 (s, 9 H).

15

Step B: Synthesis of cis-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester.

To a solution of *cis*-(4-benzyloxycarbonylamino-cyclohexyl)-carbamic acid *tert*-butyl ester (54.1 g, 0.16 mol) in ethanol was added 10% Pd/C (5.4 g). The reaction mixture was stirred at room temperature under an H₂ atmosphere for 3 hours. The H₂ atmosphere was removed and the solution filtered though celite and concentrated. The resulting precipitate was dissolved in ethyl acetate and extracted with a dilute NaOH (aq) solution. The aqueous layer was extracted twice more with ethyl acetate. The organic layers were combined, dried over MgSO₄, and concentrated. The resulting precipitate was recrystallized in ethyl acetate and hexanes to yield *cis*-(4-amino-cyclohexyl)-carbamic acid *tert*-butyl ester (28.9 g, 0.14 mol, 87%) as a white solid.

25 ESI-MS m/e 215.2 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 6.60 (d, J = 6.0 Hz, 1 H), 3.30-3.28 (m, 1 H), 2.74 (s, 1 H), 1.59-1.51 (m, 2 H), 1.45-1.37 (m, 15 H).

Step C: Synthesis of cis-[4-(4-dimethlyamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid

171

tert-butyl ester.

To a solution of cis-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester (0.5 g, 0.0023 mol) in 1 mL 2-propanol was added (2-chloro-quinazolin-4-yl)-dimethly-amine (0.53, 0.0026 mol) and DLE.A (1.22 mL, 0.0070 mol). The mixture was heated in a microwave synthesizer at 170 °C for 1 hour. The reaction was repeated 39 more times (20 g total material) and the reaction mixtures were pooled. The solvent was evaporated and the material subjected to chromatography (2-4% 2M NH₃ in MeOH / CH₂Cl₂) to yield cis-[4-(4-dimethlyamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester (22.1 g, 0.057 mol, 61%) as a colorless oil.

ESI-MS m/e 386.4 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) & 7.85 (d, J = 8.0 Hz, 1 H), 7.47 (t, J = 8.4 Hz, 1 H), 7.27 (d, J = 8.0 Hz, 1 H), 7.00 (t, J = 7.6 Hz, 1 H), 6.60 (brs, 1 H), 6.18 (brs, 1 H), 3.89-3.88 (m, 1 H), 3.39 (brs, 1 H), 3.19 (s, 6 H), 1.77-1.71 (m, 2 H), 1.68-1.52 (m, 6 H), 1.38 (s, 9 H).

Step D: Synthesis of cis-N²-(4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinazolin-2,4-diamine.

To a solution of cis-[4-(4-dimethlyamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester (22.1 g, 0.057 mol) in CH₂Cl₂ was added TFA (10 mL, 0.13 mol). The solution was stirred at room temperature for 4 hours. The excess solvent was evaporated off and the resulting oil was dissolved in CH₂Cl₂. The organic layer was extracted with a dilute NaOH (aq) / NaHCO₃ (aq) solution. The aqueous layer was extracted twice more with CH₂Cl₂ and the organic layers combined, dried over MgSO₄, and concentrated. The resulting precipitate was crystallized in ether and hexanes to yield cis-N²-(4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinazolin-2,4-diamine (15.0 g, 0.053 mol, 92%) as a pale yellow solid.

ESI-MS m/e 286.2 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) & 7.84 (d, J = 8.4 Hz, 1 H), 7.45 (t, J = 6.8 Hz, 1 H), 7.26 (d, J = 8.4 Hz, 1 H), 6.99 (t, J = 7.6 Hz, 1 H), 6.20 (brs, 1 H), 3.90-3.89 (m, 1 H),

Step E: Synthesis of

N-(3,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)ure

25 3.18 (s, 6 H), 2.79 (s, 1 H), 1.74-1.71 (m, 2 H), 1.57-1.41 (m, 8 H).

a trifluoroacetate.

To a solution of cis-N²-(4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinazolin-2,4-diamine (28.5 mg, 0.10 mmol) in 0.5 mL of Di ISO was added 3,4-dimethoxyphenylisocyanate (14.9 uL, 0.10 mmol). Note that for this reaction it was necessary to slightly heat the starting material to dissolve it in the DMSO before adding the isocyanate. The reaction mixture was stirred for 1 hour and then 0.5 mL of 50% DMSO in H₂O was added. The compound was subjected to purification by prep LCMS to yield N-(3,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea trifluoroacetate (37 mg, 0.064 mmol, 64%) as a white solid.

ESI-MS m/e 465.2 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) 8 12.10 (s, 1 H), 8.21 (s, 1 H), 8.16 (d, 10 J = 8.0 Hz, 1 H), 8.08 (brs, 1 H), 7.78 (t, J = 7.6 Hz, 1 H), 7.45 (brs, 1 H), 7.37 (t, J = 7.6 Hz, 1 H), 7.15 (s, 1 H), 6.83-6.72 (m, 2 H), 6.15 (d, J = 6.8 Hz, 1 H), 4.00 (brs, 1 H), 3.72 (s, 3 H), 3.69 (s, 3 H), 3.47 (brs, 6 H), 1.80-1.78 (m, 2 H), 1.68 (m, 6 H).

15 Example 894

N-[(cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[2-(trifluoromethoxy)phenyl]urea trifluoroacetate

Step A: Synthesis of cis-4-tert-butoxycarbonylamino-cyclohexanecarboxylic acid.

- To a solution of cis-4-amino-cyclohexanecarboxylic acid (50 g, 350 mmol) in 200 mL of THF and 380 mL of 1M NaOH (380 mmol), Boc₂O (83.5 g, 360 mmol) was added. The mixture was stirred at room temperature for 2 hr and evaporated until only water was remained. The reaction mixture was cooled to 0 °C and acidified with 1M HCl until pH about 3. The white solid formed was filtered, washed with water and hexanes to give
- 25 cis-4-tert-butoxycarbonylamino-cyclohexanecarboxylic acid (71g, 83%) as a white solid.

ESI-MS m/e $244 \text{ M} + \text{H}^+$; ¹H NMR $(400 \text{ MHz}, \text{ DMSO-de}) \delta 12.00 (b, 1 \text{ H}), 6.74 (d, J = 4.25, 1 \text{ H}), 3.30 (brs, 1 H), 2.35 (m, 1 H), 1.87 (m, 2 H), 1.55-1.37 (m, 15 H).$

173

Step B: Synthesis of cis (4-carbamoyl-cyclohexyl)-carbamic acid tert-butyl ester.

The cis-4-tert-butoxycarbonylamino-cyclohexanecarboxylic acid (68 g, 280mmol) and triethylamine (42.85 mL, 308 mmol) were dissolved in 300 mL of THF and the mixture was cooled to 0 °C. Ethyl chloroformate (29.3 mL, 308 mmol) was added dropwise. After stirring at 0 °C for 30 min, 168 mL of 25% aqueous ammonia was added dropwise. The mixture was allowed to stir at room temperature for 2 hr. The solvent was evaporated until only water was remained. To this mixture was added EtOAc. The organic layer was washed with sat. NaHCO₃, 1M HCl, brine, water, dried over Na₂SO₄ and filtered. The solvent was evaporated to give cis (4-carbamoyl-cyclohexyl)-carbamic acid tert-butyl ester (62 g, 88%) as a white solid.

10 ESI-MS m/e 243 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) & 7.10 (brs, 1 H), 6.69 (brs, 2 H), 3.41 (brs, 1 H), 2.14 (m, 1 H), 1.79 (m, 2 H), 1.59 (m, 2 H), 1.45-1.37 (m, 13 H).

Step C: Synthesis of cis-4-amino-cyclohexanecarboxylic acid amide hydrochloride.

The cis-(4-carbamoyl-cyclohexyl)-carbamic acid tert-butyl ester (62 g, 256 mmol) in 250 mL of DCM was added 250 mL of TFA. The mixture was stirred for 1 hr. The solvents were evaporated. To the residue was added 150 mL of 2M HCl in ether to give white solid. The solvent was evaporated to give cis-4-amino-cyclohexanecarboxylic acid amide hydrochloride (45 g, 98%) of white solid as the product.

ESI-MS m/e 143 M + H⁺; ¹H NMR (400 MHz, DMSO-d₀) δ 8.08 (brs, 3 H), 7.28 (s, 1 H), 6.78 (s, 20 1 H), 3.10 (m, 1 H), 2.24 (m, 1 H), 1.90 (m, 2 H), 1.66 (m, 4 H), 1.50 (m, 2 H).

Step D: Synthesis of cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexanecarboxylic acid amide.

(2-Chloro-quinazoline-4-yl)-dimethylamine (31.05 g, 150 mmol) and

25 cis-4-amino-cyclohexanecarboxylic acid amide hydrochloride (26.7 g, 150 mmol) in 150 mL of pyridine was refluxed overnight. The solvent was evaporated. DCM was added to the residue. The organic layer was washed with sat. NaHCO₃. The aqueous layer was backed extracted with DCM. The combined organic layers were dried over Na₂SO₄, filtered and evaporated. The residue was

174

purified on silica gel column twice to give a slightly brown solid which was recrystalized from DCM to give cis-4 (4-dimethylamino-quinazolin-2-ylamino)-cyclohexanecarboxylic acid amide (20.6 g, 44%) as yellow crystals.

ESI-MS m/e 314 M +H⁺; ¹H NM fR (400 MHz, DMSO-d₆) δ 8.19 (b, 1 H), 8.15 (d, J = 8.4 Hz, 1 H), 5.77 (t, J = 8 Hz, 1 H), 7.42 (d, J = 7.2 Hz, 1 H), 7.35 (t, J = 8.4 Hz, 1 H), 7.21 (s, 1 H), 6.74 (s, 1 H), 4.12 (m, 1 H), 3.46 (b, 6 H), 2.24 (m, 1 H), 1.79-1.61 (m, δ H).

Step E: Synthesis of cis-N²-(4-aminomethyl-cyclohexyl)- N⁴, N⁴-dimethyl-quinazoline-2,4-diamine.

- To a stirred solution of cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexane carboxylic acid amide (18.78 g, 60 mmol) in 200 mL of THF was added a solution of 1M BH₃ in THF (300 mL, 300 mmol). The mixture was refluxed for 2 hr. After cooling the reaction mixture to 0 °C, 100 mL of 4 M HCl and 200 mL of methanol were added. The solvents were removed under reduced pressure. The mixture was treated with 1M NaOH and the aqueous phase was extracted with
- dichloromethane. The organic layers were combined, dried over sodium sulfate, concentrated under reduced pressure, and purified on silica gel colum to give cis-N²-(4-aminomethyl-cyclohexyl)-N⁴, N⁴-dimethyl-quinazoline-2,4-diamine as a white solid (10.6 g, 59%).

ESI-MS m/e 300 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 7.84 (d, J = 8.4 Hz, 1 H), 7.46 (t, J = 6.8 Hz, 1 H), 7.26 (d, J = 8.4 Hz, 1 H), 6.99 (t, J = 6.8 Hz, 1 H), 6.28 (brs, 1 H), 4.02 (m, 1 H), 20 3.19 (brs, 6 H), 2.47 (d, J = 6.8 Hz, 2 H), 2.73 (m, 2 H), 1.68-1.33 (m, 9 H).

Step F: Synthesis of

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-[2-(trifluoromethoxy)phenyl]urea trifluoroacetate.$

A solution of cis-N²-(4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine (30 mg, 0.1 mmol) and 2-trifluoromethoxy phenylisocyanate (20 mg, 0.1 mmol) in 0.5 mL of DMSO was stirred at room temperature overnight. DMSO (0.5 mL) was added and the reaction mixture was purified by prep LCMS. The fractions contained the product were combined and lyophilized to give

175

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[2-(trifluoromethoxy)p henyl]urea trifluoroacetate (21 mg, 34%) as a white solid.

ESI-MS m/e 503 MI + H⁺; ¹H NIMR (400 MHz, DMSO-d₀) 8 12.10 (brs, 1 H), 3.23 (d, 1 = 3.0 Hz, 1 H), 8.15 (d, J = 8.0 Hz, 1 H), 8.14 (s, 1 H), 8.09 (brs, 1 H), 7.75 (m, 1 H), 7.43-7 24 (m, 4 H), 6.98 5 (m, 2 H), 4.15 (m, 1 H), 3.46 (brs, 6 H), 3.05 (m, 2 H), 1.77-1.35 (m, 9 H).

Example 395

25

2-(4-Chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-

10 nicotinamide trifluoroacetate

20 tert-butyl ester (22.1 g. 0.057 mol, 61%) as a colorless oil.

Step A: Synthesis of cis-[4-(4-dimethlyamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester.

To a solution of cis-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester (0.5 g, 0.0023 mol) in 1 mL 2-propanol was added (2-chloro-quinazolin-4-yl)-dimethyl-amine (0.53, 0.0026 mol) and DIEA (1.22 mL, 0.0070 mol). The mixture was heated in a microwave synthesizer at 170 °C for 1 hour. The reaction was repeated 39 more times (20 g total material) and the reaction mixtures were pooled. The solvent was evaporated and the material subjected to chromatography (2-4% 2M NH₃ in MeOH / CH₂Cl₂) to yield cis-[4-(4-dimethlylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid

ESI MS m/e 386.4 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 7.85 (d, J = 8.0 Hz, 1 H), 7.47 (t, J = 8.4 Hz, 1 H), 7.27 (d, J = 8.0 Hz, 1 H), 7.00 (t, J = 7.6 Hz, 1 H), 6.60 (brs, 1 H), 6.18 (brs, 1 H), 3.89-3.88 (m, 1 H), 3.39 (brs, 1 H), 3.19 (s, 6 H), 1.77-1.71 (m, 2 H), 1.68-1.52 (m, 6 H), 1.38 (s, 9 H).

Step B: Synthesis of cis-M2-(4-amino-cyclohexyl)-H4.H4-dimethyl-quinazolin-2.4-diamine.

To a solution of cis-[4-(4-dimethlylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester (22.1 g, 0.057 mol) in CH₂Cl₂ was added TFA (10 mL, 0.13 mol). The solution was

stirred at room temperature for 4 hours. The excess solvent was evaporated off and the resulting oil was dissolved in CH₂Cl₂. The organic layer was extracted with a dilute NaOH (aq) solution. The aqueous layer was extracted twice more with CH₂Cl₂ and the organic layers combined, dried over MgSO₄, and concentrated. The resulting precipitate was crystallized in ether and hexanes to yield cis-N²-(4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinazolin-2,4-diamine (15.0 g, 0.053 mol, 92%) as a pale yellow solid.

ESI MS $m/\epsilon 286.2 \text{ M} + \text{H}^+$; $^1\text{H NMR}$ (400 MHz, DMSO-d₆) 8 7.84 (d, J = 8.4 Hz, 1 H), 7.45 (t, J = 6.8 Hz, 1 H), 7.26 (d, J = 8.4 Hz, 1 H), 6.99 (t, J = 7.6 Hz, 1 H), 6.20 (brs, 1 H), 3.90-3.89 (m, 1 H), 3.18 (s, 6 H), 2.79 (s, 1 H), 1.74-1.71 (m, 2 H), 1.57-1.41 (m, 8 H).

10

Step C: Synthesis of

2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)nicotina mide trifluoroacetate.

To a solution of cis-N²-(4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinazolin-2,4-diamine (28.5 mg, 0.1 mmol) in 0.5 mL DMF was added 2-(4-chlorophenoxy)nicotinic acid (24.9 mg, 0.1mmol), HATU (45.6mg, 0.12 mmol), and DIEA (34.8 L, 0.2mmol). The reaction mixture was stirred for a couple of hours, and the compound was then subjected to purification by prep LCMS to yield 2-(4-chlorophenoxy)-N-(cis-4-([4-(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)nicotinamide trifluoroacetate (15 mg, 0.029 mmol, 29%) as a white solid.

20 ESI-MS m/e 517.4 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) 8 12.2 (s, 1 H), 8.58 (d, J = 8.0 Hz 1 H), 8.48-8.39 (m, 2 H), 8.29 (d, J = 8.0 Hz, 1 H), 8.13 (brs, 1 H), 8.02 (t, J = 4.0 Hz, 1 H), 7.75 (m, 3 H), 7.61 (t, J = 8.0 Hz, 1 H), 7.50 (m, 3 H), 4.25 (brs, 1 H), 4.21 (brs, 1 H), 3.69 (brs, 6 H), 2.00-1.80 (m, 8 H).

25

Example 896

N-(cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-2-(4-fluorophenoxy)-nicotinamide trifluoroacetate

177

Step A: Synthesis of

cis-2-chloro-[1-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohety/f]-nicotinamide.

5 3.5 mmol) in 18 mL CH₂Cl₂ was added 2-chloronicotinyl chloride (616.7mg, 3.5 mmol), DIEA (1.2 mL, 7.0mmol). The reaction mixture was stirred for 30 minutes at room temperature, the solvent was removed under vacuum, and the residue was purified by column chromatography on silca gel (2-4% 2M NH₃ in CH₃OH/ CH₂Cl₂) to yield cis-2-chloro-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-nicotinamide (0.71g, 47%).

To a solution of cis- N^2 -(4-amino-cyclohexyl)- N^4 . N^4 -dimethyl-quinazolin-2,4-diamine (1.0 g.

ESI-MS m/e 425.2 M + H $^+$; ¹H NMR (400 MHz, DMSO-d₆) δ 8.59 (brs, 1 H), 8.46 (d, J = 4.0 Hz, 1 H), 8.30 (brs, 1 H), 8.18 (d, J = 8.0 Hz, 1 H), 7.87 (d, J = 8.0 Hz, 1 H), 7.79 (t, J = 8.0 Hz, 1 H), 7.53-7.43 (m, 2 H), 7.37 (t, J = 8.0 Hz, 1 H), 4.09 (brs, 1 H), 3.93 (brs, 1 H), 3.57 (brs, 6 H), 1.90-1.62 (m, 8 H).

15 Step B: Synthesis of

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-2-(4-fluorophenoxy)nicotinamide trifluoroacetate.

cis-2-Chloro-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-nicotinamide (30 mg, 0.07 mmol) was added into a stirred solution of 4-fluorophenol (7.93mg, 0.07 mmol) and 60%

- NaH in mineral oil (5.6 mg, 0.14 mmol) in 0.5 mL DMA. The mixture was heated in a microwave synthesizer at 250°C for 1 hour. The compound was then subjected to purification by prep LCMS to yield N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-2-(4-fluorophenoxy) nicotinamide trifluoroacetate (10.3 mg, 0.021 mmol 30 %) as a white solid.
 - ESI-MS 501.3 M + H $^{+}$: ¹H NMIR (400 MHz, DMSO-d₆) δ 12.2 (s, 1 H), 8.51 (brs. 1 H), 8.38-8.34 (m,
- 25 2 H), 8.26 (d, J = 8.0 Hz, 1 H), 8.17 (brs, 1 H), 7.98 (t, J = 8.0 Hz, 1 H), 7.63 (brs, 1 H), 7.57 (t, J = 8.0 Hz, 1 H), 7.47-7.40 (m. 5 H), 4.20 (brs, 1 H), 4.17 (brs, 1 H), 3.66 (brs, 6 H), 2.00-1.94 (m. 8 H).

178

Example 897

N-(cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino) cyclohexyl)-2-(4-methoxyphenoxy)-nicotinamide trifluoroacetate

5 Step A: Synthesis of

II-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)nicotin amide trifluoroacetate.

Using a similar procedure as described in step B of Example 896, the title compound was obtained.

10 ESI-MS m/e 513.4 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.8 (s, 1 H), δ.14 (brs, 1 H), δ.00 (m, 2 H), 7.91 (brs, 1 H), 7.80 (brs, 1 H), 7.62 (t, J = 8.0 Hz, 1 H), 7.27 (brs, 1 H), 7.21 (t, J = 8.0 Hz, 1 H), 7.04 (q, J = 4.0 Hz, 1 H), 6.99 (d, J = 12.0 Hz, 2 H), 6.80 (d, J = 12.0 Hz, 2 H), 3.82 -3.76, (brs, 2 H), 3.40-3.30 (m, 6 H), 1.61-1.50 (m, 8 H).

15

Example 898

N-(cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-2-(3-methylphenoxy)-nicotinamide trifluoroacetate

20 Step A: Synthesis of

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-2-(3-methylphenoxy)nicotina mide trifluoroacetate.

Using a similar procedure as described in step B of Example 896, the title compound was obtained.

ESI-MS m/e 497.4 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.0 (brs, 1 H), δ .26 (d, J = 4.8 Hz, 1 H), δ .18 (m, 2 H), δ .07 (d, J = 6.8 Hz, 1 H), 7.88 (brs, 1 H), 7.77 (t, J = 8.0 Hz, 1 H), 7.43 (brs,1 H), 7.36 (t, J = 8.0 Hz, 1 H), 7.27 (t, J = 8.0 Hz, 1 H), 7.20 (q, J = 8.0 Hz, 1 H), 7.02-6.96 (m, 3 H), 4.10-3.90 (m, 2 H), 3.80-3.20 (m, 6 H), 2.30 (s, 3 H), 1.78-1.50 (m, 8 H).

WO 2004/087680

179

Example 399

H-(cis-4-([4-(Dimethylamino)quinagolin-2-yl]amino)cyclohexyl)-2-(2-methoxyphenoxy)-

5 nicotinamide trifluoroacetate

Step A: Synthesis of

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-2-(2-methoxyphenoxy)nicotin amide trifluoroacetate.

Using a similar procedure as described in step B of Example 896, the title compounds was obtained.

ESI-MS m/e 513.2 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.9 (s, 1 H), δ 15-8.12 (m, 4 H), 7.88 (brs, 1 H), 7.78 (t, J = 8.0 Hz, 1 H), 7.42 (brs, 1 H), 7.30-7.10 (m, 4 H), 7.14 (d, J = 8.0 Hz, 1 H), 7.00 (t, J = 8.0 Hz, 1 H), 4.15 (brs, 2 H), 3.69 (s, 3 H), 3.39 (brs, 6 H), 1.80-1.50 (m, 8 H).

15

Example 900

2-(4-Bromophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-nicotinamide trifluoroacetate

20

Step A: Synthesis of

2-(4-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)nicotina mide trifluoroacetate.

Using a similar procedure as described in step B of Example 896, the title compounds was obtained.

ESI-MS m/e $563.2 \text{ M} + \text{H}^{2}$; ¹H NMR (400 MHz, DMSO-d₆) 8 11.9 (s, 1 H), 8.16 (d, J = 8.0 Hz, 1 H), 8.02-7.98 (m, 2 H), 7.88 (d, J = 8.0 Hz, 1 H), 7.83 (brs, 1 H), 7.62 (t, J = 8.0 Hz, 1 H), 7.42 (d, J = 8.0 Hz, 2 H), 7.27 (brs, 1 H), 7.20 (t, J = 8.0 Hz, 1 H), 7.08-7.05 (q, J = 4.0 Hz, 1 H), 7.03 (d, J = 12.0 Hz, 2 H), 7.27 (brs, 1 H), 7.20 (t, J = 8.0 Hz, 1 H), 7.08-7.05 (q, J = 4.0 Hz, 1 H), 7.03 (d, J = 12.0 Hz, 2 H), 7.27 (brs, 2 Hz, 2

180

Hz, 2 H), 3.83 (brs, 2 H), 3.29 (brs, 5 H), 1.59-1.50 (m, 8 H).

Example 901

5 M-(cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-2,6-dimethoxynicotinamide trifluoroacetate

Step A: Synthesis of

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-2,6-dimethoxynicotinamide 10 trifluoroacetate.

To a solution of cis-N²-(4-amino-cyclohexyl)-N⁴.N⁴-dimethyl-quinazolin-2,4-diamine (28.5 mg, 0.1 mmol) in 0.5 mL DMF was added 2,6-dimethoxynicotinic acid (18.3 mg, 0.1 mmol), HATU (45.6 mg, 0.12 mmol), and DIEA (34.8 L, 0.2 mmol). The reaction mixture was stirred for a couple of hours, and the compound was then subjected to purification by prep LCMS to yield

15 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-2,6-dimethoxynicotinamide trifluoroacetate (9.9 mg, 0.022 mmol, 22 %) as a white solid.

ESI-MS m/e 451.2 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) 8 12.5 (s, 1 H), 8.42 (brs, 1 H), 8.13 (dd, J = 4.0, 4.0 Hz, 2 H), 7.86 (brs, 1 H), 7.74 (t, J = 8.0 Hz, 1 H), 7.39 (brs, 1 H), 7.32 (t, J = 8.0 Hz, 1 H), 6.47 (d, J = 8.0 Hz, 1 H), 4.02 (s, 3 H), 3.95 (brs, 1 H), 3.85 (s, 3 H), 3.68 (brs, 1 H), 3.42 (brs, 20 6 H), 1.80-1.68 (m, 8 H).

Example 902

 \mathbb{N}^2 -{(1S,3R)-3-[(3.5-Dichlorobenzyl)amino]cyclopentyl}- \mathbb{N}^4 - \mathbb{N}^4 -dimethylquinazoline-2,4-diamin 25 e bistrifluoroacetate.

Step A: Synthesis of (1S,3R)-cis-(3-tert-butoxycarbonylamino-cyclopentyl)-carbamic acid benzyl ester.

- (1R,3S)-N-Boc-1-aminocyclopentane-3-carboxylic acid (5.00 g, 21.8 mmol), diphenylphosphoryl azide (4.69 mL, 21.8 mmol), and triethylamine (3.04 mL, 21.8 mmol) were combined in benzene (30 mL) at room temperature. The mixture was heated to 30 °C and stirred 1 hr. Benzyl alcohol (2.26 mL, 21.8 mmol) was added and the mixture was heated to 110 °C for 16 hr. The mixture was concentrated and ethyl acetate was added. The organic phase was washed with water, saturated aqueous NaHCO₃, and brine, dried over Na₂SO₄, filtered, and concentrated. The crude product was purified by flash chromatography (silica gel, 20% ethyl acetate in hexanes) to give (1S,3R)-cis-(3-tert-butoxycarbonylamino-cyclopentyl)-carbamic acid benzyl ester (5.00 g, 69%) as a white solid.
- ESI-MS m/e 335 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 7.25 (m, 5 H), 6.83 (m, 2 H), 4.98 (s, 2 H), 3.77 (brs, 1 H), 2.13 (dt, J = 12.8, 7.6 Hz, 1 H), 1.75 (d, J = 7.2 Hz, 2 H), 1.43 (m, 2 H), 1.38 (s, 9 H), 1.22 (m, 2 H).

Step B: Synthesis of (1R,3S)-cis-(3-amino-cyclopentyl)-carbamic acid tert-butyl ester.

15 (1S,3R)-(3-tert-Butoxycarbonylamino-cyclopentyl)-carbamic acid benzyl ester (4.73 g, 14.2 mmol) and 10% Pd/C (0.24 g) were combined in methanol (27 mL) at room temperature. The mixture stirred for 4 days under a hydrogen gas atmosphere, was filtered through celite and concentrated to give (1R,3S)-cis-(3-amino-cyclopentyl)-carbamic acid tert-butyl ester as a yellow oil (2.84 g) (crude). ESI-MS m/e 201 (M+H)⁺; ¹H NMR (400 MHz, DMSO-d_e) δ 6.82 (brs, 1 H), 3.70 (m, 1 H), 2.10 (brs, 2 H), 1.97 (dt, J = 12.8, 6.8 Hz, 1 H), 1.70 (m, 2 H), 1.43 (m, 2 H), 1.38 (s, 9 H), 1.18 (m, 2 H).

Step C: Synthesis of (1S,3R)-cis-N²-(3-amino-cyclopentyl)-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine.

(2-Chloro-quinazolin-4-yl)-dimethyl-amine (0.100 g, 0.48numol), (1R,3S)-

25 (3-amino-cyclopentyl)-carbamic acid tert-butyl ester (0.096 g, 0.48 mmol), and diisopropylethylamine (0.126 mL, 0.72 mmol) were combined in isopropanol (1 mL) at room temperature. The mixture was heated to 160 °C for 40 min. utilizing a Smith synthesizer microwave apparatus. Trifluoroacetic acid (1 mL, neat) was added and the mixture was heated to 100 °C for 30 min. Then it was concentrated,

182

neutralized with saturated aqueous NaHCO3, concentrated, extracted with methanol, and concentrated again to give (1S,3R)-cis-N²-(3-amino-cyclopentyl)-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine as a yellow gum (0.130 g) (crude).

ESI-MS m/e 272 M + H⁺; ¹H NMIR (400 MHz, DMSO-d₆) δ 8.76 (brs, 1 H), 8.17 (d, J = 7.6 Hz, 1 5 H), 7.77 (d, J = 7.2 Hz, 1 H), 7.40 (brs, 1 H), 7.35 (d, J = 7.6 Hz, 1 H), 3.80 (m, 1 H), 3.40 (s, 6 H). 2.20 (m, 1 H), 1.98 (brs, 2 H) 1.70 (m, 2 H), 1.43 (m, 2 H), 1.18 (m, 2 H).

Step D: Synthesis of \mathbb{N}^2 -{(1S,3P.)-3-[(3,5-dichlorobenzyl)amino}cyclopentyl}- \mathbb{N}^4 , \mathbb{N}^4 -dimethyl quinazoline-2,4-diamine bistrifluoroacetate.

- (1S.3R)-N²-(3-Amino-cyclopentyl)-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine (0.065 g, 0.24 10 mmol) and 2,4-dimethoxybenzaldehyde (0.040 g, 0.24 mmol) were combined in methanol (1 mL) at room temperature. After stirring for 1 hr, sodium triacetoxyborohydride (0.204 g, 0.96 mmol) was added and the mixture was heated to 150°C for 40 min, utilizing a SmithSynthesizer microwave apparatus. Water (1 mL) was added and the product was purified to give
- 15 N²-{(1S,3R)-3-[(3,5-dichlorobenzyl)amino]cyclopentyl}-N⁴,N⁴-dimethyl quinazoline-2,4-diamine bistrifluoroacetate as a white solid (0.070g, 45%).

ESI-MS m/e 422 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 9.32 (brs, 1 H), 8.17 (d, J = 7.6 Hz, 1 H), 7.77 (t, J = 7.2 Hz, 1 H), 7.69 (s, 1 H), 7.61 (s, 1 H), 7.60 (s, 1 H), 7.40 (brs, 1 H), 7.35 (t, J = 7.6Hz, 1 H), 4.33 (brs, 1 H), 3.58 (m, 2 H), 3.40 (s, 6 H), 2.20 (m, 1 H), 2.06 (brs, 1 H), 1.70 (m, 2 H), 20 1.43 (m, 2 H), 1.18 (m, 2 H).

Example 903

6-(3-Chlorophenoxy)-M-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)

25 nicotinamide trifluoroacetate

Step A: Synthesis of cis-6-chloro-N-[4-(4-dimethylamino-quinazolin-2-ylamino)cyclohexyl]-nicotinamide.

183

To a solution of cis-N²-(4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinazolin-2,4-diamine (1.8 g, 6.3 mmol) in 30 mL CH₂Cl₂ was added 6-chloronicotinyl chloride (1.1g, 6.3 mmol), DŒA (2.19mL, 12.6mmol). The reaction mixture was stirred for 30 minutes at room temperature, the solvent was removed under vacuum, and the residue was purified by column chromatography on silica gel (2-4% 2M NH₃ in CH₃OH/ CH₂Cl₂= 5:10) to yield cis-6-chloro-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-nicotinamide (1.07g, 40%). ESI-MS m/e 425.0 M + H⁺; ¹H NNIR (400 MHz, DMSO-d₆) & 8.76 (brs, 1 H), 8.46 (brs, 1 H), 8.37 (brs, 1 H), 8.19 (dd, J = 8.0, 4.0 Hz, 1 H), 8.12 (d, J = 8.0 Hz, 1 H), 7.74 (t, J = 8.0 Hz, 1 H), 7.59 (d, J = 8.0 Hz, 1 H), 7.40 (brs, 1 H), 7.32 (t, J = 8.0 Hz, 1 H), 3.99 (brs, 1 H), 3.86 (brs, 1 H), 3.30 (brs, 1 H), 1.85-1.62 (m, 8 H).

Step B: Synthesis of

6-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)nicotina mide trifluoroacetate.

- 15 cis-6-Chloro-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-nicotinamide (30 mg, 0.07 mmol) was added into a stirred solution of 3-chlorophenol (17.9 mg, 0.14 mmol) and 60% NaH in mineral oil (5.6 mg, 0.14 mmol) in 0.5 mL DMA. The mixture was heated in a microwave synthesizer at 250°C for 1 hour. The compound was then subjected to purification by prep LCMS to yield
- 6-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)nicotinamide trifluoroacetate (8.2 mg, 0.016 mmol, 23 %) as a white solid.
 ESI-MS m/e 517.02 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.5 (s, 1 H), 8.63 (s, 1 H), 8.37 (brs, 1 H), 8.31 (dd, J = 8.0, 4.0 Hz, 1 H), 8.21 (d, J = 8.0 Hz, 1 H), 7.83 (t, J = 8.0 Hz, 1 H), 7.56 (m, 2 H), 7.41 (m, 3 H), 7.22 (d, J = 8.0 Hz, 2 H), 4.08 (brs, 1 H), 3.90 (brs, 1 H), 3.80-3.40 (brs, 6 H),
 25 2.00-1.51 (m, 8 H).

Example 904

M-(cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-6-(3-fluorophenoxy)-nicotinamide trifluoroacetate

5 Step A: Synthesis of

H-(cis-4-{[4-(dimethylamino)quinacolin-2-yl]amino)cyclohexyl)-6-(3-fluorophenoxy)nicotinamide trifluoroacetate.

Using a similar procedure as described in step B of Example 903, the title compounds was obtained.

10 ESI-MS m/e 501.2 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.0 (s, 1 H), 8.40 (brs, 1 H), 8.11(brs, 1 H), 8.07-8.04 (m, 1 H), 7.97 (d, J = 8.0 Hz, 1 H), 7.80 (brs, 1 H), 7.59 (t, J = 8.0 Hz, 1 H), 7.29 (m, 2 H), 7.17 (t, J = 8.0 Hz, 1 H), 6.97-6.86 (m, 3 H), 6.82 (d, J = 8.0 Hz, 1 H), 3.85 (brs, 1 H), 3.77 (brs, 1 H), 3.40-3.20 (m, 6 H), 1.87-1.49 (m, 8 H).

15

Example 905

54 %) as a white solid.

 $N-(cis-4-\{[4-(Dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-2-(3-fluorophenoxy) isonicotin amide trifluoroacetate$

20 Step A: Synthesis of cis-2-chloro-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-isonicotinamide.

To a solution of cis-N²-(4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinazolin-2,4-diamine (1.0 g, 3.5 mmol) in 18 mL CH₂Cl₂ was added 2-chlorophyridine-4-carbonyl chloride (616.7 mg, 3.5 mmol). The reaction mixture was stirred for 30 minutes at room temperature, the solvent was removed under vacuum, and the residue was purified by column chromatography on silica gel (2-4% 2M NH₃ in CH₃OH/ CH₂Cl₂= 5:10) to yield cis-2-chloro-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-isonicotinamide (0.79 g,

185

ESI-MS m/e 425.0 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 8.58 (brs, 1 H), 8.50 (d, J = 8.0 Hz, 1 H), 8.27 (brs, 1 H), 8.13 (d, J = 8.0 Hz, 1 H), 7.81 (s, 1 H), 7.74-7.69 (m, 2 H), 7.40 (brs, 1 H), 7.32 (t, J = 8.0 Hz, 1 H), 3.99 (brs, 1 H), 3.85 (brs, 1 H), 3.42 (brs, 6 H), 1.84-1.69 (m, 2 H).

5 Step B: Synthesis of

II-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-2-(3-fluorophenoxy)isonicotin amide trifluoroacetate.

cis-2-Chloro-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-isonicotinamide (30 mg, 0.07 mmol) was added into a stirred solution of 3-fluorophenol (6.34 µl, 0.07 mmol) and 60%

10 NaH in mineral oil (5.6 mg, 0.14 mmol) in 0.5 mL DMA. The mixture was heated in a microwave synthesizer at 250 °C for 1 hour. The compound was then subjected to purification by prep LCMS to yield

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-2-(3-fluorophenoxy)isonicotinami de trifluoroacetate (7.3 mg, 0.0146 mmol, 21 %) as a white solid.

ESI-MS m/e 501.4 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.1 (s, 1 H), 8.58 (brs, 1 H), 8.28 (d, J = 4.0 Hz, 1 H), 8.18 (d, J = 8.0 Hz, 1 H), 7.98 (brs, 1 H), 7.79 (t, J = 8.0 Hz, 1 H), 7.52 (d, J = 4.0 Hz, 1 H), 7.43 (m, 3 H), 7.34 (t, J = 8.0 Hz, 1 H), 7.10-7.06 (m, 2 H), 7.00 (d, J = 4.0 Hz, 1 H), 4.07 (brs, 1 H), 3.97 (brs, 1 H), 3.50 (brs, 6 H),1.89-1.75 (m, 8 H).

20

Example 906

 $N-(cis-4-\{[4-(Dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-2-(4-fluorophenoxy) is onicotin a mide trifluoroacetate$

25 Step A: Synthesis of

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-2-(4-fluorophenoxy)isonicotin amide trifluoroacetate.

186

Using a similar procedure as described in step B of Example 905, the title compound was obtained.

ESI-MS m/e 501.3 M1 + H⁺; ¹H NM R (400 MHz, DMSO-d₆) 8 12.5(s, 1 H), 8.53 (brs. 1 H), 8.23 (brs. 1 H), 8.22(d, J = 4.0 Hz, 1 H), 3.18 (d, J = 3.0 Hz, 1 H), 7.8 (t, J = 8.0 Hz, 1 H) 7.47-7.30 (m, 4 H), 5 7.28-7.14 (m, 4 H), 4.10 (brs, 1 H), 3.95 (brs, 1 H), 3.47 (brs, 6 H), 2.00-1.50 (m, 8 H).

Example 907

2-(2,3-Dichlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)aceta 10 mide trifluoroacetate

Step A: Synthesis of

2-(2,3-dichlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)aceta mide trifluoroacetate.

To a solution of cis- N²-(4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinazolin-2,4-diamine (28.5 mg, 0.1 mmol) in 0.5 mL DMF was added 2,3-dichlorophenoxyacetic acid (18.2 mg, 0.1 mmol), HATU (45.6 mg, 0.12 mmol), and DIEA (34.8 μL, 0.2 mmol). The reaction mixture was stirred for a couple of hours, and the compound was then subjected to purification by prep LCMS to yield 2-(2,3-dichlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)acetamide trifluoroacetate (12.3 mg, 27 %) as a white solid.

ESI-MS m/e $488.2 \text{ M} + \text{H}^+$; ¹H NMR (400 MHz, DMSO-d₆) 812.3 (s, 1 H), 8.16 (brs, 1 H), 8.12 (d, J = 8.0 Hz 1 H), 7.81 (brs, 1 H), 7.74 (t, J = 8.0 Hz, 1 H), 7.40 (brs, 1 H), 7.32 (t, J = 8.0 Hz, 1 H), 7.27 (t, J = 8.0 Hz, 1 H), 7.18 (d, J = 8.0 Hz, 1 H), 6.99 (d, J = 8.0 Hz, 1 H), 4.65 (s, 2 H), 3.95 (brs, 1 H), 3.76 (brs, 1 H), 3.41 (brs, 6 H), 1.72-1.62 (m, 8 H).

Example 900

H-(cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}eyclohexyl)-2-(2-naphthyloxy)acctamide

5 trifluoroacetate

Step A: Synthesis of

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-2-(2-naphthyloxy)acetamide trifluoroacetate.

- To a solution of cis-N²-(4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinazolin-2,4-diamine (28.5 mg, 0.1 mmol) in 0.5 mL DMF was added 2-naphthoxyacetic acid (20 mg, 0.1 mmol), HATU (45.6 mg, 0.12 mmol), and DIEA (34.8 μ L, 0.2mmol). The reaction mixture was stirred for a couple of hours, and the compound was then subjected to purification by prep LCMS to
- N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-2-(2-naphthyloxy)acetamide trifluoroacetate (10.0 mg, 0.021 mmol, 21%) as a white solid.

ESI-MS m/e $470.4 \text{ M} + \text{H}^{+}$; ¹H NMR (400 MHz, DMSO-d₆) 812.1 (s, 1 H), 8.13 (d, J = 12.0 Hz, 1 H), 8.02 (brs, 1 H), 7.93 (brs, 1 H), 7.80 (t, J = 8.0 Hz, 2 H), 7.74-7.70 (m, 2 H), 7.41 (t, J = 8.0 Hz, 2 H), 7.33 (m, 2H), 7.20-7.17 (m, 2H), 4.57 (s, 2H), 4.05 (brs, 1H), 3.76 (brs, 1H), 3.41 (brs, 6H), 1.71-1.62 (m, 8H).

20

Example 909

2-(3,4-Difluorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-acetamide trifluoroacetate

25

Step A: Synthesis of

cis-2-bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-acetamide.

To a solution of cis- N²-(4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinazolin-2,4-diamine (1.0 g,

188

3.5 mmol) in 18 mL CH₂Cl₂ was added bromoacetyl bromide (305 μ L, 3.5 mmol) at 0 °C. The reaction mixture was stirred for 2 hours, the solvent was removed under vacuum, and the residue was purified by column chromatography on silica gel (2-4% 2M NH₃ in CH₃OH/ CH₂Cl₂) to yield cis-2-bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-acetamide (0.95 g, 2.35

ESI-MS m/e $406.2 \text{ M} + \text{H}^+$; ¹H NMR $(400 \text{ MHz}, \text{DMSO-d}_6) \delta 8.63 \text{ (brs, 1 H)}, 3.43 \text{ (brs, 1 H)}, 8.35 \text{ (d, J} = 8.0 \text{ Hz, 1 H)}, 7.97 \text{ (t, J} = 8.0 \text{ Hz, 1 H)}, 7.62 \text{ (brs, 1 H)}, 7.55 \text{ (t, J} = 8.0 \text{ Hz, 1 H)}, 4.23 \text{ (brs, 1 H)}$

H), 4.05 (s, 2 H), 3.89 (brs, 1 H), 3.70-3.60 (brs, 6 H), 2.00-1.75 (m, 8 H).

5 mmol, 67 %), as a yellowish solid

10 Step B: Synthesis of 2-(3,4-difluorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]-amino}cyclohexyl)acetamide trifluoroacetate.

cis-2-Bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl] acetamide (60 mg, 0.15 mmol) was added into a stirred solution of 3,4-difluorophenol (19.3 mg, 0.15 mmol) and 60% NaH in mineral oil (11.8 mg, 0.30 mmol) in 1 mL DMA. The mixture was heated in

a microwave synthesizer at 250 °C for 1 hour. The compound was then subjected to purification by prep LCMS to yield 2-(3,4-difluorophenoxy)-N-(cis-4-{[4-(dimethylamino) quinazolin-2-yl]amino} cyclohexyl)acetamide trifluoroacetate (32 mg, 0.07 mmol, 47 %) as a white solid.

ESI-MS m/e $456.2 \text{ M} + \text{H}^{+}$; ¹H NMR (400 MHz, DMSO-d₆) δ 12.4 (s, 1 H), 8.25 (brs, 1 H), 8.22 (d,

20 J = 8.0 Hz, 1 H), 7.99 (brs, 1 H), 7.83 (t, J = 8.0 Hz, 1 H), 7.49 (brs, 1 H), 7.43-7.36 (m, 2 H), 7.13-7.08 (m, 1 H), 6.82 (brs, 1 H), 4.55 (s, 2 H), 4.06 (brs, 1 H), 3.81 (brs, 1 H), 3.5 (brs, 6 H), 1.89-1.75 (m, 8 H).

25 Example 910

2-(3,4-Difluorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-propanamide trifluoroacetate

Step A: Synthesis of

cis-2-bromo-H-[4-(3-dimethylamino-quinazolin-2-ylamino)-cyclohenyl)-propionamide.

To a solution of cis- N²-(4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinazolin-2,4-diamine (1.0 g, 3.5 mmol) in 18 mL CH₂Cl₂ was added 2-bromopropionyl bromide (189 μL, 1.75 mmol) at 0 °C. The reaction mixture was stirred for 2 hours, the solvent was removed under vacuum, and the residue was purified by column chromatography on silica gel (2-4% 2M NH₃ in CH₃OH/ CH₂Cl₂) to yield cis-2-bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-propionamide (0.66 g, 45%) as a white solid.

10 ESI-MS m/e 420.2 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 8.17 (m, 3 H), 7.76 (t, J = 8.0 Hz, 1 H), 7.40 (brs, 1 H), 7.32 (t, J = 8.0 Hz, 1 H), 7.55 (q, J = 4.0 Hz, 1 H), 3.99 (brs, 1 H), 3.57 (brs, 1 H), 3.41 (brs, 6 H), 1.69-1.50 (m, 11 H).

Step B: Synthesis of 2-(3,4-difluorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl}amino}cyclohexyl)propanamide trifluoroacetate.

cis-2-Bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-propionamide (60 mg, 0.14 mmol) was added into a stirred solution of 3,4-difluorophenol (18.6 mg, 0.14 mmol) and 60% NaH in mineral oil (11.4 mg, 0.29 mmol) in 1 mL DMA. The mixture was heated in a microwave synthesizer at 250 °C for 1 hour. The compound was then subjected to purification by prep

20 LCMS to yield

2-(3,4-difluorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)propanam ide trifluoroacetate (6.7 mg, 0.014 mmol, 10 %) as a white solid.

ESI-MS m/e 470.4 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.2 (s, 1 H), 8.19 (d, J = 8.0 Hz, 1 H), 7.99 (brs, 1 H), 7.81 (t, J = 8.0 Hz, 1 H), 7.46 (brs, 1 H), 7.39-7.31 (m, 2 H), 7.05-6.97 (m, 1 H),

25 6.75 (brs, 1 H), 4.80-4.73 (m, 1 H), 4.01(brs, 1 H), 3.71 (brs, 1 H), 3.47 (brs, 6 H), 1.62-1.47 (m, 8 H), 1.43 (d, J = 4.0 Hz, 3 H).

190

Example 911

2-(3,4-Difluorophenoxy)-H-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-butanamide trifluoroasetate

5 Step A: Synthesis of

cis-2-bromo-II-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohenyl]-butyramide.

To a solution of cis-N²-(4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinazolin-2,4-diamine (1.0 g, 3.5 mmol) in 18 mL CH₂Cl₂ was added 2-bromobutyryl bromide (213 μ L, 1.75 mmol) at 0 °C. The reaction mixture was stirred for 2 hours, the solvent was removed under vacuum, and the residue was

purified by column chromatography on silica gel (2-4% 2M NH₃ in CH₃OH/ CH₂Cl₂) to yield cis-2-bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-butyramide (0.53 g, 35 %) as a white solid.

ESI-MS m/e 434.2 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) 8 8.15 (brs, 1 H), 8.12 (d, J = 8.0 Hz, 2 H), 7.74 (t, J = 8.0 Hz, 1 H), 7.40 (brs, 1 H), 7.32 (t, J = 8.0 Hz, 1 H), 4.33 (t, J = 8.0 Hz, 1 H), 3.93 (brs, 1 H), 3.66 (brs, 1 H), 3.41 (brs, 6 H), 2.01-1.87 (m, 1 H), 1.85-1.76 (m, 1 H), 1.70-1.59 (m, 8 H), 0.84 (t, J = 8.0 Hz, 3 H).

Step B: Synthesis of

2-(3,4-difluorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)butan 20 amide trifluoroacetate.

cis-2-Bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-butyramide (60 mg, 0.14 mmol) was added into a stirred solution of 3,4-difluorophenol (18.6 mg, 0.14 mmol) and 60% NaH in mineral oil (10.8 mg, 0.27 mmol) in 1 mL DMA. The mixture was heated in a microwave synthesizer at 250 °C for 1 hour. The compound was then subjected to purification by prep LCMS to yield 2-(3,4-difluorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)butanamide trifluoroacetate (6.3 mg, 9.3%) as a white solid.

ESI-MS m/e 484.2 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.2 (s, 1 H), δ 12 (d, J = δ 0 Hz, 2 H), δ 10 (brs, 1 H), 7.93 (brs, 1 H), 7.74 (t, J = δ 0 Hz, 1 H), 7.40 (brs, 1 H), 7.32-7.24 (m, 2 H),

6.97-6.91 (m, 1 H), 6.70-6.67 (m, 1 H), 4.56 (t, J = 4.0 Hz, 1 H), 3.95 (brs, 1 H), 3.67 (brs, 2 H), 3.41 (brs, 6 H), 1.84-1.77 (m, 2 H), 1.75-1.56 (m, 8 H), 0.90-0.81 (t, J = 16.0 Hz, 3 H).

5 Example 912

To a solution of

 $\label{eq:continuous} II^2-(3-Chlorophenyl)-iI-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)glycinamide bistrifluoroacetate$

Step A: Synthesis of N^2 -(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]-amino} cyclohexyl)glycinamide bistrifluoroacetate.

cis-2-bromo-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-acetamide (40 mg, 0.1 mmol) in 0.5 mL DMF was added 3-chloroaniline (11.6 µL, 0.11 mmol). The reaction mixture was stirred at 100 °C, and another 0.5 mL of DMSO was added. The compound was then subjected to purification by prep LCMS to yield

 N^2 -(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)glycinamide bistrifluoroacetate (6.0 mg, 8.8 %) as a white solid.

ESI-MS m/e 453.2 M + H⁺; ¹H NMR (400 MHz, CD₃OD) 8 8.18 (d, J = 8.4 Hz, 1 H), 7.77 (t, J = 8.0 Hz, 1 H), 7.41 (m, 2 H), 7.11 (t, J = 8.0 Hz, 1 H), 6.66-6.51 (m, 3 H), 4.20 (brs, 1 H), 3.93 (brs, 20 1 H), 3.76 (s, 2 H), 3.54 (brs, 6 H), 1.87-1.17 (m, 8 H).

Example 913

2-(3,5-Difluorophenyl)-M-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-25 methyl]-2-hydroxyacetamide trifluoroacetate

Step A: Synthesis of cis-(4-amino-cyclohexylmethyl)-carbamic acid benzyl ester.

To a solution of (4-aminomethyl-cyclohexyl)-carbamic acid tert-butyl ester (21.9 g, 96.0

192

mmol) in 400 mL CH₂Cl₂ was added DIEA (16.6 mL, 96 mmol), CbzCl (11.4 mL, 79.7 mmol). The reaction mixture was stirred at room temperature for 3 hours, and the solvent was then removed under vacuum, and the residue was purified by column chromatography on silica gel (Hexane/EtQAc=1:1). The purified compound in 100 mL CH₂Cl₂ was added TFA (60mL). The solution was stirred at room temperature for 2 hours. The excess solvent was evaporated off and the resulting oil was dissolved in CH₂Cl₂. The organic layer was extracted with a dilute NaOH (aq) solution. The aqueous layer was extracted twice more with CH₂Cl₂ and the organic layers combined, dried over MgSO₄, and concentrated to yield cis-(4-amino-cyclohexylmethyl)-carbamic acid benzyl ester (20 g, 79 %) as a yellow solid.

10 ESI-MS m/e 263.2 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 7.82 (brs, 2 H), 7.39-7.29 (m, 6 H), 5.06 (s, 2 H), 3.15 (brs, 1 H), 2.98 (m, 1 H), 2.51(m, 1 H), 1.60-1.24 (m, 8 H).

Step B: Synthesis of cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester.

- cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester (0.5 g, 1.9 mmol) in 1 mL 2-propanol was added (2-chloro-quinazolin-4-yl)-dimethly-amine (0.33g, 1.58 mmol) and DIEA (661 µL, 3.8 mmol). The mixture was heated in a microwave synthesizer at 150 °C for 1 hour. The reaction was repeated 39 more times (20 g total material) and the reaction mixtures
- were pooled. The solvent was evaporated and the material subjected to chromatography (2-4% 2M NH₃ in MeOH / CH₂Cl₂) to yield
 - cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester (16 g, 49%) as a yellowish oil.

ESI-MS m/e $434.2 \text{ M} + \text{H}^+$; ¹H NMR $(400 \text{ MHz}, \text{DMSO-d}_6) 8 8.59 \text{ (brs. 1 H)}, 8.14(d, J = 8.0 \text{ Hz}, 1 25 \text{ H)}, 7.76 (t, J = 8.0 \text{ Hz}, 1 \text{ H)}, 7.43(d, J = 3.0 \text{ Hz}, 1 \text{ H)}, 7.35 (m, 7 \text{ H)}, 5.06 (s, 2 \text{ H)}, 4.24 (brs. 1 H), 3.59 (brs. 6 H), 2.85 (brs. 2 H), 1.66-1.35 (m, 9 H).$

Step C: Synthesis of

15

To a solution of

193

cis-N²-(4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine.

To cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester (16.0 g. 37 mmol) in ethanol was added 10% Pd/C (1.6 g). The reaction militure was stirred at room temperature under an H_2 atmosphere for 3 hours. The H_2 atmosphere was removed and the

5 solution filtered though celite and concentrated to yield cis-N²-(4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine (11.2g, 99%) as a yellowish solid.

ESI-NIS m/e 300.2 M + H⁺; ¹H NMIR (400 MHz, DMSO-d₆) δ 8.50 (brs, 1 H), 8.10 (d, J = 12.0 Hz, 1 H), 7.71-7.61 (m, 3 H), 7.34 (d, J = 8.0 Hz, 1 H), 7.27 (t, J = 8.0 Hz, 1 H), 4.11 (brs, 1 H), 3.30 (brs, 1 H), 2.65 (brs, 2 H), 1.67-1.19 (m, 9 H).

Step D: Synthesis of 2-(3,5-difluorophenyl)-N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl] amino}cyclohexyl)methyl]-2-hydroxyacetamide trifluoroacetate

To a solution of

- 15 cis-N²-(4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine (29.9 mg, 0.1 mmol) in 0.5 mL DMF was added 3,5-difluoromandelic acid (18.8 mg, 0.1mmol), HATU (45.6mg, 0.12 mmol), and DIEA (34.8 μL, 0.2mmol). The reaction mixture was stirred for a couple of hours, and the compound was then subjected to purification by prep LCMS to
 - 2-(3,5-difluorophenyl)-N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)
- 20 methyl]-2-hydroxyacetamide trifluoroacetate (29.5mg, 51%) as a white solid.

ESI-MS m/e $470.4 \text{ M} + \text{H}^+$; $^1\text{H} \text{ NMR} (400 \text{ MHz}, \text{CD}_3\text{OD}) \delta 8.16 (d, J = 8.0 \text{ Hz}, 1 \text{ H}), 7.76 (t, J = 8.4 \text{ Hz}, 1 \text{ H}), 7.39 (m, 2 \text{ H}), 7.12 (m, 2 \text{ H}), 6.86 (m, 1 \text{ H}), 5.04 (s, 1 \text{ H}), 4.21 (brs, 1 \text{ H}), 3.53 (brs, 6 \text{ H}), 3.21 (m, 2 \text{ H}), 1.86-1.39 (m, 9 \text{ H}).$

25

Example 914

2-(3,5-Difluorophenyl)-IN-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-2-hydroxyacetamide trifluoroacetate

194

Step A: Synthesis of

2-(3,5-diffuorophenyl)-H-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)eyelohenyl)-2-hydroxyacetamide trifluoroacetate.

To a solution of cis-N²-(4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinazolin-2,4-diamine (28.5 mg, 0.1 mmol) in 0.5 mL DMF was added 3,5-difluoromandelic acid (18.8mg, 0.1mmol), HATU (45.6 mg, 0.12 mmol), and DIEA (34.8 μL, 0.2mmol). The reaction mixture was stirred for a couple of hours, and the compound was then subjected to purification by prep LCMS to yield 2-(3,5-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-2-hydroxy acetamide trifluoroacetate (20.5 mg, 0.045 mmol, 45%) as a white solid. ESI-MS m/e 456.2 M + H⁺; ¹H NMR (400 MHz, DMSO-d₀) δ 12.3 (s, 1 H), 8.29 (d, J = 8.0 Hz, 1

ESI-MS m/e 456.2 M + H ; 'H NMR (400 MHz, DMSO-d₆) 8 12.3 (s, 1 H), 8.29 (d, J = 8.0 Hz, 1 H), 8.18 (brs, 1 H), 7.91 (m, 2 H), 7.58 (brs, 1 H), 7.49 (t, J = 8.0 Hz, 1 H), 7.25-7.22 (m, 3 H), 6.55 (brs, 1 H), 5.13 (s, 1 H), 4.15 (brs, 1 H), 3.82 (brs, 1 H), 3.58 (brs, 6 H), 1.85-1.73 (m, 8 H).

15

Example 915

cis-N-Benzyl-4-[(4-isopropylquinazolin-2-yl)amino]cyclohexanecarboxamide trifluoroacetate

Step A: Synthesis of 2-chloro-4-isopropylquinazoline.

2,4-Dichloroquinazoline (0.5 g, 2.5 mmol) and 1,2-bis(diphenylphosphino) ethane nickel (II) chloride (15 mg) were mixed with THF (10 mL), and the reaction was kept under an inert atmosphere. The reaction flask was cooled in a cold bath (~ -20 °C), and isopropyl magnesium chloride (1.25 mL of 2M solution, 2.5 mmol) introduced into the reaction through a syringe. The reaction was slowly allowed to room temperature, and stirred overnight. The reaction was quenched with addition of 1N-HCl (~5 mL), diluted with water, and extracted with DCM (3 x 10 mL). The organic layer was washed with aqueous NaHCO₃ (1 x 10 mL) and water (1 x 10 mL), dried with MgSO₄, and concentrated. The crude was purified by column chromatography (silica gel, hexanes:DCM = 90:10 to 70:30) to give 0.11 g (20 %) of 2-chloro-4-isopropylquinazoline as a white solid.

195

ESI MS m/e 207 M + H⁺; ¹H NMIR (400 MHz, CDCl₃) δ 8.16 (d, J = 8.0 Hz, 1 H), 7.97 (d, J = 8.0 Hz, 1 H), 7.89 (t, J = 8.0 Hz, 1 H), 7.63 (t, J = 8.0 Hz, 1 H), 3.90 (m, 1 H), 1.44 (d, J = 7.0 Hz, 6 H).

Step B: Synthesis of cis-4-amino-cyclohexanecarboxylic acid ethyl ester hydrochloride.

- To a suspension of cis-aminocyclohexane-4-carboxylic acid (1.5 g, 10 mmol) in EtOH (15 mL) was added concentrated HCI (1.5 mL). The reaction was stirred for 2 h at 72 °C. Removal of the volatile solvent under a vacuum gave cis-4-amino-cyclohexanecarboxylic acid ethyl ester hydrochloride (1.7 g, 96 %) as a white power, which was used directly to the next reaction without further purification.
- 10 ESI MS m/e 172 M +H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 4.43 (brs, 2 H), 4.05 (q, J = 7.2 Hz, 2 H), 3.02 (brs, 1 H), 2.48 (m, 1 H), 1.93 (m, 2 H), 1.76 (m, 2 H), 1.43-1.57 (m, 4 H), 1.17 (t, J = 7.2 Hz, 3 H).

Step C: Synthesis of cis-4-(4-isopropyl-quinazolin-2-ylamino)-cyclohexane carboxylic acid ethyl ester.

A solution of 2-chloro-4-isopropylquinazoline (0.26 g, 1.26 minol) and cis-(4-ethoxycarbonyl) aminocyclohexane hydrochloride (0.26 g, 1 eq.) in IPA (2 mL) and DIEA (0.4 mL, 2 eq.) was reacted for 4 h at 160 °C in a Smith synthesizer. The reaction was purified from column chromatography (silica gel, DCM/MeOH = 100:0 to 90:10) to give 0.25 g (58 %) of

20 cis-4-(4-isopropyl-quinazolin-2-ylamino)-cyclohexanecarboxylic acid ethyl ester.

ESI MS m/e 342 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.90 (d, J = 8.0 Hz, 1 H), 7.60 (m, 1 H), 7.55 (d, J = 8.0 Hz, 1 H), 7.17 (t, J = 8.0 Hz, 1 H), 5.22 (d, J = 7.0 Hz, 1 H), 4.21 (brs, 1 H), 4.16 (q, J = 7.0 Hz, 2 H), 3.74 (m, 1 H), 2.50 (m, 1 H), 1.96 (m, 2 H), 1.86-1.77 (m, 6 H), 1.36 (d, J = 7.0 Hz, 6 H), 1.27 (t, J = 7.0 Hz, 3 H).

25

Step D: Synthesis of cis-4-(4-isopropyl-quinazolin-2-ylamino)-cyclohexane carboxylic acid

A suspension of cis-4-(4-isopropyl-quinazolin-2-ylamino)-cyclohexane carboxylic acid ethyl

196

ester (0.25 g, 0.7 mmol) in 4N-HCl (8 mL) was stirred for 3 h at 85 °C. During the reaction, the heterogenous solution turned to be a clear solution, and then the precipitate was formed. The solid was filtered, washed with cold water several times, and dried to give 0.13 g (58 %) of cis-4(4-isopropyl-quinazolin-2-ylamino)-cyclohexane carboxylic acid as a white solid.

5 ESI MS m/e 314 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.25 (brs, 1 H), 9.56 (brs, 1 H), 8.40-8.26 (m, 2 H), 8.01 (m, 1 H), 7.59 (m, 1 H), 4.31 (brs, 1 H), 4.03 (m, 1 H), 2.62 (brs, 1 H), 2.14 (m, 2 H), 1.93-1.66 (m, 6 H), 1.37 (d, J = 6.4 Hz, 6 H).

Step E: Synthesis of cis-N-benzyl-4-[(4-isopropylquinazolin-2-yl)amino]cyclohexane-

10 carboxamide trifluoroacetate.

cis-4-(4-Isopropyl-quinazolin-2-ylamino)-cyclohexane carboxylic acid (20 mg, 0.06 mmol) and benzyl amine (7 mg, 0.06 mmol) was reacted in the presence of HATU (25 mg, 0.066 mmol and Et₃N (4 drops) at room temperature for 16 hr. cis-N-benzyl-4-[(4-isopropylquinazolin-2-yl) amino]cyclohexanecarboxamide trifluoroacetate (13 mg, 40 %) was obtained from a prep-HPLC.

ESIMS m/e $403 \text{ M} + \text{H}^{+}$; ${}^{1}\text{H} \text{ NMR} (400 \text{ MHz}, \text{DMSO-d}_{6}) \delta 9.06 (brs, 1 H), 8.24 (m, 2 H), 7.88 (brs, 1 H), 7.75-7.59 (m, 1 H), 7.45 (brs, 1 H), 7.25 (m, 2 H), 7.17 (m, 3 H), 4.24 (brs, 1 H), 4.23 (d, J = 6.0 Hz, 2 H), 3.92 (m, 1 H), 2.33 (brs, 1 H), 1.95-1.58 (m, 8 H), 1.26 (d, J = 6.4 Hz, 6 H).$

20 Example 916

cis-N-(3-Chlorobenzyl)-4-{(4-isopropylquinazolin-2-yl)amino]cyclohexanecarboxamide trifluoroacetate

Step A: Synthesis of

25 cis-H-(3-chlorobentyl)-4-[(4-isopropylquinatolin-2-yl)amino]-cyclohexanearboxamide trifluoroacetate.

Using a similar procedure as described in step E of Example 915, the title compound was obtained.

197

ESI MS m/e 437 M + H+; 1H NMR (400 MHz, DMSO-d6) 8 9.04 (brs, 1 H), 8.30 (t, J = 5.4 Hz, 1 H), 8.20 (brs, 1 H), 7.86 (brs, 1 H), 7.71-7.57 (m, 1 H), 7.45 (brs, 1 H), 7.30-7.22 (m, 3 H), 7.15 (d, J = 8.0 Hz, 1 H), 4.24 (brs, 1 H), 4.23 (d, J = 6.0 Hz, 2 H), 3.92 (m, 1 H), 2.33 (brs, 1 H), 1.95-1.58 (m, 8 H), 1.26 (d, J = 6.6 Hz, 6 H).

5

Example 917

 $3,4-Dichloro-N-[((1R,3S)-3-\{[4-(dimethylamino)quinazolin-2-yl]amino)cyclopentyl) methyll-benzamide trifluoroacetate$

10

Step A: Synthesis of cis-(1R,3S)-3-tert-butoxycarbonylamino-cyclopentanecarboxylic acid ethylformate ester.

(1S,3R)-N-Boc-1-aminocyclopentane-3-carboxylic acid (10.00 g, 43.6 mmol) was dissolved in dichloromethane (100 mL) and cooled to – 65 °C. Triethylamine (9.19 mL, 65.9 mmol) and a
15 solution of ethyl chloroformate (4.24 mL, 44.4 mmol) in dichloromethane (14 mL) were added and the mixture stirred at 0 °C for 1 hr. The mixture was acidified to pH ~6 with 1N HCl (aq) and extracted with dichloromethane. The organic phase was washed with saturated aqueous NaHCO₃, water, and brine, dried over Na₂SO₄, filtered, and concentrated to give cis-(1R,3S)-3-tert-butoxycarbonylamino-cyclopentanecarboxylic acid ethylformate ester as a clear oil.
20 ES1 MS m/e 302, M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 6.92 (brs, 1 H), 4.25 (q, J = 7.2 Hz, 2 H), 3.78 (m, 1 H), 2.98 (m, 1 H), 2.16 (m, 2 H), 1.84 (m, 2 H), 1.80 (m, 2 H), 1.38 (s, 9 H), 1.25 (t, J = 7.2 Hz, 3 H).

Step B: Synthesis of cis-(18,3R)-(3-hydroxymethyl-cyclopentyl)-carbamic acid tert-butyl ester.

The 3-tert-butoxycarbonylamino-cyclopentanecarbonylic acid ethylformate ester was then dissolved in tetrahydrofuran (106 mL) and cooled to – 65 °C. Sodium borohydride (1.91 g, 50.5 mmol) and methanol (3.39 mL) were added and the mixture stirred at – 40 °C for 30 min., then at 0 °C for 3 hr. 10% HCl (aq) was added to pH 3 and the mixture was concentrated to half volume. Then it

was extracted with ethyl acetate, washed with water, brine, dried over Na₂SO₄, filtered, and concentrated to give (1S,3R)- (3-hydroxymethyl-cyclopentyl)-carbamic acid tert-butyl ester as a white solid (8.65 g, 92%).

ESI MS m/e 216, M + H⁺; ¹H NM IR (400 MHz, DM ISO-d₆) δ 6.74 (d, J = 6.8 Hz, 1 H), 4.46 (bt, J = 5.8 Hz, 1 H), 3.70 (m, 1 H), 3.25 (t, J = 5.6 Hz, 2 H), 1.92 (m, 2 H), 1.73 (m, 2 H), 1.55 (m, 2 H), 1.38 (s, 9 H), 1.05 (m, 1 H).

Step C: Synthesis of

cis-(1S,3R)-[3-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-cyclopentyl]-carbamic acid tert-butyl ester.

cis-(1S,3R)-(3-Hydroxymethyl-cyclopentyl)-carbamic acid tert-butyl ester (8.65 g, 40.2 mmol), triphenylphosphine (10.54 g, 40.2 mmol), and phthalimide (5.91 g, 40.2 mmol) were dissolved in tetrahydrofuran (128 mL). The mixture was cooled to 0 °C and a solution of diethylazodicarboxylate (6.96 mL, 44.22 mmol) in tetrahydrofuran (30 mL) was added over a period of 1 hr. The mixture stirred at room temperature for 18 hr, concentrated, and purified by silica gel chromatography (30% ethyl acetate in hexanes) to give cis-(1S,3R)-[3-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-cyclopentyl]-carbamic acid tert-butyl ester (9.52 g, 69%) as a solid.

ESI MS m/e 345, M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) 8 7.83 (m, 4 H), 6.84 (dd, J = 11.2, 7.6

20 Hz, 1 H), 3.70 (m, 1 H), 3.54 (m, 2 H), 1.92 (m, 2 H), 1.73 (m, 2 H), .55 (m, 2 H), 1.38 (s, 9 H), 1.10 (m, 1 H).

Step D: Synthesis of cis-(1S,3R)-(3-aminomethyl-cyclopentyl)-carbamic acid tert-butyl ester.

The cis-(1S,3R)-[3-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-cyclopentyl]-

carbamic acid tert-butyl ester was suspended in 95% ethanol (143 mL), hydrazine (1.89 mL, 60.3 mmol) was added, and the mixture was heated to reflux temperature (120 °C) for 2.5 hr, then stirred at room temperature for 18 hr. The suspension was concentrated, suspended in 10% NaOH (aq) (182 mL), extracted with dichloromethane, dried over Na₂SO₄, filtered, and concentrated to give

199

cis-(1S,3R)-(3-aminomethyl-cyclopentyl)-carbamic acid tert-butyl ester as a white solid (6.25 g, ~73%) (crude).

ESI MS m/e 215, M + H⁺; ¹H NMIR (400 MHz, DMSO-d₆) δ 6.82 (d, J = 6.3 Hz, 1 H), 3.70 (m, 1 H), 1.92 (m, 2 H), 1.75 (m, 2H), 1.73 (m, 2 H), 1.58 (m, 2 H), 1.38 (s, 9 H), 1.30 (m, 2H), 1.00 (m, 1 H).

Step E: Synthesis of cis-(13,3P.)-H-(3-amino-cyclopentylmethyl)-3,4-dichlorobenzamide.

5

cis-(1S,3R)- (3-Aminomethyl-cyclopentyl)-carbamic acid tert-butyl ester (0.050 g, 0.230 mmol), 3,4-dichlorobenzoyl chloride (0.049 g, 0.230 mmol), and diisopropylethylamine (0.10 mL,

0.57 mmol) were combined in dichloromethane (2 mL) and stirred for 18 hr at room temperature. The mixture was concentrated, neutralized with saturated aqueous NaHCO₃, and extracted with dichloromethane. The organic phase was then concentrated to give cis-(1S,3R)-N-(3-amino-cyclopentylmethyl)-3,4-dichloro-benzamide as the crude product.
 ES MS m/e 287, M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 8.72 (t, J = 5.6 Hz, 1 H), 8.04 (d, J = 2.0

15 Hz, 1 H), 7.78 (d, J = 2.0 Hz, 1 H), 7.74 (s, 1 H), 3.40 (m, 2 H), 2.80 (brs, 2 H), 2.15 (m, 1 H), 1.88 (m, 2 H), 1.70 (m, 1 H), 1.58 (m, 2 H), 1.48 (m, 2 H).

Step F: Synthesis of 3,4-dichloro-N- $[((1R,3S)-3-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclopentyl)$ methyl]benzamide trifluoroacetate.

cis-(1S,3R)-(2-Chloro-quinazolin-4-yl)-dimethyl-amine (0.048 g, 0.23 mmol),
N-(3-amino-cyclopentylmethyl)-3,4-dichloro-benzamide (0.23 mmol), diisopropylethylamine (0.061 mL, 0.34 mmol), and isopropanol (1.50 mL) were combined and heated to 160 °C for 40 min. utilizing a Smith synthesizer microwave apparatus. The mixture was then purified by HPLC to give 3,4-dichloro-N-[((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclopentyl)methyl]benzam ide trifluoroacetate as a white solid (0.035 g, 26.6% over four steps).

ESI MS m/e 458, M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 8.70 (t, J = 5.2 Hz, 1 H), 8.20 (brs, 1 H), 8.14 (d, J = 8.0 Hz, 1 H), 8.04 (d, J = 1.6 Hz, 1 H), 7.80 (d, J = 2.0 Hz, 1 H), 7.78 (d, J = 2.0 Hz, 1 H), 7.74 (s, 1 H), 7.44 (brs, 1 H), 7.34 (t, J= 7.6 Hz, 1 H), 3.29 (t, J = 5.2 Hz, 2 H), 2.50 (s, 6 H), 2.24

200

(m, 1 H), 2.00 (m, 2 H), 1.76 (m, 1 H), 1.65 (m, 2 H), 1.50 (m, 2 H).

Example 916

 $5-\Pi^2-[(13.3R)-3-(\{[4-Bromo-2-(trifluoromethoxy)benzyl]amino\}methyl) cyclopentyl]-\Pi^4,\Pi^4-dimethylquinazoline-2.4-diamine bistrifluoroacetate$

Step A: Synthesis of

product.

cis-(1S,3R)-3-[(4-bromo-2-trifluoromethoxy-benzylamino)-methyl]-cyclopentylamine.

- (3-Aminomethyl-cyclopentyl)-carbamic acid tert-butyl ester (0.050 g, 0.23 mmol),
 4-bromo-2-trifluoromethoxybenzaldehyde (0.063 g, 0.23 mmol), and sodium cyanoborohydride
 (0.022 g, 0.34 mmol) were combined in methanol (1.00 mL) and stirred at room temperature for 18 hrs. The mixture was concentrated, water (1.00 mL) was added, and it was extracted with dichloromethane. To the organic phase was added trifluoroacetic acid (1.00 mL) and the mixture stirred at room temperature for 18 hrs. The mixture was concentrated, neutralized with saturated aqueous NaHCO₃, extracted with dichloromethane, and concentrated to give
- ESI MS m/e 367, M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 7.75-7.62 (m, 3 H), 4.58 (s, 1 H), 3.77 20 (s, 2 H), 3.35 (brs, 2 H), 2.48 (m, 2 H), 2.04 (m, 1 H), 1.74 (m, 2 H), 1.38 (m, 2 H), 1.30 (m, 2 H), 0.98 (m, 1 H).

(1S,3R)-3-[(4-bromo-2-trifluoromethoxy-benzylamino)-methyl]-cyclopentylamine as the crude

- $Step \ B: \ Synthesis \ of \ N^2-[(1S,3R)-3-(\{[4-bromo-2-(trifluoromethoxy)benzyl]amino)\ methyl)-cyclopentyl]-N^4, N^4-dimethylquinazoline-2, 4-diamine \ bistrifluoroacetate.$
- (2-Chloro-quinazolin-4-yl)-dimethyl-amine (0.048 g, 0.23 mmol),
 (1S,3R)-3-[(4-bromo-2-trifluoromethoxy-benzylamino)-methyl]-cyclopentylamine (0.23 mmol),
 diisopropylethylamine (0.061 mL, 0.34 mmol), and isopropanol (1.50 mL) were combined and heated
 to 160 °C for 40 min. utilizing a SmithSynthesizer microwave apparatus. The mixture was then

201

purified by HPLC to give

N²-[(1S,3R)-3-({[4-bromo-2-(trifluoromethoxy)benzyl]amino} methyl)cyclopentyl]-N⁴,N⁴-dimethylq uinazoline-2,4-diamine bistrifluoroacetate as a white solid (0.011 g, 6.2% over four steps).

ESI MS m/e 538, M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 8.45 (brs, 1 H), 8.14 (d, J = 12.0 Hz, 1 H), 7.72 (d, J = 2.0 Hz, 1 H), 7.68 (d, J = 2.0 Hz, 1 H), 7.63 (s, 1 H), 7.58 (d, J = 2.0 Hz, 1 H), 7.44 (brs, 1 H), 7.29 (bt, J = 7.6 Hz, 1 H), 4.18 (s, 2 H), 3.40 (s, 2 H), 3.40 (s, 6H) 2.25 (m, 2 H), 1.98 (m, 1 H), 1.82 (m, 2 H), 1.60 (m, 2 H), 1.40 (m, 2 H), 1.22 (m, 1 H).

10 Example 919

 $N-[(1S,3R)-3-(\{[4-(Dimethylamino)quinazolin-2-yl]amino\}methyl) cyclopentyl]-4-fluorobenza$ $mide\ trifluoroacetate$

Step A: Synthesis of (1R,3S)-N²-(3-amino-cyclopentylmethyl)-N⁴,N⁴-dimethyl-15 quinazoline-2,4-diamine.

(2-Chloro-quinazolin-4-yl)-dimethyl-amine (0.048 g, 0.23 mmol), (1S,3R)-(3-aminomethyl-cyclopentyl)-carbamic acid tert-butyl ester (0.050 g, 0.23 mmol), diisopropylethylamine (0.061 mL, 0.34 mmol), and isopropanol (1.50 mL) were combined and heated to 160 °C for 40 min. utilizing a Smith synthesizer microwave apparatus. The mixture was

- 20 concentrated, dichloromethane (2.00 mL) and trifluoroacetic acid (1.00 mL) were added, and the mixture stirred at room temperature for 18 hr. Then it was concentrated, neutralized with saturated aqueous NaHCO₃, extracted with dichloromethane, and concentrated to give (1R,3S)-N²-(3-amino-cyclopentylmethyl)-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine as the crude product.
- 25 ESI MS m/e 286, M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 7.92 (d, J = 8.0 Hz, 1 H), 7.53 (t, J = 6.0 Hz, 1 H), 7.34 (d, J = 8.0 Hz, 1 H), 7.06 (t, J = 6.0 Hz, 1 H), 6.78 (brs, 1 H), 3.25 (s, 6 H), 2.28 (m, 2 H), 2.10 (m, 2 H), 1.86 (m, 1 H), 1.75 (m, 2 H), 1.52 (m, 2 H), 1.30 (brs, 2 H), 1.17 (m, 1 H).

Step B: Synthesis of N-[(1S,3R)-3-({[4-(dimethylamino)quinazolin-2-yl]amino}methyl)-cyclopentyl]-4-fluorobenzamide trifluoroacetate.

cis-(1R,3S)-N²-(3-Amino-cyclopentylmethyl)-N⁴, N⁴-dimethyl-quinazoline-2,4-diamine (0.23 mmol), 4-fluorobenzoyl chloride (0.023 mL, 0.23 mmol), and diisopropylethylamine (0.10 mL, 0.57 mmol) were combined in dichloromethane (2.00 mL) at room temperature and stirred for 18 hrs. The mixture was concentrated, dissolved in methanol, and purified by prep-LCMS to give N-[(1S,3R)-3-({[4-(dimethylamino)quinazolin-2-yl]amino} methyl)cyclopentyl]-4-fluorobenzamide trifluoroacetate as a white solid (5 mg, 4.1 % over four steps).

ESI MS m/e 408, M + H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.09 (d, J = 8.0 Hz, 1 H), 7.76 (d, J = 5.3 Hz, 2 H), 7.74 (d, J = 5.3 Hz, 2 H), 7.66 (t, J = 8.3 Hz, 1 H), 7.30 (bm, 2 H), 7.07 (t, J = 4.9 Hz, 1 H), 4.25 (m, 1 H), 3.45 (brs, 6 H), 2.25 (m, 2 H), 2.00 (m, 1 H), 1.70 (m, 2 H), 1.62 (m, 2 H), 1.52 (m, 2

15 Example 920

H), 1.26 (m, 1 H).

 $N^2-(\{(1R,3S)-3-[(3,4-Difluorobenzyl)amino] cyclopentyl\} methyl)-N^4, N^4-dimethylquinazoline-2,\\ 4-diamine bistrifluoroacetate.$

Step A: Synthesis of

 $20 \quad N^2-(\{(1R,3S)-3-[(3,4-difluorobenzyl)amino] cyclopentyl\} methyl)-N^4,N^4-dimethylquinazoline-2,4$ -diamine bistrifluoroacetate.

(1R,3S)-N²-(3-Amino-cyclopentylmethyl)-N⁴, N⁴-dimethyl-quinazoline-2,4-diamine (0.23 mmol), 3,4-difluorobenzaldehyde (0.026 mL, 0.23 mmol), and sodium cyanoborohydride (0.022 g, 0.34 mmol) were combined in methanol (1.00 mL) and stirred at room temperature for 18 hr. Water (0.50 mL) was added and the mixture was then purified by prep-LCMS to give N²-({(1R,3S)-3-[(3,4-difluorobenzyl)amino]cyclopentyl) methyl)-N⁴,N⁴-dimethylquinazoline-2,4-dia mine bistrifluoroacetate as a white solid (0.011 g, 7.4% over four steps).

ESI MS m/e 412, M + H⁺; ¹H NMR (400 MHz, DMSO-d₀) δ 8.83 (brs. 1 H), 8.12 (d, J = 7.7 Hz, 1

203

H), 7.73 (t, J = 4.9 Hz, 1 H), 7.55 (t, J = 9.7 Hz, 1 H), 7.50 (q, J = 8.9 Hz, 1 H), 7.31 (m, 2 H), 4.09 (brs, 1 H), 3.42 (brs, 6 H), 3.36 (brs, 1 H), 2.18 (m, 2 H), 1.95 (m, 1 H), 1.69 (m, 2 H), 1.42 (m, 2 H), 1.26 (m, 2 H), 1.18 (brs, 2 H), 0.81 (m, 1 H).

5

Example 921

cis-I I-(2,3-Dimethoxybenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexane-carboxamide

10 Step A: Synthesis of cis-4-amino-cyclohexanecarboxylic acid ethyl ester hydrochloride.

To a suspension of cis-aminocyclohexane-4-carboxylic acid (1.5 g, 10 mmol) in EtOH (15 mL) was added concentrated HCl (1.5 mL). The reaction was stirred for 2 hr at 72 °C. Removal of the volatile solvent under a vacuum gave cis-4-amino-cyclohexanecarboxylic acid ethyl ester

15 hydrochloride (1.7 g, 96 %) as a white power, which was used directly to the next reaction without a further purification.

ESI MS m/e $172 \text{ M} + \text{H}^{+}$; $^{1}\text{H} \text{ NMR} (400 \text{ MHz}, \text{DMSO-d}_{6}) & 4.43 (brs, 2 \text{ H}), 4.05 (q, J = 7.2 \text{ Hz}, 2 \text{ H}), 3.02 (brs, 1 H), 2.48 (m, 1 H), 1.93 (m, 2 H), 1.76 (m, 2 H), 1.43-1.57 (m, 4 H), 1.17 (t, J = 7.2 Hz, 3 H).$

20

Step B: Synthesis of cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexane carboxylic acid ethyl ester.

The reaction was done in seven vials. Each vial contains 2-chloro-4-N,N-dimethylamino quinazoline (0.26 g, 1.25 mmol), cis-(4-ethoxycarbonyl)aminocyclohexane hydrochloride (0.25 g, 1 eq.), DIEA (0.45 mL, 2 eq.), and IPA (2 mL). The vials were heated at 155 °C for 1 hr using a Smith microwave synthesizer. The vial contents were combined and concentrated. The residue was purified on silica gel column using CH₂Cl₂/MeOH (100:0 to 85:15) to give cis-4(4-dimethylamino-quinazolin-2-ylamino)-cyclohexane carboxylic acid ethyl ester (2.2 g, 76 %)

204

as pale yellow oil.

ESI MS m/e 343 M + H⁺; ¹H NMR (400 MHz, MeOD) 8 8.17 (d, J = 8.0 Hz, 1 H), 7.76 (t, J = 8.0 Hz, 1 H), 7.40 (brs, 1 H), 7.40 (t, J = 3.0 Hz, 1 H), 4.60 (brs, 1 H), 4.16 (q, J = 6.3 Hz, 2 H), 3.53 (s, 6 H), 2.59 (m, 1 H), 1.97-1.63 (m, 8 H), 1.27 (t, J = 6.8 Hz, 3 H), the

5

Step C: Synthesis of cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexane carboxylic acid.

A suspension of cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexane carboxylic acid ethyl ester (0.35 g, 1 mmol) in 4N-HCl (10 mL) was stirred at 82 °C for 2 h. During the reaction, the 10 heterogenous solution turned to be a clear solution, and then the precipitate was formed. The solid was filtered, washed with cold water several times, and dried to give 0.29 g (90 %) of cis-4(4-dimethylamino-quinazolin-2-ylamino)-cyclohexane carboxylic acid as a white solid. ESI MS m/e 315 M +H⁺; ¹H NMR (400 MHz, DMSO-d₆) 8 12.3 (brs, 1 H), 8.13 (d, J = 7.6 Hz, 2 H), 7.74 (t, J = 7.6 Hz, 1 H), 7.37 (brs, 1 H), 7.36 (t, J = 7.6 Hz, 1 H), 4.05 (brs, 1 H), 3.32 (s, 6 H), 15 2.42 (brs, 1 H), 1.82 ~ 1.68 (m, 8 H).

Step D: Synthesis of cis-N-(2,3-dimethoxybenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]-amino}cyclohexanecarboxamide

To a suspension of the acid (25 mg, 0.08 mmol) and the 2,3 dimethoxy benzyl amine (13 mg, 0.08 mmol) in DCM (3 mL) was added HATU (33 mg, 0.088 mmol), and followed Et₃N (4 drops). The reaction was stirred overnight at room temperature under an inert atmosphere. After removal of the volatile solvent, the crude product was purified by column chromatography (silica gel, DCM/MeOH = 100:0 to 90:10) to give cis-N-(2,3-dimethoxybenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexanecarboxamid e (8 mg, 21 %).

ESI MS m/e 464 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.34 (brs, 1 H), 7.89 (d, J = 8.4 Hz, 1 H),

7.57 (t, J = 6.8 Hz, 1 H), 7.33 (d, J = 8.0 Hz, 1 H), 7.23 (t, J = 7.6 Hz, 1 H), 7.07 (brs, 1 H), 6.95 (t,

J = 7.6 Hz, 1 H), 6.89 (d, J = 8.0 Hz, 1 H), 6.76 (d, J = 8.0 Hz, 1 H), 4.56 (d, J = 5.6 Hz, 2 H), 4.30 (m,

205

1 H), 3.83 (s, 3 H), 3.80 (s, 3 H), 3.48 (s, 6 H), 2.35 (m, 1 H), 2.05-1.82 (m, 6 H), 1.66 (m, 2 H).

Example 922

5 cis-IN-(2,4-Difluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexane-carboxamide

Step A: Synthesis of cis-PI-(2,4-difluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexanecarboxamide.

Using a similar procedure as described in step D of Example 921, the title compound was obtained.

ESI MS m/e $440 \text{ M} + \text{H}^+$; $^1\text{H} \text{ NMR} (400 \text{ MHz}, \text{CDCl}_3) \delta 7.92 (d, J = 8.0 \text{ Hz}, 1 \text{ H}), 7.61 (t, J = 8.0 \text{ Hz}, 1 \text{ H}), 7.28 (m, 3 \text{ H}), 7.17 (brs, 1 \text{ H}), 6.82 (brs, 1 \text{ H}), 6.76 (t, J = 8.0 \text{ Hz}, 1 \text{ H}), 6.67 (t, J = 8.0 \text{ Hz}, 1 \text{ H}), 4.41 (d, J = 6.0 \text{ Hz}, 2 \text{ H}), 4.31 (brs, 1 \text{ H}), 3.51 (s, 6 \text{ H}), 2.39 (m, 1 \text{ H}), 1.96-1.66 (m, 8 \text{ H}).$

15

Example 923

 $cis-4-\{[4-(Dimethylamino)quinazolin-2-yl]amino\}-N-(2,3-dimethylbenzyl)cyclohexane \\ carboxamide$

20

Step A: Synthesis of

cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2,3-dimethylbenzyl)-cyclohexanecarboxa mide.

Using a similar procedure as described in step D of Example 921, the title compound was obtained.

ESI MS m/e $432 \text{ M} + \text{H}^+$; $^1\text{H} \text{ NMR} (400 \text{ MHz}, \text{CDCl}_3) & 7.91 (d, J = 8.4 \text{ Hz}, 1 \text{ H}), 7.58 (t, J = 7.6 \text{ Hz}, 1 \text{ H}), 7.27 (t, J = 7.6 \text{ Hz}, 1 \text{ H}), 7.13 (d, J = 7.6 \text{ Hz}, 1 \text{ H}), 7.06 (m, 1 \text{ H}), 6.99 (d, J = 4.4 \text{ Hz}, 2 \text{ H}), 6.90 (brs, 1 \text{ H}), 6.45 (brs, 1 \text{ H}), 4.41 (d, J = 6.0 \text{ Hz}, 2 \text{ H}), 4.25 (brs, 1 \text{ H}), 3.50 (s, 6 \text{ H}), 2.41 (m, 1 \text{ H}), 6.90 (brs, 1 \text{ H}), 6$

206

2.21 (s, 3 H), 2.14 (s, 3 H), 1.96-1.72 (m, 8 H).

Example 924

5 cis-I4-(2-Bromobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexane-carboxamid e

Step A: Synthesis of cis-N-(2-bromobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexanecarboxamide.

Using a similar procedure as described in step D of Example 921, the title compound was obtained.

ESI MS m/e $482 \text{ M} + \text{H}^+$; $^1\text{H} \text{ NMR} (400 \text{ MHz}, \text{CDCl}_3) \delta 7.91 (d, J = 8.4 \text{ Hz}, 1 \text{ H}), 7.62 (t, J = 8.0 \text{ Hz}, 1 \text{ H}), 7.43 (d, J = 7.6 \text{ Hz}, 1 \text{ H}), 7.31-7.21 (m, 4 \text{ H}), 7.05 (t, J = 7.2 \text{ Hz}, 1 \text{ H}), 6.82 (brs, 1 \text{ H}), 6.59 (brs, 1 \text{ H}), 4.48 (d, J = 6.0 \text{ Hz}, 2 \text{ H}), 4.30 (brs, 1 \text{ H}), 3.52 (s, 6 \text{ H}), 2.41 (m, 1 \text{ H}), 1.97-1.64 (m, 8 \text{ H}).$

15

Example 925

cis-N-(2,4-Dichlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxa mide

20

Step A: Synthesis of cis-N-(2,4-dichlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexanecarboxamide.

Using a similar procedure as described in step D of Example 921, the title compound was obtained.

25 ESI MS m/e $472 \text{ M} + \text{H}^+$; $^1\text{H} \text{ NMR} (400 \text{ MHz}, \text{CDCl}_3) & 7.91 (d, J = 8.0 \text{ Hz}, 1 \text{ H}), 7.61 (t, J = 8.0 \text{ Hz}, 1 \text{ H}), 7.28 (t, J = 7.6 \text{ Hz}, 1 \text{ H}), 7.25-7.19 (m, 3 H), 7.12 (d, J = 8.0 \text{ Hz}, 1 H), 6.98 (brs, 1 H), 6.83 (brs, 1 H), 4.43 (d, J = 6.0 \text{ Hz}, 2 H), 4.31 (brs, 1 H), 3.52 (s, 6 H), 2.42 (m, 1 H), 1.96-1.67 (m, 8 H).$

Example 926

cis-II-(2,3-Dichlorobencyl)-4-{[4-(dimethylamino)quinacolin-2-yl]amino)cyclohenanecarbona mide

5

Step A: Synthesis of cis-II-(2,3-dichlorobentyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohenanecarbonamide.

Using a similar procedure as described in step D of Example 921, the title compound was obtained.

10 ESI MS m/e $472 \text{ M} + \text{H}^+$; $^1\text{H} \text{ NMR} (400 \text{ MHz}, \text{CDCl}_3) \delta 8.17 (d, J = 8.4 \text{ Hz}, 1 \text{ H}), 7.75 (t, J = 7.6 \text{ Hz}, 1 \text{ H}), 7.45-7.37 (m, 3 \text{ H}), 7.30-7.24 (m, 2 \text{ H}), 4.48 (s, 2 \text{ H}), 4.26 (brs, 1 \text{ H}), 3.54 (s, 6 \text{ H}), 2.49 (m, 1 \text{ H}), 1.99-1.77 (m, 8 \text{ H}).$

15 Example 927

cis-N-(2,5-Dichlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexane-carboxamide

Step A: Synthesis of cis-N-(2,5-dichlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-20 cyclohexanecarboxamide.

Using a similar procedure as described in step D of Example 921, the title compound was obtained.

ESI MS m/e 472 M + H⁺; ¹H NMR (400 MHz, CDCl₃) 8 7.90 (d, J = 8.4 Hz, 1 H), 7.66 (t, J = 7.6 Hz, 1 H), 7.58 (brs, 1 H), 7.39 (d, J = 8.0 Hz, 1 H), 7.31-7.19 (m, 3 H), 7.10 (d, J = 8.4 Hz, 1 H), 7.01 (brs, 1 H), 4.48 (d, J = 6.0 Hz, 2 H), 4.39 (brs, 1 H), 3.53 (s, 6 H), 2.42 (m, 1 H), 1.98-1.90 (m, 6 H), 1.63 (m, 2 H).

Example 928

cis-PI-(2-Chlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexane-carboxamide

5 Step A: Synthesis of cis-IV-(2-chlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexanecarboxamide.

Using a similar procedure as described in step D of Example 921, the title compound was obtained.

ESI MS m/e $438 \text{ M} + \text{H}^+$; $^1\text{H} \text{ NMR} (400 \text{ MHz}, \text{CDCl}_3) \delta 7.90 (d, J = 8.4 \text{ Hz}, 1 \text{ H}), 7.60 (t, J = 8.0 \text{ Hz}, 1 \text{ H}), 7.31-7.09 (m, 6 \text{ H}), 6.77 (d, J = 6.8 \text{ Hz}, 1 \text{ H}), 6.66 (brs, 1 \text{ H}), 4.49 (d, J = 6.0 \text{ Hz}, 2 \text{ H}), 4.27 (brs, 1 \text{ H}), 3.51 (s, 6 \text{ H}), 2.43 (m, 1 \text{ H}), 1.95-1.68 (m, 8 \text{ H}).$

Example 929

15 cis-N-(3-Chlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexane-carboxamide

Step A: Synthesis of cis-N-(3-chlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexanecarboxamide.

Using a similar procedure as described in step D of Example 921, the title compound was obtained.

ESI MS m/e $438 \text{ M} + \text{H}^{+}$; $^{1}\text{H} \text{ NMR} (400 \text{ MHz}, \text{CDCl}_{3}) \delta 8.13 (d, J = 8.0 \text{ Hz}, 1 \text{ H}), 7.72 (t, J = 7.6 \text{ Hz}, 1 \text{ H}), 7.49-7.19 (m, 6 \text{ H}), 4.35 (s, 2 \text{ H}), 4.23 (brs, 1 \text{ H}), 3.51 (s, 6 \text{ H}), 2.44 (m, 1 \text{ H}), 2.01-1.74 (m, 8 \text{ H}).$

25

Example 930

cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}-N-(3-methoxybenzyl)cyclohexane-

carboxamide

Step A: Synthesis of cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-11-(3-methoxybenzyl)-cyclohexanecarboxamide.

5 Using a similar procedure as described in step D of Example 921, the title compound was obtained.

ESI MS m/e 434 M + H⁺; ¹H NMR (400 MHz, CDCl₃) 8 7.90 (d, J = 8.4 Hz, 1 H), 7.62 (t, J = 8.0 Hz, 1 H), 7.29 (t, J = 8.0 Hz, 1 H), 7.22 (m, 1 H), 7.14 (t, J = 8.0 Hz, 1 H), 6.85-6.78 (m, 3 H), 6.71 (d, J = 8.0 Hz, 1 H), 6.63 (brs, 1 H), 4.38 (d, J = 6.0 Hz, 2 H), 4.29 (brs, 1 H), 3.51 (s, 6 H), 2.40 (m, 1 H), 1.95-1.66 (m, 8 H).

Example 931

cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}-N-(4-methylbenzyl)cyclohexane-

15 carboxamide

Step A: Synthesis of cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(4-methylbenzyl)-cyclohexanecarboxamide.

Using a similar procedure as described in step D of Example 921, the title compound was 20 obtained.

ESI MS m/e 418 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 9.80 (brs, 1 H), 7.90 (d, J = 8.4 Hz, 1 H), 7.63 (t, J = 8.0 Hz, 1 H), 7.29 (t, J = 8.0 Hz, 1 H), 7.16 (d, J = 8.0 Hz, 2 H), 7.06 (d, J = 8.0 Hz, 2 H), 6.77 (d, J = 7.2 Hz, 1 H), 6.48 (brs, 1 H), 4.37 (d, J = 5.6 Hz, 2 H), 4.29 (brs, 1 H), 3.52 (s, 6 H), 2.37 (m, 1 H), 2.27 (s, 3 H), 1.96-1.62 (m, 8 H).

25

Example 932

cis-N-[3,5-Bis(trifluoromethyl)benzyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexa

necarboxamide

Step A: Synthesis of

 $cis-II-[3,5-bis(trifluoromethyl)benzyl]-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohemalum (a. 2.3) amino a$

5 necarboxamide.

Using a similar procedure as described in step D of Example 921, the title compound was obtained.

ESI MS m/e 540 M + H⁺; ¹H NMR (400 MHz, CDCl₃) 8 8.91 (brs, 1 H), 8.22 (brs, 1 H), 7.88 (d, J = 7.6 Hz, 1 H), 7.78 (s, 2 H), 7.68 (s, 1 H), 7.62 (t, J = 8.0 Hz, 1 H), 7.40 (d, J = 8.0 Hz, 1 H), 7.24 (t, J = 7.6 Hz, 1 H), 4.55 (d, J = 5.6 Hz, 2 H), 4.38 (m, 1 H), 3.49 (s, 6 H), 2.44 (m, 1 H), 2.19 (m, 2 H), 1.95 (m, 4 H), 1.62 (m, 2 H).

Example 933

15 cis-N-(2,4-Dimethoxybenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexane-carboxamide

Step A: Synthesis of cis-N-(2,4-dimethoxybenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]-amino}cyclohexanecarboxamide.

Using a similar procedure as described in step D of Example 921, the title compound was obtained.

ESI MS m/e 464 M + H⁺; ¹H NMR (400 MHz, CDCl₃) 8 8.53 (brs, 1 H), 7.88 (d, J = 7.6 Hz, 1 H), 7.60 (t, J = 8.0 Hz, 1 H), 7.40 (d, J = 7.6 Hz, 1 H), 7.23 (t, J = 7.6 Hz, 1 H), 7.16 (d, J = 8.4 Hz, 1 H), 6.83 (brs, 1 H), 6.38 (m, 2 H), 4.37 (d, J = 6.0 Hz, 2 H), 4.29 (m, 1 H), 3.82 (s, 3 H), 3.75 (s, 3 H), 3.48 (s, 6 H), 2.32 (m, 1 H), 2.09-1.32 (m, 6 H), 1.66 (m, 2 H).

211

cis-N-(3,4-Dimethoxybenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexane-carbomamide

Step A: Synthesis of cis-II-(3,4-dimethoxybenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]-5 amino}cyclohexanecarboxamide.

Using a similar procedure as described in step D of Example 921, the title compound was obtained.

ESI MS m/e 464 M + H⁺; ¹H NMR (400 MHz, CDCl₃) 8 8.74 (brs, 1 H), 7.87 (d, J = 8.0 Hz, 1 H), 7.61 (t, J = 7.6 Hz, 1 H), 7.41 (d, J = 8.0 Hz, 2 H), 7.23 (t, J = 7.2 Hz, 1 H), 6.91 (m, 2 H), 6.76 (d, J = 8.0 Hz, 1 H), 4.37 (d, J = 6.0 Hz, 2 H), 4.36 (m, 1 H), 3.87 (s, 3 H), 3.81 (s, 3 H), 3.48 (s, 6 H), 2.37 (m, 1 H), 2.09 (m, 2 H), 1.83 (m, 4 H), 1.63 (m, 2 H).

Example 935

15 cis-N-(3,5-Dimethoxybenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarbox amide

Step A: Synthesis of cis-N-(3,5-dimethoxybenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]-amino}cyclohexanecarboxamide.

Using a similar procedure as described in step D of Example 921, the title compound was obtained.

ESI MS m/e 464 M + H⁺; ¹H NMR (400 MHz, CDCl₃) 8 8.32 (brs, 1 H), 7.88 (d, J = 7.6 Hz, 1 H), 7.59 (t, J = 7.6 Hz, 1 H), 7.34 (d, J = 8.0 Hz, 1 H), 7.23 (t, J = 7.6 Hz, 2 H), 6.46 (d, J = 2.0 Hz, 2 H), 6.25 (t, J = 2.0 Hz, 1 H), 4.36 (d, J = 6.0 Hz, 2 H), 4.34 (bm, 1 H), 3.73 (s, 6 H), 3.48 (s, 6 H), 2.39 (m, 2 H), 2.06-1.83 (m, 6 H), 1.65 (m, 2 H).

cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}-N-(4-hydroxy-3-methoxybenzyl)-cyclohexanecarboxamide

Step A: Synthesis of

5 cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(4-hydroxy-3-methoxybenzyl)cyclohexane carboxamide.

Using a similar procedure as described in step D of Example 921, the title compound was obtained.

ESI MS m/e 450 M +H⁺; ¹H NMR (400 MHz, CDCl₃) & 8.02 (brs, 1 H), 7.88 (d, J = 7.6 Hz, 1 H), 7.63 (t, J = 8.0 Hz, 1 H), 7.36 (d, J = 8.0 Hz, 1 H), 7.26 (t, J = 8.0 Hz, 1 H), 7.04 (brs, 1 H), 6.90 (d, J = 1.2 Hz, 1 H), 6.79 (m, 2 H), 4.33 (d, J = 6.0 Hz, 3 H), 3.87 (s, 3 H), 3.55 (s, 1 H), 3.50 (s, 6 H), 2.37 (m, 1 H), 1.93-1.83 (m, 6 H), 1.65 (m, 2 H).

15 Example 937

cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}-N-(3,4,5-trimethoxybenzyl)cyclohexane-carboxamide

Step A: Synthesis of

20 cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3,4,5-trimethoxybenzyl)cyclohexane carboxamide.

Using a similar procedure as described in step D of Example 921, the title compound was obtained.

ESI MS m/e 494 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.90 (d, J = 8.4 Hz, 1 H), 7.66 (t, J = 8.0 Hz, 1 H), 7.30 (m, 2 H), 6.78 (d, J = 7.2 Hz, 1 H), 6.56 (s, 3 H), 4.34 (d, J = 6.0 Hz, 3 H), 3.82 (s, 6 H), 3.78 (s, 3 H), 3.52 (s, 6 H), 2.38 (m, 1 H), 1.97~1.62 (m, 8 H).

213

Example 938

cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}-H-(2,4,6-trimethoxybenzyl)cyclohexane-carboxamide

5 Step A: Synthesis of

cis-4- $\{[4-(dimethylamino)quinazolin-2-yl]amino\}-II-(2,4,6-trimethoxybenzyl)cyclohexanecarb oxamide.$

Using a similar procedure as described in step D of Example 921, the title compound was obtained.

10 ESI MS m/e 494 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.48 (brs, 1 H), 7.87 (d, J = 8.4 Hz, 1 H), 7.60 (t, J = 8.0 Hz, 1 H), 7.44 (d, J = 6.8 Hz, 1 H), 7.22 (t, J = 8.0 Hz, 1 H), 6.28 (brs, 1 H), 6.09 (s, 2 H), 4.45 (d, J = 5.2 Hz, 2 H), 4.20 (brs, 1 H), 3.83 (s, 6 H), 3.78 (s, 3 H), 3.48 (s, 6 H), 2.26 (m, 1 H), 1.97-1.65 (m, 8 H).

15

Example 939

 $cis-N-(1,3-Benzo dioxol-5-ylmethyl)-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexanecarboxamide$

20 Step A: Synthesis of

cis-N-(1,3-benzodioxol-5-ylmethyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanec arboxamide.

Using a similar procedure as described in step D of Example 921, the title compound was obtained.

25 ESI MS m/e 448 M + H⁺; ¹H NIMR (400 MHz, CDCl₃) 8 8.52 (brs, 1 H), 7.89 (d, J = 7.6 Hz, 1 H), 7.59 (t, J = 8.0 Hz, 1 H), 7.39 (brs, 1 H), 7.44 (d, J = 8.0 Hz, 1 H), 7.23 (t, J = 7.6 Hz, 1 H), 6.79 (s, 1 H), 6.75 (d, J = 8.0 Hz, 1 H), 6.66 (d, J = 8.0 Hz, 1 H), 5.84 (s, 2 H), 4.35 (m, 1 H), 4.32 (d, J = 6.0 Hz, 2 H), 3.48 (s, 6 H), 2.37 (m, 1 H), 2.05 (m, 2 H), 1.87 (m, 4 H), 1.63 (m, 2 H).

Example 940

cis-4-{[4-(Dimethylamino)quinacolin-2-yl]amino]-H-(2,2-diphenylethyl)cyclohexane-

5 carboxamide

Step A: Synthesis of cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-IV-(2,2-diphenylethyl)-cyclohexanecarboxamide.

Using a similar procedure as described in step D of Example 921, the title compound was 10 obtained.

ESI MS m/e $494 \text{ M} + \text{H}^+$; $^1\text{H} \text{ NMR} (400 \text{ MHz}, \text{CDCl}_3) \delta 7.84 (d, J = 8.4 \text{ Hz}, 1 \text{ H}), 7.56 (t, J = 7.6 \text{ Hz}, 1 \text{ H}), 7.46 (d, J = 8.4 \text{ Hz}, 1 \text{ H}), 7.27-7.15 (m, 13 \text{ H}), 4.38 (brs, 1 \text{ H}), 4.27 (brs, 1 \text{ H}), 3.91 (dd, J = 8.0, 6.0 \text{ Hz}, 2 \text{ H}), 3.39 (s, 6 \text{ H}), 2.16 (m, 1 \text{ H}), 1.79 (m, 4 \text{ H}), 1.60 (m, 4 \text{ H}).$

15

Example 941

cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}-N-(1,2,3,4-tetrahydronaphthalen-1-yl)cyclo hexanecarboxamide

20 Step A: Synthesis of

cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(1,2,3,4-tetrahydronaphthalen-1-yl)cycloh exanecarboxamide.

Using a similar procedure as described in step D of Example 921, the title compound was obtained.

ESI MS m/e $444 \text{ M} + \text{H}^+$; $^1\text{H} \text{ NMR} (400 \text{ MHz}, \text{CDCl}_3) \delta 7.89 (d, J = 7.6 \text{ Hz}, 1 \text{ H}), 7.63 (t, J = 7.6 \text{ Hz}, 1 \text{ H}), 7.34-7.03 (m, 6 \text{ H}), 6.80 (brs, 1 \text{ H}), 6.09 (d, J = 8.4 \text{ Hz}, 1 \text{ H}), 5.15 (q, J = 6.8 \text{ Hz}, 1 \text{ H}), 4.27 (brs, 1 \text{ H}), 3.52 (s, 6 \text{ H}), 2.83 (m, 1 \text{ H}), 2.70 (m, 1 \text{ H}), 2.36 (m, 1 \text{ H}), 2.04-1.72 (m, 12 \text{ H}).$

Example 942

cis-i I-(2,3-Dihydro-1H-inden-2-yl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino)eyelohezanec arboxamide

5

Step A: Synthesis of

cis-II-(2,3-dihydro-1H-inden-2-yl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanec arboxamide.

Using a similar procedure as described in step D of Example 921, the title compound was 10 obtained.

ESI MS m/e 430 M + H⁺; ¹H NMR (400 MHz, CDCl₃) 8 7.91 (d, J = 8.4 Hz, 1 H), 7.63 (t, J = 8.0 Hz, 1 H), 7.28 (m, 2 H), 7.15 (m, 2 H), 7.09 (m, 2 H), 6.83 (d, J = 6.8 Hz, 1 H), 6.34 (d, J = 6.8 Hz, 1 H), 4.63 (m, 1 H), 4.29 (brs, 1 H), 3.51 (s, 6 H), 3.24 (m, 2 H), 2.97 (m, 2H), 2.33 (m, 1 H), 1.97-1.68 (m, 8 H).

15

Example 943

 $cis-4-\{[4-(Dimethylamino)quinazolin-2-yl]amino\}-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]cycloh\\ exanecarboxamide$

20

Step A: Synthesis of

 $\label{lem:cis-4-lem:cis$

Using a similar procedure as described in step D of Example 921, the title compound was obtained.

ESI MS m/e $487 \text{ M} + \text{H}^{+}$; $^{1}\text{H} \text{ NMR} (400 \text{ MHz}, \text{CDCl}_{3}) 8 8.32 (brs, 1 H), 7.89 (d, J = 8.4 Hz, 1 H), 7.53 (t, J = 8.0 Hz, 1 H), 7.40 (d, J = 8.4 Hz, 1 H), 7.22 (d, J = 8.4 Hz, 1 H), 7.10 (t, J = 7.6 Hz, 1 H), 7.02 (s, 2 H), 6.81 (dd, J = 8.8, 2.0 Hz, 1 H), 5.80 (brs, 1 H), 4.21 (brs, 1 H), 3.84 (s, 3 H), 3.59 (q, J Hz, 1 Hz), 7.02 (s, 2 Hz, 1 Hz), 7.03 (s, 2 Hz, 1 Hz), 7.04 (dz, J = 8.8, 2.0 Hz, 1 Hz), 7.80 (brs, 1 Hz, 1 Hz), 7.84 (s, 3 Hz, 1 Hz), 7.85 (dz, J Hz, 1 Hz), 7.89 (dz, J Hz), 7.89 ($

WO 2004/087680

216

= 6.0 Hz, 2 H), 3.34 (s, 6 H), 2.95 (t, J = 6.4 Hz, 2 H), 2.19 (m, 1 H), 1.85 (m, 2 H), 1.72-1.63 (m, 6 H).

PCT/JP2004/004554

5 Example 944

 $\label{lem:cis-4-} cis-4-\{[4-(Dimethylamino)quinasolin-2-yl]amino\}-II-[(1R)-1-(4-nitrophenyl)ethyl]-cyclohexanecarboxamide$

Step A: Synthesis of

10 cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1R)-1-(4-nitrophenyl)ethyl]cyclohexanec arboxamide.

Using a similar procedure as described in step D of Example 921, the title compound was obtained.

ESI MS m/e 463 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.13 (d, J = 8.8 Hz, 2 H), 7.88 (d, J = 7.6 Hz, 2 H), 7.63 (m, 3 H), 7.43 (d, J = 7.6 Hz, 1 H), 7.24 (t, J = 7.6 Hz, 1 H), 5.13 (m, 1 H), 4.44 (m, 1 H), 3.48 (s, 6 H), 2.35 (m, 1 H), 2.16 (m, 2 H), 1.88 (m, 4 H), 1.76 (m, 1 H), 1.63 (m, 1 H), 1.61 (d, J = 7.2 Hz, 3 H).

20 Example 945

cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}-N-[(1S)-1-(4-nitrophenyl)ethyl]-cyclohexane carboxamide

Step A: Synthesis of

25 cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-II-[(1S)-1-(4-nitrophenyl)ethyl]cyclohexanec arboxamide.

Using a similar procedure as described in step D of Example 921, the title compound was obtained.

WO 2004/087680

217

ESI MS m/e $463 \text{ M} + \text{H}^+$; $^1\text{H} \text{ NMR} (400 \text{ MHz}, \text{CDCl}_3) \delta 8.13 (d, J = 8.8 \text{ Hz}, 2 \text{ H}), 7.88 (d, J = 7.6 \text{ Hz}, 2 \text{ H}), 7.63 (m, 3 \text{ H}), 7.43 (d, J = 7.6 \text{ Hz}, 1 \text{ H}), 7.24 (t, J = 7.6 \text{ Hz}, 1 \text{ H}), 5.13 (m, 1 \text{ H}), 4.45 (m, 1 \text{ H}), 3.49 (s, 6 \text{ H}), 2.35 (m, 1 \text{ H}), 2.16 (m, 2 \text{ H}), 1.38 (m, 4 \text{ H}), 1.77 (m, 1 \text{ H}), 1.63 (m, 1 \text{ H}), 1.61 (d, J = 7.2 \text{ Hz}, 3 \text{ H}).$

5

Example 946

 $\label{lem:cis-4-} cis-4-\{[4-(Dimethylamino)quinazolin-2-yl]amino\}-N-[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]cyclohexanecarboxamide$

10

Step A: Synthesis of

 $\label{lem:cis-4-{-dimethylamino}quinazolin-2-yl} cis-4-{-dimethylamino}-N-[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]cyclohexanecarboxamide.$

Using a similar procedure as described in step D of Example 921, the title compound was obtained.

ESI MS m/e $446 \text{ M} + \text{H}^+$; $^1\text{H} \text{ NMR} (400 \text{ MHz}, \text{CDCl}_3) & 7.85 (d, J = 8.0 \text{ Hz}, 1 \text{ H}), 7.59 (t, J = 7.6 \text{ Hz}, 1 \text{ H}), 7.39 (d, J = 8.0 \text{ Hz}, 1 \text{ H}), 7.29-7.15 (m, 6 \text{ H}), 7.12 (brs, 1 \text{ H}), 5.39 (m, 1 \text{ H}), 4.69 (brs, 1 \text{ H}), 4.39 (m, 1 \text{ H}), 4.23 (brs, 1 \text{ H}), 3.47 (s, 6 \text{ H}), 3.12 (m, 2 \text{ H}), 2.47 (m, 1 \text{ H}), 2.16-1.88 (m, 6 \text{ H}), 1.67 (m, 2 \text{ H}).$

20

Example 947

 $\label{lem:cis-4-} cis-4-\{[4-(Dimethylamino)quinazolin-2-yl]amino\}-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]cyclohexanecarboxamide$

25

Step A: Synthesis of

cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden -1-yl]cyclohexanecarboxamide.

218

Using a similar procedure as described in step D of Example 921, the title compound was obtained.

ESI MS m/e 446 M + H⁺; ¹H NMR (400 MHz, CDCl₃) 8 3.73 (brs, 1 H), 7.86 (d, J = 3.0 Hz, 1 H), 7.59 (t, J = 8.0 Hz, 1 H), 7.38 (d, J = 8.4 Hz, 1 H), 7.28-7.15 (m, 5 H), 7.11 (brs, 1 H), 5.38 (m, 1 H), 4.69 (m, 1 H), 4.39 (m, 1 H), 4.28 (brs, 1 H), 3.48 (s, 6 H), 3.12 (m, 2 H), 2.47 (m, 1 H), 2.16-1.88 (m, 6 H), 1.67 (m, 2 H).

Example 948

10 cis-4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexanecarboxylic acid (trans 2-phenylcyclopropyl)-amide

Step A: Synthesis of cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexanecarboxylic acid (2-phenylcyclopropyl)-amide.

Using a similar procedure as described in step D of Example 921, the title compound was obtained.

ESI MS m/e $430 \text{ M} + \text{H}^+; {}^1\text{H} \text{ NMR} (400 \text{ MHz}, \text{CDCl}_3) \delta 7.89 (d, J = 7.6 \text{ Hz}, 1 \text{ H}), 7.64 (t, J = 7.6 \text{ Hz}, 1 \text{ H}), 7.28 (t, J = 8.0 \text{ Hz}, 2 \text{ H}), 7.09-7.01 (m, 6 \text{ H}), 6.65 (brs, 1 \text{ H}), 4.28 (brs, 1 \text{ H}), 3.50 (s, 6 \text{ H}), 2.92 (brs, 1 \text{ H}), 2.40 (brs, 1 \text{ H}), 2.13 (m, 1 \text{ H}), 1.95-1.68 (m, 8 \text{ H}), 1.31 (m, 1 \text{ H}), 1.17 (m, 1 \text{ H}).$

Example 949

20

25

cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}-N-[(1S)-1-(4-methylphenyl)ethyl]-cyclohexanecarboxamide trifluoroacetate

Step A: Synthesis of

 $cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-N-[(1S)-1-(4-methylphenyl)ethyl]cyclohexan ecarboxamide trifluoroacetate.\\$

Using a similar procedure as described in step D of Example 921, the product was purified by prep HPLC to give the title compound.

ESI MS m/e $432 \text{ M} + \text{H}^{+}; {}^{1}\text{H} \text{ NIMR} (400 \text{ MHz}, \text{DMSO-d}_{6}) \delta 11.72 \text{ (brs. 1 H), } 3.10 \text{ (d. J} = 3.0 \text{ Hz, } 1.0 \text{ MHz})$ H), 8.08 (brs, 1 H), 7.90 (brs, 1 H), 7.71 (t, J = 8.0 Hz, 1 H), 7.37 (brs, 1 H), 7.30 (t, J = 8.0 Hz, 1 H), 5 7.11 (d, J = 8.0 Hz, 2 H), 7.04 (d, J = 8.0 Hz, 2 H), 4.81 (m, 1 H), 4.10 (brs, 1 H), 3.36 (s, 6 H), 2.26 (brs, 1 H), 2.19 (s, 3 H), 1.80-1.51 (m, 8 H), 1.24 (d, J = 7.2 Hz, 3 H).

Example 950

 $10 \quad cis-4-\{[4-(Dimethylamino)quinazolin-2-yl]amino\}-N-[(1R)-1-(1-naphthyl)ethyl]cyclohexane-line for the control of the con$ carboxamide trifluoroacetate

Step A: Synthesis of cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1R)-1-(1-naphthyl) ethyl]cyclohexanecarboxamide trifluoroacetate.

Using a similar procedure as described in step D of Example 921, the product was purified by 15 prep HPLC to give the title compound.

ESI MS m/e $468 \text{ M} + \text{H}^{+}$; ¹H NMR $(400 \text{ MHz}, \text{DMSO-d}_{6}) \delta 11.8 \text{ (brs, 1 H)}, 8.30 \text{ (d, J} = 7.6 \text{ Hz, 1})$ H), 8.10 (d, J = 8.0 Hz, 1 H), 8.03 (d, J = 8.0 Hz, 1 H), 7.94 (brs, 1 H), 7.87 (d, J = 8.4 Hz, 1 H), 7.75 (d, J = 8.4 Hz, 1 H)(d, J = 8.0 Hz, 1 H), 7.70 (t, J = 7.6 Hz, 1 H), 7.48-7.40 (m, 4 H), 7.36 (brs, 1 H), 7.29 (t, J = 7.6 Hz, 1 Hz)20 1 H), 5.64 (m, 1 H), 4.09 (brs, 1 H), 3.40 (s, 6 H), 2.28 (brs, 1 H), 1.84-1.50 (m, 8 H), 1.42 (d, J = 7.0Hz, 3 H).

Example 951

25 cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}-1 I-[3-(trifluoromethyl)benzyl]cyclohexanecarboxamide

Step A: Synthesis of cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexane

carbonyl chloride.

To a suspension of cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexane carboxylic acid (0.34 g, 1.0 mmol) in CH₂Cl₂ (20 mL) was added 2M-oxalyl chloride (7.4 mL, 1.3 eq.) in CH₂Cl₂ under an inert atmosphere. The reaction was stirred for 18 hr at room temperature. The reaction changed to a clear solution. Removal of the volatile solvent gave the crude cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexane carbonyl chloride (0.35 g, 97 %), which was directly used to the next reaction without a further purification (When the acid chloride reacted with EtOH, the formation of 343 M +H⁺ of the ethyl ester) was observed by LC-MS).

10 Step B: Synthesis of cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[3-(trifluoromethyl)-benzyl]cyclohexanecarboxamide.

To a solution of the acid chloride (24 mg, 0.07 mmol), obtained from Step A, in DCM (3 mL) was added the 3-trifluoromethylbenzyl amine (13 mg, 0.07 mmol) and followed DIEA (3 drops).

After stirring overnight at room temperature, the reaction was quenched and purified using column chromatography (silica gel, DCM/MeOH = 100:0 to 90:10) to give cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[3-(trifluoromethyl)benzyl]cyclohexanecarbox amide (18 mg, 53 %).

ESI MS m/e 472 M + H⁺; ¹H NMR (400 MHz, CDCl₃) & 7.84 (d, J = 8.4 Hz, 1 H), 7.57-7.38 (m, 7 H), 7.12 (t, J = 7.2 Hz, 1 H), 4.50 (d, J = 6.0 Hz, 2 H), 4.35 (brs, 1 H), 3.37 (s, 6 H), 2.36 (m, 1 H), 20 2.06-1.82 (m, 6 H), 1.66 (m, 2 H).

Example 952

cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}-N-(3-methoxyphenyl)cyclohexane-

25 carbozamide

Step A: Synthesis of cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-methoxyphenyl)-cyclohexanecarboxamide.

221

Using a similar procedure as described in step B of Example 951, the title compound was obtained.

ESI MS m/e 420 M + H⁴; ¹H MMR (400 MHz, CDCl₂) 8 7.35 (d, J = 7.6 Hz, 1 H), 7.56 (m, 2 H), 7.45 (d, J = 7.6 Hz, 1 H), 7.37 (brs, 1 H), 7.17 (m, 2 H), 6.59 (d, J = 8.0 Hz, 1 H) 4.42 (brs, 1 H), 3.81 (s, 3 H), 3.44 (s, 6 H), 2.45 (m, 1 H), 2.18 (m, 2 H), 1.94 (m, 4 H), 1.67 (m, 2 H).

Example 953

cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}-N-(2-methoxybenzyl)cyclohexane-

10 carboxamide

Step A: Synthesis of cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2-methoxybenzyl)-cyclohexanecarboxamide.

Using a similar procedure as described in step B of Example 951, the title compound was obtained.

ESI MS m/e $434 \text{ M} + \text{H}^+$; $^1\text{H} \text{ NMR} (400 \text{ MHz}, \text{CDCl}_3) \delta 7.83 (d, J = 8.0 \text{ Hz}, 1 \text{ H}), 7.56 (t, J = 7.2 \text{ Hz}, 1 \text{ H}), 7.45 (d, J = 8.0 \text{ Hz}, 1 \text{ H}), 7.27-7.14 (m, 4 \text{ H}), 6.88 (t, J = 7.6 \text{ Hz}, 1 \text{ H}), 6.83 (d, J = 8.0 \text{ Hz}, 1 \text{ H}), 4.45 (d, J = 5.6 \text{ Hz}, 2 \text{ H}), 4.31 (brs, 1 \text{ H}), 3.86 (s, 3 \text{ H}), 3.40 (s, 6 \text{ H}), 2.31 (m, 1 \text{ H}), 2.02-1.82 (m, 6 \text{ H}), 1.66 (m, 2 \text{ H}).$

20

Example 954

cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}-N-(3-iodobenzyl)cyclohexanecarboxamide

25 Step A: Synthesis of cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-IJ-(3-iodobenzyl)-cyclohexanecarboxamide.

Using a similar procedure as described in step B of Example 951, the title compound was obtained.

222

ESI MS m/e 530 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.86 (d, J = 8.4 Hz, 1 H), 7.66 (s, 1 H), 7.65 (d, J = 7.6 Hz, 1 H), 7.54 (m, 2 H), 7.44 (d, J = 8.0 Hz, 1 H), 7.32 (d, J = 8.0 Hz, 1 H), 7.25 (d, J = 8.0 Hz, 1 H), 7.19 (t, J = 7.6 Hz, 1 H), 7.03 (m, 2 H), 4.40 (d, J = 6.0 Hz, 3 H), 3.44 (s, 6 H), 2.38 (m, 1 H), 2.06 (m, 2 H), 1.89 (m, 4 H), 1.63 (m, 2 H).

5

Example 955

cis-N-(3,5-Dichlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexane-carboxamide

10

Step A: Synthesis of

cis-N-(3,5-dichlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxa mide.

Using a similar procedure as described in step B of Example 951, the title compound was obtained.

ESI MS m/e $472 \text{ M} + \text{H}^+$; ${}^{1}\text{H} \text{ NMR} (400 \text{ MHz}, \text{CDCl}_3) \delta 7.84 (d, J = 8.0 \text{ Hz}, 1 \text{ H}), 7.57 (t, J = 7.6 \text{ Hz}, 1 \text{ H}), 7.44 (d, J = 8.0 \text{ Hz}, 1 \text{ H}), 7.19 (bm, 4 \text{ H}), 4.40 (d, J = 6.0 \text{ Hz}, 3 \text{ H}) 3.42 (s, 6 \text{ H}), 2.38 (m, 1 \text{ H}), 2.05 (m, 2 \text{ H}), 1.89 (m, 4 \text{ H}), 1.65 (m, 2 \text{ H}).$

20

Example 956

 $cis-4-\{[4-(Dimethylamino)quinazolin-2-yl]amino\}-N-[4-(trifluoromethoxy)benzyl]-cyclohexane \\ carboxamide$

25 Step A: Synthesis of

 ${\bf cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-N-[4-(trifluoromethoxy)benzyl]cyclohexanec} arboxamide.$

223

Using a similar procedure as described in step B of Example 951, the title compound was obtained.

ESI MS m/e 488 M + H⁺; ¹H NMR (400 MHz, CDCl₃) 8 7.84 (d, J = 8.4 Hz, 1 H), 7.58 (t, J = 8.0 Hz, 1 H), 7.43 (d, J = 8.0 Hz, 1 H), 7.37-7.31 (m, 3 H), 7.19-7.11 (m, 4 H), 4.44 (d, J = 6.0 Hz, 2 H), 5 4.48 (brs, 1 H), 3.42 (s, 6 H), 2.36 (m, 1 H), 2.05 (m, 2 H), 1.89 (m, 4 H), 1.64 (m, 2 H).

Example 957

cis-N-(4-Bromobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexane-

10 carboxamide

Step A: Synthesis of cis-N-(4-bromobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexanecarboxamide.

Using a similar procedure as described in step B of Example 951, the title compound was obtained.

ESI MS m/e $488 \text{ M} + \text{H}^+$; $^1\text{H} \text{ NMR} (400 \text{ MHz}, \text{CDCl}_3) \delta 7.87 (d, J = 8.4 \text{ Hz}, 1 \text{ H}), 7.75 (brs, 1 \text{ H}), 7.62 (t, J = 7.6 \text{ Hz}, 1 \text{ H}), 7.44 (brs, 1 \text{ H}), 7.42 (d, J = 8.0 \text{ Hz}, 2 \text{ H}), 7.38 (d, J = 8.4 \text{ Hz}, 1 \text{ H}), 7.24 (m, 1 \text{ H}), 7.17 (d, J = 8.0 \text{ Hz}, 2 \text{ H}), 4.40 (d, J = 6.0 \text{ Hz}, 3 \text{ H}), 3.47 (s, 6 \text{ H}), 2.38 (m, 1 \text{ H}), 2.10 (m, 2 \text{ H}), 1.87 (m, 4 \text{ H}), 1.61 (m, 2 \text{ H}).$

20

Example 958

 $cis-4-\{[4-(Dimethylamino)quinazolin-2-yl]amino\}-N-(4-methoxybenzyl)cyclohexanecarboxamide\\$

25

Step A: Synthesis of cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-M-(4-methoxybenzyl)-cyclohexanecarboxamide

Using a similar procedure as described in step B of Example 951, the title compound was obtained.

ESI MS m/e 434 M + H⁺; ¹H NMR (400 MHz, CDCl₃) 8 7.85 (d, J = 8.4 Hz, 1 H), 7.60 (t, J = 7.6 Hz, 1 H), 7.45 (d, J = 8.4 Hz, 1 H), 7.28 (d, J = 8.8 Hz, 2 H), 7.19 (t, J = 7.6 Hz, 1 H), 6.82 (d, J = 8.4 Hz, 2 H), 4.39 (d, J = 6.0 Hz, 2H), 3.45 (s, 6 H), 2.35 (m, 1 H), 2.05 (m, 2 H), 1.87 (m, 4 H), 1.62 (m, 2 H).

Example 959

10 cis-N-(2,4-Dimethoxyphenyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarbox amide

Step A: Synthesis of

cis-N-(2,4-dimethoxyphenyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarbox amide.

Using a similar procedure as described in step B of Example 951, the title compound was obtained.

ESI MS m/e 450 M + H⁺; ¹H NMR (400 MHz, CDCl₃) 8 8.16 (d, J = 8.8 Hz, 1 H), 7.83 (d, J = 8.0 Hz, 2 H), 7.55 (m, 1 H), 7.49 (m, 1 H), 7.13 (brs, 1 H), 6.45 (s, 1 H), 6.43 (m, 1 H), 4.27 (brs, 1 H), 20 3.89 (s, 3 H), 3.77 (s, 3 H), 3.39 (s, 6 H), 2.42 (m, 1 H), 2.04-1.96 (m, 6 H), 1.75 (m, 2 H).

Example 960

cis-N-(3,5-Dichlorophenyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxa mide

Step A: Synthesis of cis-IN-(3,5-dichlorophenyl)-4-{[4-(dimethylamino)quinazolin-2-yl]-amino}cyclohexanecarboxamide.

225

Using a similar procedure as described in step B of Example 951, the title compound was obtained.

ESI MS m/e 458 M + H⁺; ¹H NIMR (400 IMHz, CDCl₅) 8 7.86 (m, 3 H), 7.60 (t, J = 7.6 Hz, 1 H), 7.45 (d, J = 8.4 Hz, 1 H), 7.20 (t, J = 7.6 Hz, 1 H), 7.01 (s, 1 H), 4.44 (brs, 1 H), 3.45 (s, 6 H), 2.47 (m, 1 5 H), 2.18 (m, 2 H), 1.96 (m, 4 H), 1.66 (m, 2 H).

Example 961

 $cis-4-\{[4-(Dimethylamino)quinazolin-2-yl]amino\}-N-(3-iodophenyl)cyclohexanecarboxamide$

Step A: Synthesis of cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-iodophenyl)-cyclohexanecarboxamide.

Using a similar procedure as described in step B of Example 951, the title compound was obtained.

ESI MS m/e 516 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.15 (s, 1 H), 7.83 (d, J = 8.0 Hz, 1 H), 7.63 (d, J = 7.2 Hz, 1 H), 7.54 (t, J = 7.6 Hz, 1 H), 7.44 (d, J = 8.0 Hz, 1 H), 7.38 (d, J = 7.6 Hz, 1 H), 7.11 (t, J = 7.6 Hz, 1 H), 7.00 (t, J = 7.6 Hz, 1 H), 4.37 (brs, 1 H), 3.36 (s, 6 H), 2.42 (m, 1 H), 2.09-1.66 (m, 8 H).

20

10

Example 962

xamide.

 $cis-4-\{[4-(Dimethylamino)quinazolin-2-yl]amino\}-N-(2-fluoro-4-nitrophenyl)cyclohexane-carboxamide$

25 Step A: Synthesis of cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2-fluoro-4-nitrophenyl)cyclohexanecarbo

226

Using a similar procedure as described in step B of Example 951, the title compound was obtained.

ESI MS m/e 453 M + H⁺; ¹H NMR (400 MHz, CDCl₃) 8 9.08 (brs, 1 H), 7.96 (m. 1 H), 7.83 (d, J = 8.0 Hz, 1 H), 7.56 (t, J = 7.6 Hz, 1 H), 7.44 (d, J = 8.0 Hz, 1 H), 7.20 (m, 1 H), 7.14 (t, J = 7.6 Hz, 1 H), 4.38 (brs, 1 H), 3.40 (s, 6 H), 2.54 (m, 1 H), 2.17 (m, 2 H), 1.97 (m, 4 H), 1.74 (m, 2 H).

Example 963

cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}-N-(2-methoxydibenzo[b,d]furan-3-yl)cycloh 10 exanecarboxamide trifluoroacetate

Step A: Synthesis of cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2-methoxy-dibenzo[b,d]furan-3-yl)cyclohexanecarboxamide trifluoroacetate.

Using a similar procedure as described in step B of Example 951, the product was purified by prep HPLC to give the tile compound.

ESI MS m/e $510 \text{ M} + \text{H}^+$; $^1\text{H} \text{ NMR} (400 \text{ MHz}, \text{DMSO-d}_6) \delta 11.8 (brs, 1 H), 9.19 (s, 1 H), 8.38 (s, 1 H), 8.12 (d, J = 7.6 Hz, 1 H), 8.01 (d, J = 8.0 Hz, 1 H), 8.00 (brs, 1 H), 7.74 (s, 1 H), 7.72 (m, 1 H), 7.57 (d, J = 8.0 Hz, 1 H), 7.38 (t, J = 8.4 Hz, 2 H), 7.29 (m, 2 H), 4.17 (brs, 1 H), 3.92 (s, 3 H), 3.39 (s, 6 H), 2.73 (brs, 1 H), 1.88-1.64 (m, 8 H).$

20

Example 964

(cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl 3,5-dichlorobenzoate

25 Step A: Synthesis of cis-(4-hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester.

To a suspension of cis-4-(tert-butoxycarbonylamino)-cyclohexanecarboxylic acid (15.0 g, 61.7 mmol) in CH₂Cl₂ (140 mL) at -65 °C was added triethylamine (13 mL, 2.7 eq.) and a solution of ethyl chloroformate (6 mL) in CH₂Cl₂ (20 mL). The reaction was stirred for 60 min. at 0 °C, and

acidified (pH = ~ 3) with 1N-HCl. The mixture was extracted with CH₂Cl₂ (2 x 70 mL), and the combined organic layers were washed with sat. aqueous Na₂CO₃ (1 x 60 mL), water (2 x 80 mL), and brine (1 x 80 mL) and dried over MgSO₄, filtered, and concentrated to give cis-(4-hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester as a colorless oil. To a solution of the crude oil in THF (150 mL) at -65 °C were added NaBH₄ (2.7 g, 73 mmol) and MeOH (4.8 mL). The reaction was stirred for 30 min. at -40 °C, and stirred for an additional 3 hr at 0 °C. The reaction was acidified with 1N-HCl, removed a half volume of solvent, and extracted with EtOAc (3 x 100 mL). The combined organic layer was washed with water (3 x 80 mL) and brine (1 x 100 mL), dried with MgSO₄, filtered, and concentrated to give the product (11.5 g, 82 %) as a white solid.

10 ESI MS m/e 230 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 4.69 (brs, 1 H), 3.78 (brs, 1 H), 3.50 (d, J = 6.4 Hz, 2 H), 2.19 (brs, 1 H), 1.70-1.55 (m, 7 H), 1.44 (s, 9 H), 1.25 (m, 2 H).

Step B: Synthesis of cis-(4-amino-cyclohexyl)-methanol hydrochloride.

20 1.81-1.57 (m, 9 H).

To a solution of cis-(4-hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester (0.5g, 2.1 mmol) in EtOAc (15 mL) was added 4M-HCl (10 mL) at room temperature. The reaction was stirred for 1.5 h at room temperature and concentrated to give a crude compound, which was washed with CH₂Cl₂ (the product was not soluble in CH₂Cl₂) to remove organic impurities to give 0.25 g (89 %) of cis-(4-amino-cyclohexyl)-methanol hydrochloride as a white solid. ESI MS m/e 130 M + H⁺; ¹H NMR (400 MHz, CD₃OD) δ 3.51 (d, J = 7.2 Hz, 2 H), 3.31 (brs, 1 H),

Step C: Synthesis of cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-methanol

A vial contains 2-chloro-4-N,N-dimethylamino quinazoline (0.31 g, 1.5 mmol),

cis-(4-amino-cyclohexyl)-methanol hydrochloride (0.25 g, 1 eq.), DIEA (0.55 mL), and IPA (2 mL).

The vial was heated at 155 °C for 1 h using a Smith microwave synthesizer. The vial contents was diluted with DCM, washed with diluted HCl and water, and concentrated. The residue was purified on silica gel column using CH₂Cl₂ and MeOH (100:0 to 80:20) to give

cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-methanol (0.16 g, 28 %) as a pale yellow solid.

ESI MS m/ \approx 301 M +H⁺; ¹H NMR (400 MHz, CDCl₃) 8 8.69 (brs, 1 H), 7.86 (d, J = 3.3 Hz, 1 H), 7.59 (t, J = 8.4 Hz, 1 H), 7.51 (d, J = 8.4 Hz, 1 H), 7.21 (t, J = 8.0 Hz, 1 H), 4.26 (brs, 1 H), 3.57 (s, 5 2 H), 3.49 (s, 6 H), 1.92 (m, 3 H), 1.65 (m, 6 H).

Step D: Synthesis of (cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl 3.5-dichlorobenzoate

To a solution of cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-methanol (25 mg, 0.08 mmol) in DCM (3 mL) was added 3,5-dichlorobenzoyl chloride (17 mg, 0.08 mmol) and followed DIEA (3 drops). The reaction was stirred overnight at room temperature under an inert atmosphere. The reaction was diluted with DCM, washed with 1N-HCl and water, and concentrated. The product was purified by column chromatography (DCM/MeOH = 100:0 to 90:10) to give (cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)methyl 3,5-dichlorobenzoate (15 mg, 15 38 %).

ESI MS m/e $473 \text{ M} + \text{H}^+$; ${}^{1}\text{H} \text{ NMR} (400 \text{ MHz}, \text{CDCl}_3) \delta 7.88 (s, 2 \text{ H}), 7.80 (d, J = 8.4 \text{ Hz}, 1 \text{ H}), 7.51 (m, 2 \text{ H}), 7.46 (t, J = 8.0 \text{ Hz}, 1 \text{ H}), 7.06 (t, J = 7.6 \text{ Hz}, 1 \text{ H}), 4.27 (m, 1 \text{ H}), 4.22 (d, J = 7.2 \text{ Hz}, 2 \text{ H}), 3.32 (s, 6 \text{ H}), 1.92 (m, 3 \text{ H}), 1.72 (m, 4 \text{ H}), 1.54 (m, 2 \text{ H}).$

20

Example 965

(cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl 3-methoxybenzoate

Step A: Synthesis of (cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl 25 3-methoxybenzoate.

Using a similar procedure as described in step D of Example 964, the title compound was obtained.

ESI MS m/e $435 \text{ M} + \text{H}^+$; ¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, J = 8.4 Hz, 1 H), 7.64-7.53 (m, 4)

229

H), 7.30 (t, J = 7.6 Hz, 1 H), 7.11 (t, J = 7.6 Hz, 1 H), 7.06 (d, J = 8.4 Hz, 1 H), 4.26 (brs, 1 H), 4.25 (d, J = 6.8 Hz, 2 H), 3.84 (s, 3 H), 3.39 (s, 6 H), 1.97 (m, 3 H), 1.72 (m, 6 H).

5 Example 966

(cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl 3-bromobenzoate

Step A: Synthesis of (cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl 3-bromobenzoate.

Using a similar procedure as described in step D of Example 964, the title compound was obtained.

ESI MS m/e $483 \text{ M} + \text{H}^+$; $^1\text{H} \text{ NMR} (400 \text{ MHz}, \text{CDCl}_3) \delta 8.15 (s, 1 H), 7.96 (d, J = 7.2 Hz, 1 H), 7.80 (d, J = 8.0 Hz, 1 H), 7.65 (d, J = 7.6 Hz, 1 H), 7.50 (s, 2 H), 7.29 (t, J = 7.6 Hz, 1 H), 7.04 (m, 1 H), 4.27 (brs, 1 H), 4.23 (d, J = 6.8 Hz, 2 H), 3.31 (s, 6 H), 1.93 (m, 3 H), 1.72 (m, 4 H), 1.56 (m, 2 H).$

15

Example 967

(cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl 3,4-difluorobenzoate

20 Step A: Synthesis of (cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl 3,4-difluorobenzoate.

Using a similar procedure as described in step D of Example 964, the title compound was obtained.

ESI MS m/e 441 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.81 (m, 3 H), 7.48 (m, 2 H), 7.22 (m, 1 H), 7.04 (t, J = 7.6 Hz, 1 H), 4.27 (brs, 1 H), 4.21 (d, J = 7.2 Hz, 2 H), 3.31 (s, 6 H), 1.92 (m, 3 H), 1.72 (m, 4 H), 1.55 (m, 2 H).

230

Example 968

3,4-Dimethoxybenzyl cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexane-carboxylate

5 Step A: Synthesis of 3,4-dimethoxybenzyl

cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxylate.

3,4-dimethoxybenzyl alcohol (12 mg, 0.07 mmol) and followed DIEA (3 drops). After stirring overnight at room temperature, the reaction was quenched and purified using column chromatography (silica gel, DCM/MeOH = 100:0 to 90:10) to give 3,4-dimethoxybenzyl cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexanecarboxylate (12 mg, 36 %). ESI MS m/e 465 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, J = 8.0 Hz, 1 H), 7.49 (t, J = 7.6 Hz, 1 H), 7.44 (d, J = 7.6 Hz, 1 H), 7.04 (t, J = 7.2 Hz, 1 H), 6.91 (d, J = 8.0 Hz, 1 H), 6.86 (s, 1 H), 6.84 (t, J = 8.0 Hz, 1 H), 5.05 (s, 2 H), 4.11 (brs, 1 H), 3.88 (s, 3 H), 3.87 (s, 3 H), 3.30 (s, 6 H), 2.51

To a solution of the acid chloride (24 mg, 0.07mmol) in DCM (3 mL) was added

Example 969

15 (m, 1 H), 1.97 (m, 2 H), 1.78 (m, 6 H).

4-(Trifluoromethoxy)benzyl cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexane-

20 carboxylate

Step A: Synthesis of 4-(trifluoromethoxy)benzyl

cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxylate.

Using a similar procedure as described in step A of Example 968, the title compound was obtained.

ESI MS m/e $489 \text{ M} + \text{H}^+$; $^1\text{H} \text{ NMR} (400 \text{ MHz}, \text{CDCl}_3) & 7.84 (d, J = 8.0 \text{ Hz}, 1 \text{ H}), 7.57 (t, J = 7.6 \text{ Hz}, 1 \text{ H}), 7.49 (d, J = 8.0 \text{ Hz}, 1 \text{ H}), 7.39 (d, J = 8.4 \text{ Hz}, 2 \text{ H}), 7.20 (d, J = 8.4 \text{ Hz}, 2 \text{ H}), 7.16 (brs, 1 \text{ H}), 5.12 (s, 2 \text{ H}), 4.08 (brs, 1 \text{ H}), 3.42 (s, 6 \text{ H}), 2.52 (m, 1 \text{ H}), 2.05 (m, 2 \text{ H}), 1.79 (m, 6 \text{ H}).$

WO 2004/087680

231

PCT/JP2004/004554

Example 970

3,5-Dimethoxybenzyl cis-4-{{4-(dimethylamino)quinazolin-2-yl]amino}cyclohenane-

5 carboxylate

Step A: Synthesis of 3,5-dimethoxybenzyl cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexanecarboxylate.

Using a similar procedure as described in step A of Example 968, the title compound was 10 obtained.

ESI MS m/e 465 M + H⁺; 1 H NMR (400 MHz, CDCl₃) 8 7.81 (d, J = 8.4 Hz, 1 H), 7.51 (t, J = 7.6 Hz, 1 H), 7.43 (d, J = 8.0 Hz, 1 H), 7.08 (t, J = 7.6 Hz, 1 H), 6.47 (d, J = 2.4 Hz, 2 H), 6.38 (t, J = 2.4 Hz, 1 H), 5.05 (s, 2 H), 4.11 (brs, 1 H), 3.77 (s, 6 H), 3.36 (s, 6 H), 2.54 (m 1 H), 2.02 (m, 2 H), 1.79 (m, 6 H).

15

Example 971

3,4,5-Trimethoxybenzyl cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexane-carboxylate

20

Step A: Synthesis of 3,4,5-trimethoxybenzyl cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxylate.

Using a similar procedure as described in step A of Example 968, the title compound was obtained.

25 ESI MS m/e 495 M + H⁺; ¹H NMR (400 MHz, CDCl₃) 8 7.79 (d, J = 8.0 Hz, 1 H), 7.49 (t, J = 7.2 Hz, 1 H), 7.43 (d, J = 7.6 Hz, 1 H), 7.04 (t, J = 7.6 Hz, 1 H), 6.56 (s, 2 H), 5.05 (s, 2 H), 4.11 (brs, 1 H), 3.85 (s, 6 H), 3.83 (s, 3 H), 3.29 (s, 6 H), 2.53 (m 1 H), 2.00 (m, 2 H), 1.79 (m, 6 H).

232

Example 972

2,3,4-Trimethoxybenzyl cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexane-carboxylate

5

Step A: Synthesis of 2,3,4-trimethoxybenzyl

cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxylate.

Using a similar procedure as described in step A of Example 968, the title compound was obtained.

10 ESI MS m/e 495 M + H⁺; ¹H NMR (400 MHz, CDCl₃) 8 7.79 (d, J = 8.0 Hz, 1 H), 7.49 (t, J = 7.6 Hz, 1 H), 7.44 (d, J = 7.6 Hz, 1 H), 7.05 (m, 1 H), 7.02 (d, J = 8.4 Hz, 1 H), 6.45 (d, J = 8.4 Hz, 1 H), 5.09 (s, 2 H), 4.10 (brs, 1 H), 3.90 (s, 3 H), 3.86 (s, 3 H), 3.85 (s, 3 H), 3.30 (s, 6 H), 2.49 (m 1 H), 2.00 (m, 2 H), 1.77 (m, 6 H).

15

Example 973

1-(2-Naphthyl)ethyl cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxylate

Step A: Synthesis of 1-(2-naphthyl)ethyl cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-20 cyclohexanecarboxylate.

Using a similar procedure as described in step A of Example 968, the title compound was obtained.

ESI MS m/e $469 \text{ M} + \text{H}^{+}$; $^{1}\text{H} \text{ NMR} (400 \text{ MHz}, \text{CDCl}_{3}) & 7.85 (m, 5 \text{ H}), 7.45 (m, 5 \text{ H}), 7.04 (d, J = 7.6 \text{ Hz}, 1 \text{ H}), 6.05 (q, J = 6.4 \text{ Hz}, 1 \text{ H}), 4.11 (brs, 1 \text{ H}), 3.28 (s, 6 \text{ H}), 2.52 (m 1 \text{ H}), 2.01 (m, 2 \text{ H}), 1.78$ 25 (m, 6 H), 1.62 (d, J = 6.4 Hz, 3 H).

PCT/JP2004/004554

3-[(Cyclopropylcarbonyl)amino]-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)b enzamide

Step A: Synthesis of cis-I I-(4-amino-cyclohexyl)-3-nitrobenzamide trifluoroacetate.

- To a suspension of cis-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester (1.1 g, 5.2 mmol) in DCM (20 mL) was added 3-nitrobenzoyl chloride (0.96 g, 5.2 mmol) and followed catalytic amount of DIEA (0.1 mL). The reaction was stirred overnight at room temperature, diluted with DCM, washed with 1N-HCl and water, and concentrated. The crude product was preliminary purified by a short pad of silica gel with DCM/MeOH (100:0 to 90:10). The product was contaminated with
- impurity having a very close rf value with the product. A solution of this crude compound (1.2 g, 3.2 mmol) in DCM/TFA (16 mL = 10/6) was stirred for 2 hr at room temperature. After removal of the volatile solvent, the solid residue was suspended in hexane, filtered, and dried to give 1.0 g (83 %) of cis-N-(4-amino-cyclohexyl)-3-nitrobenzamide trifluoroacetate.

ESI MS m/e 264 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) 8 8.64 (t, J = 2.0 Hz, 1 H), 8.49 (d, J = 4.8 Hz, 1 H), 8.37 (ddd, J = 8.0, 2.0, 0.8 Hz, 1 H), 8.27 (d, J = 8.0 Hz, 1 H), 7.81 (brs, 2 H), 7.75 (t, J = 8.0 Hz, 1 H), 3.90 (m, 1 H), 3.15 (brs, 1 H), 2.51 (m, 1 H), 1.91 (m, 2 H), 1.76-1.64 (m, 6 H).

Step B: Synthesis of

cis-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3-nitrobenzamide.

- A suspension of 2-chloro-4-N,N-dimethylamino quinazoline (0.3 g, 1.4 mmol) and cis-N-(4-amino-cyclohexyl)-3-nitrobenzamide trifluoroacetate (0.5 g, 1.35 mmol) in IPA (2.5 mL) and DIEA (0.7 mL) was reacted for 2 hr at 160 °C in a Smith synthesizer. Over 90 % conversion was observed by LC-MS. The reaction was quenched and purified by column chromatography (silica gel, DCM/MeOH = 100:0 to 85:15) to give 0.45 g (80 %) of
- 25 cis-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3-nitrobenzamide.
 ESI MS m/e 435 M + H⁺; ¹H NMR (400 MHz, CDCl₃) 8 9.04 (d, J = 7.6 Hz, 1 H), 8.73 (t, J = 2 Hz, 1 H), 8.28 (d, J = 8.4 Hz, 1 H), 8.18 (d, J = 8.0 Hz, 1 H), 7.88 (d, J = 7.2 Hz, 1 H), 7.62 (m, 2 H), 7.49 (d, J = 7.6 Hz, 1 H), 7.25 (m, 1 H), 7.16 (d, J = 8.4 Hz, 1 H), 4.38 (m, 1 H), 4.18 (m, 1 H), 3.51 (s, 6

234

H), 1.99-1.93 (m, 6 H), 1.78 (m, 2 H).

Step C: Synthesis of 3-amino-cic-H-[4-(4-dimethylamino-quinacolin-2-ylamino)-cyclohexyl]-benzamide.

- A heterogenous solution of cis-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3-nitrobenzamide (0.85 g, 1.9 mmol) and 10 % Pd/C (100 mg) in EtOH (20 mL) was stirred overnight under H₂ at room temperature. LC-MS confirmed 100 % conversion of the stating material. The reaction was filtered through a pad of celite. After removal of the volatile solvent, the residue was purified from a short pad of silica gel (DCM/MeOH = 100:0 to 80:20) to give 0.48 g
- 10 (62 %) of 3-amino-cis-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-benzamide as the desired product.

ESI MS m/e $405 \text{ M} + \text{H}^+$; $^1\text{H} \text{ NMR} (400 \text{ MHz}, \text{CDCl}_3) & 9.42 (brs, 1 H), 7.89 (d, J = 8.0 Hz, 1 H), 7.62 (m, 2 H), 7.26-7.17 (m, 4 H), 6.79 (m, 1 H), 6.72 (d, J = 8.4 Hz, 1 H), 4.36 (brs, 1 H), 4.18 (m, 1 H), 3.51 (s, 6 H), 1.94-1.78 (m, 8 H).$

15

Step D: Synthesis of 3-[(cyclopropylcarbonyl)amino]-N-(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}cyclohexyl)benzamide.

To a solution of

3-amino-cis-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-benzamide (25 mg,

- 20 0.06mmol) in DCM (3 mL) was added cyclopropanecarbonyl chloride (6 mg, 0.06 mmol) and followed DIEA (catalytic, 3 drops). After stirring overnight at room temperature, the reaction was quenched and purified from prep-HPLC [15 to 95% of CH₃CN (5%TFA)/H₂O (5% TFA)] to give 12 mg (33 %) of
- 3-[(cyclopropylcarbonyl)amino]-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)be 25 nzamide.

ESI MS m/e $473 \text{ M} + \text{H}^+$; $^1\text{H} \text{ NMR} (400 \text{ MHz}, \text{DMSD-d}_6) & 12.1 (brs, 1 H), 10.2 (s, 1 H), 8.12 (d, J = 8.0 Hz, 2 H), 7.94 (brs, 1 H), 7.93 (s, 1 H), 7.74-7.67 (m, 2 H), 7.42 (d, J = 7.8 Hz, 2 H), 7.31 (m, 2 H), 4.01 (brs, 1 H), 3.83 (brs, 1 H), 3.42 (s, 6 H), 1.83-1.68 (m, 8 H), 1.00 (m, 2 H), 0.93 (m, 2 H).$

Example 975

II-[(cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-3-[(2,2-dimethylprop anoyl)amino]benzamide

Step A: Synthesis of {cis-4-{(3-nitro-benzoylamino)-methyl}-cyclohexyl}-carbamic acid tert-butyl ester.

cis-(4-Aminomethyl-cyclohexyl)-carbamic acid tert-butyl ester (1.55 g, 6.8 mmol) and

3-nitrobenzoyl chloride (1.25 g, 6.8 mmol, 1 eq.) was reacted using the procedure of step A of

Example 974 to give 1.5 g (75 %) of {cis-4-[(3-nitro-benzoylamino)-methyl]-cyclohexyl}-carbamic acid tert-butyl ester.

ESI MS m/e 378 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.54 (t, J = 2.0 Hz, 1 H), 8.33 (d, J = 8.0 Hz, 1 H), 8.14 (d, J = 8.0 Hz, 1 H), 7.63 (t, J = 7.6 Hz, 1 H), 6.31 (brs, 1 H), 4.62 (brs, 1 H), 3.73 (brs, 1 H), 3.41 (t, J = 6.4 Hz, 2 H), 1.72-1.57 (m, 7 H), 1.44 (s, 9 H), 1.32 (m, 2 H).

Step B: Synthesis of cis-N-(4-amino-cyclohexylmethyl)-3-nitro-benzamide hydrochloride.

{cis-4-[(3-Nitro-benzoylamino)-methyl]-cyclohexyl}-carbamic acid tert-butyl ester (1.4 g, 3.7 mmol) in DCM/TFA (1:1 = 13 mL) was stirred for 2 hr at room temperature. After removal of the volatile solvent, the residue was dissolved in DCM (10 mL), and 2M-HCl in ether (~4 mL, 2 eq.) was added. After stirring for 20 min at room temperature, removal of the volatile solvent gave 1.2 g (82 %) of cis-N-(4-amino-cyclohexylmethyl)-3-nitro-benzamide hydrochloride as the desired product. ESI MS m/e 278 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) 8 8.91 (t, J = 5.6 Hz, 1 H), 8.65 (m, 1 H), 25 8.36 (d, J = 2.0 Hz, 1 H), 8.29 (d, J = 3.0 Hz, 1 H), 7.97 (brs, 2 H), 7.74 (t, J = 8.0 Hz, 1 H), 3.25 (t, J = 6.8 Hz, 2 H), 3.13 (brs, 1 H), 1.77 (m, 1 H), 1.65-1.61 (m, 4 H), 1.51 (m, 4 H).

Step C: Synthesis of cis-N-{4-(4-dimethylamino-quinazolin-2-ylamino)-

cyclohexylmethyl]-3-nitro-benzamide.

A heterogeneous solution of 2-chloro-4-N,N-dimethylamino quinazoline (0.3 g, 1.45 mmol) and cis-N-(4-amino-cyclohexylmethyl)-3-nitro-benzamide hydrochloride (0.45 g, 1 eq.) in IPA (2 mL) and DIEA (0.46 mL, 2 eq.) was irradiated for 1h 10 min, at 155 °C with a Smith microwave reactor. The reaction was quenched and purified by column chromatography (silica gel, DCM/MeOH = 100:0 to 85:15). 0.57 g (87 %) of the product was obtained.

ESI MS m/e 449 M + H⁺; ¹H NMR (400 MHz, CDCl₃) 8 8.91 (brs, 1 H), 8.76 (s, 1 H), 8.45 (d, J = 7.6 Hz, 1 H), 8.25 (d, J = 8.4 Hz, 1 H), 7.86 (d, J = 8.4 Hz, 1 H), 7.60 (m, 2 H), 7.51 (brs, 1 H), 7.42 (d, J = 8.4 Hz, 1 H), 7.21 (t, J = 8.0 Hz, 1 H), 4.35 (brs, 1 H), 3.51 (brs, 2 H), 3.49 (s, 6 H), 1.94-1.80 (m, 5 H), 1.67-1.62 (m, 4 H).

Step D: Synthesis of

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-3-[(2,2-dimethylpropanoyl)amino]benzamide

- A heterogenous solution of cis-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-3-nitro-benzamide (0.57 g, 1.27 mmol) and 10 %-Pd/C (100 mg) in EtOH (25 mL) was stirred overnight under H₂. The reaction was filtered through a pad of celite. After removal of the volatile solvent, the residue was purified from a short pad of silica gel (DCM/MeOH = 100:0 to 80:20) to give
- 20 3-amino-cis-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-benzamide (0.45 g, 83 %, ESI MS m/e 419 M + H⁺).
 - 3-Amino-cis-N-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-benzamide(30 mg, 0.07 mmol) and 2,2-dimethylpropionyl chloride (9 mmol, 0.07 mmol) was reacted in the presence of catalytic DIEA (4 drops). The product was purified from column chromatography (silica gel,
- 25 DCM/MeOH = 100:0 to 90:10) to give

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)
methyl]-3-[(2,2-dimethylpropanoyl)amino]benzamide (12 mg, 33 %).
ESI MS m/e 503 M + H⁺; ¹H NMR (400 MHz, CDCl₃) & 8.92 (brs, 1 H), 8.86 (s, 1 H), 8.35 (s, 1 H),

237

8.33 (brs, 1 H), 7.87 (d, J = 8.4 Hz, 1 H), 7.61 (m, 2 H), 7.32 (t, J = 8.0 Hz, 2 H), 7.22 (t, J = 7.2 Hz, 1 H), 6.74 (t, J = 4.8 Hz, 1 H), 4.34 (m, 1 H), 3.51 (m, 2 H), 3.48 (s, 6 H), 1.97 (m, 2 H), 1.86-1.78 (m, 3 H), 1.69-1.59 (m, 4 H), 1.44 (s, 9 H).

5

Example 976

II-[(cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-3-(propionylamino)benzamide

10 Step A: Synthesis of

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl) methyl]-3-(propionylamino) be enzamide.$

Using a similar procedure as described in step D of Example 975, the title compound was obtained.

15 ESI MS m/e 475 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 9.59 (brs, 1 H), 8.53 (brs, 1 H), 8.39 (brs, 1 H), 8.05 (s, 1 H), 7.87 (d, J = 8.4 Hz, 1 H), 7.63 (t, J = 7.6 Hz, 1 H), 7.58 (d, J = 7.6 Hz, 1 H), 7.37 (m, 2 H), 7.23 (m, 1 H), 6.44 (brs, 1 H), 4.33 (bm, 1 H), 3.54 (d, J = 5.2 Hz, 2 H), 3.48 (s, 6 H), 2.59 (q, J = 7.6 Hz, 2 H), 2.05 (m, 2 H), 1.76-1.61 (m, 7 H), 1.31 (t, J = 7.6 Hz, 3 H).

20

Example 977

 $N-\{(cis-4-\{[4-(Dimethylamino)quinazolin-2-yl\}amino\}cyclohexyl)methyl]-3-(isobutyrylamino)benzamide$

25 Step A: Synthesis of

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-3-(isobutyrylamino)b enzamide.

Using a similar procedure as described in step D of Example 975, the title compound was obtained.

ESI MS m/e 489 M + H⁺; ¹H NMR (400 MHz, CDCl₃) 8 9.59 (brs, 1 H), 8.50 (brs, 1 H), 8.40 (brs, 1 H), 8.17 (s, 1 H), 7.87 (d, J = 8.4 Hz, 1 H), 7.62 (t, J = 7.6 Hz, 1 H), 7.56 (d, J = 7.6 Hz, 1 H), 7.35 (m, 2 H), 7.23 (m, 1 H), 6.54 (brs, 1 H), 4.32 (m, 1 H), 3.51 (d, J = 5.6 Hz, 2 H), 3.48 (s, 6 H), 2.88 (m, 1 H), 2.03 (m, 2 H), 1.76-1.62 (m, 7 H), 1.32 (d, J = 7.6 Hz, 6 H).

Example 978

10 N-[(cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-3-[(3-methylbutanoyl)amino]benzamide

Step A: Synthesis of

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-3-[(3-methylbutanoyl)amino]benzamide.

Using a similar procedure as described in step D of Example 975, the title compound was obtained.

ESI MS m/e 503 M + H⁺; ¹H NMR (400 MHz, CDCl₃) 8 9.71 (brs, 1 H), 8.60 (d, J = 7.2 Hz, 1 H), 8.43 (d, J = 8.4 Hz, 1 H), 8.15 (s, 1 H), 7.88 (d, J = 8.4 Hz, 1 H), 7.62 (t, J = 7.6 Hz, 1 H), 7.56 (d, J = 7.6 Hz, 1 H), 7.35 (m, 2 H), 7.23 (m, 1 H), 6.57 (brs, 1 H), 4.32 (m, 1 H), 3.49 (s, 8 H), 2.44 (d, J = 7.2 Hz, 2 H), 2.33 (m, 1 H), 2.02 (m, 2 H), 1.77-1.62 (m, 7 H), 1.07 (d, J = 7.6 Hz, 6 H).

Example 979

25 3-[(Cyclopropylcarbonyl)amino]-I I-[(cis-4-{[::-(dimethylamino)quinazolin-2-yl]amino)cyclohe xyl)methyl]benzamide

Step A: Synthesis of 3-[(cyclopropylcarbonyl)amino]-N-[(cis-4-{[4-(dimethylamino)-

239

quinazolin-2-yl]amino}cyclohexyl)methyl]benzamide.

Using a similar procedure as described in step D of Example 975, the title compound was obtained.

ESI MS m/e 487 M + H⁺; ¹H NMR (400 MHz, CDCl₃) 8 10.1 (brs, 1 H), 8.60 (brs, 1 H), 8.34 (d, J = 8.4 Hz, 1 H), 8.09 (s, 1 H), 7.86 (d, J = 8.4 Hz, 1 H), 7.60 (t, J = 7.6 Hz, 1 H), 7.54 (d, J = 8.0 Hz, 1 H), 7.41 (d, J = 8.4 Hz, 1 H), 7.29 (t, J = 8.0 Hz, 1 H), 7.23 (m, 1 H), 6.61 (brs, 1 H), 4.28 (m, 1 H), 3.51 (d, J = 6.0 Hz, 2 H), 3.48 (s, 6 H), 2.08 (m, 3 H), 1.78-1.61 (m, 7 H), 1.09 (m, 2 H), 0.87 (m, 2 H).

10

Example 980

 $3-[(Cyclobutylcarbonyl)amino]-N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexvl) methyl] benzamide$

15 Step A: Synthesis of

3-[(cyclobutylcarbonyl)amino]-N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexy l)methyl]benzamide.

Using a similar procedure as described in step D of Example 975, the title compound was obtained.

20 ESI MS m/e 501 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 9.45 (brs, 1 H), 8.68 (brs, 1 H), 8.41 (d, J = 7.2 Hz, 1 H), 8.13 (s, 1 H), 7.87 (d, J = 8.4 Hz, 1 H), 7.63 (t, J = 7.6 Hz, 1 H), 7.56 (d, J = 7.6 Hz, 1 H), 7.40 (d, J = 7.6 Hz, 1 H), 7.32 (t, J = 7.6 Hz, 1 H), 7.23 (m, 1 H), 6.50 (brs, 1 H), 4.32 (m, 1 H), 3.51 (d, J = 5.6 Hz, 2 H), 3.49 (s, 6 H), 2.48 (m, 2 H), 2.31 (m, 2 H), 2.06-1.59 (m, 12 H).

25

Example 981

3-[(Cyclopentylcarbonyl)amino]-N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohe xyl)methyl]benzamide

240

Step A: Synthesis of 3-[(cyclopentylcarbonyl)amino]-N-[(cis-4-{[4-(dimethylamino)-quinazolin-2-yl]amino}eyclohezyl)methyl]benzamide.

Using a similar procedure as described in step D of Example 975, the title compound was obtained.

ESI MS m/ ϵ 515 M + H⁺; ¹H NMR (400 MHz, CDCl₃) 8 9.60 (brs, 1 H), 8.56 (brs, 1 H), 8.40 (d, J = 5.6 Hz, 1 H), 8.17 (s, 1 H), 7.87 (d, J = 8.4 Hz, 1 H), 7.61 (t, J = 7.6 Hz, 1 H), 7.56 (d, J = 7.6 Hz, 1 H), 7.37 (d, J = 7.6 Hz, 1 H), 7.33 (t, J = 7.6 Hz, 1 H), 7.23 (m, 1 H), 6.50 (brs, 1 H), 4.32 (m, 1 H), 3.52 (d, J = 5.2 Hz, 2 H), 3.48 (s, 6 H), 3.05 (m, 1 H), 2.06-1.60 (m, 17 H).

10

Example 982

 $3-[(Cyclohexylcarbonyl)amino]-N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl] benzamide$

15

Step A: Synthesis of

3-[(cyclohexylcarbonyl)amino]-N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]benzamide.

Using a similar procedure as described in step D of Example 975, the title compound was 20 obtained.

ESI MS m/e 529 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 9.53 (brs, 1 H), 8.61 (brs, 1 H), 8.40 (d, J = 6.8 Hz, 1 H), 8.20 (s, 1 H), 7.87 (d, J = 7.6 Hz, 1 H), 7.60 (t, J = 7.6 Hz, 1 H), 7.56 (d, J = 7.6 Hz, 1 H), 7.34 (m, 2 H), 7.23 (m, 1 H), 6.49 (brs, 1 H), 4.33 (m, 1 H), 3.53 (d, J = 4.0 Hz, 2 H), 3.49 (s, 6 H), 2.59 (m, 1 H), 2.06-1.60 (m, 19 H).

25

Example 983

cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}-N-{3-[(2,2-dimethylpropanoyl)amino]-

241

benzyl}cyclohexanecarboxamide

Step A: Synthesis of cis-[-4-(3-nitrobencylearbamoyl)-cyclohenyl]-carbamic acid text-butyl ester.

- 5 cis-4-(tert-Butoxycarbonylamino)-cyclohexanecarboxylic acid (2.0 g, 8.2 mmol) and 3-nitrobenzyl amine hydrochloride (1.54 g, 8.2 mmol, 1eq) in DCM (30 mL) was reacted in the presence of HATU (3.5 g, 9.02 mmol, 1.1 eq.) and Et₃N (~4 mL). The reaction was diluted with DCM, washed with 1N-HCl and water, dried over MgSO₄, and concentrated. From column chromatography (silica gel, DCM/MeOH = 100:0 to 95 to 5), 2.7 g (90 %) of
- 10 cis-[-4-(3-nitrobenzylcarbamoyl)-cyclohexyl]-carbamic acid tert-butyl ester was isolated.

 ESI MS m/e 378 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.11 (brs, 1 H), 8.09 (s, 1 H), 7.60 (d, J = 8.0 Hz, 1 H), 7.48 (t, J = 7.6 Hz, 1 H), 6.17 (brs, 1 H), 4.72 (brs, 1 H), 4.53 (d, J = 6.0 Hz, 2 H), 3.74 (brs, 1 H), 2.27 (m, 1 H), 1.80-1.71 (m, 6 H), 1.65-1.59 (m, 2 H), 1.45 (s, 9 H).

15 Step B: Synthesis of cis-4-amino-cyclohexanecarboxylic acid 3-nitro-benzamide hydrochloride.

cis-[4-(3-Nitrobenzylcarbamoyl)-cyclohexyl]-carbamic acid tert-butyl ester (2.5 g, 6.6 mmol) was reacted in TFA/DCM (1:2 = 23 mL) for 2 hr at room temperature. After removal of the solvents, the residue was dissolved in DCM (15 mL), and added 2M-HCl in ethyl ether (2 eq.). After stirring

20 for 20 min at room temperature, the volatile solvent was removed to give cis-4-amino-cyclohexanecarboxylic acid 3-nitro-benzamide hydrochloride (2.0 g, 95 %) as a yellowish white solid.

ESI MS m/e 278 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) 8 8.53 (t, J = 6.0 Hz, 1 H), 8.07 (d, J = 7.6 Hz, 1 H), 8.06 (s, 1 H), 7.84 (brs, 2 H), 7.68 (d, J = 7.6 Hz, 1 H), 7.59 (t, J = 7.6 Hz, 1 H), 4.37 (d, J = 6.4 Hz, 2 H), 3.13 (m, 1 H), 2.40 (m, 1 H), 1.89 (m, 2 H), 1.68 (m, 4 H), 1.57 (m, 2 H).

Step C: Synthesis of cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexanecarboxylic acid 3-nitro-benzamide.

A solution of 2-chloro-4-N,N-dimethylamino quinazoline (0.35 g, 1.7 mmol) and cis-4-amino-cyclohexanecarboxylic acid 3-nitro-benzamide hydrochloride (0.5 g, 1 eq.) in IPA (2.5 mL) and DIEA (0.7 mL) was reacted for 1 h 10 min at 155 °C in a Smith synthesizer. The reaction was quenched and purified by column chromatography (silica gel, DCM/MeOH = 100:0 to 35:15).

5 0.56 g (75 %) of cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexanecarboxylic acid 3-nitro-benzamide was isolated.

ESI MS m/e 449 M + H⁺; ¹H NMR (400 MHz, CDCl₃) 8 9.12 (brs, 1 H), 8.24 (brs, 1 H), 8.15 (s, 1 H), 8.03 (d, J = 8.0 Hz, 1 H), 7.88 (d, J = 8.0 Hz, 1 H), 7.69 (d, J = 8.0 Hz, 1 H), 7.62 (t, J = 8.0 Hz, 1 H), 7.44 (m, 2 H), 7.24 (t, J = 7.6 Hz, 1 H), 4.54 (d, J = 6.4 Hz, 2 H), 4.48 (m, 1 H), 3.50 (s, 6 H), 10 2.43 (tt, J = 12.4, 4.0 Hz, 1 H), 2.16 (m, 2 H), 1.90 (m, 4 H), 1.63 (m, 2 H).

Step D: Synthesis of cis-4(4-dimethylamino-quinazolin-2-ylamino)-cyclohexanecarboxylic acid 3-aminobenzyl amide.

A heterogenous solution of

- cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexanecarboxylic acid 3-nitro-benzamide (0.55 g, 1.22 mmol) and 10 % Pd/C (100 mg) in EtOH (15 mL) was stirred overnight under H₂ atmosphere at room temperature. The reaction was filtered through a pad of celite. After removal of the volatile solvent, the residue was purified from a short pad of silica gel (DCM/MeOH = 100:0 to 80:20) to give 0.46 g (91 %) of cis-4(4-dimethylamino-quinazolin-2-ylamino)-cyclohexane carboxylic acid
- 20 3-aminobenzyl amide.

ESI MS m/e 419 M + H⁺; ¹H NMR (400 MHz, CDCl₃) 8 9.00 (brs, 1 H), 7.86 (d, J = 8.4 Hz, 1 H), 7.59 (t, J = 8.0 Hz, 1 H), 7.45 (d, J = 8.4 Hz, 1 H), 7.37 (brs, 1 H), 7.22 (t, J = 7.6 Hz, 1 H), 7.01 (t, J = 7.6 Hz, 1 H), 6.73 (s, 1 H), 6.66 (d, J = 7.6 Hz, 1 H), 6.49 (d, J = 7.6 Hz, 1 H), 4.39 (m, 1 H), 4.35 (d, J = 6.0 Hz, 2 H), 3.80 (brs, 2 H), 3.47 (s, 6 H), 2.36 (m, 1 H), 2.05 (m, 2 H), 1.88 (m, 4 H), 1.63 (m, 2 H).

Step E: Synthesis of cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-{3-[(2,2-dimethyl-propanoyl)amino]benzyl}cyclohexanecarboxamide.

Using a similar procedure as described in step D of Example 975, the title compound was obtained.

ESI MS m/e 503 M + H⁺; ¹H NMR (400 MHz, CDCl₃) 8 9.05 (brs, 1 H), 2.13 (brs, 1 H), 7.89 (brs, 1 H), 7.87 (d, J = 8.0 Hz, 1 H), 7.62 (t, J = 7.6 Hz, 1 H), 7.49 (s, 1 H), 7.38 (d, J = 8.4 Hz, 1 H), 7.22 (t, J = 8.0 Hz, 2 H), 7.01 (brs, 1 H), 7.00 (d, J = 7.2 Hz, 1 H), 4.43 (d, J = 5.6 Hz, 2 H), 4.39 (m, 1 H), 3.48 (s, 6 H), 2.37 (tt, J = 12.0, 3.6 Hz, 1 H), 2.07 (m, 2 H), 1.97 (m, 4 H), 1.63 (m, 2 H), 1.36 (s, 9 H).

10 Example 984

cis-4-{[4-(Dimethylamino)quinazolin-2-yl]amino}-N-[3-(propionylamino)benzyl]cyclohexane-carboxamide

Step A: Synthesis of cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[3-

15 (propionylamino) benzyl]cyclohexanecarboxamide.

Using a similar procedure as described in step D of Example 975, the title compound was obtained.

ESI MS m/e 475 M +H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.96 (m, 2 H), 8.04 (d, J = 8.4 Hz, 1 H), 7.88 (d, J = 8.0 Hz, 1 H), 7.64 (t, J = 7.6 Hz, 1 H), 7.41 (d, J = 8.4 Hz, 1 H), 7.37 (s, 1 H), 7.27-7.18 (m, 2 H), 6.91 (d, J = 7.6 Hz, 1 H), 6.70 (brs, 1 H), 4.45 (d, J = 5.6 Hz, 2 H), 4.39 (m, 1 H), 3.50 (s, 6 H), 2.53 (q, J = 7.6 Hz, 2 H), 2.37 (m, 1 H), 2.04~1.94 (m, 6 H), 1.66 (m, 2 H), 1.25 (t, J = 7.6 Hz, 3 H).

Example 985

25 cis-4-{[4-(Pimethylamino)quinazolin-2-yl]amino}-H-[3-(isobutyrylamino)benzyl]cyclohexane-carboxamide

Step A: Synthesis of cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[3-

244

(isobutyrylamino) benzyl]cyclohexanecarboxamide.

Using a similar procedure as described in step D of Example 975, the title compound was obtained.

ESI MS m/e $489 \text{ M} + \text{H}^{+}$; ¹H NMR $(400 \text{ MHz}, \text{CDCl}_2) \delta 8.91 \text{ (brs, 2 H)}, 8.04 \text{ (d, J} = 7.2 \text{ Hz, 1 H)}.$ 5 7.88 (d, J = 7.6 Hz, 1 H), 7.64 (t, J = 7.6 Hz, 1 H), 7.42 (s, 1 H), 7.40 (d, J = 8.0 Hz, 1 H), 7.27-7.18 (m, 2 H), 6.92 (d. J = 8.0 Hz, 1 H), 6.70 (brs, 1 H), 4.44 (d. J = 5.6 Hz, 2 H), 4.39 (m. 1 H), 3.49 (s.6 H), 2.80 (m, 1 H), 2.37 (m, 1 H), 2.05-1.94 (m, 6 H), 1.66 (m, 2 H), 1.26 (d, J = 6.4 Hz, 6 H).

10 Example 986

cis-N-{3-[(Cyclopropylcarbonyl)amino]benzyl}-4-{[4-(dimethylamino)quinazolin-2yl]amino} cyclohexanecarboxamide

Step A: Synthesis of cis-N-{3-[(cyclopropylcarbonyl)amino]benzyl}-4-{[4-(dimethylamino)-15 quinazolin-2-yllamino}cyclohexanecarboxamide.

Using a similar procedure as described in step D of Example 975, the title compound was obtained.

ESI MS m/e $487 \text{ M} + \text{H}^{+}$; ¹H NMR (400 MHz, CDCh) δ 9.24 (brs. 1 H), 9.00 (brs. 1 H), 7.99 (d. J = 8.0 Hz, 1 H), 7.88 (d, J = 8.0 Hz, 1 H), 7.62 (t, J = 7.6 Hz, 1 H), 7.40 (d, J = 8.0 Hz, 1 H), 7.36 (s, J = 8.0 Hz, 1 H), 7.86 (s, J = 8.0 Hz, 1 H), $7.86 \text{ ($ 20 1 H), 7.27-7.15 (m, 2 H), 6.90 (d, J = 6.8 Hz, 1 H), 6.81 (brs, 1 H), 4.45 (d, J = 5.6 Hz, 2 H), 4.40 (m, 1 H), 3.49 (s, 6 H), 2.37 (m, 1 H), 2.08-1.94 (m, 7 H), 1.66 (m, 2 H), 1.03 (m, 2 H), 0.80 (m, 2 H).

Example 987

25 cis-FI-{3-[(Cyclopentylearbonyl)amino]bencyl}-4-{[4-(dimethylamino)quinazolin-2-yl]amino}c yclohexanecarboxamide

Step A: Synthesis of cis-N-{3-[(cyclopentylcarbonyl)amino]benzyl}-4-{[4-(dimethylamino)-

quinazolin-2-yllamino}cyclohexanecarboxamide.

Using a similar procedure as described in step D of Example 975, the title compound was obtained.

ESI MS m/e 515 M + H⁴; ¹H NMR (400 MHz, CDCl₃) 8 8.88 (brs, 1 H), 8.87 (brs, 1 H), 8.02 (d, J = 7.2 Hz, 1 H), 7.88 (d, J = 8.4 Hz, 1 H), 7.63 (t, J = 7.6 Hz, 1 H), 7.40 (s, 1 H), 7.39 (d, J = 8.0 Hz, 1 H), 7.27-7.17 (m, 2 H), 6.92 (d, J = 7.6 Hz, 1 H), 6.74 (brs, 1 H), 4.44 (d, J = 6.0 Hz, 2 H), 4.40 (m, 1 H), 3.49 (s, 6 H), 2.95 (m, 1 H), 2.37 (m, 1 H), 2.04~1.65 (m, 16 H).

10 Example 988

cis-N-{3-[(Cyclohexylcarbonyl)amino]benzyl}-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cy clohexanecarboxamide

Step A: Synthesis of cis-N-{3-[(cyclohexylcarbonyl)amino]benzyl}-4-{[4-(dimethylamino)-

15 quinazolin-2-yl]amino}cyclohexanecarboxamide.

Using a similar procedure as described in step D of Example 975, the title compound was obtained.

ESI MS m/e 515 M + H⁺; ¹H NMR (400 MHz, CDCl₃) δ 9.06 (brs, 1 H), 8.66 (brs, 1 H), 8.02 (d, J = 6.8 Hz, 1 H), 7.88 (d, J = 8.0 Hz, 1 H), 7.62 (t, J = 7.6 Hz, 1 H), 7.41 (d, J = 8.4 Hz, 1 H), 7.40 (s, 1 H), 7.26-7.18 (m, 2 H), 6.93 (d, J = 8.0 Hz, 1 H), 6.81 (brs, 1 H), 4.45 (d, J = 5.6 Hz, 2 H), 4.41 (brs, 1 H), 3.49 (s, 6 H), 2.48 (m, 1 H), 2.37 (m, 1 H), 2.09-1.25 (m, 18 H).

Example 989

25 3-Chloro-II-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino)cyclohexyl)-benzamide

Step A: Synthesis of [cis-4-(4-dimethylamino-6,7-difluoro-quinazolin-2-yamino)-

246

cyclohexyl] carbamic acid tert-butyl ester.

A suspended solution of 2-chloro-6,7-difluoro-4-dimethylamino quinazoline (0.52 g, 2.1 mmol) and cis-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester (0.45 g, 1eq.) in IPA (2.5 mL) and DIEA (1 mL, ~2eq.) was reacted for 2 hr 30 min at 155 °C in a Smith microwave synthesizer. The reaction was quenched and purified by column chromatography (DCM:MeOH = 100:0 to 90:10) to give 0.28 g (33 %) of [cis-4-(4-dimethylamino-6,7-difluoro-quinazolin-2-yamino)-cyclohexyl] carbamic acid tert-butyl ester.

ESIMS m/e 422 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 8.10 (brs, 1 H), 7.40 (brs, 1 H), 6.80 (brs, 1 H), 4.02 (q, J = 7.0 Hz, 1 H), 3.82 (brs, 1 H), 3.30 (s, 6 H), 1.65-1.50 (m, 8 H), 1.30 (s, 9 H).

Step B: Synthesis of cis-4-(4-dimethylamino-6,7-difluoro-quinazolin-2-yamino)-4-aminocyclohexane trifluoroacetate.

A solution of [cis-4-(4-dimethylamino-6,7-difluoro-quinazolin-2-yamino)-cyclohexyl] carbamic acid tert-butyl ester (0.28g, 0.66 mmol) in TFA/DCM (1:2 = 16 mL) was stirred at room temperature for 1.5 hr. After removal of the volatile solvent, the crude product (0.27 g, 95 %) was directly used to next reaction without a further purification.

ESI MS m/e 322 M + H⁺.

Step C: Synthesis of

10

20 3-chloro-N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)benzami de.

cis-4-(4-Dimethylamino-6,7-difluoro-quinazolin-2-yamino)-4-amino cyclohexane trifluoroacetate (25 mg, 0.06 mmol) and 3-chlorobenzoyl chloride (10 mg, 0.06 mmol) was stirred overnight at room temperature in the presence of a catalytic amount of DIEA (3 drops). The compounds were purified from prep-HPLC to give

3-chloro-N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino} cyclohexyl)benzamide (9 mg, 27 %).

ESI MS m/e 460 M + H⁺; 1 H NMR (400 MHz, DMSO-d₆) δ 12.06 (brs, 1 H), 8.29 (brs, 1 H), 8.23

247

(m, 1 H), 8.04 (brs, 1 H), 7.83 (s, 1 H), 7.74 (d, J = 8.0 Hz, 1 H), 7.54 (d, J = 8.0 Hz, 1 H), 7.20 (brs, 1 H), 7.44 (t, J = 8.0 Hz, 1 H), 3.98 (brs, 1 H), 3.83 (brs, 1 H), 3.36 (s, 6 H), 1.82 (brs, 2 H), 1.68 (brs, 6 H).

5

Example 990

3,4-Dichloro-I I-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino)cyclohexyl)-benzamide

10 Step A: Synthesis of 3,4-dichloro-N-(cis-4-{{4-(dimethylamino)-6,7-difluoroquinazolin-2-yl}-amino}cyclohexyl)benzamide.

Using a similar procedure as described in step C of Example 989, the title compound was obtained.

ESI MS m/e 496 M + H⁺; ¹H NMR (400 MHz, DMSO-d₆) 8 12.6 (brs, 1 H), 8.36 (brs, 1 H), 8.28 (brs, 1 H), 8.20 (m, 1 H), 8.03 (d, J = 2.0 Hz, 1 H), 7.77 (dd, J = 8.0, 2.0 Hz, 1 H), 7.69 (d, J = 8.0 Hz, 1 H), 7.45 (brs, 1 H), 3.98 (brs, 1 H), 3.83 (brs, 1 H), 3.41 (s, 6 H), 1.83 (brs, 2 H), 1.68 (brs, 6 H).

Example 991

20 N-(cis-4-{[4-(Dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)-3,5-dimethoxybe nzamide trifluoroacetate

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-cyclohexyl)-3,5-dimethoxybenzamide trifluoroacetate.

Using a similar procedure as described in step C of Example 989, the title compound was obtained.

ESIMS m/e $486 \text{ M} + \text{H}^+$; $^1\text{H} \text{ NMR} (400 \text{ MHz}, \text{DMSO-d}_6) \delta 12.1 (brs, 1 H), 8.20 (m, 1 H), 8.09 (brs, 2H), 7.50 (m, 1 H), 6.92 (d, J = 2.0 Hz, 2 H), 6.58 (t, J = 2.0 Hz, 1 H), 4.00 (brs, 1 H), 3.80 (brs, 1 H), 6.92 (d, J = 2.0 Hz, 2 H), 6.58 (t, J = 2.0 Hz, 1 H), 4.00 (brs, 1 H), 3.80 (brs, 1 H), 6.92 (d, J = 2.0 Hz, 2 H), 6.58 (t, J = 2.0 Hz, 1 H), 4.00 (brs, 1 H), 6.92 (d, J = 2.0 Hz, 2 H), 6.58 (t, J = 2.0 Hz, 1 H), 4.00 (brs, 1 H), 6.92 (d, J = 2.0 Hz, 2 H), 6.58 (t, J = 2.0 Hz, 1 H), 6.92 (d, J = 2.0 Hz, 2 H), 6.58 (t, J = 2.0 Hz, 1 H), 6.92 (d, J = 2.0 Hz, 2 H), 6.58 (t, J = 2.0 Hz, 1 H), 6.92 (d, J = 2.0 Hz, 2 H), 6.58 (t, J = 2.0 Hz, 1 H), 6.92 (d, J = 2.0 Hz, 2 H), 6.92 (d, J = 2.0 Hz,$

248

H), 3.72 (s, 6 H), 3.37 (s, 6 H), 1.82 (brs, 2 H), 1.67 (brs, 6 H).

Examples 992-1003

Compounds 992 to 1008 were prepared in a similar manner as described in Example 890 using the appropriate benzylamine and the carboxylic acid intermediate from Step E.

Examples 1009-1014

Compounds 1009 to 1014 were prepared in a similar manner as described in Example 893 using the appropriate isocyanate (i.e., Compound 1009 to 1013) or thioisocyanate (i.e., Compound 1014) and the amine intermediate from Step D.

Examples 1015-1029

Compounds 1015 to 1029 were prepared in a similar manner as described in Example 894 using the appropriate isocyanate and the amine intermediate from Step E.

Examples 1030-1043

Compounds 1030 to 1043 were prepared in a similar manner as described in Example 896 using the appropriate phenol and the nicotinamide intermediate from Step A.

20

Examples 1044-1049

Compounds 1044 to 1049 were prepared in a similar manner as described in Example 902 using the appropriate benzaldehyde and the amine intermediate from Step C.

25 Examples 1050-1072

Compounds 1050 to 1072 were prepared in a similar manner as described in Example 903 using the appropriate phenol and the nicotinamide intermediate from Step A.

249

Examples 1073 and 1074

Compounds 1073 and 1074 were prepared in a similar manner as described in Example 905 using the appropriate phenol and the nicotinamide intermediate from Step A.

5 Examples 1075-1004

Compounds 1075 to 1084 were prepared in a similar manner as described in Example 907 using the appropriate phenoxyacetic acid and the amine intermediate from the Example in 895 Step B.

10 Examples 1085-1091

Compounds 1085 to 1091 were prepared in a similar manner as described in Example 912 using the appropriate aniline and the bromoacetamide.

Examples 1092-1104

15 Compounds 1092 to 1104 were prepared in a similar manner as described in Example 913 using the appropriate carboxylic acid and the amine intermediate from Step C.

Examples 1105-1115

Compounds 1105 to 1115 were prepared in a similar manner as described in Example 914 20 using the appropriate carboxylic acid and the amine intermediate from the Example in 895 Step B.

Examples 1116-1119

Compounds 1116 to 1119 were prepared in a similar manner as described in Example 915 using the appropriate benzylamine and the carboxylic acid intermediate from Step D.

Examples 1120-1130

25

Compounds 1120 to 1130 were prepared in a similar manner as described in Example 917 using the appropriate acid chloride and the amine intermediate from Step D.

Example 1131

Compound 1131 was prepared in a similar manner as described in Example 918 using 3,5-dichlorobenzaldehyde.

5

Examples 1132 and 1133

Compounds 1132 and 1133 were prepared in a similar manner as described in Example 919 using the appropriate acid chloride and the amine intermediate from Step A.

10 Example 1134

Compound 1134 was prepared in a similar manner as described in Example 920 using the appropriate benzaldehyde and the amine intermediate from Example 919 Step A.

Examples 1135-1195

Compounds 1135 to 1195 were prepared in a similar manner as described in Example 921 using the appropriate arylamine and the carboxylic acid intermediate from Step C.

Examples 1196-1199

Compounds 1196 to 1199 were prepared in a similar manner as described in Example 951 using the appropriate arylamine and the acid chloride intermediate from Step A.

Examples 1200-1204

Compounds 1200 to 1204 were prepared in a similar manner as described in Example 974 using the appropriate acid chloride and aniline intermediate from Step C.

25

Examples 1205-1211

Compounds 1205 to 1211 were prepared in a similar manner as described in Example 989 using the appropriate acid chloride and amine intermediate from Step B.

Ex. No	 	MS	class
992	cis-N-benzyl-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexanecarboxamide	440.5	2
993	cis-N-(3,5-dimethoxybenzyl)-4-{[4-(dimethylamino)-6,7-	500.4	2
 -	difluoroquinazolin-2-yl]amino)cyclohexanecarboxamide cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-		-
994	(4-methoxybenzyl)cyclohexanecarboxamide	470.4	1
995	cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-(3-methoxybenzyl)cyclohexanecarboxamide	470.3	2
996	cis-N-[(6-chloropyridin-3-yl)methyl]-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexanecarboxamide	475.3	2
997	cis-N-(2,4-difluorobenzyl)-4-{[4-(dimethylamino)-6,7-	476.3	3
998	difluoroquinazolin-2-yl]amino}cyclohexanecarboxamide cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-	508.5	
	[3-(trifluoromethyl)benzyl]cyclohexanecarboxamide cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-		
999	[4-(trifluoromethyl)benzyl]cyclohexanecarboxamide	508.4	2
1000	cis-N-(2,4-dichlorobenzyl)-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexanecarboxamide	508	1
1001	cis-N-(3,5-dichlorobenzyl)-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexanecarboxamide	508	1
1002	cis-N-(4-bromobenzyl)-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexanecarboxamide	518.2	1
1003	cis-N-(2-bromobenzyl)-4-{[4-(dimethylamino)-6,7-	518.2	
1004	difluoroquinazolin-2-yl]amino}cyclohexanecarboxamide cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-	524.6	1
	[4-(trifluoromethoxy)benzyl]cyclohexanecarboxamide cis-N-[3,5-bis(trifluoromethyl)benzyl]-4-{[4-(dimethylamino)-		
1005	6,7-difluoroquinazolin-2-yl]amino}cyclohexanecarboxamide	576.2	3
1006	cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-(3-iodobenzyl)cyclohexanecarboxamide	566.2	2
1007	cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N- [(1S)-1-(4-methylphenyl)ethyl]cyclohexanecarboxamide	468.4	1
1008	cis-N-[1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexanecarboxamide	532.2	2
1009	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- N'-[3-(trifluoromethoxy)phenyl]urea	489.4	1
1010	N-(3,4-dimethoxyphenyl)-N'-(cis-4-{[4-	465.2	1
1011	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea N-(2-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-	439.4	2
	yl]amino}cyclohexyl)urea N-(2,6-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-		
1012	2-yl]amino}cyclohexyl)urea	473.4	3
1013	N-(2,3-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea	473.4	3
1014	N-(2-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea	499.4	2

Ex. No.		MS	class
1015	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methoxyphenyl)urea	449,4	2
1016	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethoxyphenyl)urea	463.4	2
1017	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	449.4	2
1018	yl]amino} cyclohexyl)methyl]-N'-(3-methoxyphenyl)urea N-(3,4-dimethoxyphenyl)-N'-[(cis-4-{[4-	479.4	3
1019	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2,4-dimethoxyphenyl)-N'-[(cis-4-{[4-	479.4	2
1020	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2,5-dimethoxyphenyl)-N'-[(cis-4-{[4-	479.4	2
<u> </u>	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea N-(2-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	,,,, <u>,,</u>	
1021	yl]amino}cyclohexyl)methyl]urea N-(3-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-	453.4	2
1022	yl]amino}cyclohexyl)methyl]urea	453.4	2
1023	N-(4-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea	453.4	2
1024	N-(3,5-dichlorophenyl)-N'-[(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea	487.4	1
1025	N-(2,6-dichlorophenyl)-N'-[(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea	487.4	1
1026	N-(3,4-dichlorophenyl)-N'-[(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea	487.4	2
1027	N-(2,5-dichlorophenyl)-N'-[(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea	487.4	2
1028	N-(2,3-dichlorophenyl)-N'-[(cis-4-{[4-	487.4	1
1029	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(2,4-dichlorophenyl)-N'-[(cis-4-{[4-	487.4	2
1030	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	501.30	1
1031	2-(2-fluorophenoxy)nicotinamide 2-(2-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-	517.40	1
1032	yl]amino}cyclohexyl)nicotinamide 2-(2-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-	561.30	1
	yl]amino}cyclohexyl)nicotinamide N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
1033	2-[2-(trifluoromethoxy)phenoxy]nicotinamide N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	567.40	1
1034	2-(3-fluorophenoxy)nicotinamide	501.50	1
1035	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)- 2-(3-methoxyphenoxy)nicotinamide	513.40	1
1036	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)- 2-[3-(trifluoromethoxy)phenoxy]nicotinamide	567.50	1
1037	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-2-[4-(trifluoromethoxy)phenoxy]nicotinamide	567.40	1

Ex. No.		MS	class
1038	2-(3,4-difluorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)nicotinamide	519.60	1
1039	2-(3,5-dimethoxyphenoxy)-N-(cis-4-{[4-	543.20	1
1040	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)nicotinamide 2-(2,3-dimethoxyphenoxy)-N-(cis-4-{[4-	543.20	1
1040	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)nicotinamide N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		1
1041	2-(3,4,5-trimethoxyphenoxy)nicotinamide	573.50	1
1042	2-(4-chloro-3-fluorophenoxy)-N-(cis-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexyl)nicotinamide	535.10	1
1043	2-(3-chloro-4-fluorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)nicotinamide	535.40	1
1044	N2-{(1S,3R)-3-[(2,4-dimethoxybenzyl)amino]cyclopentyl}-	422	3
	N4,N4-dimethylquinazoline-2,4-diamine N4,N4-dimethyl-N2-((1S,3R)-3-{[3-(trifluoromethyl)benzyl]-	430	-
	amino) cyclopentyl) quinazoline-2,4-diamine N2-((1S,3R)-3-{[2-fluoro-5-(trifluoromethyl)benzyl]amino}-		-
1046	cyclopentyl)-N4,N4-dimethylquinazoline-2,4-diamine	448	
1047	N4,N4-dimethyl-N2-((1S,3R)-3-{[4-(trifluoromethoxy)benzyl]-amino}cyclopentyl)quinazoline-2,4-diamine	446	3
1048	N2-((1S,3R)-3-{[4-bromo-2-(trifluoromethoxy)benzyl]- amino}cyclopentyl)-N4,N4-dimethylquinazoline-2,4-diamine	524	3
1049	N2-{(1S,3R)-3-[(3,4-difluorobenzyl)amino]cyclopentyl}-N4,N4-dimethylquinazoline-2,4-diamine	398	3
1050	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	501	
1051	6-(2-fluorophenoxy)nicotinamide 6-(2-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-	517	3
	yl]amino}cyclohexyl)nicotinamide 6-(2-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-		
	yl]amino}cyclohexyl)nicotinamide	561	3
1053	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- 6-(2-methylphenoxy)nicotinamide	498	
1054	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- 6-(2-methoxyphenoxy)nicotinamide	513	1
1055	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-6-(3-methylphenoxy)nicotinamide	498	1
1056	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	513	1
1057	6-(3-methoxyphenoxy)nicotinamide N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	551	
	6-[3-(trifluoromethyl)phenoxy]nicotinamide N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
1058	6-[3-(trifluoromethoxy)phenoxy]nicotinamide	56 8	
1059	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)- 6-(4-fluorophenoxy)nicotinamide	501	3
1060	6-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)nicotinamide	518	1

Ex. No.	compound name	MS	class
1061	6-(4-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-	561	3
1001	yl]amino}cyclohexyl)nicotinamide)
1062	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	567	3
1002	6-[4-(trifluoromethoxy)phenoxy]nicotinamide		
1063	6-(3,5-difluorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-	519	3
	2-yl]amino}cyclohexyl)nicotinamide	91 9	
1064	6-(2,3-difluorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-	519	1
	2-yl]amino}cyclohexyl)nicotinamide		<u> </u>
1065	6-(3,4-difluorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-	519	1
	2-yl]amino) cyclohexyl)nicotinamide		ļ
1066	6-(2,3-dimethoxyphenoxy)-N-(cis-4-{[4-	543	1
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)nicotinamide		
1067	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)- 6-(3,4,5-trimethoxyphenoxy)nicotinamide	574	2
 _	6-(4-chloro-2-methoxyphenoxy)-N-(cis-4-{[4-		-
1068	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)nicotinamide	548	2
	6-(4-chloro-3-fluorophenoxy)-N-(cis-4-{[4-		-
1069	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)nicotinamide	535	1
	6-(3-chloro-4-fluorophenoxy)-N-(cis-4-{[4-		 -
1070	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)nicotinamide	535	2
1071	6-(3,5-dimethoxyphenoxy)-N-(cis-4-{[4-	5.10	
1071	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)nicotinamide	543	2
1072	6-(3-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-	5.61	
10/2	yl]amino}cyclohexyl)nicotinamide	561	3
1073	2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-	517	2
10/3	yl]amino}cyclohexyl)isonicotinamide	21/	
1074	2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-	517	lı
	yl]amino}cyclohexyl)isonicotinamide		<u> ` </u>
1075	2-(3,4-dichlorophenoxy)-N-(cis-4-{[4-	488.2	1 1
	(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)acetamide		
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	448.4	3
	2-(3,4-dimethylphenoxy)acetamide		
1077	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	524.2	2
	2-(2,4,5-trichlorophenoxy)acetamide N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
	2-(4-fluorophenoxy)acetamide	438.2	1
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
	2-(3-methylphenoxy)acetamide	434.2	1 1
	(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
1080	2-(4-methoxyphenoxy)acetamide	450.2	1
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	,	
	2-(3-methoxyphenoxy)acetamide	450.2	1
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
	2-(2-methoxyphenoxy)acetamide	450.2	2
	2-(2,4-dichlorophenoxy)-N-(cis-4-{[4-	10.5.5	
1083	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)acetamide	488.2	2

Ex. No.	compound name	MS	class
1084	4-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-	496.5	3
	yl]amino}cyclohexyl)benzamide		
1085	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	419.4	1 , ;
	N2-phenylglycinamide		
1086	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	433.4	1 1
<u></u>	N2-(3-methylphenyl)glycinamide		
1087	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	437.4	1 1
<u> </u>	N2-(3-fluorophenyl)glycinamide	· · · · · · · · · · · · · · · · · · ·	
1088	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	433.4	1 1
	N2-methyl-N2-phenylglycinamide		
1089	N2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-	453.2	1
<u></u>	yl]amino}cyclohexyl)glycinamide N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
1090	N2-(3-methoxyphenyl)glycinamide	449.2	1
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		+
1091	N2-(4-fluorophenyl)glycinamide	437.2	1
	2-(2,6-difluorophenyl)-N-[(cis-4-{[4-(dimethylamino)quinazolin-		
1092	2-yl]amino}cyclohexyl)methyl]-2-hydroxyacetamide	470	3
	2-(2,3-difluorophenyl)-N-[(cis-4-{[4-(dimethylamino)quinazolin-		
1093	2-yl]amino}cyclohexyl)methyl]-2-hydroxyacetamide	470	3
	2-(2,5-difluorophenyl)-N-[(cis-4-{[4-(dimethylamino)quinazolin-		
1094	2-yl]amino}cyclohexyl)methyl]-2-hydroxyacetamide	470	3
	2-(3,4-difluorophenyl)-N-[(cis-4-{[4-(dimethylamino)quinazolin-		
1095	2-yl]amino}cyclohexyl)methyl]-2-hydroxyacetamide	470	3
1006	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	464	
1096	cyclohexyl)-methyl]-2-hydroxy-2-(4-methoxyphenyl)acetamide	464	2
1007	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	464	
1097	cyclohexyl)-methyl]-2-hydroxy-2-(3-methoxyphenyl)acetamide	404	
1098	2-(4-bromophenyl)-N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	512	3
1098	yl]amino}cyclohexyl)methyl]-2-hydroxyacetamide	<u> </u>	3
1099	2-(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	468	3
1099	yl]amino}cyclohexyl)methyl]-2-hydroxyacetamide	400	
1100	(2S)-2-(3-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)-	468	2
1100	quinazolin-2-yl]amino}cyclohexyl)methyl]-2-hydroxyacetamide		<u> </u>
1101	(2R)-2-(2-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)-	468	2
1101	quinazolin-2-yl]amino}cyclohexyl)methyl]-2-hydroxyacetamide		
1102	(2R)-N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	434	3
	yl]amino}cyclohexyl)methyl]-2-hydroxy-2-phenylacetamide		
1103	(2S)-N-[(cis-4-{[4-(dimethylamino)quinazolin-2-	434	3
	yl]amino}cyclohexyl)methyl]-2-hydroxy-2-phenylacetamide	· · · · · · · · · · · · · · · · · · ·	
	N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-	700	
1104	cyclohexyl)-methyl]-2-hydroxy-2-[3-(trifluoromethyl)phenyl]-	502	2
	acetamide		
1105	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	450.00	1
	2-hydroxy-2-(4-methoxyphenyl)acetamide		
	2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-	454.20	2
	yl]amino}cyclohexyl)-2-hydroxyacetamide		

Ex. No.		MS	class
1107	2-(4-bromophenyl)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-	498.40	2
1107	yl]amino) cyclohexyl)-2-hydroxyacetamide	470.40	
1108	2-(3,4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)quinazolin-	456.20	2
	2-yl]amino}cyclohexyl)-2-hydroxyacetamide	450.20	
1109	2-(2,3-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)quinazolin-	456.20	3
	2-yl]amino}cyclohexyl)-2-hydroxyacetamide	156.26	
1110	2-(2,6-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)quinazolin-	456.20	3
	2-yl]amino}cyclohexyl)-2-hydroxyacetamide		
1111	(2R)-2-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-	454.20	1
	quinazolin-2-yl]amino}cyclohexyl)-2-hydroxyacetamide N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-		
1112	2-hydroxy-2-[3-(trifluoromethyl)phenyl]acetamide	488.20	1
	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-		
1113	2-hydroxy-2-(3-methoxyphenyl)acetamide	450.20	1 1
	(2S)-2-(2-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinazolin-		
1114	2-yl]amino)cyclohexyl)-2-hydroxyacetamide	454.50	1 1
1115	2-(2,5-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)quinazolin-		
1115	2-yl]amino}cyclohexyl)-2-hydroxyacetamide	456.30	2
1116	cis-4-[(4-isopropylquinazolin-2-yl)amino]-N-(3-	122.2	
	methoxybenzyl)cyclohexanecarboxamide	433.3	
	cis-4-[(4-isopropylquinazolin-2-yl)amino]-N-(4-	417.3	
	methylbenzyl)cyclohexanecarboxamide	417.5	
11112	cis-N-(3-fluoro-4-methylbenzyl)-4-[(4-isopropylquinazolin-2-	435.2	
	yl)amino]cyclohexanecarboxamide		
	cis-N-(2,5-dichlorobenzyl)-4-[(4-isopropylquinazolin-2-	471.3	
	yl)amino]cyclohexanecarboxamide		
	N-[((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-	450.4	1 1
	yl]amino}cyclopentyl)methyl]-3,5-dimethoxybenzamide 4-chloro-N-[((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-		
	yl]amino}cyclopentyl)methyl]benzamide	424.2	2
	3-chloro-N-[((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-		
11//1	yl]amino)cyclopentyl)methyl]benzamide	424.2	1 1
	2,4,6-trichloro-N-[((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-		1
	yl]amino}cyclopentyl)methyl]benzamide	492	1
	N-[((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-yl]amino}-	15/ 0	
1124	cyclopentyl)methyl]-3-fluoro-4-(trifluoromethyl)benzamide	476.2	3
1125	N-[((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-yl]amino}-	176.3	
	cyclopentyl)methyl]-2-fluoro-4-(trifluoromethyl)benzamide	476.2	3
11/0/	N-[((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-	526.4	3
	yl]amino]cyclopentyl)methyl]-2,5-bis(trifluoromethyl)benzamide	320.4	
- 1 1 2 7 1	N-[((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-	458.2	1
	yl]amino}cyclopentyl)methyl]-3-(trifluoromethyl)benzamide	15015	
11/81	N-[((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-	474.4	3
	yl]amino}cyclopentyl)methyl]-4-(trifluoromethoxy)benzamide		
	N-[((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-	426.2	2
	yl]amino}cyclopentyl)methyl]-2,5-difluorobenzamide		

Ex. No.		MS	class
1130	N-[((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-	426.2	1 1
1130	yl]amino}cyclopentyl)methyl]-3,5-difluorobenzamide		
1131	N2-((1S,3R)-3-{[(3,5-dichlorobenzyl)amino]methyl}-	444	1 1
	cyclopentyl)-N4,N4-dirnethylquinazoline-2,4-diamine		
1132	N-[(1S,3R)-3-({[4-(dimethylamino)quinazolin-2-	403.2	3
	yl]amino}methyl)cyclopentyl]-3-fluorobenzamide]
1133	N-[(1S,3R)-3-({[4-(dimethylamino)quinazolin-2-	426.2	3
	yl]amino}methyl)cyclopentyl]-2,4-difluorobenzamide N4,N4-dimethyl-N2-[((1R,3S)-3-{[3-(trifluoromethyl)benzyl]-		
1134	amino}cyclopentyl)methyl]quinazoline-2,4-diamine	444	
	cis-N-benzyl-4-{[4-(dimethylamino)quinazolin-2-		1
1135	yl]amino}cyclohexanecarboxamide	404.3	1 1
	cis-N-[(6-chloropyridin-3-yl)methyl]-4-{[4-		
1136	(dimethylamino)quinazolin-2-yl]amino)cyclohexanecarboxamide	439.3	1
	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1R)-1-(3-	1.10.0	1.
1137	methoxyphenyl)ethyl]cyclohexanecarboxamide	448.3	1
	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[1-(4-	126.2	
1138	fluorophenyl)ethyl]cyclohexanecarboxamide	436.3	1
1139	cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-{[4-	452.3	1 1
1139	(dimethylamino)quinazolin-2-yl]amino)cyclohexanecarboxamide		1 1
1140	cis-N-[1-(4-bromophenyl)ethyl]-4-{[4-	496.4	1 1
1140	(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide		
1141	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1S)-1-(1-	468.7	1
	naphthyl)ethyl]cyclohexanecarboxamide		 -
1142	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3,5-	432.4	1
	dimethylbenzyl)cyclohexanecarboxamide		
1143	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-fluoro-4-	436.4	2
-	methylbenzyl)cyclohexanecarboxamide cis-N-(3-chloro-2-methylbenzyl)-4-{[4-		
1144	(dimethylamino)quinazolin-2-yl]amino)cyclohexanecarboxamide	452.2	1
	cis-N-(5-chloro-2-methylbenzyl)-4-{[4-		
1145	(dimethylamino)quinazolin-2-yl]amino)cyclohexanecarboxamide	452.2	2
ļ	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(5-fluoro-2-	126.1	1 .
1146	methylbenzyl)cyclohexanecarboxamide	436.4	1
11.47	cis-N-(3-chloro-2,6-difluorobenzyl)-4-{[4-	474.4	1
1147	(dimethylamino)quinazolin-2-yl]amino)cyclohexanecarboxamide	4/4.4	1 1
1148	cis-N-(biphenyl-3-ylmethyl)-4-{[4-(dimethylamino)quinazolin-2-	480.2	1 1
1148	yl]amino}cyclohexanecarboxamide	400.2	<u> </u>
1149	cis-N-(biphenyl-4-ylmethyl)-4-{[4-(dimethylamino)quinazolin-2-	480.2	
114.	yl]amino}cyclohexanecarboxamide		
1150	cis-N-(6-chloro-2-fluoro-3-methylbenzyl)-4-{[4-	470.4	1 1
	(dimethylamino)quinazolin-2-yl]amino)cyclohexanecarboxamide	- · · - · · - · · · · · · · · · · · · ·	
1151	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2-	422.2	1 1
	fluorobenzyl)cyclohexanecarboxamide		
1152	cis-N-(2,6-difluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-	440.4	1
	yl]amino}cyclohexanecarboxamide		1

Ex. No.		MS	class
1153	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[4-	472.4	1
	(trifluoromethyl)benzyl]cyclohexanecarboxamide	.,	
1154	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)-N-(1-	454.4	1
	naphthylmethyl)cyclohexanecarbonamide		<u> </u>
1155	cis-N-(4-chlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide	438.2	1
 	cis-N-(3,4-dichlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-		
1156	yl]amino}cyclohexanecarboxamide	472.4	1
	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-		
1157	fluorobenzyl)cyclohexanecarboxamide	422.2	
1158	cis-N-(2,5-difluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-	440.4	,
1138	yl]amino}cyclohexanecarboxamide	440.4	1
1159	cis-N-(2,3-difluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-	440.4	
1137	yl]amino}cyclohexanecarboxamide		
1160	cis-N-(3-bromobenzyl)-4-{[4-(dimethylamino)quinazolin-2-	482.4	1
<u> </u>	yl]amino}cyclohexanecarboxamide cis-N-(3-bromo-4-fluorobenzyl)-4-{[4-		
1161	(dimethylamino)quinazolin-2-yl]amino)cyclohexanecarboxamide	501.2	1
 	cis-N-(4-bromo-2-fluorobenzyl)-4-{[4-		
1162	(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide	501.2	1
11.62	cis-N-(5-bromo-2-fluorobenzyl)-4-{[4-	501.0	,
1163	(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide	501.2	1
1164	cis-N-(4-chloro-2-fluorobenzyl)-4-{[4-	456.4	1
1104	(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide	+50.4	1
1165	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-	418.2	1
	methylbenzyl)cyclohexanecarboxamide		
1166	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2-	418.2	1
-	methylbenzyl)cyclohexanecarboxamide cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[2-		
1167	(trifluoromethoxy)benzyl]cyclohexanecarboxamide	488.4	1
	cis-N-(2,5-difluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-		
1168	yl]amino}cyclohexanecarboxamide	440.4	1
1169	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2,3,4-	458.2	1
1109	trifluorobenzyl)cyclohexanecarboxamide	438.2	1
1170	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2,4,5-	458.2	1
1170	trifluorobenzyl)cyclohexanecarboxamide	150.2	
1171	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3,4,5-	458.2	1
	trifluorobenzyl)cyclohexanecarboxamide		
1172	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2,3,6-trifluorobenzyl)cyclohexanecarboxamide	458.2	1
ļ	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[3-fluoro-5-		
1173	(trifluoromethyl)benzyl]cyclohexanecarboxamide	490.4	1
1,,,,,	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[4-fluoro-2-	100 1	
1174	(trifluoromethyl)benzyl]cyclohexanecarboxamide	490.4	1
1175	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[2-fluoro-4-	490.4	1
11/2	(trifluoromethyl)benzyl]cyclohexanecarboxamide	470.4	1

Ex. No.	compound name	MS	class
1176	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[4-fluoro-3-(trifluoromethyl)benzyl]cyclohexanecarboxamide	490.4	1
1177	cis-4-{[4-(dimethylamino)quinazolin-2-yt]amino}-N-[2-fluoro-3-(trifluoromethyl)benzyl]cyclohexanecarboxamide	490.4	1
1178	cis-N-[4-chloro-3-(trifluoromethyl)benzyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide	506.2	1
1179	cis-N-(2-chloro-6-fluorobenzyl)-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide	456.2	1
1180	cis-N-(4-chloro-2-fluorobenzyl)-4-{[4-	456.2	1
1181	(dimethylamino)quinazolin-2-yl]amino)cyclohexanecarboxamide cis-N-(3-chloro-4-fluorobenzyl)-4-{[4-(dimethylamino)quinazolin 2-yl]amino) cyclohexanecarboxamide	456.2	1
1182	(dimethylamino)quinazolin-2-yl]amino)cyclohexanecarboxamide cis-N-(2-chloro-4-fluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexanecarboxamide	456.2	1
1183	cis-N-[2-chloro-5-(trifluoromethyl)benzyl]-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide	506.2	1
1184	cis-N-[2-(difluoromethoxy)benzyl]-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide	470.4	1
1185	cis-N-[3-(difluoromethoxy)benzyl]-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide	470.4	1
	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[3- (trifluoromethoxy)benzyl]cyclohexanecarboxamide	488.4	1
1187	cis-N-(2,4-dichloro-6-methylbenzyl)-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide	486.2	2
1188	cis-N-(2,6-dimethoxybenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide	464.2	1
1189	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1R)-1-phenylethyl]cyclohexanecarboxamide	418.4	1
1100	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1S)-1-(4-methoxyphenyl)ethyl]cyclohexanecarboxamide	448.4	1
1101	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1R)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide	448.4	1
1192	cis-N-[bis(4-methoxyphenyl)methyl]-4-{[4- (dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide	540.4	1
1193	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[2- (trifluoromethyl)benzyl]cyclohexanecarboxamide	472.4	1
1194	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-9H-fluoren- 9-ylcyclohexanecarboxamide	478.2	1
1105	cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[4- (methylsulfonyl)benzyl]cyclohexanecarboxamide	482.2	1
1196	cis-N-(6-chloropyridin-3-yl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide	425.1	1
1197	cis-N-(2-chloropyridin-3-yl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide	425.1	3
1198	cis-N-1H-benzimidazol-2-yl-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide	430.3	3

Ex. No.	compound name	MS	class
1199	cis-N-(5-bromo-4-tert-butyl-1,3-thiazol-2-yl)-4-{[4-	531.1	3
1199	(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide	331.1	
1200	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-	461.4	1
1200	3-(propionylamino)benzamide	401.4	1_1_
1201	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	489.4	2
1201	3-[(3-methylbutanoyl)amino]benzamide	407.4	
1202	N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-	489.5	2
1202	3-[(2,2-dimethylpropanoyl)amino]benzamide	409.5	2
1203	3-[(cyclopentylcarbonyl)amino]-N-(cis-4-{[4-	501.4	1
1203	(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)benzamide	301.4	1
1204	3-(acetylamino)-N-(cis-4-{[4-(dimethylamino)quinazolin-2-	447.4	1
1204	yl]amino}cyclohexyl)benzamide	447.4	1
1205	N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-	426	1
1205	yl]amino}cyclohexyl)benzamide	420	1
1206	N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-	440	1 1
1200	yl]amino)cyclohexyl)-4-methylbenzamide	440	1
1207	N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-	444	1
1207	yl]amino)cyclohexyl)-4-fluorobenzamide	+++	
1208	N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-	456	1
1200	yl]amino}cyclohexyl)-3-methoxybenzamide	750	1
1209	N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-	462	1 1
1209	yl]amino)cyclohexyl)-3,4-difluorobenzamide	702	
1210	N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-	494	1
[yl]amino{cyclohexyl)-3-(trifluoromethyl)benzamide		72.7	
1211	N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-	510	3
1211	yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide	510	

261

Example 1212

[cis-4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid isobutyl ester

Step A: Synthesis of [cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]5 carbamic acid isobutyl ester.

To a solution of N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinazoline-2,4-diamine obtained in step E of example 1 (300 mg) in CHCl₃ (3 mL) were added Et₃N (307 μL) and isobutyl chloroformate (158 mg). The mixture was stirred at ambient temperature for 16 hr. To the reaction was added saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 25% to 66% EtOAc in hexane) to give [cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid isobutyl ester (195 mg) as a pale yellow oil. ESI MS m/e 386, M + H⁴; ¹H NMR (300 MHz, CDCl₃) δ 0.93 (d, J = 6.84 Hz, 6 H), 1.51-1.98 (m, 9 H), 3.27 (s, 6 H), 3.69 (brs, 1 H), 3.84 (d, J=6.84 Hz, 2 H), 4.04-4.20 (m, 1 H), 4.69 (brs, 1 H), 4.86-4.98 (m, 1 H), 6.98-7.08 (m, 1 H), 7.40-7.54 (m, 2 H), 7.82 (d, J = 7.93 Hz, 1 H).

Example 1213

20

 $1\hbox{-}[{\it cis}\hbox{-}4\hbox{-}(4\hbox{-}{\bf Dimethylamino}\hbox{-}{\bf quinazolin-}2\hbox{-}{\bf ylamino})\hbox{-}{\bf cyclohexyl}]\hbox{-}3\hbox{-}{\bf ethyl-thiourea\ hydrochloride}$

Step A: Synthesis of 1-[cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3-ethyl-thiourea hydrochloride.

To a solution of N^2 -(cis-4-amino-cyclohexyl)-N', N'-dimethyl-quinazoline-2,4-diamine obtained in step E of example 1 (300 mg) in DMSO (3 mL) was added ethyl isothiocyanate (100 mg).

The mixture was stirred at ambient temperature for 20 hr. To the reaction mixtuer was added H₂O (20 ml) and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 50% EtOAc in hexane) to give a colorless amorphous. To a solution of the above material in EtOAc (2 mL)

262

was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. A suspension of the residue in Et₂O (20 mL) was stirred at ambient temperature for 1 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 80 °C under reduced pressure to give 1-[cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-

5 3-ethyl-thiourea hydrochloride (296 mg) as a white solid.

ESI MS m/e 373, M (free) + H⁺; ¹H NMR (300 MHz, DMSO-d6) δ 1.07 (t, J = 7.23 Hz, 3 H), 1.54-1.93 (m, 8 H), 3.30-3.63 (m, 8 H), 3.95-4.23 (m, 2 H), 7.28-7.57 (m, 3 H), 7.70-7.86 (m, 1 H), 8.03-8.26 (m, 2 H), 12.52 (brs, 1 H).

10

Example 1214

1-[cis-4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3-(1,1-dimethyl-propyl)-thiourea hydrochloride

15 Step A: Synthesis of 1-[cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3-(1,1-dimethyl-propyl)-thiourea hydrochloride.

Using the procedure for the step A of example 1213, the title compound was obtained. ESI MS m/e 415, M (free) + H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 0.77 (t, J = 7.5 Hz, 3 H), 1.16 (s, 3 H), 1.36 (s, 3 H), 1.41-1.99 (m, 10 H), 3.48 (s, 6 H), 3.90-4.3 (m, 2 H), 7.18-7.54 (m, 3 H), 7.78 (t, J = 7.5 Hz, 1 H), 8.17 (d, J = 9.0 Hz, 1 H), 8.28 (brs, 1 H), 12.87 (brs, 1 H).

Assay Procedures

Example 1215

ASSAY FOR DETERMINATION OF CONSTITUTIVE ACTIVITY OF NON-ENDOGENOUS

25 GPCPs

A. Intracellular IP3 Accumulation Assay

On day 1, cells to be transfected can be plated onto 24 well plates, usually 1x10⁵ cells/well (although his umber can be optimized. On day 2 cells can be transfected by firstly mixing 0.25ug

263

DNA (e.g., pCMV vector or pCMV vector comprising polynucleotide enocoding receptor) in 50 ul serum free DMEM/well and 2 ul lipofectamine in 50 µl serum-free DMEM/well. The solutions are gently mixed and incubated for 15-30 min at room temperature. Cells are washed with 0.5 ml PES and 400 µl of serum free media is mixed with the transfection media and added to the cells. The cells 5 are then incubated for 3-4 hrs at 37°C/5%CO₂ and then the transfection media is removed and replaced with 1ml/well of regular growth media. On day 3 the cells are labeled with ³H-myo-inositol. Briefly, the media is removed and the cells are washed with 0.5 ml PBS. Then 0.5 ml inositol-free/serum free media (GIBCO BRL) is added/well with 0.25 µCi of ³H-myo-inositol/ well and the cells are incubated for 16-18 hrs o/n at 37°C/5%CO₂ On Day 4 the cells are washed with 0.5 10 ml PBS and 0.45 ml of assay medium is added containing inositol-free/serum free media 10μΜ pargyline 10 mM lithium chloride or 0.4 ml of assay medium and 50 ul of 10x ketanserin (ket) to final concentration of 10 µM. The cells are then incubated for 30 min at 37 °C. The cells are then washed with 0.5 ml PBS and 200 ul of fresh/ice cold stop solution (1M KOH; 18 mM Na-borate; 3.8 mM EDTA) is added/well. The solution is kept on ice for 5-10 min or until cells were lysed and then 15 neutralized by 200 μl of fresh/ice cold neutralization sol. (7.5 % HCL). The lysate is then transferred into 1.5 ml eppendorf tubes and 1 ml of chloroform/methanol (1:2) is added/tube. The solution is vortexed for 15 sec and the upper phase is applied to a Biorad AG1-X8™ anion exchange resin (100-200 mesh). Firstly, the resin is washed with water at 1:1.25 W/V and 0.9 ml of upper phase is loaded onto the column. The column is washed with 10 mls of 5 mM myo-inositol and 10 ml of 5 mM 20 Na-borate/60mM Na-formate. The inositol tris phosphates are eluted into scintillation vials containing 10 ml of scintillation cocktail with 2 ml of 0.1 M formic acid/1 M ammonium formate. The columns are regenerated by washing with 10 ml of 0.1 M formic acid/3M ammonium formate and

25 Example 1216

High Throughput Functional Screening: FLIPRTM

rinsed twice with H₂O and stored at 4°C in water.

Subsequently, a functional based assay was used to confirm the lead hits, referred to as FLIPRTM (the Fluorometric Imaging Plate Reader) and FDSS6000TM (Functional Drug Screening System). This assay utilized a non-endogenous, constitutively active version of the MCH receptor.

The FLIPR and FDSS assays are able to detect intracellular Ca2+ concentration in cells, which 5 can be utilized to assess receptor activation and determine whether a candidate compound is an. for example, antagonist, inverse agonist or agonist to a Gq-coupled receptor. The concentration of free Ca2+ in the cytosol of any cell is extremely low, whereas its concentration in the extracellular fluid and endoplasmic reticulum (ER) is very high. Thus, there is a large gradient tending to drive Ca2+ into the cytosol across both the plasma membrane and ER. The FLIPRTM and FDSS6000TM systems 10 (Molecular Devices Corporation, HAMAMATSU Photonics K.K.) are designed to perform functional cell-based assays, such as the measurement of intracellular calcium for high-throughput screening. The measurement of fluorescent is associated with calcium release upon activation of the Gq-coupled receptors. Gi or Go coupled receptors are not as easily monitored through the FLIPR™ and FDSS6000TM systems because these G proteins do not couple with calcium signal pathways.

Fluorometric Imaging Plate Reader system was used to allow for rapid, kinetic measurements of intracellular fluorescence in 96 well microplates (or 384 well microplates). Simultaneous measurements of fluorescence in all wells can be made by FLIPR or FDSS6000TM every second with high sensitivity and precision. These systems are ideal for measuring cell-based functional assays such as monitoring the intracellular calcium fluxes that occur within seconds after activation of the 20 Gq coupled receptor.

15

Briefly, the cells are seeded into 96 well at 5.5x10⁴ cells/well with complete culture media (Dulbecco's Modified Eagle Medium with 10 % fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate and 0.5 mg/ml G418, pH 7.4) for the assay next day. On the day of assay, the media is removed and the cells are incubated with 100 µl of loading buffer (4 µM Fluo4-AM in complete 25 culture media containing 2.5 mlM Probenicid, 0.5 mg/ml and 0.2% bovine serum albumin) in 5% CO₂ incubator at 37°C for 1 hr. The loading buffer is removed, and the cells are washed with wash buffer (Hank's Balanced Salt Solution containing 2.5 mM Probenicid, 20 mM HEPES, 0.5 mg/ml and 0.2% bovine serum albumin, pH 7.4)). One hundred fifty µl of wash buffer containing various

concentrations of test compound is added to the cells, and the cells are incubated in 5% CO₂ incubator at 37°C for 30 min. Fifty µl of wash buffer containing various concentration of MCH are added to each well, and transient changes in [Ca²⁺]i evoked by MCH are monitored using the FLIPR or FDSS in 96 well plates at Ex. 488 nm and Em. 530 nm for 290 second. When antagonist activity of compound is tested, 50 nM of MCH is used.

Use of FLIPR™ and FDSS6000TM can be accomplished by following manufacturer's instruction (Molecular Device Corporation and HAMAMATSU Photonics K.K.).

Representative examples are shown below.

Compound No.	IC ₅₀ (nM)
Example 1	13
Example 2	13
Example 3	4.9
Example 898	3.3
Example 909	0.97

10

15

The results shown in the previous tables are in accordance with the classification as defined below.

- Class 1 : The value of percent of control at 10^{-7} M was less than 40% or the value of IC₅₀ was less than 50 nM.
- Class 2 : The value of percent of control at 10^{-7} M was from 40% to 60% or the value of IC₅₀ was from 50 nM to 200 nM.
- Class 3 : The value of percent of control at 10^{-7} M was more than 60% or the value of IC₅₀ was more than 200 nM.

20

The compounds in Examples 886 to 991 were tested and they showed IC50 activities less than about 50 μM .

266

Example 1217

Receptor Binding Assay

In addition to the methods described herein, another means for evaluating a test compound is by determining binding affinities to the MCH receptor. This type of assay generally requires a radiolabelled ligand to the MCH receptor. Absent the use of known ligands for the MCH receptor and radiolabels thereof, compounds of Formula (I) can be labelled with a radioisotope and used in an assay for evaluating the affinity of a test compound to the MCH receptor.

A radiolabelled MCH compound of Formula (I) can be used in a screening assay to identify/evaluate compounds. In general terms, a newly synthesized or identified compound (i.e., test compound) can be evaluated for its ability to reduce binding of the "radiolabelled compound of Formula (I)" to the MCH receptor. Accordingly, the ability to compete with the "radio-labelled compound of Formula (I)" or Radiolabelled MCH Ligand for the binding to the MCH receptor directly correlates to its binding affinity of the test compound to the MCH receptor.

15 ASSAY PROTOCOL FOR DETERMINING RECEPTOR BINDING FOR MCH:

A. MCH RECEPTOR PREPARATION

293 cells (human kidney, ATCC), transiently transfected with 10 ug human MCH receptor and 60 ul Lipofectamine (per 15-cm dish), are grown in the dish for 24 hours (75% confluency) with a media change and removed with 10 ml/dish of Hepes-EDTA buffer (20mM Hepes + 10 mM EDTA, 20 pH 7.4). The cells are then centrifuged in a Beckman Coulter centrifuge for 20 minutes, 17,000 rpm (JA-25.50 rotor). Subsequently, the pellet is resuspended in 20 mM Hepes + 1 mM EDTA, pH 7.4 and homogenized with a 50- ml Dounce homogenizer and again centrifuged. After removing the supernatant, the pellets can be stored at -80°C, until used in binding assay. When used in the assay, membranes are thawed on ice for 20 minutes and then 10 mL of incubation buffer (20 mM Hepes, 1 mM MgCl₂, 100 mM NaCl, pH 7.4) added. The membranes are then vortexed to resuspend the crude membrane pellet and homogenized with a Brinkmann PT-3100 Polytron homogenizer for 15 seconds at setting 6. The concentration of membrane protein is determined using the BRL Bradford protein assay.

B. BINDING ASSAY

buffer containing 50mM Tris HCl (pH 7.4), 10mM MgCl₂, and 1mM EDTA; 5-50ug protein) is added to 96-well polyproylene microtiter plates followed by addition of 100ul of assay buffer and 50ul of Padiolabelled MCH Ligand. For nonspecific binding, 50 ul of assay buffer is added instead of 100ul and an additional 50ul of 10uM cold lMCH is added before 50ul of Radiolabelled MCH Ligand is added. Plates are then incubated at room temperature for 60-120 minutes. The binding reaction is terminated by filtering assay plates through a Microplate Devices GF/C Unifilter filtration plate with a Brandell 96-well plate harvestor followed by washing with cold 50 mM Tris HCl, pH 7.4 containing 0.9% NaCl. Then, the bottom of the filtration plate are sealed, 50 μl of Optiphase Supermix is added to each well, the top of the plates are sealed, and plates are counted in a Trilux MicroBeta scintillation counter. For compound competition studies, instead of adding 100 μl of assay buffer, 100 μl of appropriately diluted test compound is added to appropriate wells followed by addition of 50 μl of Radiolabelled MCH Ligand.

C. CALCULATIONS

The test compounds are initially assayed at 1 and 0.1 µM and then at a range of concentrations chosen such that the middle dose would cause about 50% inhibition of a Radio-MCH Ligand

20 binding (i.e., IC₅₀). Specific binding in the absence of test compound (B₀) is the difference of total binding (B_T) minus non-specific binding (NSB) and similarly specific binding (in the presence of test compound) (B) is the difference of displacement binding (B_D) minus non-specific binding (NSB).

IC₅₀ is determined from an inhibition response curve, logit-log plot of % B/B₀ vs concentration of test compound.

25 K_i is calculated by the Cheng and Prustoff transformation:

$$K_i = IC_{50} / (1 + [L]/K_D)$$

wherein [L] is the concentration of a Radio-MCH Ligand used in the assay and K_D is the dissociation constant of a Radio-MCH Ligand determined independently under the same binding

268

conditions.

It is intended that each of the patents, applications, printed publications, and other published documents mentioned or referred to in this specification be herein incorporated by reference in their entirety.

Those skilled in the art will appreciate that numerous changes and modifications may be made to the preferred embodiments of the invention and that such changes and modifications may be made without departing from the spirit of the invention. It is therefore intended that the appended claims cover all such equivalent variations as fall within the true spirit and scope of the invention.

CLAIMS

1. A compound of Formula (I):

$$Q \sim V \sim R_1$$
(I)

5

wherein Q is:

$$X_2$$
 X_3
 X_4
 X_4

 R_1 is selected from the group consisting of:

(i) C₁₋₈ alkyl, and

 C_{1-8} alkyl substituted by substituent(s) independently selected from the group consisting of:

•oxo,

15

- •halogen,
- •C₁₋₅ alkoxy carbonyl,
- •C₁₋₅ alkoxy,
- •C₁₋₅ alkoxy substituted by carbocyclic aryl,
- emono-C₁₋₅ alkylamino,

20

- \bullet mono- C_{1-5} alkylamino substituted by carbocyclic aryl,
- ·di-C₁₋₅ alkylamino,
- •di-C₁₋₅ alkylamino substituted by carbocyclic aryl,

•C₁₋₅ alkylthio, °C₃₋₆ cycloalkyl, $\circ C_{3-6}$ cycloalkyl substituted by C_{1-5} alkyl, °C₃₋₆ cycloalkenyl, 5 ·carbocyclyl, ecarbocyclic aryl, *carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: ••hydroxy, 10 ··halogen, ••nitro, ••amino, ••C₁₋₅ alkylcarbonylamino, ••C₃₋₆ cycloalkylcarbonylamino, ··carbocyclic aryl, 15 ••C₁₋₅ alkyl, ••C₁₋₅ alkyl substituted by halogen, ••C₁₋₅ alkylsulfonyl, ••C₂₋₆ alkenyl, ••C₁₋₅ alkoxy, and 20 ••C₁₋₅ alkoxy substituted by halogen, ·mono-carbocyclic arylamino, •mono-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of: 25 «halogen, ••C₁₋₅ alkyl, ••C₁₋₅ alkyl substituted by halogen,

••C₁₋₅ alkoxy, and

271

••C₁₋₅ alkoxy substituted by halogen, odi-carbocyclic arylamino, *di-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of: 5 **halogen, ∞C₁₋₅ alkyl, «C₁₋₅ alkyl substituted by halogen, ••C₁₋₅ alkoxy, and ••C₁₋₅ alkoxy substituted by halogen, 10 •carbocyclic aryloxy, •carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of: ··halogen, •• C_{1-5} alkyl, 15 ••C₁₋₅ alkyl substituted by halogen, ••C₁₋₅ alkoxy, ••C₁₋₅ alkoxy substituted by halogen, and ••carbocyclic aryl, •hydroxy, 20 •heterocyclyl, and •heterocyclyl substituted by halogen, (ii) C2.5 alkenyl, and C₂₋₅ alkenyl substituted by substituent(s) independently selected from the group consisting of: 25 oxo, and •carbocyclic aryl, (iii) C₂₋₅ alkynyl,

C₃₋₁₂ cycloalkyl, and

(iv)

C₃₋₁₂ cycloalkyl substituted by carbocyclic aryl, (v) carbocyclyl, and carbocyclyl substituted by substituent(s) independently selected from the group consisting of: 5 hydroxy, and «carbocyclic aryl, carbocyclic aryl, and (vi)carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: 10 ·halogen, •cyano, •nitro, •amino, $\cdot C_{1-10}$ alkyl, 15 •C₁₋₁₀ alkyl substituted by substituent(s) independently selected from the group consisting of: ••halogen, ••oxo, and ••carbocyclic aryl, 20 ·carboxy, •C₁₋₅ alkoxy carbonyl, $\cdot C_{1-7}$ alkoxy, •C₁₋₇ alkoxy substituted by substituent(s) independently selected from the group consisting of: 25 «halogen, and ••carbocyclic aryl, •C₃₋₆ cycloalkoxy,

carbocyclic aryloxy,

•carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of: ehalogen, ∞nitro, 5 °°C₁₋₅ alkyl, ∘ C₁₋₅ alkyl substituted by halogen, [∞]C₁₋₅ alkoxy, and *•C₁₋₅ alkoxy substituted by halogen, •heterocyclyloxy, 10 •heterocyclyloxy substituted by substituent(s) independently selected from the group consisting of: ··halogen, ••nitro, •• C_{1-5} alkyl, 15 ••C₁₋₅ alkyl substituted by halogen, ••C₁₋₅ alkoxy, and ••C₁₋₅ alkoxy substituted by halogen, •mono-C₁₋₅ alkylamino, •di-C₁₋₅ alkylamino, 20 •C₁₋₅ alkylcarbonylamino, •C₃₋₆ cycloalkylcarbonylamino, •C₁₋₅ alkoxy carbonylamino, •carbocyclic aryl azo, *carbocyclic aryl azo substituted by substituent(s) independently selected 25 from the group consisting of: **mono-C₁₋₅ alkylamino, and ••di-C₁₋₅ alkylamino,

 $\cdot C_{1-5}$ alkylthio,

		L. / 1
		•C ₁₋₅ alkylthio substituted by halogen,
		carbocyclic arylthio,
		ecarbocyclic arylthio substituted by nitro,
		°arnino sulfonyl,
5		oheterocyclyl sulfonyl,
		°C ₃₋₆ cycloalkyl,
		°C ₃₋₆ cycloalkyl substituted by C ₁₋₅ alkyl,
		°carbocyclic aryl,
		•carbocyclic aryl substituted by C ₁₋₅ alkoxy,
10		•hydroxy,
		•heterocyclyl, and
		•heterocyclyl substituted by C ₁₋₅ alkyl,
	(vii)	heterocyclyl, and
		heterocyclyl substituted by substituent(s) independently selected from the
15		group consisting of:
		•halogen,
		•C ₁₋₅ alkyl,
		•C ₁₋₅ alkyl substituted by halogen,
		•C ₁₋₅ alkoxy,
20		•C ₁₋₅ alkoxy substituted by halogen,
		•C ₁₋₅ alkoxy carbonyl,
		•C ₁₋₅ alkoxy carbonyl substituted by carbocyclic aryl,
		•carbocyclic aryloxy,
		•carbocyclic aryloxy substituted by substituent(s) independently selected
25		from the group consisting of:
		••halogen,
		••nitro,

••cyano,

275

••hydroxy, ۰۰C₁₋₅ alkyl, [∞]C₁₋₅ alkyl substituted by halogen, «mono-C₁₋₅ alkylamino, 5 **di-C₁₋₅ alkylamino, ∘ C₁₋₅ alkylcarbonylamino, °°C₃₋₆ cycloalkylcarbonylamino, «C₁₋₅ alkoxy, ••C₁₋₅ alkoxy substituted by halogen, 10 ••C₃₋₆ cycloalkyl, ••C₂₋₅ alkenyl, •• C_{2-5} alkynyl, ••carboxy, ••C₁₋₅ alkoxycarbonyl, 15 ••mono-C₁₋₅ alkylaminocarbonyl, ••di-C₁₋₅ alkylaminocarbonyl, ••mono-C₃₋₆ cycloalkylaminocarbonyl, ••di-C₃₋₆ cycloalkylaminocarbonyl, ••mono-C₁₋₅ alkylaminocarbonylamino, 20 ••di-C₁₋₅ alkylaminocarbonylamino, ••mono-C₃₋₆ cycloalkylaminocarbonylamino, ••di-C₃₋₆ cycloalkylaminocarbonylamino, ••C₁₋₅ alkylthio, «•C₁₋₅ alkylthio substituted by halogen, 25 ∘•C₁₋₅ alkylsulfinyl, ••C₁₋₅ alkylsulfinyl substituted by halogen, ••C₁₋₅ alkylsulfonyl, and

••C₁₋₅ alkylsulfonyl substituted by halogen,

276

heterocyclyloxy, oheterocyclyloxy substituted by substituent(s) independently selected from the group consisting of: «halogen, 5 •enitro, ∘∘C₁₋₅ alkyl, «C₁₋₅ alkyl substituted by halogen, «C₁₋₅ alkoxy, and ••C₁₋₅ alkoxy substituted by halogen, 10 •carbocyclic aryl, and •heterocyclyl; R_2 is C_{1-5} alkyl or $-N(R_{2a})(R_{2b})$; wherein R_{2a} and R_{2b} are independently hydrogen or C₁₋₅ alkyl; R_3 is C_{1-5} alkyl; 15 R₄ is -NHNH₂, -NHNHBoc, -N(R_{4a})(R_{4b}), morpholino, 4-acetyl-piperazyl, or 4-phenyl-piperazyl; wherein R4a is hydrogen or C1-5 alkyl; R4b is C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: •hydroxy, $\cdot C_{1.5}$ alkoxy, 20 ·amino, •-NHBoc, •C₃₋₆ cycloalkyl, •carbocyclic aryl, •carbocyclic aryl substituted by substituent(s) independently selected from 25 the group consisting of: ··halogen,

••C₁₋₅ alkyl,

••C₁₋₅ alkoxy, and

••-SO₂NH₂, and

·heterocyclyl,

C₃₋₆ cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

5

·halogen,

°C₁₋₅ alkyl,

 ${}^{\varsigma}C_{1-5}$ alkoxy, and

a group of Formula (III):

10

wherein Boc is carbamic acid *tert*-butyl ester and G is C_{1-5} alkyl or C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

•carbocyclic aryl,

15

•halogenated carbocyclic aryl, and

•carbocyclic aryl substituted by C₁₋₅ alkoxy;

L is selected from the group consisting of Formulae (IV) to (XIX):

20

10

15

20

wherein R_5 and R_6 are independently hydrogen or C_{1-5} alkyl; and A and B are independently a single bond, $-CH_2$ -, or $-(CH_2)_2$ -;

 X_1 , X_2 , X_3 and X_4 are independently selected from the group consisting of hydrogen, halogen, C_{1-4} alkyl, C_{1-4} alkyl substituted by halogen, C_{1-4} alkylthio, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfonyl, C_{1-4} alkoxy, C_{1-4} alkoxy substituted by halogen, nitro, amino, mono- C_{1-4} alkylamino, di- C_{1-4} alkylamino, piperidyl, morpholinyl, mono- C_{1-4} alkylaminosulfonyl, di- C_{1-4} alkylaminosulfonyl and hydroxy; provided that at least one substituent selected from the group consisting of X_1 , X_2 , X_3 and X_4 is not hydrogen; and

Y is selected from the group consisting of:

5

10

15

20

- (i) -C(O)NR₇-, -C(S)NR₇-, or -C(O)O- when L is selected from the group
 consisting of Formulae (IV) to (IIII); wherein R₇ is hydrogen or C₁₋₅ alkyl;
- (ii) -S(O)₂-, -C(O)-, a single bond or -CH₂- when L is selected from the group consisting of Formulae (IV) to (XI), and Q is Formula (IIa) or (IIb);
- (iii) -S(O)₂-, -C(O)-, a single bond or -CH₂- when L is selected from the group consisting of Formulae (VII) to (XI), and Q is Formula (He); and
- (iv) -OC(O)- when L is selected from the group consisting of Formulae (XII) to (XIX);

wherein carbocyclic aryl is phenyl, naphthyl, or biphenyl; carbocyclyl is indanyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, adamantly, 9*H*-fluorenyl, menthyl, 1,2,3,4-tetrahydro-naphthalen-1-yl, or 1*H*-indolyl;

heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl,
3,4-dihydro-2*H*-benzo[b][1,4]dioxepinyl, 4,5,6,7-tetrahydro-benzo[b]thienyl,
4*H*-benzo[1,3]dioxinyl, benzo[1,3]dioxolyl, benzo[2,1,3]thiadiazolyl,
benzothiazolyl, furyl, isoxazolyl, morpholinyl, oxazolyl, piperidyl, pyrazolyl, pyridyl,
tetrahydrofuryl, thienyl, dibenzofuranyl, 1*H*-benzoimidazolyl, or thiazolyl; and
halogen is fluoro, chloro, bromo, or iodo;

- The compound according to claim 1 wherein Q is Formulae (IIa), (IIb), or (IIc);
 R₁ is selected from the group consisting of:
- (i) C₁₋₈ alkyl, and

 C₁₋₈ alkyl substituted by substituent(s) independently selected from the group consisting of:

 •halogen,

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

•C₁₋₅ alkoxy carbonyl,

280

•C₁₋₅ alkoxy, $\circ C_{1-5}$ alkoxy substituted by carbocyclic aryl, omono-C₁₋₅ alkylamino, «di-C₁₋₅ alkylamino, 5 •C_{3.6} cycloalkyl, °C₃₋₆ cycloalkenyl, ecarbocyclyl, ecarbocyclic aryl, •carbocyclic aryl substituted by substituent(s) independently selected from 10 the group consisting of: ••hydroxy, ••halogen, ••nitro, ••C₁₋₅ alkylcarbonylamino, 15 ••C₃₋₆ cycloalkylcarbonylamino, $\cdot \cdot C_{1-5}$ alkyl, ••C₁₋₅ alkyl substituted by halogen, ••C₁₋₅ alkylsulfonyl, ••C₂₋₆ alkenyl, 20 ••C₁₋₅ alkoxy, ••C₁₋₅ alkoxy substituted by halogen, and ••carbocyclic aryl, •heterocyclyl, and *heterocyclyl substituted by halogen, 25 (ii) C₂₋₅ alkenyl, and C₂₋₅ alkenyl substituted by carbocyclic aryl, C₂₋₅ alkynyl, (iii)

(iv)

C₃₋₁₂ cycloalkyl, and

WO 2004/087680

5

10

15

20

25

281 C₃₋₁₂ cycloalkyl substituted by carbocyclic aryl. (v) carbocyclyl, and carbocyclyl by substituent(s) independently selected from the group consisting of: hydroxy, and ecarbocyclic aryl, (vi) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: ·halogen, •cyano, •nitro, •C₁₋₁₀ alkyl, •C₁₋₁₀ alkyl substituted by substituent(s) independently selected from the group consisting of: ••halogen, ••oxo, and ••carbocyclic aryl, carboxy, •C₁₋₅ alkoxy carbonyl, \cdot C₁₋₇ alkoxy, •C₁₋₇ alkoxy substituted by substituent(s) independently selected from the group consisting of: ••halogen, and • carbocyclic aryl, carbocyclic aryloxy,

•carbocyclic aryloxy substituted by nitro,

•mono-C₁₋₅ alkylamino,

282

		•di-C ₁₋₅ alkylamino,
		°C ₁₋₅ alkoxy carbonylamino,
		ecarbocyclic aryl ago,
		ocarbocyclic aryl azo substituted by substituent(s) independently selected
5		from the group consisting of:
		**mono-C ₁₋₅ alkylamino, and
		···di-C ₁₋₅ alkylamino,
		•C ₁₋₅ alkylthio,
		•C ₁₋₅ alkylthio substituted by halogen,
10		•carbocyclic arylthio,
		•carbocyclic arylthio substituted by nitro,
		•amino sulfonyl,
		•heterocyclyl sulfonyl,
		•C ₃₋₆ cycloalkyl,
15		•C ₃₋₆ cycloalkyl substituted by C ₁₋₅ alkyl,
		•carbocyclic aryl,
		•heterocyclyl, and
		•heterocyclyl substituted by C ₁₋₅ alkyl,
	(vii)	heterocyclyl, and
20		heterocyclyl substituted by substituent(s) independently selected from the
		group consisting of:
		•halogen,
		$\bullet C_{1-5}$ alkyl,
		•C ₁₋₅ alkyl substituted by halogen,
25		${}^{\circ}C_{1-5}$ alkoxy,
		•C ₁₋₅ alkoxy carbonyl,
		•C ₁₋₅ alkoxy carbonyl substituted by carbocyclic aryl,
		•carbocyclic aryloxy,

283

·carbocyclic aryl, and

cheterocyclyl;

 R_2 is -N(R_{2a})(R_{2b}), wherein R_{2a} is hydrogen or C_{1-5} alkyl; R_{2b} is C_{1-5} alkyl; R_3 is C_{1-5} alkyl;

5

 R_4 is -N(R_{4a})(R_{4b}) wherein R_{4a} is hydrogen or $C_{1.5}$ alkyl; R_{4b} is $C_{1.5}$ alkyl; L is selected from Formula (V), (VIII), (III), (III), (IIVI), or (IIVII); X_1, X_2, X_3 and X_4 are independently selected from the group consisting of hydrogen, halogen, and $C_{1.4}$ alkyl; provided that at least one substituent selected from the group consisting of X_1, X_2, X_3 and X_4 is not hydrogen; and

10

Y is selected from the group consisting of:

- (i) $-C(O)NR_7$ -, $-C(S)NR_7$ -, or -C(O)O- when L is selected from the group consisting of Formula (V), (VIII), (IX), (XIII), (XVI), or (XVII); wherein R_7 is hydrogen or C_{1-5} alkyl;
- (ii) $-S(O)_2$ -, -C(O)-, a single bond or $-CH_2$ when L is selected from the group consisting of Formula (VIII) or (IX); and
- (iii) -OC(O)- when L is selected from the group consisting of Formula (XIII), (XVI), or (XVII);

wherein carbocyclic aryl is phenyl or naphthyl;
carbocyclyl is indanyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl,
adamantly, 9H-fluorenyl, menthyl, 1,2,3,4-tetrahydro-naphthalen-1-yl, or

20

1*H*-indolyl;

15

heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl,

3,4-dihydro-2*H*-benzo[b][1,4]dioxepinyl, 4,5,6,7-tetrahydro-benzo[b]thienyl, 4*H*-benzo[1,3]dioxinyl, benzo[1,3]dioxolyl, benzo[2,1,3]thiadiazolyl,

25

benzothiazolyl, furyl, isoxazolyl, morpholinyl, oxazolyl, piperidyl, pyrazolyl, pyridyl, tetrahydrofuryl, thienyl, dibenzofuranyl, 1H-benzoimidazolyl, or thiazolyl; and

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

halogen is fluoro, chloro, bromo, or iodo;

WO 2004/087680

3. The compound according to claim 2 wherein Q is Formula (He); or a pharmaceutically acceptable salt, hydrate or solvate thereof.

5 4. The compound according to claim 3 wherein R_1 is selected from the group consisting of:

(i) C_{1-5} alkyl, and

C_{1.5} alkyl substituted by substituent(s) independently selected from the group consisting of:

 $\cdot C_{1-5}$ alkoxy carbonyl,

10 •carbocyclic aryl,

15

20

25

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

··halogen,

••C₁₋₅ alkyl,

••C₂₋₅ alkenyl, and

••C₁₋₅ alkoxy,

•C₁₋₅ alkylthio, and

·heterocyclyl,

(ii) C₃₋₆ cycloalkyl, and

C₃₋₆ cycloalkyl substituted by carbocyclic aryl,

(iii) carbocyclyl,

(iv) carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

^chalogen,

*cyano,

•nitro,

•C₁₋₅ alkyl,

285

•C₁₋₅ alkyl substituted by substituent(s) independently selected from the group consisting of: ⇔halogen, ∞oxo, and 5 ecarbocyclic aryl, °C₁₋₅ alkoxy carbonyl, °C₁₋₇ alkoxy, ${}^{\circ}C_{1.7}$ alkoxy substituted by substituent(s) independently selected from the group consisting of: 10 ··halogen, and ••carbocyclic aryl, •cycloalkoxy, •carbocyclic aryloxy, •mono-C₁₋₅ alkylamino, 15 •di-C₁₋₅ alkylamino, $\cdot C_{1-5}$ alkylthio, •C₁₋₅ alkylthio substituted by halogen, •carbocyclic aryl, •heterocyclyl, and 20 •heterocyclyl substituted by C_{1.5} alkyl, (v) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: ·halogen, 25 °C₁₋₅ alkyl, •C₁₋₅ alkyl substituted by halogen, •C₁₋₅ alkoxy carbonyl •C₁₋₅ alkoxy carbonyl substituted by carbocyclic aryl, and

286

```
carbocyclic aryl;
```

L is Formula (V);

and

Y is $-C(O)NR_7$; wherein R_7 is hydrogen or C_{1-5} alkyl;

5 wherein carbocyclic aryl is phenyl or naphthyl;

carbocyclyl is indanyl, adamantly, or 9H-fluorenyl;

heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl,

3,4-dihydro-2*H*-benzo[b][1,4]dioxepinyl, 4*H*-benzo[1,3]dioxinyl,

benzo[1,3]dioxolyl, benzothiazolyl, furyl, isoxazolyl, piperidyl, pyridyl, or thienyl;

10 and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

- 5. The compound according to claim 4 wherein R_{4a} is hydrogen or methyl; R_{4b} is methyl; R_5 and 15 R_6 are hydrogen; A is a single bond and B is a single bond or -CH₂-; and R_7 is hydrogen; or a pharmaceutically acceptable salt, hydrate or solvate thereof.
 - 6. The compound according to claim 5 wherein R₁ is selected from the group consisting of:
 - (i) C₁₋₅ alkyl, and

20 C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of:

- •C₁₋₅ alkoxy carbonyl,
- •carbocyclic aryl,

*carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

··halogen,

- $\cdot \cdot C_{1-5}$ alkyl,
- ••C₂₋₅ alkenyl, and

25

WO 2004/087680

287

		••C ₁₋₅ alkoxy,
		°C ₁₋₅ alkylthio, and
		«heterocyclyl,
	(ii)	C ₃₋₆ cycloalkyl, and
5		C ₃₋₆ cycloalkyl substituted by carbocyclic aryl,
	(iii)	carbocyclyl,
	(iv)	carbocyclic aryl, and
		carbocyclic aryl substituted by substituent(s) independently selected from the
		group consisting of:
10		•halogen,
		•cyano,
		•nitro,
		•C _{1.5} alkyl,
		•C ₁₋₅ alkyl substituted by halogen,
15		•C ₁₋₅ alkoxy carbonyl,
		${}^{\bullet}C_{1-5}$ alkoxy,
		• C_{1-5} alkoxy substituted by halogen,
		•cycloalkoxy,
		•carbocyclic aryloxy,
20		•C ₁₋₅ alkylthio, and
		•carbocyclic aryl,
	(v)	heterocyclyl, and
		heterocyclyl substituted by substituent(s) independently selected from the
		group consisting of:
25		°halogen,
		•C ₁₋₅ alkyl,
		${}^{\bullet}C_{1-5}$ alkyl substituted by halogen, and
		•carbocyclic aryl;

288

wherein carbocyclic aryl is phenyl or naphthyl;
carbocyclyl is 9H-fluorenyl;
heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl,
3,4-dihydro-2H-benzo[b][1,4]dioxepinyl, 4H-benzo[1,3]dioxinyl,
benzo[1,3]dioxolyl, furyl, isoxazolyl, or thienyl; and
halogen is fluoro, chloro, bromo, or iodo;
or a pharmaceutically acceptable salt, hydrate or solvate thereof.

7. The compound according to claim 6 wherein R_1 is selected from the group consisting of:

 $10 \hspace{1.5cm} \text{(i)} \hspace{1.5cm} C_{1.5} \hspace{0.1cm} \text{alkyl, and}$

15

25

C₁₋₅ alkyl substituted by substituent(s) independently selected from the group consisting of:

•C₁₋₅ alkoxy carbonyl,

•carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

- ••halogen,
- ••C₁₋₅ alkyl, and
- ••C₂₋₅ alkenyl,

20 $\cdot C_{1-5}$ alkylthio,

(ii) C_{3.6} cycloalkyl, andC_{3.6} cycloalkyl substituted by carbocyclic aryl,

(iii) carbocyclic aryl, andcarbocyclic aryl substituted by substituent(s) independently selected from thegroup consisting of:

·halogen,

•cyano,

•nitro,

289

```
•C<sub>1-5</sub> alkyl,
                                  {}^{\circ}C_{1-5} alkyl substituted by halogen,
                                  {}^{\circ}C_{1-5} alkoxy carbonyl,
                                  ·C<sub>1-5</sub> alkoxy,
 5
                                  ecycloalkoxy,

    carbocyclic aryloxy,

                                  °C<sub>1-5</sub> alkylthio, and
                                  *carbocyclic aryl,
                        (iv)
                                 heterocyclyl, and
10
                                  heterocyclyl substituted by substituent(s) independently selected from the
                                  group consisting of:
                                  •C<sub>1-5</sub> alkyl,
                                  •C<sub>1-5</sub> alkyl substituted by halogen, and
                                  •carbocyclic aryl;
15
                                  wherein carbocyclic aryl is phenyl or naphthyl;
                                 heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl,
                        3,4-dihydro-2H-benzo[b][1,4]dioxepinyl, benzo[1,3]dioxolyl, furyl, or isoxazolyl;
                        and
                                 halogen is fluoro, chloro, bromo, or iodo;
20
                        or a pharmaceutically acceptable salt, hydrate or solvate thereof.
```

8. The compound according to claim 1 selected from the group consisting of:

N-benzyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-(2-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-biphenyl-2-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-(4-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-butyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-cyclohexyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;

N-(2-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea; N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,6-dimethylphenyl)-

N-(2.4-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)-

5 urea;

urea;

N-(2,4-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,3-dimethylphenyl)urea;

ethyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}-10 amino)benzoate;

ethyl 4-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}amino)benzoate;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-ethylphenyl)urea;

15 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethyl-6methylphenyl)urea;

ethyl N-{[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}leucinate;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-fluorophenyl)urea;

20 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[1-(3isopropenylphenyl)-1-methylethyllurea;

methyl N-{[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}methioninate:

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(4-methoxyphenyl)-

25 urea:

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxyphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3-methoxyphenyl)-

urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[4-(methylthio)-phenyl]urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-methoxybenzyl)-

5 urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-1-naphthylurea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[(2S)-2-phenylcyclopropyl]urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-phenylurea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-phenoxyphenyl)-urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-pentylurea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[2-(trifluoromethyl)-phenyl]urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-methylphenyl)urea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-mesitylurea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3-methylphenyl)urea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methylphenyl)urea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[1-(1-naphthyl)ethyl]-

20 urea;

methyl N-{[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}-phenylalaninate;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,4,6-trichlorophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(1-phenylethyl)urea;

1-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3-(1-phenyl-ethyl)-urea;

1-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3-(1-naphthalen-1-yl-ethyl)-urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-[2-(methylthio)-

phenyl]urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,3,5,6-tetrachlorophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,3-dimethyl-6-

5 nitrophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,4,6-tribromophenyl)urea;

N-(2,4-dibromo-6-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

10 N-(2,4-dibromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-urea;

N-(2,4-dichlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-urea;

N-(2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

15 cyclohexyl)urea;

 $N-(2,5-dimethoxyphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)urea;\\$

N-(2,6-diethylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-urea;

20 N-(2-chloro-5-nitrophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

N-[2-chloro-6-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]-amino}cyclohexyl)urea;

 $N-(2-chloro-6-methylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-1-(dimethylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-1-(dimethylphenyl)-N'-(dimethylph$

25 cyclohexyllurea;

N-(2-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea; N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-ethoxyphenyl)urea; N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-ethyl-6isopropylphenyl)urea;

10 nitrophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethylphenyl)urea;

N-(cis-4-{[4-(dimethylamine)quinazolin-2-yl]amine} cyclohexyl)-N'-(2-fluorobenzyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-iodophenyl)urea;

5 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-isopropyl-6-methylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-isopropylphenyl)-urea:

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxy-4-

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxy-5-methylphenyl)urea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2-methyl-3-nitrophenyl)urea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methyl-4-nitrophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methyl-5-nitrophenyl)urea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2-methylbenzyl)urea;$

20 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-nitrophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-propylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-phenoxyphenyl)-

urea;

N-(2-tert-butyl-6-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

25 cyclohexyl)urea;

N-(2-tert-butylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[3-(methylthio)-

phenyl]urea;

 $N-1, 3-benzo dioxol-5-yl-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-urea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3,4,5-

5 trimethoxyphenyl)urea;

N-(3,4-dichlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)-urea;

N-(3,4-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-urea;

10 N-(3,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

 $N-(3,5-difluor ophenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-urea;$

N-(3,5-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

15 cyclohexyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3,5-dimethylphenyl)-urea;

methyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}-amino)benzoate;

20 N-(3-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

N-(3-chloro-4-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

 $N-(3-chloro-4-methoxyphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-(dimethylamino)quinazolin-2-yl]$

25 cyclohexyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(3-ethylphenyl)urea; N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(3-fluorobenzyl)urea; N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-

yl]amino}cyclohexyl)urea;

N-(4-bromo-2,6-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea:

N-(4-bromobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)urea;

5 N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(4-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

N-(4-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-ethoxyphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-fluoro-2-

nitrophenyl)urea;

10

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-fluorobenzyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-iodophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(4-methoxy-2-methylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-methylbenzyl)urea;

N-(5-chloro-2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(5-fluoro-2-methylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-9H-fluoren-9-ylurea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-phenylethyl)urea;

N-cyclopentyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

25 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(diphenylmethyl)urea;

N-[1-(4-bromophenyl)ethyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

cyclohexyl)urea;

N-(4-bromo-2,6-dimethylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

296

cyclohexyl)urea;

N-(4-bromo-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohemyl)urea;

ethyl N-{[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}-

5 phenylalaninate;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[2-(2-thienyl)ethyl]urea;

N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2yl]amino}cyclohexyl)urea;

10 N-(2,6-dibromo-4-isopropylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2yl]amino}cyclohexyl)urea;

N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-15 yl]amino}cyclohexyl)urea;

N-(4-butyl-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[5-methyl-2-(trifluoromethyl)-3-furyl]urea;

20 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(6-fluoro-4H-1,3benzodioxin-8-yl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N-(3,5-dimethylisoxazol-4-yl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3-methyl-5-

25 phenylisoxazol-4-yl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-N'-(5-methyl-3phenylisoxazol-4-yl)urea;

N-(2-bromophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-

297

methyl]urea;

N-biphenyl-2-yl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-butyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea;

5 N-(3-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-cyclohexyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(3-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-10 methyl]urea;

N-(2-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,6dimethylphenyl)urea;

15 N-(3,4-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(2,4-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(2,4-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-20 methyl]urea;

N-(3,5-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(2,3-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

25 N-(2,6-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,3dimethylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4ethylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-(2-ethyl-6methylphenyl)urea;

5 ethyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonyl)leucinate;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4fluorophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-

10 fluorophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2fluorophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[1-(3isopropenylphenyl)-1-methylethyl]urea;

15 $methyl\ N-(\{[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]amino\}-((dimethylamino)quinazolin-2-yl]amino)+((dimethylamino)quinazolin-2-yl]amino((dimethylamino)quinazolin-2-yl)+((dimethylamino)quinazolin-2$ carbonyl)methioninate;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4methoxyphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-methyl-2-20 nitrophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2methoxyphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3methoxyphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[4-25 (methylthio)phenyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-1naphthylurea;

299

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-phenylurea;\\$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-pentylurea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)methyl]-N'-[2-(trifluoromethyl)phenyl]urea;\\$

5 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-methylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-mesitylurea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,4,6-trichlorophenyl)urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) methyl]-N'-(1-yl) amino \} cyclohexyl) methyl - N'-(1-yl) amino \} cycl$

15 phenylethyl)urea;

 $1\hbox{-}[4\hbox{-}(4\hbox{-}dimethylamino\hbox{-}quinazolin\hbox{-}2-ylamino)\hbox{-}cyclohexylmethyl]\hbox{-}3\hbox{-}(1\hbox{-}phenyl\hbox{-}ethyl)\hbox{-}urea;}$

1-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-3-(1-naphthalen-1-ylethyl)-urea;

 $N-(2,6-diisopropylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-1]-(2,6-diisopropylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino}-1]-(2,6-diisopropylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino}-1]-(2,6-diisopropylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino}-1]-(2,6-diisopropylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino}-1]-(2,6-diisopropylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino}-1]-(2,6-diisopropylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino}-1]-(2,6-diisopropylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino}-1]-(2,6-diisopropylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino}-1]-(2,6-diisopropylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino}-1]-(2,6-diisopropylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino}-1]-(2,6-diisopropylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino}-1]-(2,6-diisopropylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino}-1]-(2,6-diisopropylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino}-1]-(2,6-diisopropylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino}-1]-(2,6-diisopropylphenyl)-N'-[(cis-4-(dimethylamino)quinazolin-2-yl]-(2,6-diisopropylphenyl)-N'-[(cis-4-(dimethylamino)quinazolin-2-yl]-(2,6-diisopropylphenyl)-(2,6-diisopropylphenylph$

20 cyclohexyl)methyl]urea;

N-[2-(difluoromethoxy)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[2-(methylthio)phenyl]urea;

25 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,3,5,6-tetrachlorophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,3-dimethyl-6-nitrophenyl)urea;

- N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,4,6-tribromophenyl)urea;
- $N-(2,4-dibromo-6-fluorophenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino)-cyclohexyl)methyl]urea;\\$
- 5 N-(2,4-dichlorobenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;
 - N-(2,5-dimethoxyphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;
- N-(2,6-dibromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-10 cyclohexyl)methyl]urea;
 - N-(2,6-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;
 - N-(2,6-diethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;
- N-(2-chloro-5-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;
 - N-[2-chloro-6-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]-amino}cyclohexyl)methyl]urea;
- N-(2-chloro-6-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-20 cyclohexyl)methyl]urea;
 - $N-(2-chlorobenzyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)-methyl]urea;$
 - N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethyl-6-isopropylphenyl)urea;
- N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethylphenyl)urea;
 - N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-fluoro-5-nitrophenyl)urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(2-fluorobenzyl)urea;$

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)methyl]-N'-(2-iodophenyl)urea;\\$

5 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-isopropyl-6-methylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-isopropylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methoxy-5-10 methylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methoxy-5-nitrophenyl)urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} eyclohexyl) methyl]-N'-(2-methyl-3-nitrophenyl) urea;$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methyl-4-nitrophenyl)urea;

 $N-[(\text{cis-4-}\{[4-(\text{dimethylamino})\text{quinazolin-2-yl}]\text{amino}}) \text{ cyclohexyl}) \text{methyl}]-N'-(2-\text{methyl-5-nitrophenyl}) \text{ urea};$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methyl-6-20 nitrophenyl)urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) methyl]-N'-(2-methylbenzyl) urea;$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-nitrophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-propylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-phenoxyphenyl)urea;

302

N-(2-tert-butyl-6-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

N-(2-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;

5 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-[3-(methylthio)phenyl]urea;

N-(3,4-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;

N-(3,5-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-10 methyl]urea;

 $N-(3,5-dimethoxyphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)methyl]urea;\\$

 $N-(3-chloro-2-methylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)methyl]urea;\\$

N-(3-chloro-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) methyl]-N'-(3-ethylphenyl) urea;$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[3-fluoro-5-20 (trifluoromethyl)phenyl]urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(3-fluorobenzyl)urea;\\$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4,5-dimethyl-2-nitrophenyl)urea;

N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(4-bromo-2,6-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2yl]amino}cyclohexyl)methyl]urea;

M-(4-chloro-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinacolin-2-yl]amino)cyclohexyl)methyl]urea;

N-(4-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-5 methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-fluoro-2nitrophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-

10 fluorobenzyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4iodophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-methoxy-2methylphenyl)urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl) methyl]-N'-(4-methyl-3-yl) methyl-3-yl) meth$ 15 nitrophenyl)urea;

 $N-(5-chloro-2-methylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-1]-(dimethylamino)-1]-(di$ cyclohexyl)methyl]urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclohexyl) methyl]-N'-(5-fluoro-2-yl) methyllon met$ 20 methylphenyl)urea;

N-cyclopentyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(diphenylmethyl)urea;

N-(4-bromo-2,6-dimethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-25 cyclohexyl)methyl]urea;

N-(4-bromo-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(2,6-dibromo-4-isopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl)methyl]-N'-3-thienylurea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[5-methyl-2-

5 (trifluoromethyl)-3-furyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(6-fluoro-4H-1,3-benzodioxin-8-yl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3,5-dimethylisoxazol-4-yl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methyl-5-phenylisoxazol-4-yl)urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(5-methyl-3-phenylisoxazol-4-yl)urea; and$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[3-(trifluoromethoxy)-15 phenyl]urea;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

- 9. The compound according to claim 1 selected from the group consisting of:

 N-(2-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;
- 20 N-biphenyl-2-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-butyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

 $N-(2-chlorophenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) urea;\\$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,6-dimethylphenyl)-

urea;

- N-(2,4-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;
 - $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclohexyl)-N'-(2,3-dimethylphenyl)-urea;$

ethyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}-amino)benzoate;

 $N-(cis-4-\{[4-(dimethylamino)quinacolin-2-yl]amino) cyclohexyl)-N'-(2-ethyl-6-methylphenyl)urea;\\$

5 ethyl N-{[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]-carbonyl} leucinate;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(4-fluorophenyl)urea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-[1-(3-isopropenylphenyl)-1-methylethyl]urea;

methyl N-{[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]-carbonyl} methioninate;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[4-(methylthio)phenyl]urea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-1-naphthylurea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[(2S)-2-phenylcyclopropyl]urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-phenoxyphenyl)urea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-pentylurea;$

20 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[2-(trifluoromethyl)-phenyl]urea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-mesitylurea;$

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2-methylphenyl)urea;$

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-[1-(1-naphthyl)ethyl]-N'-[1-$

25 urea;

methyl N-{[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)amino]carbonyl}-phenylalaninate;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,4,6-

306

trichlorophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(1-phenylethyl)urea;
1-[4-(4-Dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-3-(1-phenyl-ethyl)-urea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2,3,5,6-

5 tetrachlorophenyl)urea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2,4,6-tribromophenyl)urea;$

N-(2,4-dibromo-6-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

10 N-(2,4-dibromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-urea;

N-(2,4-dichlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-urea;

N-(2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

15 cyclohexyl)urea;

N-(2,6-diethylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-urea;

N-[2-chloro-6-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]-amino}cyclohexyl)urea;

20 N-(2-chloro-6-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

N-(2-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)urea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-ethoxyphenyl)urea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-ethyl-6-

25 isopropylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-ethylphenyl)urea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-fluorobenzyl)urea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-iodophenyl)urea;

WO 2004/087680

PCT/JP2004/004554

307

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-isopropyl-6-methylphenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinacolin-2-yl]amino}cyclohexyl)-N'-(2-isopropylphenyl)-urea;

5 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methyl-3-nitrophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methyl-4-nitrophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methyl-5-

10 nitrophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methylbenzyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-nitrophenyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-propylphenyl)urea;

N-(2-tert-butyl-6-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

15 cyclohexyl)urea;

N-(2-tert-butylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-urea:

N-1,3-benzodioxol-5-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3,4,5-trimethoxyphenyl)urea;

N-(3,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

 $N-(3-chloro-2-methylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-1-(dimethylamino)quinazolin-2-yl]$

25 cyclohexyl)urea;

N-(3-chloro-4-methoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)urea;

N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]-

308

amino) cyclohexyl) urea;

N-(4-bromo-2,6-difluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohenyl)urea;

N-(4-bromobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

5 N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino) cyclohexyl) urea;

N-(4-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(4-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

10 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-fluorobenzyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-methoxy-2methylphenyl)urea;

N-(5-chloro-2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

15 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(diphenylmethyl)urea; N-[1-(4-bromophenyl)ethyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

N-(4-bromo-2,6-dimethylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

20 N-(4-bromo-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea;

ethyl N-{[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonyl}phenylalaninate;

N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-

25 yl]amino} cyclohexyl)urea;

N-(2,6-dibromo-4-isopropylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2yl]amino}cyclohexyl)urea;

N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-

yl]amino}cyclohexyl)urea;

N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)urea:

N-(4-butyl-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

5 cyclohexyl)urea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[5-methyl-2-(trifluoromethyl)-3-furyl]urea;

 $N-(\circ is-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(3-methyl-5-phenylisoxazol-4-yl)urea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(5-methyl-3-phenylisoxazol-4-yl)urea;

N-(2-chlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,6-

15 dimethylphenyl)urea;

N-(2,4-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;

N-(3,5-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;

20 N-(2,3-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)methyl]-N'-(2,3-dimethylphenyl)urea;$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethyl-6-

25 methylphenyl)urea;

ethyl N-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]amino}-carbonyl)leucinate;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(4-dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(4-dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(4-dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methylamino|cyclohexyl]-N'-(4-dimethylamino)quinazolin-2-yl]amino|cyclohexyl]-N'-(4-dimethylamino)quinazolin-2-yl]amino|cyclohexyl]-N'-(4-dimethylamino)quinazolin-2-yl]amino|cyclohexyl]-N'-(4-dimethylamino)quinazolin-2-yl]amino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|cyclohexylamino|c$

fluorophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[4-(methylthio)phenyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-phenylurea;

5 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[2-(trifluoromethyl)phenyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-methylphenyl)urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) methyl]-N'-mesitylurea;$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,4,6-trichlorophenyl)urea;

N-(2,6-diisopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

15 cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,3-dimethyl-6-nitrophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,4,6-tribromophenyl)urea;

20 N-(2,4-dibromo-6-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

N-(2,6-dibromo-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]urea;

N-(2,6-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-25 methyl]urea;

N-(2,6-diethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;

N-[2-chloro-6-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]-

amino}cyclohexyl)methyl]urea;

 $N-(2-chloro-6-methylphenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)methyl]urea;$

N-(2-chlorobenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-5 methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethyl-6-isopropylphenyl)urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(2-ethylphenyl)urea; \\$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-iodophenyl)urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) methyl]-N'-(2-isopropyl-6-methylphenyl) urea;$

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) methyl]-N'-(2-yl) amino (all continuo proposition of the prop$

15 isopropylphenyl)urea;

25 cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methoxy-5-methylphenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methyl-3-nitrophenyl)urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-methyl-6-nitrophenyl)urea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-(2-propylphenyl)urea;$

N-(2-tert-butyl-6-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

N-(2-tert-butylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]urea;

 $N-(3,4-difluor ophenyl)-N'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)-n'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)-n'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl)-n'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl)-n'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl)-n'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl)-n'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl)-n'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl)-n'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl)-n'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl)-n'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl)-n'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl)-n'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-n'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-n'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-n'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-n'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-n'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-n'-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-n'-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-n'-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-n'-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-n'-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-n'-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-n'-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-n'-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-n'-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-n'-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-n'-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-n'-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexyl]-n'-[(cis-4-(dimethylamino)quinazolin-2-yl]amino]cyclohexylamino[cis-4-(dimethylamino)quinazolin-2-yl]amino[cis-4-(dimethylamino)quinazolin-2-yl]$

methyl]urea;

N-(3,5-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(3-chloro-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-5 cyclohexyl)methyl]urea;

N-(3-chloro-4-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-(4-bromo-2,6-difluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]-10 amino } cyclohexyl) methyl] urea;

N-(4-cyanophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-

15 (diphenylmethyl)urea;

N-(4-bromo-2,6-dimethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]urea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-[5-methyl-2-(trifluoromethyl)-3-furyl]urea; and

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(3-methyl-5-20 phenylisoxazol-4-yl)urea;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

•mono-C₁₋₅ alkylamino,

- The compound according to claim 3 wherein R₁ is selected from the group consisting of: 10.
- C₁₋₈ alkyl, and 25 (i) C₁₋₈ alkyl substituted by substituent(s) independently selected from the group consisting of:

313

```
•di-C<sub>1-5</sub> alkylamino,
                                   •C<sub>3-6</sub> cycloalkyl,
                                   °C<sub>3-6</sub> cycloalkenyl,
                                   ecarbocyclic aryl,
                                   «carbocyclic aryl substituted by substituent(s) independently selected from
 5
                                   the group consisting of:
                                            «halogen,
                                            «C<sub>1-5</sub> alkyl, and
                                             ••C<sub>1-5</sub> alkoxy,
10
                                   •heterocyclyl,
                         (ii)
                                   C<sub>2-5</sub> alkynyl,
                                   C2-5 alkenyl, and
                         (iii)
                                   C<sub>2-5</sub> alkenyl substituted by carbocyclic aryl,
                         (iv)
                                   C<sub>3-12</sub> cycloalkyl,
15
                         (v)
                                   carbocyclyl,
                                   carbocyclic aryl, and
                         (vi)
                                   carbocyclic aryl substituted by substituent(s) independently selected from the
                                   group consisting of:
                                   ·halogen,
20
                                   •cyano,
                                   •nitro,
                                   •C<sub>1-10</sub> alkyl,
                                   {}^{\bullet}C_{1-10} alkyl substituted by substituent(s) independently selected from the
                                   group consisting of:
25
                                             «halogen, and
                                             **OXO.
                                   ·carboxy,
```

•C₁₋₅ alkoxy carbonyl,

314

•C_{1.5} alkoxy, °C₁₋₅ alkoxy substituted by substituent(s) independently selected from the group consisting of: ∞halogen, and 5 **carbocyclic aryl, ocarbocyclic aryloxy, ecarbocyclic aryloxy substituted by nitro, *mono-C_{1.5} alkylamino, •di-C₁₋₅ alkylamino, 10 •C₁₋₅ alkoxy carbonylamino, •carbocyclic aryl azo, •carbocyclic aryl azo substituted by substituent(s) independently selected from the group consisting of: ••mono-C₁₋₅ alkylamino, and 15 ••di-C₁₋₅ alkylamino, •C₁₋₅ alkylthio, •C₁₋₅ alkylthio substituted by halogen, •carbocyclic arylthio, •carbocyclic arylthio substituted by nitro, 20 •amino sulfonyl, •heterocyclyl sulfonyl, •C₃₋₆ cycloalkyl, •C₃₋₆ cycloalkyl substituted by C_{1-5} alkyl, *carbocyclic aryl, and 25 cheterocyclyl, (vii) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the

group consisting of:

•C	-	alk	v1	
- 0 1	- 5	anx	γı	•

•C₁₋₅ alkoxy carbonyl,

ecarbocyclic arylony.

ecarbocyclic aryl, and

cheterocyclyl;

L is Formula (V); and

Y is $-C(S)NR_7$; wherein R_7 is hydrogen or C_{1-5} alkyl;

wherein carbocyclic aryl is phenyl or naphthyl;

carbocyclyl is indanyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, or

10 adamantly;

5

15

20

heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl,

4,5,6,7-tetrahydro-benzo[b]thienyl, benzo[1,3]dioxolyl, benzo[2,1,3]thiadiazolyl, furyl, isoxazolyl, morpholinyl, oxazolyl, piperidyl, pyrazolyl, pyridyl, tetrahydrofuryl,

or thienyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

- The compound according to claim 10 wherein R_{4a} is hydrogen or methyl; R_{4b} is methyl; R_5 and R_6 are hydrogen; A is a single bond; B is a single bond or -CH₂-; and R_7 is hydrogen; or a pharmaceutically acceptable salt, hydrate or solvate thereof.
- 12. The compound according to claim 11 wherein R₁ is selected from the group consisting of:
 - (i) C₁₋₆ alkyl, and

 $C_{1-\delta}$ alkyl substituted by substituent(s) independently selected from the group

consisting of:

•C₃₋₆ cycloalkyl,

•C3-6 cycloalkenyl,

•carbocyclic aryl,

316

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: ∞halogen, ∘∘C₁₋₅ alkyl, and 5 °C1-5 alkoxy, heterocyclyl, C₃₋₁₂ cycloalkyl, (ii) (iii) carbocyclyl, carbocyclic aryl, and (iv) carbocyclic aryl substituted by substituent(s) independently selected from the 10 group consisting of: ·halogen, •cyano, •nitro, 15 •C₁₋₅ alkyl, •C_{1.5} alkyl substituted by halogen, •C₁₋₅ alkoxy carbonyl, •C₁₋₅ alkoxy, •C₁₋₅ alkoxy substituted by halogen, 20 •mono-C₁₋₅ alkylamino, •di-C₁₋₅ alkylamino, •C₁₋₅ alkylthio, and •carbocyclic aryl, heterocyclyl, and (v) heterocyclyl substituted by substituent(s) independently selected from the 25 group consisting of: •C₁₋₅ alkyl,

•C₁₋₅ alkoxy carbonyl, and

317

```
carbocyclic aryl;
                            wherein carbocyclic aryl is phenyl or naphthyl;
                            carbocyclyl is indanyl, bicyclo[2,2,1]heptyl, or bicyclo[2,2,1]heptenyl;
                            heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1,3]dioxolyl,
5
                    isoxazolyl, tetrahydrofuryl, or thienyl; and
                            halogen is fluoro, chloro, bromo, or iodo;
                    or a pharmaceutically acceptable salt, hydrate or solvate thereof.
```

The compound according to claim 12 wherein R₁ is selected from the group consisting of: 13.

10 C₁₋₅ alkyl, and (i) C_{1-5} alkyl substituted by substituent(s) independently selected from the group consisting of: ·carbocyclic aryl, •carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: 15

- ··halogen, and
- ••C₁₋₅ alkoxy,

carbocyclic aryl, and

- (ii) carbocyclyl,
- (iii) carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
 - ·halogen,
 - •cyano,
 - onitro,
- 25 °C₁₋₅ alkyl,

20

- •C₁₋₅ alkyl substituted by halogen,
- •C₁₋₅ alkoxy carbonyl,
- •C₁₋₅ alkoxy,

318

•C₁₋₅ alkoxy substituted by halogen,

ºmono-C₁₋₅ alkylamino,

«di-C₁₋₅ alkylamino, and

carbocyclic aryl,

5 (iv) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

°C₁₋₅ alkyl,

•C₁₋₅ alkoxy carbonyl, and

10 •carbocyclic aryl;

wherein carbocyclic aryl is phenyl or naphthyl;

carbocyclyl is bicyclo[2.2.1]heptyl;

heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1,3]dioxolyl,

isoxazolyl, or thienyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

14. The compound according to claim 1 selected from the group consisting of:

N-(4-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-

20 thiourea;

N-(4-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-thiourea;

N-cyclohexyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-cyclopentyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea;

N-(4-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-

thiourea:

N-(2,4-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-thiourea;

N-(2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

 $N-(ois-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclohexyl)-N'-(2,o-dimethylphenyl)-thiourea;$

5 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethyl-6-isopropylphenyl)thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(4-fluorophenyl)-thiourea;\\$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-hexylthiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-isobutylthiourea;

10

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-methoxybiphenyl-3-yl)thiourea;

N-(1,3-benzodioxol-5-ylmethyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[4-(methylthio)phenyl] -thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(4-methoxyphenyl)-thiourea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxyphenyl)-20 thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-1-naphthylthiourea; \\ N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(4-nitrophenyl)-thiourea; \\ N-(cis-4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(4-nitrophenyl)-thiourea; \\ N-(cis-4-(dimethylamino)quinazolin-2-yl]amino$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(pentafluorophenyl)-25 thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-propylthiourea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3,4,5-trimethoxyphenyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-methylphenyl)thiourea;

N-(3,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-ethylphenyl)-5 thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[2-(methylthio)phenyl]thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-[2-(trifluoromethoxy)-N'-[2-$ 10 phenyl]thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,3,4-trifluorophenyl)thiourea;

N-(2,5-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(2-chloro-4-nitrophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-15 cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethylphenyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-iodophenyl)-20 thiourea:

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxy-4nitrophenyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxy-5methylphenyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(3-iodophenyl)-25 thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3-methoxyphenyl)thiourea;

N-[4-(difluoromethoxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazotin-2-yl]amino} cyclohexyl)-N'-[4-(trifluoromethyl)-phenyl]thiourea;

5 N-(4-bromo-2-chlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-iodophenyl)-thiourea:

N-(5-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

10 cyclohexyl)thiourea;

 $N-[(1S,4R)-bicyclo[2.2.1]hept-2-yl]-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)thiourea;$

 $N-[2-(4-chlorophenyl)ethyl]-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl)thiourea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,4,6-tribromophenyl)thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclohexyl)-N'-(2,4,6-trichlorophenyl)-thiourea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-mesitylthiourea;

20 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,4-dimethylphenyl)-thiourea;

 $N-(2,6-diethylphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-thiourea;\\$

N-(2,6-diisopropylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

25 cyclohexyl)thiourea;

N-(2-bromo-4-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

N-(2-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-

thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethyl-6-methylphenyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-isopropylphenyl)-5 thiourea;

 $N-(3,5-dimethoxyphenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl) thiourea; \\$

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclohexyl)-N'-(3,5-dimethylphenyl)-thiourea;$

N-(3-chloro-4-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

methyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]-carbonothioyl}amino)benzoate;

N-(4-bromo-2,6-dimethylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-

15 yl]amino}cyclohexyl)thiourea;

N-(4-bromo-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

 $N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)thiourea;$

20 N-(4-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-[1-(4-fluorophenyl)-ethyl] thiourea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-fluorobenzyl)-

25 thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclohexyl)-N'-(4-isopropylphenyl)-thiourea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-methoxybenzyl)-

thiourea;

methyl 4-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]-carbonothioyl}amino)benzoate;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(1-phenylethyl)-

5 thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(diphenylmethyl)-thiourea;\\$

 $N-(cyclohexylmethyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)-thiourea;\\$

N-cyclooctyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;
N-cyclopropyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(1-naphthylmethyl)-thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,2-diphenylethyl)-

15 thiourea;

 $N-(2,3-dimethoxybenzyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-thiourea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,4,5-trimethylphenyl)thiourea;

20 N-[2-(2,5-dimethoxyphenyl)ethyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

N-biphenyl-2-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-fluorobenzyl)-thiourea;

25 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methyl-4-nitrophenyl)thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} \ cyclohexyl)-N'-(2-methylbenzyl)-thiourea;$

N-(3-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

ethyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)benzoate;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3-ethylphenyl)-5 thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3-fluorobenzyl)thiourea:

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3-methoxybenzyl)-10 thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3-methylbenzyl)thiourea;

N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2yl]amino}cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-fluoro-2-15 methylphenyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-methoxy-2methylphenyl)thiourea;

N-(5-chloro-2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-20 cyclohexyl)thiourea;

N-(2,3-dihydro-1H-inden-5-yl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-cycloheptyl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea; N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[(1R)-1-phenylethyl]-

N-(2-cyclohex-1-en-1-ylethyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

25 thiourea:

cyclohexyl)thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2,3-dimethylphenyl)-N'-(2,3-dimet$

325

thiourea;

N-(2,4-dibromo-6-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(2,4-dichloro-6-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-5 cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,5-dimethylphenyl)thiourea;

N-(2-bromo-4-isopropylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

10 N-(2-bromo-5-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethoxyphenyl)thiourea:

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-isopropyl-6-15 methylphenyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxybenzyl)thiourea;

N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2yl]amino}cyclohexyl)thiourea;

20 N-1.3-benzodioxol-5-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(3-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-[4-bromo-2-(trifluoromethoxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-25 yllamino}cyclohemyl)thiourea;

N-(4-chloro-2,5-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-phenylbutyl)-

326

thiourea;

 $N-bicyclo[2.2.1] hept-2-yl-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl) thiourea; \\$

methyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]-

5 carbonothioyl) amino)-4-methylthiophene-2-carboxylate;

methyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino}-carbonothioyl}amino)thiophene-2-carboxylate;

 $N-(2-bromo-4-fluorophenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl) thiourea;\\$

10 N-(4-butyl-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

N-[4-(dimethylamino)-1-naphthyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(5-methyl-3-

15 phenylisoxazol-4-yl)thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,6-dimethylphenyl)thiourea;

N-(2,6-dichlorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethyl-6-isopropylphenyl)thiourea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-isobutylthiourea;$

N-(1,3-benzodioxol-5-ylmethyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-

25 yllamino) cyclohexyl) methyl] thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-nitrophenyl)thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-

327

(pentafluorophenyl)thiourea;

 $N-\{(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) methyl]-N'-(tetrahydrofuran-2-ylmethyl) thiourea;$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino) cyclohexyl)methyl]-N'-[2-

5 (trifluoromethoxy)phenyl]thiourea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) methyl]-N'-(2,3,4-trifluorophenyl) thiourea;$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethylphenyl)thiourea;

10 N-(5-chloro-2-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)methyl]thiourea;

N-[(1S,4R)-bicyclo[2.2.1]hept-2-yl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea;

N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-15 cyclohexyl)methyl]thiourea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) methyl]-N'-(2,4,6-tribromophenyl) thiourea;$

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,4,6-trichlorophenyl)thiourea;

20 N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-mesitylthiourea;

N-(2,6-diethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-methyl]thiourea;

N-(2,6-diisopropylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

25 cyclohexyl)methyl]thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-ethyl-6-methylphenyl)thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-

isopropylphenyl)thiourea;

N-(4-bromo-2,6-dimethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea;

N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-5 yl]amino}cyclohexyl)methyl]thiourea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) methyl]-N'-[1-(4-kyl)methyl$ fluorophenyl)ethyl]thiourea;

N-(5-chloro-2-methoxyphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea;

 $N-[(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}cyclohexyl)methyl]-N'-1-2-yl]$ 10 (diphenylmethyl)thiourea;

N-cyclododecyl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea;

N-(cyclohexylmethyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-15 methyl]thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,3,5,6tetrachlorophenyl)thiourea;

N-(2,3-dimethoxybenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea;

N-(2,4-dichlorobenzyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-20 methyl]thiourea;

 $N-\{(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl) methyl]-N'-(2-methoxy-5-yl)amino\} cyclohexyl) methylly lamino amino amin$ nitrophenyl)thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(4-methoxy-2-25 methylphenyl)thiourea;

N-(2,4-dibromo-6-fluorophenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea;

N-(2,4-dichloro-6-methylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

cyclohexyl)methyl]thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,5dimethylphenyl)thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)methyl]-N'-(2-

5 ethoxyphenyl)thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-isopropyl-6methylphenyl)thiourea;

N-[4-bromo-2-(trifluoromethoxy)phenyl]-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2yl]amino}cyclohexyl)methyl]thiourea;

10 N-bicyclo[2.2.1]hept-2-yl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea;

N-bicyclo[2.2.1]hept-5-en-2-yl-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea;

N-(cyclopropylmethyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yllamino}cyclohexyl)-15 methyl]thiourea; and

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-vl]amino}cyclohexyl)methyl]-N'-(5-methyl-3phenylisoxazol-4-yl)thiourea;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

20 15. The compound according to claim 1 selected from the group consisting of:

N-(4-bromophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(4-cyanophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

25 N-(2,4-dichlorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)thiourea;

N-(2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2,6-dimethylphenyl)-thiourea;$

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} eyelohexyl)-N'-(2-ethyl-6-isopropylphenyl) thiourea;$

5 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxyphenyl)-thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-1-naphthylthiourea;
N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(3,4,5-trimethoxyphenyl)thiourea;

N-(3,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2-ethylphenyl)-thiourea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methoxy-4-15 nitrophenyl)thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclohexyl)-N'-(2-methoxy-5-methylphenyl) thiourea;$

 $N-(4-bromo-2-chlorophenyl)-N'-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}-cyclohexyl) thiourea;\\$

20 N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-iodophenyl)-thiourea;

 $N-(cis-4-\{\{4-(dimethylamino)quinazolin-2-yl\}amino\}\ cyclohexyl)-N'-(2,4,6-tribromophenyl) thiourea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2,4,6-trichlorophenyl)-25 thiourea:

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ cyclohexyl)-N'-mesitylthiourea;$

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2,4-dimethylphenyl)-thiourea;$

N-(2,6-diethylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(2-bromo-4-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(2-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-5 thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethyl-6methylphenyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-isopropylphenyl)-10 thiourea;

methyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)benzoate;

N-(4-bromo-2,6-dimethylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2yl]amino}cyclohexyl)thiourea;

N-(4-bromo-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-15 cyclohexyl)thiourea;

N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2yllamino cyclohexyl) thiourea;

N-(4-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

20 cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(1-naphthylmethyl)thiourea;

N-(2,3-dimethoxybenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)-N'-(2,4,5-25 trimethylphenyl)thiourea;

> N-biphenyl-2-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea; N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-methyl-4-

332

nitrophenyl)thiourea;

N-(3-chlorobenzyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-thiourea:

ethyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]-

5 carbonothioyl) amino) benzoate;

N-[4-chloro-2-(trifluoromethyl)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino)cyclohexyl)thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ eyclohexyl)-N'-(4-fluoro-2-methylphenyl) thiourea;$

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(4-methoxy-2-methylphenyl)thiourea;

N-(5-chloro-2,4-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-[(1R)-1-phenylethyl]-15 thiourea;

 $N-(cis-4-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclohexyl)-N'-(2,3-dimethylphenyl)-thiourea;$

N-(2,4-dibromo-6-fluorophenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

20 N-(2,4-dichloro-6-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(2-ethoxyphenyl)-thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino} cyclohexyl)-N'-(2-isopropyl-6-25 methylphenyl)thiourea;

N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-1,3-benzodioxol-5-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-

333

thiourea;

N-(3-chloro-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-[4-bromo-2-(trifluoromethoxy)phenyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-

5 yl]amino}cyclohexyl)thiourea;

N-(4-chloro-2,5-dimethoxyphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-bicyclo[2,2,1]hept-2-yl-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

10 methyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)-4-methylthiophene-2-carboxylate;

methyl 3-({[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)amino]carbonothiovl}amino)thiophene-2-carboxylate;

N-(4-butyl-2-methylphenyl)-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

15 cyclohexyl)thiourea;

N-[4-(dimethylamino)-1-naphthyl]-N'-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)thiourea;

N-(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-N'-(5-methyl-3phenylisoxazol-4-yl)thiourea;

N-(2,6-diethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)-20 methyl]thiourea;

N-(4-bromo-2,6-dimethylphenyl)-N'-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]thiourea;

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2,3,5,6-

25 tetrachlorophenyl)thiourea; and

N-[(cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexyl)methyl]-N'-(2-isopropyl-6methylphenyl)thiourea;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

The compound according to claim 3 wherein R_1 is selected from the group consisting of: 16. R₁ is selected from the group consisting of: (i) C₁₋₈ alkyl, and C_{1-8} alkyl substituted by substituent(s) independently selected from the group 5 consisting of: ·halogen, •C₁₋₅ alkoxy, •C₁₋₅ alkoxy substituted by carbocyclic aryl, ·carbocyclyl, 10 ·carbocyclic aryl, •carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: ••halogen, ••nitro, and 15 ••C₁₋₅ alkoxy, C2-5 alkenyl, (ii) carbocyclyl, (iii) (iv) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the 20 group consisting of: ·halogen, $\cdot C_{1-5}$ alkyl, *C₁₋₅ alkyl substituted by halogen, and ${}^{\circ}C_{1-5}$ alkoxy; 25 L is Formula (V); and Y is -C(O)O-;

wherein carbocyclic aryl is phenyl or naphthyl;

carbocyclyl is 9H-fluorenyl or menthyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate or solvate thereof.

- The compound according to claim 16 wherein R_{4a} is hydrogen or methyl; R_{4b} is methyl; R₅ and R₆ are hydrogen; A is a single bond; and B is a single bond or -CH₂-; or a pharmaceutically acceptable salt, hydrate or solvate thereof.
 - 18. The compound according to claim 1 selected from the group consisting of:
- cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid
 - 2-benzyloxy-ethyl ester;
 - cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid
 - 4,5-dimethoxy-2-nitro-benzyl ester;
 - cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid 2-chloro-benzyl
- 15 ester;
- cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid
- 4,5-dimethoxy-2-nitro-benzyl ester;
- cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid 4-nitro-benzyl ester;
- cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexyl]-carbamic acid benzyl ester; cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid 2-chloro-benzyl ester;
 - cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid 4-nitro-benzyl ester; and
- 25 cis-[4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester;
 - or a pharmaceutically acceptable salt, hydrate or solvate thereof.

19. The compound according to claim 3 wherein:

R₁ is C₁₋₈ alkyl, and

 C_{1-8} alkyl substituted by substituent(s) independently selected from the group consisting of:

5 carbocyclic aryl,

*carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

- ∘•halogen,
- ••C_{1.5} alkyl,
- ••C₁₋₅ alkyl substituted by halogen,
 - ••C₁₋₅ alkoxy, and
 - ••C₁₋₅ alkoxy substituted by halogen,

 R_4 is $-N(R_{4a})(R_{4b})$ wherein R_{4a} and R_{4b} are independently C_{1-5} alkyl;

L is Formula (VIII) or (IX) wherein R₅ and R₆ are both hydrogen; A and B are each

15 independently a single bond or - CH_2 -; and

Y is a single bond;

wherein carbocyclic aryl is phenyl; and

halogen is fluoro or chloro;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

20

10

20. The compound according to claim 19 wherein:

 R_1 is C_{1-8} alkyl, and

C_{1.8} alkyl substituted by substituent(s) independently selected from the group consisting of:

25 °carbocyclic aryl,

*carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

••C₁₋₅ alkoxy, and

PCT/JP2004/004554

337

••C₁₋₅ alkoxy substituted by halogen,

wherein carbocyclic aryl is phenyl; and

halogen is fluoro or chloro;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

5

21. The compound according to claim 20 wherein:

R₄ is -N(CH₃)₂; L is Formula (VIII) or (IX) wherein A is a single bond and B is -CH₂-,

or A is -CH₂- and B is a single bond; and Y is a single bond;

wherein carbocyclic aryl is phenyl; and

10 halogen is fluoro;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

22. The compound according to claim 1 is:

 $N^2-[(1S,3R)-3-(\{[4-bromo-2-(trifluoromethoxy)benzyl]amino\}-methyl)cyclopentyl]-N^4,N^4-[(1S,3R)-3-(\{[4-bromo-2-(trifluoromethoxy)benzyl]amino\}-methyl)cyclopentyl]-N^4,N^4-[(1S,3R)-3-(\{[4-bromo-2-(trifluoromethoxy)benzyl]amino\}-methyl)cyclopentyl]-N^4,N^4-[(1S,3R)-3-(\{[4-bromo-2-(trifluoromethoxy)benzyl]amino\}-methyl)cyclopentyl]-N^4,N^4-[(1S,3R)-3-(\{[4-bromo-2-(trifluoromethoxy)benzyl]amino]-methyl)cyclopentyl]-N^4,N^4-[(1S,3R)-3-(\{[4-bromo-2-(trifluoromethoxy)benzyl]amino]-methyl)cyclopentyl]-N^4,N^4-[(1S,3R)-3-(\{[4-bromo-2-(trifluoromethoxy)benzyl]amino]-methyl)cyclopentyl]-N^4,N^4-[(1S,3R)-3-([4-bromo-2-(trifluoromethoxy)benzyl]amino]-methyl)cyclopentyl]-N^4,N^4-[(1S,3R)-3-([4-bromo-2-(trifluoromethoxy)benzyl]amino]-methyl)cyclopentyl]-N^4,N^4-[(1S,3R)-3-([4-bromo-2-(trifluoromethoxy)benzyl]amino]-methyl)cyclopentyl]-N^4,N^4-[(1S,3R)-3-([4-bromo-2-(trifluoromethoxy)benzyl]amino]-methyl)cyclopentyl]-N^4,N^4-[(1S,3R)-3-([4-bromo-2-(trifluoromethoxy)benzyl]amino]-methyllocyclopentyl]-N^4,N^4-[(1S,3R)-3-([4-bromo-2-(trifluoromethoxy)benzyl]-N^4,N^4-[(1S,3R)-3-([4-bromo-2-(trifluoromethoxy)benzyl]-N^4,N^4-[(1S,3R)-3-([4-bromo-2-(trifluoromethoxy)benzyl]-N^4,N^4-[(1S,3R)-3-([4-bromo-2-(trifluoromethoxy)benzyl]-N^4,N^4-[(1S,3R)-3-([4-bromo-2-(trifluoromethoxy)benzyl]-N^4,N^4-[(1S,3R)-3-([4-bromo-2-(trifluoromethoxy)benzyl]-N^4,N^4-[(1S,3R)-3-([4-bromo-2-(trifluoromethoxy)benzyl]-N^4,N^4-[(1S,3R)-3-([4-bromo-2-(trifluoromethoxy)benzyl]-N^4,N^4-[(1S,3R)-3-([4-bromo-2-(trifluoromethoxy)benzyl]-N^4,N^4-[(1S,3R)-3-([4-bromo-2-(trifluoromethoxy)benzyl]-N^4,N^4-[(1S,3R)-3-([4-bromo-2-(trifluoromethoxy)benzyl]-N^4,N^4-[(1S,3R)-3-([4-bromo-2-([$

15 dimethylquinazoline-2,4-diamine;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

23. The compound according to claim 3 wherein:

 R_1 is selected from the group consisting of:

20

25

(i) C_{1-8} alkyl, and

C₁₋₈ alkyl substituted by substituent(s) independently selected from the group

consisting of:

•carbocyclic aryl,

*carbocyclic aryl substituted by substituent(s) independently selected from

the group consisting of:

••hydroxy,

··halogen,

••nitro,

		••C ₁₋₅ alkylcarbonylamino,
		°*C ₃₋₆ cycloalkylcarbonylamino,
		$^{\circ\circ}C_{1 ext{-}5}$ alkyl,
		••C ₁₋₅ alkyl substituted by halogen,
5		••C ₁₋₅ alkylsulfonyl,
		°°C ₁₋₅ alkoxy,
		«C ₁₋₅ alkoxy substituted by halogen, and
		«carbocyclic aryl,
		•heterocyclyl, and
10		•heterocyclyl substituted by halogen,
	(ii)	C ₃₋₁₂ cycloalkyl, and
		C ₃₋₁₂ cycloalkyl substituted by carbocyclic aryl,
	(iii)	carbocyclyl, and
		carbocyclyl by substituent(s) independently selected from the group
15		consisting of:
		•hydroxy, and
		•carbocyclic aryl,
	(iv)	carbocyclic aryl, and
		carbocyclic aryl substituted by substituent(s) independently selected from the
20		group consisting of:
		•halogen,
		•C ₁₋₅ alkoxy, and
		•nitro,
	(v)	heterocyclyl, and
25		heterocyclyl substituted by substituent(s) independently selected from the
		group consisting of:
		•halogen, and

•C₁₋₅ alkoxy,

 R_4 is -N(R_{4a})(R_{4b}) wherein R_{4a} and R_{4b} are each independently C_{1-5} alkyl;

L is Formula (XIII); wherein R₅ and R₆ are both hydrogen; A is a single bond and B is a single bond or -CH₂-; and

Y is $-C(O)NR_{7}$, wherein R_{7} is hydrogen or C_{1-5} alkyl;

wherein carbocyclic aryl is phenyl or naphthyl;

carbocyclyl is indanyl, 9H-fluorenyl, 1,2,3,4-tetrahydro-naphthalen-1-yl, or 1*H*-indolyl;

heterocyclyl is benzo[1,3]dioxolyl, pyridyl, dibenzofuranyl,

1H-benzoimidazolyl, or thiazolyl; and

10 halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate or solvate thereof.

The compound according to claim 23 wherein: 24.

 R_1 is selected from the group consisting of:

C₁₋₈ alkyl, and 15 (i)

> C_{1.8} alkyl substituted by substituent(s) independently selected from the group consisting of:

·carbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from

the group consisting of:

••hydroxy,

••halogen,

••nitro,

«C₁₋₅ alkylcarbonylamino,

∘ C₁₋₅ alkyl,

••C₁₋₅ alkyl substituted by halogen,

••C₁₋₅ alkylsulfonyl,

••C₁₋₅ alkoxy,

5

20

25

••C₁₋₅ alkoxy substituted by halogen, and

**carbocyclic aryl,

heterocyclyl, and

heterocyclyl substituted by halogen,

5 (ii) C_{3-12} cycloalkyl, and

10

15

20

 C_{3-12} cycloalkyl substituted by carbocyclic aryl,

- (iii) carbocyclyl,
- (iv) carbocyclic aryl, andcarbocyclic aryl substituted by substituent(s) independently selected from thegroup consisting of:
 - •halogen, and
 - •nitro,
- (v) heterocyclyl, and

heterocyclyl substituted by substituent(s) independently selected from the group consisting of:

- ·halogen, and
- •C₁₋₅ alkoxy,

wherein carbocyclic aryl is phenyl or naphthyl;

carbocyclyl is indanyl, 9H-fluorenyl, or 1,2,3,4-tetrahydro-naphthalen-1-yl;

heterocyclyl is benzo[1,3]dioxolyl, or pyridyl;

and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

25 25. The compound according to claim 24 wherein R_4 is $-N(CH_3)_2$; A and B are both a single bond; and Y is $-C(O)NH_{-1}$;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

```
26.
           The compound according to claim 1 selected from the group consisting of:
           cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2,3-dimethylbenzyl)-
   cyclohexanecarboxamide;
           cis-N-(2-bromobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
 5 cyclohexanecarboxamide;
            cis-N-(2-chlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(4-methylbenzyl)-
    cyclohexanecarboxamide;
10
            cis-N-[3,5-bis(trifluoromethyl)benzyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
            cis-N-(2,4-dimethoxybenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
           cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(1,2,3,4-
15 tetrahydronaphthalen-1-yl)cyclohexanecarboxamide;
            cis-N-(2,3-dihydro-1H-inden-2-yl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1S)-1-(4-nitrophenyl)ethyl]-
    cyclohexanecarboxamide;
20
            cis-N-(3,5-dichlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[4-(trifluoromethoxy)benzyl]-
    cyclohexanecarboxamide;
            cis-N-(4-bromobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
25 cyclohexanecarboxamide:
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(4-methoxybenzyl)-
    cyclohexanecarboxamide;
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2-fluoro-4-nitrophenyl)-
```

cyclohexanecarboxamide:

cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-fluoro-4-methylbenzyl)cyclohemanecarbomamide;

cis-N-(5-chloro-2-methylbenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

5 cyclohexanecarboxamide; and

cis-N-(2,4-dichloro-6-methylbenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

10 27. The compound according to claim 1 selected form the group consisting of:

cis-N-(2,3-dimethoxybenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

cyclohexanecarboxamide;

cis-N-(2.4-difluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide:

- 15 cis-N-(2,4-dichlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide;
 - cis-N-(2,3-dichlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide;

cis-N-(2,5-dichlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

20 cyclohexanecarboxamide:

cis-N-(3-chlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-methoxybenzyl)cyclohexanecarboxamide;

- 25 cis-N-(3,4-dimethoxybenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide;
 - cis-N-(3,5-dimethoxybenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide;

```
cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(4-hydroxy-3-methoxybenzyl)-
    cyclohexanecarboxamide:
           cis-N-(1,3-benzodioxol-5-ylmethyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
 5
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1R)-1-(4-nitrophenyl)ethyl]-
    cyclohexanecarboxamide;
           cis-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexanecarboxylic acid (trans-
    2-phenylcyclopropyl)-amide;
           cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1S)-1-(4-methylphenyl)ethyl]-
10 cyclohexanecarboxamide;
           cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1R)-1-(1-naphthyl)ethyl]-
    cyclohexanecarboxamide;
           cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[3-(trifluoromethyl)benzyl]-
    cyclohexanecarboxamide;
15
           cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-methoxyphenyl)-
    cyclohexanecarboxamide;
           cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-iodobenzyl)-
    cyclohexanecarboxamide;
           cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(4-methoxybenzyl)-
20 cyclohexanecarboxamide;
           cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-iodophenyl)-
    cyclohexanecarboxamide;
           cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[3-(propionylamino)benzyl]-
    cyclohexanecarboxamide;
           cis-N-benzyl-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide;
25
           cis-N-[(6-chloropyridin-3-yl)methyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
```

cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1R)-1-(3-methoxyphenyl)ethyl]-

```
cyclohexanecarboxamide;
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[1-(4-fluorophenyl)ethyl]-
    cyclohexanecarboxamide;
            cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
 5 cyclohexanecarboxamide;
            cis-N-[1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1S)-1-(1-naphthyl)ethyl]-
    cyclohexanecarboxamide:
10
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3,5-dimethylbenzyl)-
    cyclohexanecarboxamide;
            cis-N-(3-chloro-2-methylbenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(5-fluoro-2-methylbenzyl)-
15 cyclohexanecarboxamide;
            cis-N-(3-chloro-2,6-difluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
            cis-N-(biphenyl-3-ylmethyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
20
            cis-N-(biphenyl-4-ylmethyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
            cis-N-(6-chloro-2-fluoro-3-methylbenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2-fluorobenzyl)-
25 cyclohexanecarboxamide;
            cis-N-(2,6-difluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[4-(trifluoromethyl)benzyl]-
```

```
cyclohexanecarboxamide;
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(1-naphthylmethyl)-
    cyclohexanecarboxamide;
            cis-N-(4-chlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
 5 cyclohexanecarboxamide;
            cis-N-(3,4-dichlorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-fluorobenzyl)-
    cyclohexanecarboxamide;
10
            cis-N-(2,5-difluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
           cis-N-(2,3-difluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
            cis-N-(3-bromobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
15 cyclohexanecarboxamide;
            cis-N-(3-bromo-4-fluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
            cis-N-(4-bromo-2-fluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
20
            cis-N-(5-bromo-2-fluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
            cis-N-(4-chloro-2-fluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3-methylbenzyl)-
25 cyclohexanecarboxamide;
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2-methylbenzyl)-
    cyclohexanecarboxamide;
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[2-(trifluoromethoxy)benzyl]-
```

346

```
cyclohexanecarboxamide;
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2,3,4-trifluorobenzyl)-
    cyclohexanecarboxamide:
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2,4,5-trifluorobenzyl)-
 5 cyclohexanecarboxamide;
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(3,4,5-trifluorobenzyl)-
    cyclohexanecarboxamide;
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-(2,3,6-trifluorobenzyl)-
    cyclohexanecarboxamide;
10
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[3-fluoro-5-(trifluoromethyl)benzyl]-
    cyclohexanecarboxamide;
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[4-fluoro-2-(trifluoromethyl)benzyl]-
    cyclohexanecarboxamide;
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[2-fluoro-4-(trifluoromethyl)benzyl]-
15 cyclohexanecarboxamide;
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[4-fluoro-3-(trifluoromethyl)benzyl]-
    cyclohexanecarboxamide;
            cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[2-fluoro-3-(trifluoromethyl)benzyl]-
    cyclohexanecarboxamide;
20
            cis-N-[4-chloro-3-(trifluoromethyl)benzyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
            cis-N-(2-chloro-6-fluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
            cis-N-(3-chloro-4-fluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
25 cyclohexanecarboxamide;
            cis-N-(2-chloro-4-fluorobenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-
    cyclohexanecarboxamide;
```

cis-N-[2-chloro-5-(trifluoromethyl)benzyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

347

cyclohexanecarboxamide;

cis-N-[2-(difluoromethoxy)benzyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide;

cis-N-[3-(difluoromethoxy)benzyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

5 cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[3-(trifluoromethoxy)benzyl]cyclohemanecarboxamide;

cis-N-(2,6-dimethoxybenzyl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide;

10 cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1R)-1-phenylethyl]cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[(1S)-1-(4-methoxyphenyl)ethyl]cyclohexanecarboxamide;

cis-N-[bis(4-methoxyphenyl)methyl]-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-

15 cyclohexanecarboxamide;

25

cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[2-(trifluoromethyl)benzyl]cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-9H-fluoren-9ylcyclohexanecarboxamide;

20 cis-4-{[4-(dimethylamino)quinazolin-2-yl]amino}-N-[4-(methylsulfonyl)benzyl]cyclohexanecarboxamide; and

cis-N-(6-chloropyridin-3-yl)-4-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclohexanecarboxamide;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

28. The compound according to claim 3 wherein:

 R_1 is selected from the group consisting of:

(i) C_{1-8} alkyl, and

348

C₁₋₈ alkyl substituted by substituent(s) independently selected from the group consisting of:

«carbocyclic aryl,

*carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

[∞]C₁₋₅ alkoxy, and

«C₁₋₅ alkony substituted by halogen,

(ii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

·halogen, and

 $\cdot C_{1-7}$ alkoxy,

 R_4 is $-N(R_{4a})(R_{4b})$ wherein R_{4a} and R_{4b} are each independently $C_{1.5}$ alkyl;

L is Formula (XIII) wherein R₅ is hydrogen; A is a single bond and B is a single bond

15 or -CH₂-; and

Y is -C(O)O- or -OC(O)-;

wherein carbocyclic aryl is phenyl or naphthyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

29. The compound according to claim 28 wherein R_4 is $-N(CH_3)_2$; or a pharmaceutically acceptable salt, hydrate or solvate thereof.

30. The compound according to claim 3 wherein:

25 R_1 is selected from the group consisting of:

carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

10

5

20

349

·halogen,

°C1-10 alkyl.

°C₁₋₁₀ alkyl substituted by halogen,

°C₁₋₇ alkoxy, and

5 °C₁₋₇ alkoxy substituted by halogen,

 R_4 is $-N(R_{4a})(R_{4b})$ wherein R_{4a} and R_{4b} are each independently C_{1-5} alkyl;

L is Formula (VIII) or (IX) wherein A and B are each independently a single bond or

-CH₂-; and

Y is -C(O)-,

wherein carbocyclic aryl is phenyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

- The compound according to claim 30 wherein R₄ is -N(CH₃)₂; R₅ and R₆ are both hydrogen;
 and A is a single bond, and B is -CH₂-; or A is a -CH₂-, and B is a single bond,
 or a pharmaceutically acceptable salt, hydrate or solvate thereof.
 - 32. The compound according to claim 1 selected from the group consisting of:

 3,4-dichloro-N-[((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclopentyl)-
- 20 methyl]benzamide;

 $N-[(1S,3R)-3-(\{[4-(dimethylamino)quinazolin-2-yl]amino\} methyl) cyclopentyl]-4-fluorobenzamide;$

4-chloro-N-[((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclopentyl)methyl]-benzamide; and

N-[((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-yl]amino) cyclopentyl)methyl]-3,5-difluorobenzamide;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

350

33. The compound according to claim 1 selected from the group consisting of:

 $N-[((1R,3S)-3-\{[4-(dimethylamino)quinazolin-2-yl]amino\}\ eyelopentyl)methyl]-3,5-dimethoxybenzamide;$

2,4,6-trichloro-N-[((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclopentyl)-

5 methyl]benzamide;

N-[((1R,3S)-3-{[4-(dimethylamino)quinazolin-2-yl]amino}cyclopentyl)methyl]-3-fluoro-4-(trifluoromethyl)benzamide;

 $N-[((1R,3S)-3-\{[4-(dimethylamino)quinazolin-2-yl]amino\} cyclopentyl) methyl]-4-(trifluoromethoxy) benzamide; and$

N-[(1S,3R)-3-({[4-(dimethylamino)quinazolin-2-yl]amino}methyl)cyclopentyl]-2,4-difluorobenzamide;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

34. The compound according to claim 2 wherein Q is Formula (IIa).

15

35. The compound according to claim 34 wherein:

R₁ is selected from the group consisting of:

(i) C_{1-8} alkyl, and

 C_{1-8} alkyl substituted by carbocyclic aryl.

20

(ii) carbocyclic aryl, and

carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

- ·halogen,
- $\cdot C_{1-10}$ alkyl,

25

- ${}^{\circ}C_{1,10}$ alkyl substituted by halogen,
- •C₁₋₇ alkoxy, and
- •C₁₋₇ alkoxy substituted by halogen,

 R_2 is $-N(R_{2a})(R_{2b})$, wherein R_{2a} and R_{2b} are each independently C_{1-5} alkyl;

L is Formula (V) wherein R₅ and R₆ are both hydrogen; A and B are both a single bond;

 X_1 , X_2 , II_3 and X_4 are independently selected from the group consisting of hydrogen, halogen, and $C_{1,4}$ alkyl; provided that at least one substituent selected from the group consisting of X_1 , X_2 , X_3 and X_4 is not hydrogen; and

Y is -C(O)-;

wherein carbocyclic aryl is phenyl; and
halogen is fluoro, chloro, bromo, or iodo;
or a pharmaceutically acceptable salt, hydrate or solvate thereof.

10

5

- 36. The compound according to claim 35 wherein R_2 is $-N(CH_3)_2$; and X_1 , X_2 , X_3 and X_4 are independently selected from the group consisting of hydrogen, fluoro, and methyl; provided that at least one substituent selected from the group consisting of X_1 , X_2 , X_3 and X_4 is not hydrogen;
- or a pharmaceutically acceptable salt, hydrate or solvate thereof.
 - 37. The compound according to claim 1 selected from the group consisting of:

 N-(cis-4-{[4-(dimethylamino)-6-methylquinazolin-2-yl]amino}cyclohexyl)-2,2diphenylacetamide;
- N-(cis-4-{[4-(dimethylamino)-6-methylquinazolin-2-yl]amino}cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide;

N-(cis-4-{[4-(dimethylamino)-6-methylquinazolin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide; and

N-(cis-4-{[4-(dimethylamino)-6-methylquinazolin-2-yl]amino}cyclohexyl)-3,4,5-

25 trimethoxybenzamide;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

38. The compound according to claim 1 selected from the group consisting of:

352

3-chloro-N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino} cyclohexyl)-benzamide;

3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohemyl)-benzamide;

5 N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide;

N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)-4-

methylbenzamide;

N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)-4-fluorobenzamide;

N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)-3-methoxybenzamide;

N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)-3,4-

15 difluorobenzamide; and

25

N-(cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

20 39. The compound according to claim 34 wherein:

R₁ is selected from the group consisting of:

(i) C_{1-8} alkyl, and

C₁₋₈ alkyl substituted by substituent(s) independently selected from the group consisting of:

ecarbocyclic aryl,

•carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

··halogen,

353

•• C₁₋₅ alkyl,

∘ C₁₋₅ alkyl substituted by halogen,

←C₁₋₅ alkoxy, and

∘ C₁₋₅ alkoxy substituted by halogen,

(ii) heterocyclyl, and

5

10

15

20

heterocyclyl substituted by halogen,

 R_2 is $-N(R_{2a})(R_{2b})$, wherein R_{2a} and R_{2b} are each independently C_{1-5} alkyl;

L is Formula (XIII);

 X_1 , X_2 , X_3 and X_4 are independently hydrogen or halogen; provided that at least one substituent selected from the group consisting of X_1 , X_2 , X_3 and X_4 is not hydrogen; and

Y is $-C(O)NR_7$ - wherein R_7 is hydrogen or C_{1-5} alkyl;

wherein carbocyclic aryl is phenyl;

heterocyclyl is pyridyl; and

halogen is fluoro, chloro, bromo, or iodo;

or a pharmaceutically acceptable salt, hydrate or solvate thereof.

- 40. The compound according to claim 39 wherein R₂ is -N(CH₃)₂; L is Formula (XIII) wherein A and B are both a single bond; X₁, X₂, X₃ and X₄ are independently hydrogen or fluoro; provided that at least one substituent selected from the group consisting of X₁, X₂, X₃ and X₄ is not hydrogen; and Y is -C(O)NH-; or a pharmaceutically acceptable salt, hydrate or solvate thereof.
- 41. The compound according to claim 1 selected from the group consisting of:

cis-N-benzyl-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-cyclohexanecarboxamide;

cis-N-(3,5-dimethoxybenzyl)-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-cyclohexanecarboxamide;

cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-(3-methoxybenzyl)-cyclohexanecarboxamide;

cis-N-[(6-chloropyridin-3-yl)methyl]-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]-amino}cyclohexanecarboxamide;

- 5 cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-[3-(trifluoromethyl)-benzyl]cyclohexanecarboxamide;
 - cis-4-{{4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-[4-(trifluoromethyl)-benzyl]cyclohexanecarboxamide;
- cis-N-[3,5-bis(trifluoromethyl)benzyl]-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-10 yl]amino}cyclohexanecarboxamide;
 - $\label{lem:cis-4-} cis-4-\{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-(3-iodobenzyl)-cyclohexanecarboxamide; and$
 - $\label{lem:cis-N-[1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino} cyclohexanecarboxamide;$
- or a pharmaceutically acceptable salt, hydrate or solvate thereof.
 - 42. The compound according to claim 1 selected from the group consisting of:

 cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-(4-methylbenzyl)
 cyclohexanecarboxamide;
- cis-N-(3-chlorobenzyl)-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-cyclohexanecarboxamide;
 - cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-[(1R)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide;
- cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-(4-methoxybenzyl)-25 cyclohexanecarboxamide;
 - $\label{lem:cis-N-2-yl} cis-N-(2,4-dichlorobenzyl)-4-\{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino\}-cyclohexanecarboxamide;$
 - $cis-N-(3,5-dichlorobenzyl)-4-\{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino\}-1-(3,5-dichlorobenzyl)-4-\{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino\}-1-(dimethylamino)-1-(dimet$

355

```
cyclohexanecarboxamide;
```

cis-N-(4-bromobenzyl)-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-cyclohexanecarboxamide;

cis-N-(2-bromobenzyl)-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-

5 cyclohexanecarboxamide;

 $\label{lem:cis-4-lem:cis$

cis-4-{[4-(dimethylamino)-6,7-difluoroquinazolin-2-yl]amino}-N-[(1S)-1-(4-methylphenyl)ethyl]cyclohexanecarboxamide;

- or a pharmaceutically acceptable salt, hydrate or solvate thereof.
 - 43. The compound according to claim 2 wherein Q is Formula (IIb).
 - 44. The compound according to claim 43 wherein:

 R_1 is selected from the group consisting of:

C₁₋₈ alkyl, and

 C_{1-8} alkyl substituted by substituent(s) independently selected from the group consisting of:

- •carbocyclic aryl,
- •carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
 - ••halogen,
 - ${}^{\bullet \bullet}C_{1-5}$ alkyl, and
 - ∘•C₁₋₅ alkoxy,

25 R_3 is C_{1-5} alkyl;

20

L is Formula (XIII); wherein R₅ and R₆ are both hydrogen; A and B are both a single bond;

Y is $-C(O)NR_7$ -;

356

wherein carbocyclic aryl is phenyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate or solvate thereof.

- 5 45. The compound according to claim 44 wherein R₃ is isopropyl; and Y is -C(O)NH-: or a pharmaceutically acceptable salt, hydrate or solvate thereof.
- The compound according to claim 1 is:
 cis-N-(3-chlorobenzyl)-4-[(4-isopropylquinazolin-2-yl)amino]cyclohexanecarboxamide;
 or a pharmaceutically acceptable salt, hydrate or solvate thereof.
 - 47. The compound according to claim 1 wherein R₁ is selected from hydrogen, -CO₂'Bu, or -CO₂Bn (Bn is a benzyl group);

 R_2 is -N(R_{2a})(R_{2b}), wherein R_{2a} is hydrogen or C_{1-5} alkyl; R_{2b} is C_{1-5} alkyl;

15 R_3 is C_{1-5} alkyl;

20

 R_4 is $-N(R_{4a})(R_{4b})$ wherein R_{4a} is hydrogen or C_{1-5} alkyl; R_{4b} is C_{1-5} alkyl;

L is selected from Formula (V), (VIII), (IX), (XIII), (XVI), or (XVII);

 $X_1,\,X_2,\,X_3$ and X_4 are independently selected from the group consisting of hydrogen,

halogen, and C₁₋₄ alkyl; provided that at least one substituent selected from the group

consisting of X_1 , X_2 , X_3 and X_4 is not hydrogen; and

Y is a single bond;

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

- 48. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 47 in combination with a pharmaceutically acceptable carrier.
 - 49. A method for the prophylaxis or treatment of improving memory function, sleeping and

arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction comprising administering to an individual suffering from said condition a therapeutically effective amount of a compound according to any one of claims 1 to 47 or a pharmaceutical composition according to claim 48.

- 10 50. A method for the prophylaxis or treatment of an eating disorder, obesity or an obesity related disorder comprising administering to an individual suffering from said condition a therapeutically effective amount of a compound according to any one of claims 1 to 47 or a pharmaceutical composition according to claim 48.
- 15 51. A method for the prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy comprising administering to an individual suffering from said condition a therapeutically effective amount of a compound according to any one of claims 1 to 47 or a pharmaceutical composition according to claim 48.
- 20 52. A compound according to any one of claims 1 to 47 or a pharmaceutical composition according to claim 48 for use in a method of treatment of the human or animal body by therapy.
- A compound according to any one of claims 1 to 47 or a pharmaceutical composition

 according to claim 48 for use in a method of prophylaxis or treatment of an eating disorder,
 obesity or an obesity related disorder of the human or animal body by therapy.
 - 54. A compound according to any one of claims 1 to 47 or a pharmaceutical composition

according to claim 48 for use in a method of prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy of the human or animal body by therapy.

- 55. A compound according to any one of claims 1 to 47 for the manufacture of a medicament for use in the prophylaxis or treatment of an eating disorder, obesity or obesity related disorders.
 - A compound according to any one of claims 1 to 47 for the manufacture of a medicament for use in the prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy.

10

57. A method of producing a pharmaceutical composition comprising admixing a compound according to any one of claims 1 to 47 and a pharmaceutically acceptable carrier.

INTERNATIONALSEARCHREPORT

International application No.

PCT/JP2004/004554

CLASSIFICATIONOFSUBJECTMATTER C07D239/84,A61K31/517,A61P25/28,25/20,25/22,25/24,3/04,9/12,9/00,25/16,25/08,3/00 According to International Patent Classification (IPC) or to both national classification and IPC FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C07D239/84, A61R31/517, A61P25/28, 25/20, 25/22, 25/24, 3/04, 9/12, 9/00, 25/16, 25/08, 3/00 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Japanese Utility Model Gazette 1922-1996, Japanese Publication of Unexamined Utility Model Applications 1971-2004, Japanese Registered Utility Model Gazette 1994-2004, Japanese Gazette Containing the Utility Model 1996-2004 Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN/CAS C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X WO 97/20823 A2 (NOVARTIS AZ) 1997.06.12 1-48,52-57 & AU 9676929 A & ZA 9610020 A Α GIARDINA, D., et al., "Structure-Activity 1-48,52-57 Relationships in Prazosin-Related Compounds. 2. Role of the Piperazine Ring on .alpha.-Blocking Activity", Journal of Medicinal Chemistry (1993), 36(6), pp690-8 Α ELSLAGER, E.F., et al., "Synthesis and 1-48,52-57 Antimalarial Effects of N2-aryl-N4-[(dialkylamino)alkyl] - and 4-aryl-N2-[(dialkylamino)alkyl]-2,4quinazolinediamines", Journal of Medicinal Chemistry (1981), 24(2), pp127-40 **|** Further documents are listed in the continuation of Box C. See patent family annex. Special categories of cited documents: later document published after the international filing date or priority date and not in conflict with the application but cited to document defining the general state of the art which is not considered to be of particular relevance understand the principle or theory underlying the invention earlier application or patent but published on or after the international filing date document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such "O" document referring to an oral disclosure, use, exhibition or other combination being obvious to a person skilled in the art document published prior to the international filing date but later "&" document member of the same patent family than the priority date claimed Date of the actual completion of the international search Date of mailing of the international search report 15. 6. 2004 28.05.2004 Name and mailing address of the ISA/JP Authorized officer 8519 4P Japan Patent Office Satoshi MORIYASU

Telephone No. +81-3-3581-1101 Ext. 3452

3-4-3, Kasumigaseki, Chiyoda-ku, Tokyo 100-8915, Japan

INTERNATIONALSEARCHREPORT

International application No. PCT/JP2004/004554

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT						
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.				
PX	WO 03/028641 A2 (TAISHO PHARMACEUTICAL CO., LTD) 2003.04.10	1-48,52-57				

INTERNATIONALSEARCHREPORT

International application No.

PCT/JP2004/004554

Bo	ox No.	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)		
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:				
1.		Claims Nos.: 49-51 because they relate to subject matter not required to be searched by this Authority, namely: Claims 49-51 pertain to a method for treatment of the human body by therapy.		
2.		Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:		
3.		Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).		
Во	x No. 1	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)		
Th	For How sig	mational Searching Authority found multiple inventions in this international application, as follows: mula (I), Q-L-Y-R1, in claim 1 involves a great number of compounds. ever, the common structure among those compounds does not appear to be a nificant structural element. Therefore, the inventions related to pounds are not deemed to form a single general inventive concept.		
1.		As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.		
2.	V	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.		
3.		As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:		
4.		No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:		
Re	mark (The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.		

International application No.

PCT/JP2004/004554

Formula (I), Q-L-Y-R1, consists of 4 parts which are defined broadly and ambiguously and vary immensely. It involves a great number of compounds so that complete search is unable to be done. Claim 1 is neither clear nor concise.